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Background: Stroke survivors are at high risk of experiencing cognitive 
problems, which can severely compromise independence in daily activities, 
social participation, and quality of life. With limited evidence to support current 
interventions, finding ways to improve cognitive function is recognised as a 
priority for research relating to life after stroke. Prognosis research may 
contribute to this endeavour by informing the development and implementation 
of preventive and therapeutic strategies - from describing the natural history of 
post-stroke cognitive change, through identifying its relevant predictors and 
developing methods of estimating individual outcome probability, to supporting 
the application of stratified medicine.  
Prognosis research into post-stroke cognition is still developing, with little 
evidence regarding some of its more fundamental questions. These relate to the 
relevance of: i) potentially modifiable factors, ii) differential effects of risk 
factors, depending on paths of influence and co-occurrence, and iii) population 
heterogeneity in the trajectory of post-stroke cognitive change. Through 
focusing on these three topics, the purpose of this thesis is to improve our 
understanding of the cognitive change that occurs following stroke and its 
associations with individual characteristics.  
Methods: Firstly, to gain a better insight into current advances in prognosis 
research in post-stroke cognition, I performed a systematic review of prognostic 
rules for predicting cognitive impairment and delirium following stroke. I 
considered these findings in specifying the aims and design of my subsequent, 
observational studies.  
I conducted two cross-sectional investigations in a sample of stroke survivors 
from the UK Biobank. Through a series of regression analyses, I assessed the 
associations of performance on four cognitive tasks with two groups of predictors 
of particular interest: 1) self-reported physical activity and sedentary behaviour, 
and 2) proxies of social engagement. 
Using data from consecutive patients admitted to a hyper-acute stroke unit, I 
then investigated the influence of cardiovascular risk factors on acute post-
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stroke cognitive performance. In a moderated mediation analysis, I tested the 
assumptions that the effects of these factors are partially mediated by stroke 
severity and prior dementia, and may be dependent on comorbidity.  
In my final, longitudinal study, based on the Assessing Post-Stroke Psychology 
Longitudinal Evaluation (APPLE) dataset, I conducted a latent class growth 
analysis to identify and describe differential trajectories of cognitive change, 
occurring over one year following stroke. Through subsequent regression 
analyses, I then explored factors that predicted trajectory class membership.  
Findings: Through a systematic review of the literature, I identified seven 
prognostic rules predicting post-stroke cognitive impairment (including 
dementia) and four predicting post-stroke delirium. The most commonly 
incorporated predictors were: demographics, imaging findings, stroke type, and 
symptom severity. Among seven studies that assessed in the original sample how 
well a prognostic rule discriminated between participants who developed the 
outcome of interest and those who did not, performance was reported as being 
good to excellent. Only one rule had been validated in an independent dataset, 
showing fair discriminatory power.  
In the first of two UK Biobank studies, I found relatively consistent, although 
weak associations for two types of sedentary behaviour, where the daily 
duration of watching TV was associated with poorer cognitive performance, 
while duration of computer use was associated with better performance. Some 
effects remained significant after adjusting for demographic, health-related, 
and lifestyle factors. Physical activity, however, was not independently 
associated with performance on any of the considered tasks. In the second 
study, reported loneliness was the only proxy of social engagement to be 
associated with most cognitive tasks, consistently predicting poorer 
performance.  
Findings from my analysis of data from a hyper-acute stroke unit setting 
supported the mediatory role of stroke severity and prior cognitive impairment 
in the effects of specific cardiovascular risk factors on acute cognition. Poorer 
cognitive performance was associated with atrial fibrillation through increased 
stroke severity, and with previous stroke through an increased risk of prevalent 
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dementia. Conversely, through an association with reduced stroke severity, 
better performance seemed predicted by vascular disease (in the presence of 
hypertension and absence of diabetes) and by previous transient ischaemic 
attack. 
In the APPLE dataset, I identified four distinct trajectories of cognitive change: 
i) with high early cognitive function, improving over following weeks and 
thereafter declining; ii) with some early cognitive deficits, followed by 
improvement in function and then relative stability; iii) with comparatively poor 
initial function, which after a stage of steeper improvement continued to 
improve at a slower rate; and iv) with severe cognitive deficits, followed by 
improvement at a near-constant rate. Overall, participants representing the two 
trajectories with greatest initial cognitive deficits were characterised by older 
age, lower education, higher prevalence of pre-stroke cognitive impairment, and 
greater stroke severity. 
Conclusions: In summary, my findings speak to the complex nature of cognitive 
change following stroke and its associations with individual characteristics. This 
is apparent on more than one level. What can be considered a single variable, 
such as sedentary behaviour, may be multifaceted. Entailing distinct properties, 
particular variable components are likely to have differential effects on post-
stroke cognitive function. The effects of specific factors may moreover differ 
depending on the path of influence and the constellation of coexisting variables. 
Finally, post-stroke cognitive change is a heterogenous process, both on a 
between- and within-individual level.  
These observations suggest that it is important to consider how, in what form, 
under what conditions, and for whom, a possibly causal factor can affect post-
stroke cognitive outcome. A lack of evidence-based assumptions regarding these 
aspects to inform the development of a statistical model may lead to 
misidentification of relevant associations. This is in turn likely to have 
implications at the stage of intervention development and implementation, 
limiting application. Recognising and at least partly accounting for the 
complexities I observed in my series of studies could contribute to bridging a gap 
between the potential and actual impact of prognosis research on improving 
cognitive function following stroke.  
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Chapter 1 Introduction 
In this chapter, I present concepts that are fundamental to my thesis, with a 
focus on cognition and stroke. After describing cognitive disorders in terms of 
their clinical features, and their prevalence and impact following stroke, I give 
special consideration to the topic of assessing cognitive function in healthcare 
and research settings. I regard this issue as a cornerstone of investigations into 
post-stroke cognition, including those within the area of prognosis research, 
which will be the theme of my next chapter.  
1.1 Cognitive change 
Cognition is central to how we perceive, understand, and interact with the 
world, and as such - central to our being. It encompasses many functions, from 
processing and interpretation of sensory stimuli, through remembering events 
and information, to use of language and complex operations on abstract 
concepts, such as in mathematical problem-solving or forming of philosophical 
doctrines. An obvious reflection is that it takes time for the full scope of 
cognitive abilities to become attainable for us, and so perhaps it is most 
intuitive to associate the term “cognitive change” with the dynamic 
development that occurs in childhood. Cognition, however, changes throughout 
the entire lifespan.  
Some abilities, involving knowledge and skills acquired and consolidated through 
experience, education, and cultural influences (e.g. vocabulary, or familiarity 
with historical or geographical facts) may continue to improve into old age (1-3). 
Other abilities, relating to processing and learning of new information, and 
applying reasoning and problem-solving skills in a relatively unfamiliar context, 
begin to decline from the age of around 30 (1-3). This is recognised as an 
inherent part of “healthy aging”. 
However, in some cases, either due to the type of functions that deteriorate, or 
the speed and extent of decline, change is indicative of a cognitive disorder, 
that is, a deficit in cognition that goes beyond what is attributable to the normal 
aging process. These problems are recognised as mild cognitive impairment or a 
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mild neurocognitive disorder (as referred to in the 5th edition of the Diagnostic 
and Statistical Manual of Mental Disorders [DSM-5]) where they do not preclude 
an individual from living independently, although the performance of some 
activities is slower and more effortful than it was previously, entails more 
errors, and requires use of compensatory strategies (4-7). Conversely, in its 
severe form, cognitive impairment compels the individual to rely on the help of 
others to manage the requirements of daily life. This is a key aspect of dementia 
or, as termed more broadly, a major neurocognitive disorder (6, 8). 
With influences present at every stage of life, multiple variables are associated 
with cognitive decline and acquired cognitive impairment, including: genes, 
socioeconomic background, education, occupation, environmental exposures, 
social engagement, lifestyle choices, and health-related conditions (9-11). 
Among the latter, stroke – of which there are over 80 million prevalent cases 
worldwide (12) – has been consistently demonstrated as a major contributing 
factor, at least doubling the risk of developing dementia (13). 
1.2 Stroke 
The World Health Organisation (WHO) and National Institute for Health and Care 
Excellence (NICE) traditionally define stroke as a clinical syndrome of vascular 
origin, characterised by sudden onset of rapidly developing signs of a focal or 
global disturbance of cerebral function, lasting at least 24 hours or leading to 
death (14, 15). Episodes where neurological dysfunction is suspected to be 
caused by ischaemia, yet symptoms resolve within 24 hours and there is no 
evidence of acute infarction, are identified as a transient ischaemic attack (TIA) 
(15).  
In recent years, however, these classic definitions of stroke and TIA have been 
increasingly recognised as outdated and of limited usefulness in a clinical setting 
(16, 17). A statement from the American Heart Association and American Stroke 
Association highlighted the importance of accounting for advances in science and 
technology for defining stroke and its diagnosis (16). Neuroimaging was discussed 
as a valuable source of objective evidence of central nervous system infarction, 
needed to supplement findings from clinical observation. Specifically, use of 
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neuroimaging can help to: i) characterise a lesion (its location, size, shape, and 
extent); ii) differentiate between an ischaemic (resulting from the obstruction 
of an artery) and a haemorrhagic (a focal collection of blood from the rupture of 
a vessel) stroke; iii) identify a silent brain infarct, where there is no history of 
acute neurological dysfunction attributable to a lesion; iv) differentiate between 
a stroke and a stroke mimic (e.g. brain tumour, migraine); and v) differentiate 
between a stroke and a TIA.      
The role of neuroimaging in fulfilling the latter objective has become 
particularly emphasised through increasing controversy over applying a time-
based criterion alone to differentiate between stroke and TIA. As studies have 
indicated that permanent infarction occurs in around one third of patients with 
symptoms lasting under 24 hours, it is argued that failing to recognise the 
limitations of this traditional rule of thumb may have led to misdiagnoses and 
thus inappropriate treatment (16, 18). In the context of cognition, it is moreover 
relevant that there is some evidence to suggest an association between TIA and 
longer-term cognitive problems (19, 20). With this in mind, while I focus on 
stroke, many of the concepts I discuss in this chapter are also relevant to cases 
of TIA.  
1.3 Cognitive disorders following stroke 
1.3.1 Syndromes, prevalence, and impact 
The neurological damage caused by stroke, as well as the medical complications 
that may follow, entail a risk that is rarely considered in relation to the general 
home-dwelling population – that of delirium. One in four stroke survivors are 
likely to be affected by this condition during the first days post-ictus. Delirium is 
characterised by disturbed attention and cognitive function, with a sudden onset 
and fluctuating course (21). Although generally considered a transient state, the 
effects of delirium are not always reversible, with potential severe implications 
in terms of length of hospital stay, disability, subsequent cognitive decline, and 
mortality (22). Delirium can be particularly difficult to recognise following 
stroke, due to the likely co-occurrence of pre-existing and/or acute cognitive 
impairment.  
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Estimates suggest that around 10% of individuals have dementia prior to index 
stroke, while within just the six months that follow, another 10% are likely to 
develop new dementia (23). At least three times as many stroke survivors are 
indicated to have mild global cognitive impairment, deficits in single cognitive 
domains, or subjective cognitive complaints (24-27). Indeed, a number of studies 
suggest that the majority of the stroke population will be affected by some form 
of short-term or persisting cognitive problems (25, 26), with potentially severe, 
adverse implications for individual outcomes. These include reduced functional 
gains from rehabilitation, inability to return to work, limited social 
participation, dependency in activities of daily living, increased risk of mood 
disorders, and poor quality of life (28-32).  
In addition to personal losses, post-stroke cognitive difficulties may affect the 
well-being of family members and increase caregiver burden (33-35). There are 
further ramifications at a societal level, with the presence of cognitive disorders 
associated with increased healthcare costs, stemming from longer initial 
hospitalisation, greater risk of later readmission and institutionalisation, and 
increased use of outpatient and home-based support (36).  
1.3.2 Improving cognitive function following stroke 
Given this high prevalence and extensive, detrimental impact of cognitive 
disorders, it seems unsurprising that in relation to life after stroke, finding ways 
to improve cognitive function has been determined as a number one research 
priority, in consensus by stroke survivors, caregivers, and health professionals 
(37). To date, there is limited evidence to support current interventions (38). 
One of the main postulated approaches involves use of strategies found to 
contribute to favourable stroke outcomes in general, including: treatments in 
the stroke unit to prevent acute complications, early rehabilitation, and 
pharmacological and lifestyle interventions for reducing the burden of 
cardiovascular risk factors and preventing recurrent stroke (39).  
Importantly, however, findings regarding the impact of such strategies on 
improving cognitive outcomes, specifically, seem thus far inconclusive. For 
example, while some studies have reported favourable effects for thrombolytic 
therapy, active blood pressure lowering, and lipid lowering, others indicated 
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neutral results (40-46). Moreover, two randomised controlled trials 
demonstrated no benefit of multicomponent interventions to reduce 
cardiovascular risk burden for the improvement of post-stroke cognition; one 
involved pharmacological strategies and lifestyle modifications, the other – only 
non-pharmacological strategies, although this included encouraging compliance 
with prescribed medication (47, 48). 
Similarly, there are uncertainties regarding the effectiveness of interventions 
that directly target post-stroke cognitive function through use of restorative and 
compensatory strategies, i.e. cognitive rehabilitation. The authors of a recent 
systematic review and meta-analysis made an encouraging finding that such 
approaches had a small (across 7 controlled studies) to moderate (across 13 pre-
post studies) positive effect on post-stroke cognition (49). At the same time, 
however, all included studies were rated as being of low quality and high risk of 
bias. Further, there was no evidence to indicate whether the observed effects 
were long-lasting, with only three studies including a follow-up assessment, the 
latest conducted one month after completing the tested strategy.   
In view of the above, there is a need to continue developing and/or tailoring 
interventions to improve cognitive function following stroke. Such endeavours 
involve a multi-stage process, from understanding the distinct features and 
natural history of post-stroke cognitive problems, through identifying their 
determinants and opportunities for modifying their course or manifestation, to 
testing and eventually implementing person-tailored interventions in routine 
clinical practice. There is one component that is essential to success at any 
stage – the ability to accurately detect a post-stroke cognitive disorder.  
Assessing cognitive function following stroke is in itself a challenging task. 
Before I refer to issues around the selection, feasibility, and applicability of 
assessment approaches, it seems important to consider a more fundamental 
challenge – defining vascular cognitive syndromes for the purpose of diagnosis. 
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1.3.3 Challenges to diagnosing neurocognitive disorders 
following stroke  
Traditionally, endorsed definitions of dementia primarily encapsulated features 
of Alzheimer’s disease, treating impairment in memory and continuing decline in 
cognitive function as core criteria for diagnosis (50). However, cognitive 
disorders of vascular origin are often characterised by deficits in attention, 
speed of information processing, and executive function, and do not necessarily 
progress over time (51, 52).The recognition of this gap in the conceptual 
approach to diagnosis has prompted much debate over developing and 
implementing definitions of “vascular cognitive impairment” and “vascular 
dementia” for both clinical and research use, with controversies regarding 
diagnosis, classification, and terminology present to this day (50, 53, 54).    
Overall, proposed criteria focus on the presence of a relationship between 
cognitive deficits and cerebrovascular disease, evidenced by focal neurological 
signs on examination (e.g. hemiparesis, dysarthria) and/or neuroimaging findings 
(presence of infarcts, lacunes, and white matter lesions) (55-57). A degree of 
uncertainty is inherent – pure vascular dementia is considered rare in an older 
adult population, with brain lesions of vascular origin possibly contributing to or 
merely co-occurring with the effects of ongoing neurodegenerative processes 
(38, 58). While there have been attempts to validate suggested diagnostic 
criteria for vascular cognitive disorders (59-61), consensus recommendations are 
still lacking, and a definite diagnosis can only be reached through including 
findings from post-mortem investigations (58). 
In relation to stroke, these challenges in the application of diagnostic labels 
have led some experts in the field to adopt a more pragmatic approach to 
defining subsequent cognitive disorders. Specifically, the term “post-stroke 
dementia” has been proposed for any dementia that develops following stroke, 
without imposing specific criteria regarding the underlying neuropathological 
process(es) (38). Within this framework, post-stroke dementia constitutes a sub-
type of: vascular cognitive impairment, vascular dementia, and post-stroke 
cognitive impairment. In view of the practical advantages, when referring to 
post-stroke cognitive disorders throughout my thesis, I apply a similar approach – 
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assuming a temporal relation between stroke and cognitive change, while 
recognising that the former does not necessarily act as the predominant causal 
factor.   
1.3.4 Assessment of post-stroke cognitive function 
1.3.4.1 Identifying cognitive disorders in a clinical context 
Early screening for cognitive deficits is recommended in all stroke survivors, 
although currently there is no consensus regarding an optimal approach to 
assessment (62). While the specific content of screening measures varies, they 
are generally designed to be brief and require relatively little training for 
correct administration (63). Typically, at least a few different cognitive 
functions are assessed, such as language, attention, or learning memory. 
However, rather than performance on individual tasks, it is the sum score that is 
of particular focus, serving as an indicator of global cognitive status. Deciding on 
the most appropriate screening tool from the many that are currently available 
will, at least in part, depend on the circumstances and setting.  
In the first hours and days following stroke, attending to a patient’s medical 
needs is likely to be prioritised over an assessment of cognitive function (62). 
Nonetheless, in interest of the former, it is necessary to recognise delirium to 
initiate appropriate interventions as early as possible (64, 65). Validated 
measures such as the 4 A’s Test (4AT) (66, 67) and the Confusion Assessment 
Method for the Intensive Care Unit (CAM-ICU) (68) combine relatively good 
accuracy with high feasibility in the stroke context, taking under five minutes to 
complete, and being suitable for patients with motor, visual, and speech 
impairments (69).  
In addition, some insight into a patient’s cognitive state in the hyperacute phase 
can be gained through initial neurological examinations. Despite not 
representing cognitive screening tools per se, the Glasgow Coma Scale (GCS) 
(70), National Institutes of Health Stroke Scale (NIHSS) (71, 72) or Canadian 
Neurological Scale (CNS) (73) all include items relevant to cognitive function 
(e.g. orientation, speech comprehension and production).  
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Once a patient is medically stable, a more comprehensive assessment can be 
considered, although feasibility is likely to remain a key concern (62). On one 
side, there is the issue of limited resources in terms of time, space, staffing and 
funds. On the other, there are factors relevant to the patient’s condition, such 
as becoming easily fatigued, experiencing distress, or being unable to complete 
certain cognitive tasks due to acquired deficits (e.g. drawing a clock with upper 
limb weakness, or object naming with a severe visual deficit) (74).  
The latter is an important issue even in relation to some of the most widely used 
screening tools for identifying cognitive impairment (75), such as the Mini-Mental 
State Examination (MMSE) (76) or the Montreal Cognitive Assessment (MoCA) 
(77). As these measures were not specifically designed for use in a stroke 
setting, it is important to interpret findings with caution, and potentially 
consider adjusting the originally determined cut-off values, so that chosen tools 
are more “fit for purpose” (78, 79). However, deciding on optimal cut-offs is in 
itself a considerable challenge, due to a common trade-off between two key test 
properties – sensitivity and specificity (80).  
Sensitivity refers to the proportion of individuals who have a certain condition 
that are correctly identified as having it (81, 82). Specificity relates to the 
proportion of individuals who while not having the condition are correctly 
classified as not having it (81, 82). Regardless of which test property is favoured, 
some negative consequences are to be anticipated. Poorer sensitivity entails a 
higher probability of genuine cognitive disorders being missed, and thus some 
individuals not receiving the follow-up and support they need; poorer specificity 
may lead to more individuals experiencing unnecessary distress and stigma due 
to an erroneous indication of an impairment, as well as misallocation of 
healthcare resources.  
Given the limitations of cognitive screening tools, the implications of 
misidentifying the presence vs. absence of cognitive disorders, and the dynamic 
process of post-stroke recovery, in a clinical context, findings from early, brief 
testing are not recognised as definitive or fulfilling a diagnostic purpose (83). 
Rather, they may serve to monitor for potential change in function, and inform 
initial care plan decisions, particularly regarding whether a more detailed 
cognitive assessment, involving use of a comprehensive neuropsychological test 
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battery, is recommended (83, 84). Such assessments are considerably longer, 
and require specialist training to conduct and interpret, entailing increased test 
burden for stroke survivors and health system costs. For these reasons, 
comprehensive neuropsychological assessments are offered to only selected 
individuals, with suspected cognitive problems (62, 75). 
Neuropsychological test batteries, comprising of multiple tasks, are designed to 
determine the presence and severity of deficits in specific cognitive functions, 
relative to population normative data (83, 85). This provides a more in-depth 
understanding of an individual’s unique cognitive profile, which may involve 
either single domain (e.g. within executive function) or multidomain (e.g. within 
learning memory and executive function) impairment. Findings from such an 
assessment can serve an important role in tailoring rehabilitation interventions 
according to individual needs (83).  
Although comprehensive neurological assessments are recognised as the gold 
standard for identifying and characterising cognitive deficits following stroke 
(62, 75), they are not the only source of information that needs to be considered 
for a clinical diagnosis of a mild or major neurocognitive disorder. As indicated 
in the DSM-5 criteria (6), other key aspects include a subjective concern of the 
individual or informant over a decline in cognitive function from previous status, 
and the effect of cognitive deficits on performing daily activities (8). It is 
important to note that these criteria are not stroke-specific, which can entail 
certain challenges. Specifically, it may be difficult to discern the impact of 
cognitive problems on day-to-day functioning and independence, as following 
stroke they are often accompanied by physical impairments, constituting 
another plausible cause of disability (38).  
1.3.4.2 Identifying cognitive disorders in research 
Reflecting clinical practice guidelines, current research recommendations 
advocate for all stroke trials to include an assessment of cognitive outcomes 
(86). This is suggested to involve a two-step procedure: i) an informant-based 
assessment to ensure study groups are well-matched in terms of pre-stroke 
cognitive status, and ii) a neuropsychological assessment, conducted between 
three to six months post-stroke. Regarding the latter, it has been proposed that 
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at a minimum the assessment should comprise a screening measure for global 
cognitive impairment (such as the MoCA) and additional brief tasks targeting 
attention and executive function (86).  
However, across the whole landscape of research around post-stroke cognition, 
there is much variability in assessment methods, suggesting that the choice of 
approach is likely guided by individual study aims, the setting, and potential 
challenges and limitations (87). Providing a feasible solution, a screening tool 
will often be the only measure used to discriminate between individuals with 
and without a post-stroke cognitive disorder (87, 88). Similarly, to at least 
partially reduce the resource burden associated with large multicentre follow-up 
studies, investigators may opt to conduct remote assessments (e.g. over the 
telephone or online), or even retrospectively derive data regarding presence of 
cognitive disorders from medical records. Further, in some studies the use of 
objective assessment methods will be replaced by self-report or informant-based 
questionnaires to determine cognitive outcomes (26).   
While in many cases a given assessment approach is simply viewed as a means to 
an end (the latter being the detection of a post-stroke cognitive disorder), in 
some research it is the method itself that is of primary interest. An example is 
provided by studies that investigate the accuracy of cognitive tests developed 
for use in the general population when applied specifically to stroke (69, 79). 
Other studies may focus on the development and performance of novel and/or 
stroke-specific methods. In recent years, this has not only involved investigations 
into direct assessments of cognitive function (e.g. 89, 90), but also the use of 
biomarkers, including metabolic, genetic, inflammatory and neuropathological 
factors (38, 91-93). 
Such studies, determining how well a measure can discriminate between 
individuals with and without a certain condition as compared to a reference 
standard, represent diagnostic research (94). This is one of two areas falling 
under the broader scope of prediction research, at the centre of which is 
estimating the probability of something presently unknown (95). The second 
area – prognosis research – is the focus of my next chapter, as a topic that is of 
key relevance to this thesis.   
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1.4 Summary 
Stroke significantly increases the risk of cognitive problems, which may have a 
profound impact on affected individuals, their families, and health and social 
care structures. To date, there is limited evidence in support of specific 
interventions to improve post-stroke cognitive function in the longer-term. 
Accurate detection of cognitive problems is an essential component of 
investigations that could eventually lead to the development and 
implementation of effective therapeutic strategies.  
There are, however, many challenges to assessing cognitive function following 
stroke, including limited resources and a consequent need for their 
prioritisation, difficulties experienced by stroke survivors in participating in 
assessments due to acquired impairments, and limited applicability of endorsed 
cognitive measures developed for use in the general population. Diagnostic 
studies contribute to the development of more appropriate and accurate 
methods for identifying post-stroke cognitive disorders, including tests that 
accommodate common deficits (e.g. visual impairments, hemi-spatial neglect, 
or aphasia), as well as the use of novel biomarkers.
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Chapter 2 Prognosis research: objectives, 
components, and advances in the area of post-
stroke cognition 
Having described concepts that are fundamental to my thesis as relating to 
cognitive function and stroke, I proceed to describing the context within which I 
address issues of interest – that of prognosis research. In this chapter, I firstly 
provide an overview of the types of investigations that prognosis research 
encompasses, with emphasis on their specific aims and relevant methodological 
approaches. I then present findings from prognosis studies focusing on post-
stroke cognitive outcomes, concluding with a reflection on current advances in 
this area of research. 
2.1 What is prognosis research? 
While diagnostic studies focus on conditions that are already present, but not 
yet detected, prognosis studies focus on the development of future outcomes 
(95). This sets a unique purpose for prognosis research – to address this risk of an 
unfavourable outcome so that future health can be improved (96). As outlined 
within the PROGnosis RESearch Strategy (PROGRESS) (96), the types of 
investigations that contribute to achieving this goal can be divided into four 
themes: i) fundamental prognosis research, ii) prognostic factor research (also 
referred to as predictor finding research), iii) prognostic model research, and iv) 
stratified medicine research. Evidence collected under earlier themes serves to 
inform investigations under subsequent ones. 
2.2 Fundamental prognosis research 
This first theme in prognosis research describes the natural history and clinical 
course of a health condition (97). Its aim is to estimate the “baseline risk” for a 
particular outcome in a specific population, which typically involves an 
observational approach (98). Studies within this theme allow to answer such 
questions as: “On average in the UK, what is the risk of death within five years 
of heart failure?” or “How likely is the development of delirium among acute 
stroke unit inpatients?”. Fundamental prognosis research also provides grounds 
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for comparing baseline risks across different clinical contexts (96), for example, 
to determine whether five-year mortality rates following heart failure differ 
between hospitals, countries or across decades. Such findings may provide 
important insights into how specific health policies and aspects of local routine 
care shape patient outcomes, and aid in identifying potential targets for system 
improvement.    
2.3 Prognostic factor research 
Clinical contexts constitute only one of many types of variables that can be 
associated with the development of a future health-related outcome. Identifying 
these variables is the focus of the second theme – prognostic factor research 
(99). Different approaches can be applied to investigate this topic, with the 
chosen method likely to impact on how much confidence can be placed in the 
findings obtained. Evidence from studies estimating the correlation between a 
single presumed prognostic factor (candidate predictor) and an outcome of 
interest, with both assessed at the same point in time (cross-sectional design), is 
considered suitable only for hypothesis-generating purposes (97). This is due to 
the significant limitations such an approach entails.  
Firstly, the nature of the association between two variables can change over 
time. For example, evidence suggests that in late life high blood pressure is 
associated with a reduced risk of dementia (100). Recognising this relationship 
would not, however, be applicable to estimating risk of future dementia in mid-
life, as here the association is reversed – high blood pressure increases the risk 
of poor future cognitive outcome (100). 
Secondly, in a univariable analysis, the effects of other variables are 
unaccounted for, which can lead to spurious findings, and thus erroneous 
conclusions regarding studied associations. This issue is illustrated by a 
commonly observed relationship between female sex and unfavourable health 
outcomes. In some cases, the estimated association reflects a genuine 
phenomenon, driven by biological or socio-cultural mechanisms, such as the 
finding that obese women are at greater risk of heart failure than obese men 
(101). However, such associations may also be driven by age – as women on 
  38 
average live longer than men (102), the oldest participants in a study sample are 
more likely to be female. 
For the above reasons, research evidence regarding prognostic factors is 
considered more reliable where it stems from multivariable analyses of 
longitudinal data (103). This requires conducting observations on at least two 
different timepoints, where information regarding the outcome is preferably 
collected later than data on multiple candidate predictors. The latter are 
simultaneously included in an analysis, allowing to quantify their independent 
associations with the outcome, that is, the direction and strength of their 
relationship when the influence of other, potentially relevant factors is 
controlled for.  
It is important to note that while similarities exist, such an investigation is not 
equivalent to aetiological research. The latter aims to explain the cause of an 
outcome, while the purpose of prognosis research is solely to predict it; as such, 
there is no need to determine whether observed associations are causal or non-
causal (103, 104). Nonetheless, identifying causal factors is also recognised as 
being of particular value in the context of prognosis research. One reason is that 
causal factors may serve as targets for intervention, assuming that it is possible 
to improve the outcome through their modification. Where the variable is non-
modifiable, e.g. as generally is the case for genetic factors, it may still be highly 
relevant to predicting differential treatment responses – a property of key 
interest in the area of stratified medicine (105).  
Moreover, where the relationship between a factor and outcome is causal, based 
on biological (or other) pathways, it is more likely to be consistently present 
across different populations, entailing enhanced generalisability of research 
findings (106). While the latter is of concern in any study, specifically for 
prognostic model research, generalisability is a quality that essentially 
determines its value (107).  
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2.4 Prognostic model research 
Prognostic model research involves three phases: model development, external 
validation with potential updating, and investigation of the impact of 
implementing a prognostic model in clinical practice (106). Conceptually, this 
multi-stage process is not intended to be finite – it is argued that model 
validation and updating should be ongoing, ensuring applicability throughout 
varying contexts and changing times. This notion, combined with a need for 
relatively large sample sizes from different settings, and longitudinal study 
designs, entails that prognostic model research is time-consuming and resource-
intensive. As such, it seems unsurprising that, in many cases, research work 
relating to a prognostic model does not extend past its initial development 
(106).  
2.4.1 Model development 
In prognostic model development studies, variables identified as associated with 
an outcome through prognostic factor research are combined to estimate the 
probability for an individual to develop that outcome (103, 106). It is noteworthy 
that a prognostic model may be identical to a multivariable model used for the 
exploration of candidate predictors. Moreover, both types of investigations – 
relevant to prognostic factors and prognostic models – are often conducted in a 
single study. Consequently, it may be difficult to distinguish between the two 
prognosis research themes.  
A key difference lies in the focus of a study (97). In prognostic factor research, 
of particular interest is quantifying the relationship between individual variables 
and a future outcome. In prognostic model research, the focus is on identifying a 
set of factors, which collectively can accurately estimate the likelihood of the 
future outcome. The final result of such work can be referred to as a clinical or 
risk prediction model, or a prognostic rule, index or score (106). It may be 
presented directly in the form of a multiple regression equation: 
Ln[p/(1-p)] = α + β1X1 + β2X2 + β3X3 + β4X4… 
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This formula applies to logistic regression, used for binary outcomes, where Ln is 
a natural log, p – the estimated probability of the future outcome, α – the 
intercept, βN – the estimated coefficient that reflects the association between a 
predictor and the outcome, and XN – the value of the predictor.  
Alternatively, based on the specified equation, researchers may aim to develop 
a simplified, more user-friendly tool. This will often involve rounding up 
estimated predictor coefficients to integers to produce a risk score, where 
points are assigned according to the presence/value of included risk factors and 
then summed. The total score can then be related to pre-determined cut-offs, 
indicating the associated level of risk for an unfavourable outcome.  
An example of such an approach is illustrated by ASTRAL – a risk score developed 
for the prediction of an unfavourable functional outcome (functional 
dependency) following acute stroke (108). The incorporated predictors and 
scoring system are presented in Table 2-1. As reported by the authors, example 
scores of 23, 31, and 38 correspond to a 20%, 50% and 80% likelihood of an 
unfavourable outcome, respectively.  
Table 2-1 ASTRAL variables and scoring system. 
Variable Level/category Score 
Acute glucose <3.7 or >7.3 mmol/L 1 
Age Per every 5 years 1 
Any stroke-related visual field defect Yes 2 
Level of consciousness Decreased 3 
Symptom onset to treatment time >3 hours 2 
Stroke severity as per NIHSS Per every point 1 
 
The same publication also demonstrated another approach to framing a 
prognostic rule – through use of a graphical representation. Here, this involved a 
display of multiple, coloured charts. Different charts applied to different 
combinations of risk factors, while each colour corresponded to a different 
probability of the future outcome (e.g. light blue: 30 to 39%, dark red – 80 to 
89%). 
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2.4.1.1 Assessment of prognostic model performance 
The process of prognostic model development should also involve an assessment 
of the model’s performance (106). Although some indication is provided by the 
amount of variance in the outcome explained by the chosen set of predictors, it 
is also essential to estimate model discrimination and calibration (109). 
Discrimination relates to the ability of a prognostic model to distinguish between 
individuals who develop the outcome and those who do not (110). The primary 
method for assessing this property is the concordance statistic (C-statistic), 
which for binary outcomes corresponds to the area under the receiver operating 
characteristic curve (AUROC) (109, 111). Possible values range from 0.50, 
indicating a discriminatory ability equivalent to chance, to 1.00, indicating 
perfect discrimination (112).  
Calibration refers to the level of agreement between observed and predicted 
outcome probabilities (113). It is preferably assessed through inspection of 
calibration plots (113). The results of the Hosmer-Lemeshow test (114) may also 
be reported to complement graphical evaluation, yet as a stand-alone measure 
it is considered inappropriate (despite often being used in this capacity) (111). 
The test has been recognised to have limited power to detect poor calibration, is 
oversensitive in large samples, and cannot inform about the direction of 
miscalibration (107) 
The assessment of discrimination and calibration is a key component of model 
validation, which at the stage of development is either apparent or internal 
(106, 115). In apparent validation, performance is evaluated directly in the 
dataset that was used for model development. Findings suggesting low 
prognostic ability immediately indicate potential issues in the derivation 
process. At the same time, encouraging results are considered as insufficient 
evidence of a model’s prognostic value. This is because obtained performance 
estimates are likely to be overoptimistic, as the coefficients reflecting 
predictor-outcome associations were optimised for that specific data (109, 116). 
Methods applied for internal validation are intended to at least partially correct 
for this issue. One technique – split-sample – involves dividing the initial study 
sample into separate development and validation cohorts (117). This approach, 
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however, is criticized for the loss in statistical power it inherently entails. 
Therefore, current recommendations advise employing data re-use techniques, 
one of which is an extension of the split-sample method – cross-validation (109). 
In this case, the sample is randomly divided into a number of equal-sized groups 
(the number being specified by the researcher) and one group serves as a 
validation set, while all remaining groups are involved in model development 
(117). The process is repeated multiple times until every group served as a 
validation set once. Model performance is estimated as an average across all 
repetitions. For example, a 10-fold cross validation involves 10 repetitions, 
where for each one a different group, constituting 10% of the overall sample, 
will be used for validation, and the remaining 9 groups, constituting 90% of the 
sample, will be used for model development.  
A second data re-use technique, currently recognised as the most efficient 
approach to internal validation, is bootstrap resampling (117). Bootstrapping 
mimics the process of generating a sample from an underlying population. 
Random samples are drawn with replacement from the initial study cohort, 
generating bootstrap samples of the same size. Some study participants may not 
be included in a specific bootstrap sample at all, while others may reappear in a 
generated dataset multiple times. In Table 2-2, I presented a basic example of 
what bootstrap samples may look like, using a single variable (height) for ten 
participants.  
Table 2-2 Illustration of four bootstrap samples drawn with replacement from the 
height of ten participants. 
Sample (N = 10) Participant height (cm) 
Original  162, 183, 177, 172, 155, 164, 171, 161, 188, 158 
Bootstrap 1 183, 155, 164, 171, 188, 158, 155, 183, 158, 171 
Bootstrap 2 162, 177, 172, 155, 171, 177, 177, 162, 155, 172 
Bootstrap 3 172, 164, 161, 188, 158, 162, 155, 183, 161, 164 
Bootstrap 4 183, 155, 155, 183, 171, 171, 188, 155, 172, 183 
The prognostic model is developed in the bootstrap samples and then validated 
in the original dataset (118). The decrease in model performance between the 
bootstrap and the original samples provides an estimate of optimism – 
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subtracting it from the apparent performance indicates what predictive ability 
can be expected from the model in future cohorts. However, it is only through 
external validation that the latter can be truly determined.    
2.4.2 External validation 
Before describing this stage in prognostic model research, it is important to note 
that some researchers distinguish a form of performance evaluation that in 
terms of stringency is recognised as intermediate between internal and external 
validation (119, 120). This is temporal validation, where the model is tested in a 
new sample of participants, recruited at a later period from the same setting 
(e.g. hospital site) as the development sample. Despite including different 
individuals, the case-mix is plausibly similar to the original cohort, as the 
validation sample is still drawn from the same underlying population. As follows, 
there will remain doubts as to how well the model will perform in a different 
context.  
Quantifying the latter is the goal of external validation, which allows to verify 
the generalisability of a prognostic model (120, 121). The extent of any 
conclusions will depend on the form of external validation. A common approach, 
referred to as geographical validation, essentially involves applying the model to 
a sample from a different location (122). This in itself encompasses a range of 
options, from testing at a different centre within the same region, to applying 
the model in a sample from a different country (or continent), entailing effects 
of cultural, ethnic and health system dissimilarities.  
Another approach, termed methodologic validation, allows to determine 
whether prognostic accuracy is maintained despite using different methods of 
collecting data and inconsistencies in operationalisation of variables (121). Any 
challenges in this regard are particularly likely to be exposed when the model is 
tested by different, independent investigators, with some factors plausibly more 
robust to variability in assessment than others. For example, while hardly any 
inconsistencies can be expected in the measurement of age, concluding on 
whether a participant has hypertension may differ depending on whether one 
relies on a diagnosis present in existing medical records, prescription of 
antihypertensive medication, or acute measures of blood pressure. 
  44 
External validation can further focus on differences regarding population 
characteristics (121). These can pertain to the prevalence of risk factors, as well 
as attributes of the condition that constitutes the outcome – its incidence, 
degrees of severity across the sample, or its clinical course. Finally, the 
generalisability of a prognostic model can be evaluated in relation to differences 
in follow-up duration, that is, the length of the interval between a specific 
baseline event (e.g. having a stroke or receiving a cancer diagnosis) and 
outcome assessment (121).  
It is important to note that while these distinctions provide a useful framework 
for describing and understanding the multiple aspects of prognostic model 
generalisability, it is likely that an external validation will differ from the model 
development study on more than one account. For example, if a prognostic 
model is developed in a sample of hospital inpatients admitted with myocardial 
infarction in Scotland, subsequent validation in a similar population in China 
(i.e. with the same diagnosis, recruited from a comparable clinical setting) 
would likely entail more than just geographical diversity, but also variability in 
prevalence of risk factors, their measurement, and the clinical course of the 
condition (e.g. due to differences in routine clinical care).  
2.4.3 Prognostic model updating 
If on external validation the performance of a prognostic model is found to be 
unsatisfactory, it may be potentially improved through use of an updating 
method. This can simply involve model recalibration. In cases where a decline in 
prognostic accuracy is attributed to a difference in the incidence of an outcome 
as compared to the development sample, the average predicted probability can 
be adjusted to align with the currently observed event rate (equivalent to 
updating the intercept) (123, 124). Where it appears that estimated predictor 
coefficients in the original model were overfitted, these can also be adjusted – 
by a single adjustment factor, assuming that the relative effects of predictors 
are similar, but the absolute effect sizes ought to be either larger or smaller 
(equivalent to updating the intercept and slope) (123, 124). To clarify, 
overfitting is a common issue, where maximising adherence of a developed 
model to the unique characteristics of a used dataset leads to increased model 
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complexity, overoptimistic initial performance estimates, and limited 
applicability to new samples (125).   
If recalibration alone is insufficient to achieve an expected level of prognostic 
performance in a new sample, investigators may consider replacing or adding 
model predictors. The decision-making process can be guided by different 
rationales. One involves promoting methodologic generalisability, by substituting 
variables associated with high inter-rater variability with ones that can be 
measured more reliably (106). Another is based on a previously mentioned 
argument, favouring the inclusion of prognostic factors with a causal relationship 
with the outcome, and thus that are more likely to show consistent associations 
across different contexts.  
Thirdly, the development and increasing availability of new techniques may lead 
to identifying novel prognostic factors for addition to existing models, or can 
provide a more accurate measurement of variables that had been previously 
considered, for example, as in the case of rating white matter changes based on 
magnetic resonance brain imaging as compared to computed tomography (126). 
It is also this rationale that seems to strongly justify the abovementioned 
recommendation for prognostic models to be continuously updated.  
2.4.4 Prognostic model impact 
Studies in this area aim to determine whether the implementation of a 
prognostic model leads to better outcomes than are achieved through routine 
clinical practice (127). Such investigations focus on improvements in individual 
outcomes or the cost-effectiveness of care, where change is attributable to the 
influence of prognostic model use on clinical decision-making (106). This is 
preferably assessed in randomised controlled trials (128).  
A fundamental understanding in prognostic model impact research is that even 
for a model with excellent prognostic ability to be of benefit, it must first lead 
to a change in clinician behaviour (127). One important issue in this context 
relates to feasibility. Collecting predictor information may be recognised as too 
costly or time consuming in a routine care setting, or unacceptable to the target 
population (e.g. due to the invasiveness of a procedure), while the whole 
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process of estimating individual outcome risk may be viewed as too complex or 
confusing. Other concerns may be over practicing “cookbook medicine”, with 
prognostic rules considered too generic, and their use undermining a 
comprehensive, individual approach to patient needs (128, 129). Clinicians may 
moreover doubt the tools validity and accuracy, and assume that clinical 
judgement is overall superior (128). 
2.5 Stratified medicine research 
2.5.1 What is stratified medicine? 
From both research and clinical perspectives, people tend to be grouped on the 
basis of sharing a few particular traits that are of importance in a specific 
context, e.g. women who are pregnant, children with asthma, or older adults 
with arthritis. However, in relation to many other characteristics, including 
individual risk factor profiles, there may be much heterogeneity within a 
conceptualised group. This can entail variability in the clinical course of a 
condition, the likelihood of particular future outcomes, and individual treatment 
response. Taking this into consideration is the cornerstone of stratified 
medicine, which aims to maximise the beneficial impact of healthcare through 
targeting interventions according to the clinical characteristics of specific 
patient subgroups (105).  
At a basic level, stratifying the use of treatments may be guided by an 
individual’s absolute risk for an unfavourable outcome (105). When the relative 
effect of an intervention is found to be similar across all patients, the absolute 
reduction in the probability for the unfavourable outcome will be greatest for 
those who were initially at highest risk. For example, if a treatment is 
associated with a relative risk reduction in stroke incidence by one third (33%), 
for a person whose baseline risk of having a stroke was estimated at 60%, this 
will translate to an absolute risk reduction of 20%, while for a person with an 
initial risk at 15% - to an absolute risk reduction of around 5% (130). In cases 
where an intervention is costly or entails nonnegligible side effects, it may be 
offered only to those who are likely to benefit the most.  
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A second approach involves stratifying treatment based on the presence of a 
factor (or factors) that may influence the effect it has (105). This can relate to 
both potential benefits of an intervention, as well any harms. For example, 
there is strong evidence supporting use of oral anticoagulation in patients with 
atrial fibrillation to prevent embolic stroke, however, use of anticoagulants also 
predisposes to bleeding (131). While for many individuals the protective benefits 
will outweigh the risks, for those with a high baseline probability of bleeding, 
such as in cases of high alcohol consumption or liver disease, the danger of 
major haemorrhage may tip the scales in the opposite direction (132).  
2.5.2 The role of prognosis research in stratified medicine 
Prognosis research contributes to stratified medicine on multiple levels (105). 
Firstly, it may inform prioritisation of topics for investigation, for example, by 
indicating high heterogeneity in the clinical course and prognosis for a certain 
condition (as in systemic lupus erythematosus (133)), or significant 
interindividual differences in the metabolism of a particular drug (134). 
Secondly, prognosis research is relevant to both abovementioned approaches to 
treatment stratification: on one hand, building the necessary evidence base to 
accurately estimate the baseline risk of an unfavourable outcome, and on the 
other, leading to identification of prognostic factors that can predict differential 
treatment response.  
Regarding the latter, in some cases decisions regarding the appropriateness of a 
specific treatment may be guided by the presence of one particular factor. An 
example of such a scenario is often illustrated by the discovery that trastuzumab 
significantly improves disease-free and overall survival in women with breast 
cancer who have a positive human epidermal growth factor receptor 2 (HER-2) 
gene status (135, 136). At the same time, compared to women with a negative 
HER-2 status, they benefit less from other, standard cancer treatments, and 
have a poorer baseline prognosis (without use of trastuzumab). 
In other cases, therapeutic decision-making may be aided by use of validated 
prognostic rules, involving an assessment of multiple factors. Returning to the 
above example on atrial fibrillation management, as a first step, current 
recommendations suggest that patients are assessed for their risk of stroke 
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based on the CHA2DS2VASc score (131, 137, 138). Where the risk is very low, 
anticoagulation treatment may be withheld to avoid unnecessary exposure to 
adverse effects of medication, as well as incurring healthcare expenses. Where 
the risk is considerable, the next step is to assess the probability of bleeding 
using the HAS-BLED score (139). Patients at high risk of both stroke and bleeding 
are candidates for an alternative, invasive intervention, involving closure of the 
percutaneous left atrial appendage (140). 
Finally, prognostic research may assess the impact of newly introduced 
approaches to treatment stratification. Similarly as in the context of prognostic 
model impact studies, such investigations can focus on: clinician adherence and 
changes to behaviour, including barriers and facilitators to implementing a 
specific approach; the influence on patient outcomes, including both beneficial 
and adverse effects; and cost-effectiveness. 
2.6 Prognosis research into post-stroke cognitive 
outcomes 
Although this may not have been evident from my formulation of the topic, I 
included some examples of research in this area in Chapter 1. The studies I 
referenced can be classed as pertaining to the theme of fundamental prognosis 
research, leading to such observations as: “one in four stroke survivors are at 
risk of developing delirium in an acute setting” (21) or “one in ten individuals 
are likely to develop new dementia within one year of stroke onset” (23).  
The second statement, relating to post-stroke dementia, is derived from a highly 
influential publication (cited nearly 1500 times) that is also of particular 
relevance to the second prognosis research theme – identification of prognostic 
factors. This is a systematic review and meta-analysis from 2009 by Pendlebury 
and Rothwell, who reviewed 73 papers, involving a total of 7511 stroke survivors 
(23). 
2.6.1 Predictors of post-stroke cognitive impairment 
Alongside determining the incidence of both pre- and post-stroke dementia, the 
authors of the review quantified pooled effects for multiple risk factors, both 
pre-dating the stroke, as well as specific to it. Among relevant demographics 
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were older age, female sex, low educational attainment, and being of either 
black or Hispanic ethnic origin. In relation to prior health-related conditions, the 
authors determined associations with diabetes mellitus, atrial fibrillation, 
previous stroke, disability, prior cognitive decline, and neurological changes 
identified through imaging – leukoaraiosis (white matter abnormalities) and 
cerebral atrophy.  
Regarding features of the index stroke, the risk of developing dementia was 
reported to increase with greater severity, greater infarct volume, left 
hemisphere lesions, and haemorrhages (as compared to ischaemic strokes). The 
review further indicated the relevance of acute symptoms and complications, 
including: aphasia, incontinence, seizures, confusion, hypotension, and hypoxic 
ischaemic episodes. Finally, individuals who either had multiple infarcts or a 
recurrent stroke were approximately 2.5 more likely to develop dementia.  
In comparison, two recent reviews of prognostic factors for post-stroke cognitive 
impairment presented a narrower focus, mainly relating to novel biomarkers 
(141, 142). Reflecting a narrative approach, one publication specifically 
examined the evidence for inflammatory (e.g. C-reactive protein, interleukin 6 
and 10), metabolic (e.g. homocysteine, retinoic acid), growth factor (e.g. brain-
derived neurotrophic factor, insulin-like growth factor), oxidative damage (e.g. 
8-hydroxydeoxyguanosine, malondialdehyde), and genetic biomarkers (e.g. 
cystatin C, calpain-10) (141). In their conclusions, the authors highlighted that 
accounting for these factors can improve the accuracy of outcome prognosis. At 
the same time, they suggested that to this end, combining information on 
multiple biomarkers may be necessary, and that present findings require further 
support from large-scale clinical trials.  
Interestingly, the authors of the other, in this case systematic review (including 
66 papers), concluded that there was no convincing evidence to indicate the 
prognostic value of genetic or biochemical markers, with considerable 
inconsistencies in results across selected studies (142). Their findings did, 
however, support the relevance of cerebral atrophy to the prognosis of post-
stroke cognitive function, as previously reported by Pendlebury and Rothwell 
(23).  
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2.6.2 Predictors of post-stroke delirium 
Research findings suggest that there is some overlap between prognostic factors 
for delirium and those identified as relevant to cognitive impairment following 
stroke, despite considerable differences in nature and clinical course of the two 
types of disorders. This perhaps seems unsurprising, given that both arise from a 
background of neuropathophysiology and are interrelated, although the nature 
of this relationship remains poorly understood (143). As identified in a recent 
scoping review of 25 publications (144), examples of shared predictors for post-
stroke delirium and dementia that were reported across multiple studies 
included: older age, atrial fibrillation, previous stroke, prior cognitive decline, 
leukoaraiosis, cerebral atrophy, and left hemisphere and haemorrhagic index 
strokes.  
Other risk factors seemed specific to delirium, although in some cases it is 
difficult to discern whether this reflects a genuine lack of associations with post-
stroke cognitive impairment, or whether these variables have been rarely 
considered as candidate predictors for the latter. These factors included: 
metabolic disturbances (e.g. abnormal levels of sodium, glucose, urea nitrogen, 
and capillary oxygen saturation), high total number of medications, 
anticholinergic medications, and acute deficits and complications, namely, 
dysphagia, visuospatial neglect, and chest and urinary tract infections.   
2.6.3 Reflection on the current stage of research  
Reviews such as the ones I describe above (for other examples see: (39, 145-
147)) seem now invaluable for researchers and clinicians with an interest in 
prognostic factors for post-stroke cognitive outcomes. Of course, as in any 
research area, combining findings from multiple studies provides a higher level 
of evidence (148, 149). However, in addition to this argument, an attempt to 
draw conclusions on an individual basis from the full scope of existing 
publications on this topic could quickly become overwhelming. 
In contrast, studies on post-stroke cognition within the next prognosis theme – 
relating to prognostic models - appear much less evident in the current research 
landscape. A 2017 review described three prognostic rules for prediction of post-
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stroke cognitive impairment, two of which specifically focused on development 
of dementia (150). However, in keeping with the narrative nature of the 
publication, there was no explicit mention of how the existing literature was 
searched, or why these particular development studies were selected. Moreover, 
post-stroke delirium was not within the scope of the review. As follows, the 
stage of progress in prognostic model research for post-stroke cognitive disorders 
seems at present unclear. I address this gap in the following chapter.  
2.7 Summary 
The ultimate purpose of prognosis research is to improve future health 
outcomes. Contributing to achieving this goal is a wide scope of investigations, 
representing four main themes: fundamental prognosis research, prognostic 
factor research, prognostic model research, and stratified medicine research. 
Many studies on post-stroke cognition have been conducted within the first two 
of these themes, providing insight into the natural history of cognitive change, 
the baseline risks of developing cognitive disorders, and factors that are 
associated with the latter. Currently, much less evident are examples of 
research pertaining to the third theme, for which the first objective is to 
combine information on multiple prognostic factors to quantify individual 
prognosis.
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Chapter 3 Prognostic rules for predicting 
cognitive outcome following stroke: 
A systematic review 
As I presented across the two previous chapters, to date, many studies have 
been conducted on post-stroke cognition within the first two prognosis research 
themes, as distinguished in PROGRESS – fundamental prognosis and prognostic 
factor research. The purpose of this chapter is to gain a better insight into 
current advances within the subsequent theme, relating to prognostic model 
research. To this end, I conducted a systematic review of prognostic rules for 
predicting cognitive impairment and delirium following stroke. My findings made 
an important contribution to informing the aims and design of subsequent 
studies, included as part of this thesis. This chapter is an adaptation of my 
published work (151).  
3.1 Introduction 
Increasing global prevalence and immense personal and societal costs of 
acquired cognitive disorders have led policymakers, researchers, and clinicians 
to prioritise identification of individuals at high risk. As a result, many 
prognostic rules for predicting cognitive impairment and decline have been 
developed in the general population, with a recent systematic review on this 
topic having identified 61 (152). The authors found the following predictors to 
be included across several rules: age, sex, education, physical activity, alcohol 
intake, body mass index (BMI), diabetes, systolic blood pressure, cholesterol 
levels, cardiovascular disease, depression, apolipoprotein E gene (APOE) status, 
and baseline performance on cognitive tasks.  
Nearly half as many (27) prognostic rules have also been reported for prediction 
of delirium in older adult inpatients (aged over 60) (153). Across models that had 
been externally validated, the most frequently incorporated predictors were: 
age, pre-existing cognitive impairment, sensory impairment, functional 
disability, and severity of the acute illness.  
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Considering the predictors listed above, it seems that many of these variables 
are likely to remain relevant to the development of cognitive disorders following 
stroke. Nonetheless, there are strong arguments for creating dedicated 
prognostic rules for use in this clinical population. These include: different 
prevalence rates of common risk/protective factors; the importance of unique 
predictors, specific to the index stroke and consequent treatment; and practical 
considerations relevant to the acute setting, where some data may be difficult 
to collect (e.g. where involving an extensive assessment of function), while 
other information becomes easily accessible (e.g. through conducting routine 
blood tests). Results from a recent study provide further support for this notion 
(154). Specifically, the authors found that applied in a sample of nearly 1300 
stroke survivors, the discriminatory power of three externally validated 
prognostic rules developed for use in the general population was poor             
(C-statistic ranging from 0.53 to 0.66).  
Through scoping the literature, I concluded that there appeared to be no 
published systematic review addressing tools for individual cognitive outcome 
prognosis following stroke. To fill this gap, assisted by other researchers, I 
identified, described, and appraised existing prognostic rules for predicting post-
stroke cognitive impairment and delirium (152). In assessing rule performance 
and utility, I considered the development process, and any external validation 
and impact studies.  
3.2 Methods 
This review is based on a pre-registered protocol, available on the PROSPERO 
International Prospective Register of Systematic Reviews (registration number: 
CRD42020170428). In its design, conduct and reporting, I followed the Checklist 
for critical Appraisal and data extraction for systematic Reviews of prediction 
Modelling Studies (CHARMS) (155) and Preferred Reporting for Systematic Review 
and Meta-Analyses (PRISMA) guidelines (156). The completed PRISMA checklist is 
presented in Appendix 1. Together with another researcher (KM), trained and 
experienced in conducting systematic reviews, we independently completed all 
aspects of study selection, data extraction and critical appraisal. We discussed 
and resolved disagreements through consensus. Where an agreement could not 
be reached, we consulted a third, senior researcher (TQ).  
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3.2.1 Search strategy 
We searched four electronic databases from inception to November 13, 2019: 
MEDLINE (via OVID), EMBASE (via OVID), PsycINFO (via EBSCO), and CINAHL (via 
EBSCO). I developed the search strategy (presented in full in Appendix 2) in 
consultation with a Cochrane Information Specialist, based on validated search 
filters (157-160). For all databases, the search involved terms relevant to stroke, 
cognition and prognosis, combined with the Boolean operator AND. I applied 
limits to retrieve only human studies published in English. To complement the 
database search, we additionally screened reference lists of relevant reviews. 
Based on publications identified through both procedures, we conducted 
backward and forward citation searches, the latter using Google Scholar.  
3.2.2 Study selection 
We screened titles and abstracts using the Rayyan Qatar Computing Research 
Institute online application (161). We applied intentionally broad inclusion 
criteria, aiming to identify publications reporting on the development, validation 
or impact assessment of prognostic rules for any global post-stroke cognitive 
outcome.  
We included full papers, published in peer-reviewed journals. Eligible 
development studies recruited adult participants with a clinical diagnosis of 
ischaemic or haemorrhagic stroke. In relation to design, we included prospective 
cohort, retrospective cohort and case-control studies. Studies that self-
identified as cross-sectional were eligible if predictor data related to an earlier 
time-point than the outcome, e.g. with information on input variables extracted 
from medical records. Randomised control trials were considered for inclusion if 
a prognostic model had been developed in the control arm or the effect of the 
intervention was accounted for. Regarding outcomes, we included studies 
applying one or more of the following assessment methods: (i) validated brief 
screening tools; (ii) neuropsychological batteries; (iii) expert individual or 
consensus diagnosis, using recognised medical classification criteria.  
We excluded studies involving survivors of subarachnoid haemorrhage, due to 
differing pathophysiology, clinical course, and risk of unfavourable outcomes. 
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Further, we excluded case studies, as these could not fulfil data and analysis 
requirements for derivation of prognostic models. We considered rules designed 
to predict outcome in one specific cognitive domain (e.g. language or spatial 
attention) to be beyond the scope of this review. We applied no limits based on 
study setting, follow-up duration, or type of incorporated predictors. In the final 
stage, we excluded publications that did not provide a method for estimating 
individual outcome probability (e.g. using a mathematical formula, graphical 
tool or online calculator). 
In relation to validation and impact studies, we applied only two inclusion 
criteria. Firstly, we required the availability of a published paper describing the 
development of the considered prognostic rule. Secondly, the study sample 
needed to be comparable to the derivation cohort (i.e. a population of adult 
stroke survivors).  
3.2.3 Data extraction 
We used a pre-specified, piloted proforma to extract data from selected 
prognostic rule development studies, including information on: study setting, 
development sample characteristics, predictor and outcome variables, methods 
of model derivation and validation, and measures of prediction rule 
performance. The latter was also of primary interest in relation to external 
validation studies. Where relevant information had not been reported, yet may 
have been assumed to be easily available (e.g. regarding study setting), we 
contacted the study authors, requesting additional details.  
For recording prognostic rule validation strategies, we distinguished four levels 
(as I described in sections 2.4.1.1 and 2.4.2 of Chapter 2), listed in order of 
increasing stringency (119): 
1. apparent validation – predictive ability is assessed directly in the 
derivation cohort; 
2. internal validation – the initial dataset is split or data re-use techniques 
are applied, such as cross-validation or bootstrapping, to quantify 
overfitting and adjust for optimism in estimates of model performance; 
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3. temporal validation – performance is evaluated in a sample of participants 
recruited subsequently from the same centre(s), independently of the 
original data; 
4. external validation – predictive ability is assessed in new and independent 
data, collected from an appropriate participant population in a different 
centre, sometimes also by different investigators.  
Among measures of performance, we prioritised estimates of discrimination and 
calibration, as properties that are necessary (although not sufficient) to ensure 
practical value of prognostic tools (109). To aid interpretation of reported 
estimates of discriminatory power as reflected by AUROC values, we applied the 
following rule of thumb: <0.51 – of no value/equivalent to chance; 0.51 to 0.69 – 
poor; 0.70 to 0.79 – fair; 0.80 to 0.89 – good; 0.90 to 0.99 – excellent; 1.00 – 
perfect (162). 
In cases where assessment of discrimination and/or calibration was not 
reported, we sought information on any alternative measures of prognostic rule 
performance. This particularly involved classification measures, such as: 
sensitivity, specificity, positive predictive value and negative predictive value.  
3.2.4 Quality assessment 
We assessed risk of bias for each included study using the Prediction model Risk 
of Bias Assessment Tool (PROBAST) (95). The tool comprises four domains: 
participants, predictors, outcome and analysis. Domains are appraised 
separately and then considered jointly to make an overall judgement. Overall 
risk of bias is concluded to be high if rated as high for at least one domain. 
PROBAST additionally incorporates an assessment of study applicability - three 
domains (with the exclusion of analysis) are judged based on their relevance to 
the population and settings targeted by the review. I had previously described 
some of the key considerations involved in assessing quality of prognostic studies 




Following deduplication, we initially screened 16,828 titles and abstracts (Figure 
3-1). From publications considered in full-text review, we included 10 studies. 
We identified no additional papers through backward or forward citation 
searching. All relevant studies presented the development of a prognostic rule 
(two alternative rules in one case), with only one including a report on an 
external validation. As follows, we found no independent external validation 
publications, or studies quantifying the impact of using a prognostic rule in 
practice.  
In total, 3143 participants from seven different Asian and European countries 
were involved in the development of identified prognostic rules. On average, the 
rules consisted of five input variables (range: 3 – 7). Predicted post-stroke 
outcomes included any form of global cognitive impairment, dementia and 
delirium. For all studies, we rated the overall risk of bias to be high.  
Due to differences in clinical course, considered risk factors, and in turn – 
related modelling challenges – I have described prognostic rules for cognitive 
impairment and delirium separately. Features of identified studies are 
summarised in Table 3-1, while Table 3-2 presents characteristics of participant 
samples. Table 3-3 includes information on properties of the 11 prognostic rules, 
with Table 3-4 providing a general overview of types of incorporated predictors.  
Table 3-5 presents risk of bias ratings, using a “traffic light” colour code. 






Figure 3-1 Flowchart of study selection and inclusion process. 
 
Records identified through 
database searching  
(N = 22,465) 
Additional records identified 
through other sources  
(N = 1) 
Records after duplicates removed  
(N = 16,828) 
Records screened 
(N = 17,390) 
Records identified from 
reference lists and 
forward citation searching  
(N = 562) 
Full-text articles 
assessed for eligibility  
(N = 355) 
Studies included  
(N = 10) 
Records excluded 
(N = 17,035) 
Full-text articles excluded  
(N = 345) 
•analysis of predictor-outcome 
associations without providing 
a prognostic rule (N = 185) 
•not a primary study in peer-
reviewed journal (N = 122) 
•outcome not related to global 
cognitive status (N = 19) 
•not exclusively participants with 
stroke (N = 9) 
•not a prognostic study (N = 5) 
• single predictor (N = 4) 
• full text unavailable (N = 1) 
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3.3.1 Prognostic rules for cognitive impairment 
3.3.1.1 Overview 
Seven studies addressed the probability of developing post-stroke cognitive 
impairment (164-170), including one aiming to predict a favourable outcome (no 
cognitive impairment) (169), and two specifically focusing on risk of dementia 
(168, 170). The CHANGE (164) score was developed to overcome limitations of 
an earlier prognostic rule – SIGNAL2 (167) – and was derived using the same 
dataset. Both rules were intended for use in cases of non-disabling stroke 
(modified Rankin Scale [mRS] score ≤ 2) (171). The nomogram created by Gong 
et al. (166) was the only tool aiming to predict cognitive impairment following 
intracranial haemorrhage, exclusively.  
Six prediction models were derived based on logistic regression analysis, while 
one study applied a Chi-square Automatic Interaction Detection (CHAID) 
algorithm (170). On average, the identified prognostic rules included five 
variables (range: 3 – 7), pertaining to: demographics (in five rules), imaging 
findings (in five), symptom severity (in three), stroke type (in two), baseline 
function (in 2), and medical history (in two). Among the five studies that 
estimated discrimination, the reported AUROC in apparent validation ranged 
from 0.81 (169) to 0.91 (166). CHANGE (164) was the only prognostic rule to be 
externally validated, using data from a cohort of Chinese participants with 
ischaemic stroke (derivation cohort was from Singapore). Here, discriminatory 
power was found to be fair (0.75), compared to good (0.82) in apparent 
validation, although estimated 95% confidence intervals (CIs) overlapped.  
Three studies provided a graphical assessment of calibration. For both CHANGE 
(164) and SIGNAL2 (167), the fit between observed and predicted probabilities of 
cognitive impairment seemed close, with a more pronounced mismatch for the 
highest score values. Importantly, however, calibration of SIGNAL2 (167) had 
only been assessed in the derivation cohort. Gong et al. (166) concluded their 
nomogram had good calibration in the development dataset, with best fit 
evident for lowest and highest scores. However, the already visible differences 
between observed and predicted probabilities for middle-range scores became 
strongly apparent upon internal validation. For lower middle-range nomogram 
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values, the probability of cognitive impairment was underestimated, while for 
higher middle-range values – considerably overestimated.  
3.3.1.2 Risk of bias and applicability 
For each study, we rated the risk of bias to be high in the domain of analysis. 
Two reasons were applicable to all cases: inappropriate handling of missing data 
(participants with missing data excluded/no explicit mention of approach), and 
not accounting for data complexities (use of analysis methods that do not allow 
for inclusion of censored participants). Two studies did not estimate 
discriminatory power (168, 170), while calibration was not assessed 
appropriately (165) or at all (168-170) in four studies. Assessment of rule 
performance was limited to apparent validation in two studies (165, 168), while 
no validation procedure was reported by Salihovic et al. (170).  
Given the broad review question, applicability was overall of low concern, with 
one exception in the domain of predictors. Munsch et al. (169) obtained 
information on one of the input variables – stroke location – based on the 
outcome, using lesion symptom mapping, rather than prior to outcome 
assessment. 
3.3.2 Prognostic rules for delirium 
3.3.2.1 Overview 
Three studies aimed to predict risk of post-stroke delirium (172-174), producing 
four prognostic rules – in a pilot attempt (recognizing sample size limitations), 
Kostalova et al. (172) presented two alternatives. All prognostic models were 
developed based on logistic regression analysis. On average, the prediction rules 
included five variables (range: 4 – 7), pertaining to: demographics (in all rules), 
imaging findings (in two), symptom severity (in two), stroke type (in three), 
baseline function (in one), acute medical complications (in two), and laboratory 
markers (in two) (Table 3-3 and Table 3-4). The latter two variable categories 
were unique to prognostic rules for delirium, not being included among 
predictors of cognitive impairment.  
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On account of the fluctuating course of delirium, in all studies the outcome was 
assessed on multiple occasions. Kostalova et al. (172) and Kotfis et al. (173) 
conducted assessments daily for up to eight and six days, respectively, including 
the day of hospital admission. Oldenbeuving et al. (174) screened for delirium on 
two separate days within a seven-day period from admission. 
Out of the two studies that assessed discrimination in apparent validation, 
Oldenbeuving et al. (174) reported the higher estimate – AUROC = 0.84, 
compared to 0.80 and 0.73 reported by Kotfis et al. (173), for outcome 
measured at an earlier and later time-point, respectively. Oldenbeuving et al. 
(174) had also applied the most stringent form of validation – temporal – 
reporting an AUROC of 0.83. 
3.3.2.2 Risk of bias and applicability   
For all studies, we rated the risk of bias to be high in domains of outcome and 
analysis. Regarding the former, common concerns related to lack of blinding to 
predictors, or even use of predictor knowledge to inform outcome assessment. In 
terms of analysis, we judged the risk of bias to be high due to insufficient 
sample size, inappropriate handling of missing data and/or data complexities, 
and no evaluation of rule calibration. Assessment of discrimination was omitted 
from the study by Kostalova et al. (172), while Kotfis et al. (173) applied no 
method to adjust for optimism in estimating the performance of DELIAS.  
We rated applicability to be of high concern in studies by Kostalova et al. (172) 
and Oldenbeuving et al. (174), due to risk of overlap in timing of predictor and 
outcome assessments. Based on reported information, we were not able to 
ascertain whether a similar issue applied to the study by Kotfis et al. (173), 






Table 3-1 Characteristics of included studies. 




duration Stroke type Exclusion criteria of note 








to Dec 2012 
Retrospective 
cohort 
3 to 6 
months 
Ischaemic 
Discharge mRS > 2; pre-stroke 
cognitive impairment; neurologic 
or psychiatric comorbidities; 
impairment impeding cognitive 
assessment 




of university hospital 
June 2017 
to May 2018 
Prospective 
cohort 
6 to 12 
months 
Ischaemic 
Major mental illness; pre-existing 
dementia; impairment impeding 
cognitive assessment 






to Oct 2018 
Retrospective 
cohort 




Pre-existing dementia; previous 
stroke 






to Dec 2012 
Retrospective 
cohort 
3 to 6 
months 
Ischaemic 
Discharge mRS > 2; pre-stroke 
cognitive impairment; neurologic 
or psychiatric comorbidities; 
impairment impeding cognitive 
assessment 




of university hospital 
Nov 1995 
to Oct 1999 
Prospective 
cohort 
3 months Ischaemic 
Severe medical comorbidity; pre-
existing dementia with nonvascular 
aetiology 
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Table 3-1 Characteristics of included studies. Continued 




duration Stroke type Exclusion criteria of note 
Prognostic rules for cognitive impairment 




of university hospital 
Jun 2012 






History of cerebral infarct with 
functional deficit; pre-existing 
psychiatric disorders other than 






at a university clinical 
centre 
Sep 2011 






Pre-existing cognitive impairment, 
recurrent stroke, aphasia impeding 
cognitive assessment 





Stroke unit of 
university hospital 
Jan 2009 






History of head trauma, 
neurosurgery or psychosis; RASS <-3 
(deep sedation, unarousable) 




of district general 
hospital 
Jun 2015 
to Mar 2018 
Prospective 
cohort 
5 days Ischaemic Haematology disorders 
Oldenbeuving 
et al., 2014 
Netherlands 






Up to 7 days 
Ischaemic 
and haemorrhagic 
Severe intellectual disability; severe 
language barrier 
mRS indicates modified Rankin Scale; RASS, Richmond Agitation-Sedation Scale. 
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Table 3-2 Participant characteristics for included studies. 
Study 
Model development 
sample, N Age, years, mean (SD) Women, N (%) NIHSS Score, median (IQR) 
Participants with 
outcome, N (%) 
Prognostic rules for cognitive impairment 
Chander et al., 
2017; CHANGE 
209 61.7 (12.5) 67 (32.1%) Not reported 78 (37.3%) 
Ding et al., 2019 145 
No cognitive disorder group: 
Mdn = 61, IQR: 48.5 - 69.0; 
cognitive disorder group: 
Mdn = 64, IQR: 60.0 - 73.0 
42 (29.0%) 
No cognitive disorder group: 
3.0 (1.0 - 5.0); cognitive 
disorder group: 4.0 (2.0 - 7.0) 
77 (53.1%) 
Gong et al., 2019 92 57.3 (12.2) 28 (30.4%) Not reported 69 (54.3%)/127*  
Kandiah et al., 2016; 
SIGNAL2 
209 61.7 (12.5) 67 (32.1%) Not reported 78 (37.3%) 
Lin et al., 2003 283 64.4 (8.4) 95 (33.6%) M = 3.6, SD = 3.1 26 (9.2%) 
Munsch et al., 2016 198 
No cognitive disorder group: 
Mdn = 60; range: 29 – 84; 
cognitive disorder group: 
Mdn = 69, range: 34 – 95 
77 (35.8%)/215** 
No cognitive disorder group: 
3.0, range: 1.0 – 10.0; 
cognitive disorder group: 4.0, 
range: 1.0 – 25.0 
77 (38.9%) 
Salihovic et al., 2018 275 
Females: 66.3 (2.0); 
Males: 65.1 (1.5) 
103 (37.5%) 
Score of 0 - 7: N = 163 (59.3%); 
score of 8 - 14: N = 89 (32.4%); 
score > 14: N = 23 (8.4%) 
190 (69.1%) 
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Table 3-2 Participant characteristics for included studies. Continued 
Study 
Model development 
sample, N Age, years, mean (SD) Women, N (%) NIHSS Score, median (IQR) 
Participants with 
outcome, N (%) 
Prognostic rules for delirium 
Kostalova et al., 
2012 
100 73.5 (11.5) 47 (47.0%) 
No cognitive disorder group: 
9.0, 5th - 95th percentile range: 
4.0 – 17.0; cognitive disorder 
group: 11.0, 5th - 95th percentile 
range: 5.0 - 16.0 
43 (43.0%) 
Kotfis et al., 2019; 
DELIAS 
1001 Mdn = 71.0, IQR: 64.0 - 82.0 478 (47.8%) 
No cognitive disorder group: 8.0 
(4.0 - 14.0); cognitive disorder 
group: 18.0 (12.0 - 21.5) 
172 (17.2%) 
Oldenbeuving et al., 
2014 
527 72.0, range: 29.0 – 96.0 239 (45.4%) 5.0, range: 0.0 – 36.0 62 (11.8%) 
*Combined development and validation cohorts. 
**Sample before excluding subjects with no outcome data. 
IQR indicates interquartile range; M, mean; Mdn, median; NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation. 
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Table 3-3 Characteristics of included prognostic rules. 
Study Predictors Outcome Assessment 
Validation, strategy and 
corresponding AUROC (95% CI) 
Prognostic rules for cognitive impairment 
Chander et al., 
2017; CHANGE 
Age, education, acute nonlacunar cortical 
infarcts, chronic lacunes, white matter 
hyperintensities, global cortical atrophy 
Cognitive 
impairment 
Structured clinical interview and 
MMSE, MoCA if further confirmation 
required 
Apparent: 0.82 (0.76, 0.88); 
temporal: 0.78 (0.71, 0.85); 
external: 0.75 (0.71, 0.79) 
Ding et al., 2019 
Age, education, acute nonlacunar infarcts, 




MMSE, MoCA, neuropsychological 
battery, assessment based on CDR 
and DSM-4 criteria 
Apparent: 0.88 (0.83, 0.94) 
Gong et al., 2019 





Apparent: 0.91; internal with data 
splitting based on recruitment 
period: 0.92 (CIs not reported) 
Kandiah et al., 
2016; SIGNAL2 
Age, education, acute nonlacunar cortical 
infarcts, chronic lacunes, white matter 




Structured clinical interview and 
MMSE, MoCA if further confirmation 
required 
Apparent: 0.83 (0.77, 0.88); 
temporal: 0.78 (0.70, 0.85) 
Lin et al., 2003 
Age, occupation, previous stroke, vascular 
territory of infarction, NIHSS score, MMSE 
score, FIM motor score 
Dementia 
Consensus diagnosis based on CDR 
CERAD, neuropsychological battery, 
and criteria of Alzheimer’s Disease 
and Related Disorders Association, 
ICD-10NA, NINDS, and NINDS-AIREN  
Apparent: 93.4% of participants 
correctly classified according 
to outcome 
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Table 3-3 Characteristics of included prognostic rules. Continued 
Study Predictors Outcome Assessment 
Validation, strategy and 
corresponding AUROC (95% CI) 
Prognostic rules for cognitive impairment 
Munsch et al., 
2016 
Age, infarct volume, NIHSS score, stroke 
location expressed as number of eloquent 







Apparent: 0.81 (0.75, 0.87); internal 
with 10-fold cross validation and 
1000 bootstrap replications: 0.77 
(0.69, 0.84); internal with data 
splitting based on recruitment 
period: 0.78 (0.70, 0.85) 
Salihovic et al., 
2018 
Complex figure test score, narrative 
memory score, numerical memory score 
Vascular dementia 
Diagnosis using clinical exams and 
neuropsychological testing, based on 
DSM-4 and ICD-10 
Not assessed 
Prognostic rules for delirium 
Kostalova et al., 
2012; Rule 1 
Age, intracerebral haemorrhage, lesion 
volume, gamma-glutamyl transferase, 
bilirubin 
Delirium 
Consensus diagnosis based on DSM-4 
criteria, CAM-ICU 
Internal with 2-fold cross-validation; 
correctly classified 69.0% of subjects 
with delirium and 84.2% without 
Kostalova et al., 
2012; Rule 2 
Age, intracerebral haemorrhage, lesion 
volume, SOFA-Max 
Delirium 
Consensus diagnosis based on DSM-4 
criteria, CAM-ICU 
Internal with 2-fold cross-validation; 
correctly classified 65.1% of subjects 




Table 3-3 Characteristics of included prognostic rules. Continued 
Study Predictors Outcome Assessment 
Validation, strategy and 
corresponding AUROC (95% CI) 
Prognostic rules for delirium 
Kotfis et al., 2019; 
DELIAS 
Age, NIHSS score, hemianopia, aphasia, 
neutrophil to lymphocyte ratio, 
leukocytes, c-reactive protein 
Early-onset 
delirium (up to 24 
hours), delirium up 
to 5 days 
CAM-ICU and investigator assessment 
based on DSM-5 criteria 
Apparent, for early onset delirium: 
0.80; for delirium up to 5 days: 0.73 
(CIs not reported) 
Oldenbeuving et 
al., 2014 
Age, stroke subtype, NIHSS score, infection Delirium CAM 
Apparent: 0.84 (0.80, 0.89); 
temporal: 0.83 (0.77, 0.90) 
AUROC, area under the receiver operating characteristic; CAM(ICU), Confusion Assessment Method (for the Intensive Care Unit); CDR, Clinical Dementia Rating Scale; 
CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CI, confidence interval; DSM, Diagnostic and Statistical Manual of Mental Disorders; FIM, Functional 
Independence Measure; GCS, Glasgow Coma Scale; ICD-10NA, International Classification of Diseases, tenth revision: Neurological Adaptation; MMSE, Mini-Mental State 
Examination; MoCA, Montreal Cognitive Assessment; NIHSS, National Institutes of Health Stroke Scale; NINDS(AIREN), National Institute of Neurological Disorders and 
Stroke (Association Internationale pour la Recherche et l’Enseignement en Neurosciences); SOFA-Max: Sequential Organ Failure Assessment, maximum score. 
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Prognostic rules for cognitive impairment     
Chander et al., 2017; CHANGE ✓    ✓    
Ding et al., 2019 ✓ ✓   ✓    
Gong et al., 2019   ✓ ✓ ✓    
Kandiah et al., 2016; SIGNAL2 ✓    ✓    
Lin et al., 2003 ✓ ✓ ✓ ✓    ✓ 
Munsch et al., 2016 ✓  ✓  ✓    
Salihovic et al., 2018        ✓ 
Prognostic rules for delirium     
Kostalova et al., 2012; Rule 1 ✓   ✓ ✓  ✓  
Kostalova et al., 2012; Rule 2 ✓   ✓ ✓ ✓   
Kotfis et al., 2019; DELIAS ✓  ✓    ✓ ✓ 
Oldenbeuving et al., 2014 ✓  ✓ ✓  ✓   
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Table 3-5 Risk of bias rating for included studies. 
Study Participants Predictors Outcome Analysis 
Overall 
rating 
Prognostic rules for cognitive impairment 
Chander et al., 
2017; CHANGE 
     
Ding et al., 
2019 
     
Gong et al., 
2019 
     
Kandiah et al., 
2016; SIGNAL2 
     
Lin et al., 2003 
     
Munsch et al., 
2016 
     
Salihovic et al., 
2018 
     
Prognostic rules for delirium 
Kostalova et 
al., 2012 
     
Kotfis et al., 
2019; DELIAS 
     
Oldenbeuving 
et al., 2014 
     




We identified 11 prognostic rules for prediction of post-stroke cognitive 
outcomes, three of which had been published just within a year before the 
literature search date. However, we found no independent external validation 
studies, or reports on assessing implementation of prognostic rules in practice. 
Research into prognosis of post-stroke cognitive outcomes is an expanding area, 
but still at its early stages, with a primary focus on development of novel 
strategies, rather than validation or application. 
3.4.1 Clinical implications 
Based on our findings, I cannot indicate preferred prognostic rules for prediction 
of either post-stroke delirium or longer-term cognitive outcome. All included 
studies had strengths and limitations. The highest discriminatory power in 
apparent validation was reported by Gong et al., whose study was also the only 
one to be rated as having low risk of bias in as many as three out of four 
domains. However, both development and validation cohorts were small, and 
graphical assessment revealed considerable rule miscalibration. 
Chander et al. (CHANGE) and Oldenbeuving et al. applied the most stringent 
validation strategies out of studies predicting post-stroke cognitive impairment 
and delirium, respectively. Both publications, moreover, had the advantage of 
producing clear scoring systems, allowing easy estimation of individual 
prognosis. Conversely, the same two studies had the highest number of domains 
rated as high risk of bias (three out of four). Although it is important to highlight 
that CHANGE was the only externally validated prognostic rule, it is nonetheless 
arguable whether the tool’s reported fair discriminatory power would be 
considered sufficient to merit implementation in clinical practice. 
A fundamental challenge is that without external validation studies, the 
generalisability of developed prognostic rules cannot be assessed, or their 
predictive accuracy directly compared against one another. Further, to choose 
an optimal prognostic rule, it is also essential to consider the target population 
and setting. Many tools may not be applicable in an unselected stroke 
population, for example, where development cohorts exclusively comprised 
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survivors of ischaemic stroke (164, 165, 167-169, 173), intracranial haemorrhage 
(166), or non-disabling stroke (164, 167).  
Generalisability may also be compromised if a prognostic rule relies on predictor 
information that is not routinely available in all healthcare systems. An example 
is incorporation of scores based on MRI scans, which may not be attainable in 
resource-poor settings. Apart from considerations relevant from clinician 
perspective, it is also necessary to account for concerns raised by stroke 
survivors and their families, determining at the individual level whether the 
process of estimating future cognitive outcomes and its consequences is 
acceptable (175).  
3.4.2 Research challenges 
The processes of data extraction and quality assessment have highlighted some 
of the many challenges inherent to prognostic research. Collecting longitudinal 
data from large study samples is associated with high resource requirements and 
a prolonged delay from project inception to producing first research outputs. As 
such, it is not surprising that many investigators opt for use of existing datasets. 
The practical advantages of this approach, however, often come at a cost of 
obtaining relevant data. For example, given that Chander et al. (164) reported 
NIHSS scores for the external validation cohort, but not for the development 
cohort, it seems this information was not available for the latter. Consequently, 
despite existing evidence on the importance of this variable, stroke severity 
could not have been considered as a predictor for inclusion in SIGNAL2 (167) or 
CHANGE (164).  
An additional trade-off occurs with use of records from routine care registries. In 
this case, access to data from large clinical populations, unaffected by 
participation bias, is coupled with quality concerns. The encompassed 
individual-level information is not collected for research purposes, and therefore 
it cannot be expected that variables are measured consistently, in adherence to 
standardised protocols, such as used in research studies (176, 177).  
A number of challenges are also specific to research into stroke and cognition. 
Participant deaths, high rates of losses to follow-up, and incomplete assessments 
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due to stroke-related impairments (74) can all contribute to missing data and 
biased study samples, where healthier individuals are overrepresented. 
Moreover, there is no consensus method of diagnosing post-stroke cognitive 
disorders (178). Adhering to medical classification criteria offers the most 
holistic approach to assessing cognitive function, with information from multiple 
sources being considered, however it also introduces incorporation bias. For 
example, a diagnosis of delirium according to DSM-5 criteria (6), requires 
obtaining evidence of a potential cause, such as infection. In other words, 
knowledge of predictor status is used to inform outcome assessment. 
Consequently, the strength of the association between the two can be 
overestimated, in turn leading to optimistic estimates of prognostic rule 
performance.  
The latter may also result from recruiting participants who experienced 
cognitive disorders prior to index stroke (116). The included studies that aimed 
to predict cognitive impairment had indeed avoided this issue through applied 
exclusion criteria. However, this selection process leads to obtaining a study 
sample that is not representative of a real-world stroke population. Given the 
overlap between risk factors for stroke and age-related cognitive decline, it is 
not surprising that the prevalence of pre-stroke dementia is estimated to be 
around twice as high (10%) as in the general population (20, 23), with even more 
stroke survivors likely to have experienced milder forms of pre-stroke cognitive 
impairment.  
Many of the described pitfalls seem impossible to avoid. However, through our 
risk of bias assessment, we also identified methodological problems that could 
have been at least partially ameliorated. For example, the most common 
approach we observed to model development involved use of logistic regression 
in a complete-case analysis. The consequent exclusion of participants could have 
been avoided through applying data imputation techniques and conducting a 
time-to-event analysis, retaining those with incomplete follow-up (116).  
Another recurring problem relates to relying on significance in univariable 
analysis for selection of input variables, which may lead to omission of important 
predictors (179). For this task, use of a nonstatistical strategy is recommended, 
where predictors are chosen based on previous evidence, and in view of 
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feasibility and measurement reliability. Recognition of such amendable 
limitations, and application of the comprehensive, rigorous and explicit guidance 
presented within the recently published PROBAST tool, can help raise standards 
in design, conduct and reporting of future prognostic studies. 
3.4.3 Strengths and limitations 
To my knowledge, this is the first systematic review to focus on prognostic rules 
for prediction of post-stroke cognitive outcome. The opportunity to use the 
relatively novel PROBAST tool posed an important advantage to completing this 
work. Lack of a consensus approach to risk of bias assessment has limited 
previous reviews in the area of prognostic research (180). A further strength 
relates to tailoring the search strategy, and applying broad inclusion criteria, so 
as to promote comprehensiveness.  
However, due to limited resources, we only retrieved studies published in 
English. Moreover, requiring that publications provide a method to estimate the 
individual probability of cognitive outcomes, we would have excluded studies 
relying on more complex prediction techniques, such as machine learning. 
However, this was deliberate to ensure usefulness of my review to clinicians and 
researchers, through focusing on methods which allow immediate application, 
provided predictor information is readily available.  
3.4.4 Future directions and specific thesis aims 
This systematic review of prognostic rules (including development procedures 
and content) has complemented the literature review presented in the 
Introduction and allowed me to identify areas of research that so far seem to 
have received little attention. Firstly, modifiable risk and protective factors, 
e.g. pertaining to lifestyle, are rarely considered among predictors of post-
stroke cognitive outcome. Their relevance to cognition has been evidenced by 
prognostic model studies in the general population (152), and it seems 
implausible that such associations would cease to be important following stroke. 
In addition to the possibility of explaining some of the variability in post-stroke 
cognitive function, the importance in identifying modifiable predictors lies in 
representing an opportunity to reduce the risk of an unfavourable outcome.  
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The second topic that seems under-researched, relates to circumstances in 
which particular variables influence post-stroke cognitive outcome. As evident, 
for example, in cases of multimorbidity, relevant factors can appear in 
combination rather than isolation. Patterns of co-occurrence may determine how 
cognition is ultimately affected. Moreover, individual characteristics may be 
relevant to post-stroke cognition in different ways. For example, some variables 
may primarily contribute to pre-stroke cognitive decline, with others affecting 
clinical features of the index stroke, or the longer-term recovery process.  
The latter point ties into a third issue – accounting for changes over time. As 
discussed in the Introduction, evidence suggests that cognitive function can 
fluctuate even in the chronic phase after stroke. With outcomes measured at a 
single time-point, as done in reviewed prognostic studies, it is not possible to 
determine whether individual cognitive status is following a stable, improving or 
declining trajectory. Individuals recognised as “cognitively intact” may still be 
experiencing meaningful deterioration in cognitive function, and therefore, in 
the longer-term, be at greater risk of developing dementia than those 
“cognitively impaired”, but stable or improving.  
In the following thesis chapters, I will address these three issues, with an 
overarching aim to improve our understanding of the cognitive change that 
occurs following stroke and its associations with individual characteristics. 
Findings from conducted studies may not only contribute to increased accuracy 
of future prognostic models, but also inform strategies to prevent unfavourable 
outcome and improve cognitive function. 
3.5 Summary 
Prognostic model research relevant to post-stroke cognitive outcomes is at a 
relatively early stage. From 11 identified prognostic rules (7 predicting cognitive 
impairment and 4 delirium) only one had been externally validated, and none 
had been assessed in terms of impact. Limited evidence regarding performance 
and generalisability, coupled with a high risk of bias in all model development 
studies, hinders recommending use of specific prognostic rules in clinical 
practice. Nonetheless, findings from the reviewed studies have important 
implications for future research, including subsequent projects in my thesis.
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Chapter 4 Potentially modifiable predictors of 
post-stroke cognition: Are physical activity, 
sedentary behaviour, and social engagement 
relevant? 
Through my review of the existing literature, I identified three themes relevant 
to prognosis research on post-stroke cognition that so far seem under-
investigated. In this chapter, I address the first one – the relevance of 
potentially modifiable factors to cognitive function following stroke. Using data 
from a large, population-based general-purpose cohort, the UK Biobank, I 
conducted two separate studies in a subsample of participants with a history of 
stroke and TIA. In the first study, I focused on habitual physical activity and 
sedentary behaviour, and in the second – on different aspects of social 
engagement.  
After defining key terms, I introduce proposed theories and evidence in support 
of an association between these factors and cognitive function, some of which 
point to the possible causal nature of these relationships. I then present a shared 
Methods section, following which I report and discuss the results of each study 
separately. Finally, I draw general conclusions from both investigations, 
considering the implications of my findings to the development of novel 
interventions for improving cognitive outcomes, as well as the applicability of 
such data resources as the UK Biobank for future prognostic stroke research.  
4.1 Introduction 
In prognosis research, if the sole priority was to create highly accurate 
prognostic tools, predictors would only be regarded for the strength of their 
independent association with an outcome. Yet, arguably, there is another crucial 
task to consider – understanding which of these predictors can be modified in 
order to improve the outcome (99). In relation to cognitive impairment and 
decline, two such factors – physical activity patterns and social engagement – 
were first targeted decades ago (e.g. see 181, 182).  
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Since then, research interest in physical activity as a modifiable determinant of 
cognitive function from childhood to older age has increased exponentially, 
resulting in a considerable body of supportive evidence (183, 184). In contrast, 
although many studies have successfully demonstrated an association between 
social engagement and cognition (185, 186), the presence of a causal 
relationship is still largely debated (187). Nonetheless, concepts of healthy 
cognitive aging have incorporated social engagement as one of their key 
components (188, 189).  
4.1.1 Definitions 
Physical activity is defined as “any bodily movement produced by skeletal 
muscles that results in energy expenditure” (190, page 126). Based on oxygen 
consumption, physical activity can be categorised according to three levels of 
intensity: light (e.g. walking, washing dishes); moderate, characterised by an 
increased heart rate, breathing harder, and feeling warmer than normal (e.g. 
mowing the lawn, dancing); and vigorous, associated with sweating and 
breathing hard and fast (e.g. running, carrying heavy loads) (191).  
In addition to assessing one’s physical activity as an essential component of a 
healthy lifestyle, the importance of considering sedentary behaviour as an 
independent factor has been increasingly recognised (192). The term ‘sedentary 
behaviour’ encompasses waking-time activities that require low levels of energy 
expenditure, and are performed while sitting, reclining or lying down. In the 
context of cognition, it is also relevant to note a novel distinction being made 
between mentally active sedentary behaviours (e.g. doing a crossword puzzle) 
and mentally passive ones (e.g. watching TV) (193).  
In comparison to the above, social engagement appears to be a concept more 
difficult to define, with apparent inconsistencies in operationalisation and 
measurement across studies. However, three domains of interest are typically 
distinguished (194): social networks, relating to structure, composition and 
content of an individual’s interpersonal ties (195-197); social support, relating to 
the level of emotional and instrumental resources available to an individual 
(198, 199); and social participation, relating to involvement in activities with a 
social component (200, 201). Another important distinction is made between 
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objective measures of social engagement (e.g. how often do you meet with 
friends) and subjective measures (e.g. feeling lonely) (202, 203).    
4.1.2 Routes to affecting cognition 
There are many putative pathways through which physical activity, sedentary 
behaviour and social engagement may influence cognitive functioning. One 
perspective focuses on indirect effects, driven by impacts on general health and 
wellbeing.  
Regarding the relationship between physical activity and health, research has 
provided a particularly rich evidence base for the formers benefits, including: 
reduced blood pressure and risk of blood clot formation, enhanced insulin 
sensitivity and glucose tolerance, and improvements in body composition 
(increase in lean mass and reduction in fat), blood distribution, and plasma lipid 
and lipoprotein profile (204). As follows, physical activity is associated with a 
reduced likelihood of developing cardiovascular diseases, which are risk factors 
for cognitive impairment and decline.  
Across multiple observational and experimental studies, findings regarding 
specific effects of sedentary behaviour on physiology appear overall less 
consistent (205); although a number of reports have indicated that prolonged 
sitting results in detrimental changes to insulin sensitivity, glucose tolerance and 
plasma triglyceride levels (206). Evidence moreover suggests that sedentary 
behaviour is associated with an increased risk of fatal and non-fatal 
cardiovascular diseases and events (207). 
In addition, activity patterns may affect cognitive functioning through impact on 
mental health. Specifically, sedentary behaviour has been associated with 
depression and depressive symptoms (205), while physical activity has been 
found to favourably influence mood. The latter relates to both enhancing 
positive affect, as well as ameliorating depression, and reducing anxiety and 
stress (208).   
Changes in stress levels have also been proposed as the primary pathway through 
which health is affected by factors reflecting social engagement (209). 
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Perceived, involuntary social isolation is hypothesised to evoke a physiological 
stress response, which as a chronic state may lead to dysregulation of the 
endocrine, immune, and cardiovascular systems (210-212). Consequently, this 
experience is associated with increased blood pressure and heart rate, chronic 
inflammation, poor sleep quality, slower wound healing and greater 
susceptibility to infection (213-217). These cumulative processes have been 
described as causing overall accelerated aging, which also involves 
neurodegeneration, mostly attributed to elevated levels of glucocorticoids (209, 
211, 218). In addition, stress is considered to trigger unhealthy behaviours, such 
as excessive alcohol consumption (219), smoking (220) and disordered eating 
(221, 222).  
Conversely, social support has been associated with improved outcomes 
following health and life-threating events, such as transport accidents (223), 
heart failure (224), and surgery (225, 226). These observations are attributed to 
social support acting as a buffer against stress, induced by the event, as well as 
enhancing adherence to medical advice (e.g. taking prescription medication). 
Alongside effects obtained by modifying health and wellbeing, there is potential 
for activity patterns and social engagement to influence neural structure and 
function in a more direct manner. One concept that simultaneously accounts for 
the contribution of both types of factors to brain health is embedded in a line of 
animal model studies on the impact of an enriched environment (188). Such an 
environment, of which opportunity for physical activity and social interaction 
are key constituents, provides complex stimulation for its inhabitants. Living in 
these conditions is argued to enhance neuronal plasticity on molecular, cellular 
and structural levels, and thus benefit cognitive functioning (227). In this 
context, social isolation and excess of mentally passive sedentary behaviours is 
considered equivalent to functioning in an impoverished environment, associated 
with cognitive decline (228). 
4.1.3 Physical activity, sedentary behaviour, social engagement, 
and cognition in the context of stroke 
There is a clear application for the described concepts to the context of stroke – 
a highly stressful, potentially life-threatening event, typically associated with 
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prevalent cardiometabolic comorbidities. Adding to this notion are proposed 
further dual-path effects of environmental enrichment, specific to neurological 
and cognitive recovery following brain damage. The first hypothesised route, 
beginnings of which reach childhood, is through enhancing cognitive reserve, in 
turn reducing the manifestation of neuropathology and supporting functional 
compensation (229). The second route involves enhancement of multiple, 
beneficial physiological processes in the acute and subacute stroke phases, 
including: synaptogenesis, axonal sprouting, axonal and dendritic remodelling, 
neurogenesis, and angiogenesis (230). 
In relation to physical activity itself, there are also some indications that its role 
in modifying cognitive outcomes could begin even prior to index stroke. In a 
study on mice, the authors reported that engaging in voluntary exercise for four 
weeks preceding experimental traumatic brain injury resulted in increased 
activation of anti-apoptotic and anti-inflammatory pathways, and improved 
recovery of cognitive function (231). In humans, on the other hand, an 
association has been observed between physical activity prior to stroke and 
alleviated stroke severity – an important determinant of cognitive function 
(232).  
Although currently there seem to be no findings supporting a direct link between 
improved post-stroke cognition and pre-stroke physical activity, there is high 
quality evidence indicating a favourable effect of post-stroke physical activity. 
In a meta-analysis of 14 randomised controlled trials (N = 736), the authors 
concluded that structured physical activity training had a positive overall impact 
on post-stroke cognitive performance, with a small to moderate mean effect size 
(233). Cognitive gains were largest for programmes that combined aerobic and 
strength training, and were apparent even where the intervention was 
introduced in the chronic phase of stroke. When domain-specific performance 
was considered, improvement was reported for attention and processing speed, 
while no significant effects were observed for executive function or working 
memory.  
These results may appear conclusive, however the topic of physical activity and 
post-stroke cognition is not yet exhausted. Alongside reported methodological 
limitations of studies included in the review, it is noteworthy that structured 
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training does not cover the whole spectrum of physical activities that people can 
engage in. This is important, as despite interventions being tailored to 
accommodate post-stroke motor deficits, it is likely that many stroke survivors 
would find objective and subjective barriers to engaging in such programmes 
(234, 235); particularly, as it is plausible that those who agreed to participate 
and completed the interventions, were more active, health-orientated 
individuals.  
As follows, there is still a need to improve our understanding of how typical, 
day-to-day physical activity, encompassing chores and leisure activities alongside 
intentional exercise, is associated with post-stroke cognition. An apparent link 
could provide grounds for implementing less demanding interventions, more 
acceptable and sustainable in the long term for a wider population of stroke 
survivors. Considering physical activity and sedentary behaviour in conjunction, 
a clinically meaningful change could be sought even just by breaking up 
prolonged sitting time with brief bouts of light-intensity indoor walking (236, 
237). 
This notion seems of particular relevance given that stroke survivors are 
reported to spend significantly more time sitting than their peers (10.9 
hours/day vs 8.2 hours/day) (238). However, to date, little is known about the 
effects of interrupting sedentary behaviour on post-stroke outcomes, beyond one 
study demonstrating a decrease in systolic blood pressure (239). As such, it is the 
cumulative evidence, pieced together from studies involving animal models and 
non-stroke populations (240), that is the main indicator of a possible detrimental 
effect of sedentary behaviour on cognitive function following stroke.  
Similarly, more research is needed to describe the relationship between social 
life and post-stroke cognition – one that is likely complex, with social isolation 
recognised as a risk factor for stroke (241), and stroke contributing to social 
isolation (242-244). At present, it seems that only one study (N = 272) has 
addressed this topic directly (245). The authors found that baseline social ties 
and emotional support were independent predictors of better performance on a 
cognitive summary score at six months, while emotional support was further 
associated with greater improvement from baseline to follow-up. When 
individual tasks were considered, social ties predicted immediate and delayed 
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recall, while emotional support was associated with immediate recall only. Yet 
no significant relationships were found for tasks assessing attention, language 
and executive function, nor for performance on the MMSE.  
Complementing these observations are reports of stroke survivors showing 
progressive functional improvement with high levels of social support, while 
(ultimately) experiencing functional deterioration with low support (246-248). 
Although cognition was not assessed in these studies, if an association exists 
between social engagement and post-stroke functional recovery, one with 
cognitive recovery also seems plausible.   
4.1.4 The present studies 
I conducted two observational studies to investigate the associations of post-
stroke cognitive performance with: physical activity and sedentary behaviour 
(Study A), and social engagement (Study B). I made three assumptions regarding 
Study A: i) the effects of physical activity and sedentary behaviour are 
independent from one another (to a degree), and therefore both should be 
accounted for; ii) the effects of physical activity and sedentary behaviour may 
depend on their type; while also iii) the accumulated time spent being physically 
active and sedentary may be relevant to cognitive performance.  
In relation to Study B, I assumed that both objective and subjective aspects of 
social engagement are relevant to post-stroke cognitive function, and their 
effects might differ. Further, based on the described studies in stroke 
populations, I hypothesised that associations for all predictors of interest are 
likely to depend on what cognitive function is being assessed. I aimed to ensure 
that plausible confounders were accounted for, recognising that many variables 
may be simultaneously relevant to: a) activity patterns and cognition, and b) 
social engagement and cognition.  
4.2 Methods  
I used anonymised, individual participant level data held in the UK Biobank. The 
UK Biobank project is overseen by the National Health Service (NHS) National 
Research Ethics Service (approval letter dated 17th June 2011, Ref 11/NW/0382) 
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and has received ethical approval from the Community Health Index Advisory 
Group (approved 7th December 2006, application no. 06-007). I conducted this 
research under application no. 17689. In reporting the two studies, I followed 
the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines (249). Study B, relating to social engagement, has been 
published (250). I edited and expanded the content of my paper for the purpose 
of this thesis chapter.   
4.2.1 Study setting and participants  
The UK Biobank includes data from over 502,500 participants. Baseline 
assessments took place between 2006 and 2010, across 22 centres in the United 
Kingdom. During the study visit, participants answered questions regarding 
sociodemographic, health, mood and lifestyle factors, completed cognitive 
tasks, and had a range of physical measurements taken. A more detailed 
description of the UK Biobank has been provided previously (251). 
I focused on baseline data from participants who self-reported a history of 
stroke or TIA (data field 20002). I included cases of TIA on account of similar 
prevalence of risk factors for cognitive decline as in stroke populations (252), 
and evidence of longer-term cognitive sequalae (253). As per UK Biobank 
assessment procedures, information on medical conditions was obtained during a 
two-stage process. Firstly, through a touch-screen questionnaire, participants 
were asked whether they had a history of one or more illnesses, including 
stroke. Responses were subsequently confirmed during a verbal interview with a 
trained nurse. In cases where the participant was uncertain of the type of 
condition they had had, they were asked to describe the illness, so that the 
nurse could assist in defining it. If the interview revealed an erroneous 
indication of a medical condition, the initial response was amended.  
To identify eligible study participants, I considered four items in the repository 
under the cerebrovascular disease category: “stroke” (code 1081), “ischaemic 
stroke” (code 1583), “brain haemorrhage” (code 1491), and “transient ischaemic 
attack” (code 1082). To ensure a consistent approach throughout my thesis, 
unlike in the published version of Study B (250), I did not include cases of 
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subarachnoid haemorrhage. I further excluded participants who reported the 
occurrence of stroke or TIA before the age of 18. 
4.2.2 Measures  
4.2.2.1 Predictors of interest in study A 
I included three self-reported measures of physical activity and three of 
sedentary behaviour, relating to duration on a typical day. This included: 
walking, moderate physical activity, vigorous physical activity, driving, computer 
use (excluding work-related use), and watching TV. Participants were requested 
to estimate an average time if the duration of activities differed considerably 
throughout the week. Variables relating to physical activity were recorded in 
minutes, while sedentary behaviours were recorded in hours. At the stage of 
data collection, answers indicating either negative values (<0) or duration 
exceeding 24 hours (1440 minutes) were rejected. By summing time spent on the 
three activities from each category, I additionally derived variables representing 
total daily physical activity and total daily sedentary behaviour duration. For 
both variables, I excluded cases where the sum exceeded 24 hours. 
4.2.2.2 Predictors of interest in study B 
I selected six variables reflecting both objective and subjective aspects of social 
engagement: frequency of family and/or friend visits (made and received), 
satisfaction with family relationships, satisfaction with friendships, frequency of 
opportunities to confide in someone, loneliness, and participation in social 
activities. I grouped responses relating to frequency of interactions into four 
categories: never, once every few months to once a month, one to four times a 
week, and daily or almost daily. I dichotomised satisfaction with relationships to 
“satisfied” and “not satisfied”. Similarly, I dichotomised experience of loneliness 
into “lonely” and “not lonely”. Regarding participation in social activities, I 
distinguished seven categories: reporting no engagement in social activities, 
attending a sports club or gym, going to a pub or a social club, participation in a 
religious group, attending an adult education class, other group activity, and 
engagement in multiple group activities. 
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4.2.2.3 Measures of cognitive performance 
I chose four baseline cognitive tasks as outcome measures for both studies A and 
B. This included: reaction time, verbal-numerical reasoning (referred to as 
“Fluid Intelligence” in the UK Biobank), visual memory (referred to as “Pairs 
Matching”) and prospective memory. Reasoning and prospective memory tasks 
had been added to the assessment procedure at a later stage of recruitment, 
and therefore were completed by fewer participants (254). 
The reaction time task (data field 20023) included 12 rounds (4 training rounds, 
8 trials) of card-matching, based on the game “Snap”. Participants were 
presented with two cards at a time and asked to press a button as quickly as 
possible if they were identical. Performance on the task was measured as the 
average response time across eight trial rounds in milliseconds. Times under 50 
milliseconds and over 2000 milliseconds were considered invalid, and thus 
excluded from the dataset. 
The verbal-numerical reasoning task (data field 20016) involved answering 13 
multiple choice logic/reasoning-type questions, within a 2-minute time limit. 
Performance was measured as the unweighted sum of correctly answered 
questions, with a maximum of 13 points.  
In the visual memory task (data field 399) participants were presented with a set 
of matching pairs of cards and requested to memorise their positions. The cards 
were then turned over, and the subjects asked to select matching pairs in as few 
attempts as possible. The task included rounds with three and six pairs of cards, 
with performance measured as the number of errors in each round. In order to 
avoid a ceiling effect, for my analyses I only used results from the six-pair round, 
as it was more likely for participants to make an error. 
For the prospective memory task (data field 20018), an initial instruction was 
given early in the cognitive assessment section. Participants were informed that 
at a later stage they will be shown four coloured shapes and asked to touch a 
blue square. Instead, however, they are to touch an orange circle. Originally, 
performance was grouped into three categories: incorrect response/task 
skipped, correct on first attempt, correct on second attempt. However, for the 
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purpose of my analyses, I dichotomised the outcome according to whether 
participants correctly responded on their first attempt or not.   
All cognitive tasks were completed using a touchscreen. Additional information 
on cognitive testing in the UK Biobank can be found in the online Data Showcase 
under the “Cognitive function” category (category ID: 100026). Previous 
publications have described cognitive data from the repository with more detail, 
including information on test reliability and validity (255-258). 
4.2.2.4 Covariates  
Based on previous research, I identified factors simultaneously associated with 
physical activity, social engagement and cognition, which could act as 
confounders (i.e. lead to observing spurious associations between factors of 
interest and the outcomes). Firstly, I considered demographics: age (as a 
continuous variable, in years), sex, educational attainment, and the Townsend 
deprivation index score. I dichotomised education based on whether participants 
reported attainment of a college or university degree. The Townsend deprivation 
index is a measure of material deprivation based on rates of unemployment, car 
and home ownership, and household overcrowding in a given population (259). 
Each participant was assigned a deprivation index score at recruitment, based on 
a preceding national census. Negative values indicate relative affluence, while 
positive values indicate material deprivation.  
Secondly, I included factors related to general health status and functioning: 
self-reported walking pace (three categories: brisk, steady/average, or slow), 
activity-limiting disability (dichotomised into present or absent), subjective 
health rating (four categories: excellent, good, fair, or poor), and BMI (entered 
into the analysis as a continuous variable). Disability was determined based on 
responses to a question on employment status (data field 6142). In answer to 
this questionnaire item, participants were able to select multiple response 
options, one of which was “unable to work because of sickness or disability”. 
I considered an activity-limiting disability to be present if this response was 
selected either on its own or in conjunction with another option, for example, 
“retired” or “unemployed”.  
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I additionally considered the presence of specific conditions that have been 
associated with vascular dementia and poorer cognitive outcomes in stroke 
populations (260-262): hypertension, diabetes and atrial fibrillation. In relation 
to mental health, I assumed a relevant association of physical activity patterns, 
social engagement and cognition with depression (263-265). I identified 
participants with a history of depressive episodes applying a method used in a 
previous UK Biobank-based study, combining responses that jointly indicated 
experiencing a period of feeling down, depressed, disinterested or 
unenthusiastic for at least two weeks, and seeking professional help (266). 
The third category of covariates included lifestyle factors: frequency of alcohol 
intake (never/special occasions only, one to three times a month, one to four 
times a week, and daily/almost daily), and smoking (never, previous or current). 
These were treated as ordinal variables. Finally, I included two factors relating 
to the index cerebrovascular event: type (stroke or TIA), and time elapsed 
between the most recent stroke/TIA and baseline assessment, as a continuous 
variable measured in years.   
4.2.3 Statistical analysis  
4.2.3.1 Procedures 
Following data inspection, I noted a positive skew for the following variables: 
walking, moderate physical activity, vigorous physical activity, driving, computer 
use, and total daily physical activity (six variables of interest in Study B); as well 
as for reaction time and visual memory data (outcomes in both studies). I used a 
natural log transformation to correct for this. For all variables apart from 
reaction time, I preceded the transformations by adding a constant (one) to all 
task results, to accommodate for possible values of zero. I performed the data 
transformations using the International Business Machines Corporation (IBM) 
Statistical Package for the Social Sciences (SPSS), version 24. 
In both studies, I conducted a series of regression models to investigate 
associations between predictors of interest and performance on cognitive tasks. 
I used linear regression for three outcomes – reaction time, verbal-numerical 
reasoning and visual memory, and logistic regression for prospective memory. 
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The types of models that I developed are described below, separately for Studies 
A and B. I performed all analyses in Stata, version 14.2 (StataCorp LLC). 
Due to a high proportion of missing data for some of the considered predictor 
and outcome measures (even reaching 2/3), I determined that data imputation 
would not be appropriate (267), and applied a complete-case analysis approach 
instead. Therefore, sample sizes varied by model and cognitive task. In studies 
based on large samples, such as included in the UK Biobank, statistically 
significant results can be obtained for even trivial effects (268). To account for 
this, as well as for multiple testing, I adopted a relatively strict approach, 
adjusting the traditionally recognised significance threshold according to the 
number of predictors in the most complex model (20 variables). Specifically, I 
set the threshold to 0.003 (0.05/20). 
4.2.3.2 Study A models 
I developed two groups of models in Study A. The first group accounted for the 
types of physical activity and sedentary behaviour that were reported. There 
were three models where the three types of physical activity were entered 
together, and three models where the three types of sedentary behaviour were 
entered together. In both cases, the first of these three models was unadjusted, 
incorporating only predictors of interest. The second was a partially adjusted 
model, where I included demographics (age, sex, education, and deprivation). 
The third model was fully adjusted, where I additionally accounted for health-, 
lifestyle- and stroke-related factors (walking pace, disability, subjective health 
rating, BMI, hypertension, diabetes, atrial fibrillation, depression, alcohol 
intake, smoking status, type of index cerebrovascular event, and time elapsed 
between the event and baseline assessment). Finally, I developed a fourth type 
of model, labelled “complete”, combining all types of physical activity and 
sedentary behaviour, and all potential covariates.  
In the second group, I used total daily physical activity and total daily sedentary 
duration as predictors of interest. Here, I also developed four types of models, 
equivalent to the ones described above for the first group. In both model groups, 
I conducted separate unadjusted, partially adjusted, fully adjusted and 
complete models for each of the four cognitive tasks.  
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4.2.3.3 Study B models 
The development of models in Study B reflected that of Study A. I created 
separate unadjusted, partially adjusted and fully adjusted models for each 
individual proxy of social engagement. I then incorporated all proxies into a 
single, complete model, adjusting for all considered covariates. I conducted 
every type of model for each of the cognitive tasks.  
4.2.3.4 Presentation of results 
I aimed to present my results in a manner that is both informative and intuitive. 
For analyses based on linear regression, I reported unstandardised coefficients 
(betas) to clearly indicate changes in values of the outcome measures. For 
logistic regression analyses, I reported odds ratios (OR). 
I recognised that interpretation of coefficients is not straightforward where 
studied variables were log-transformed. In such cases, I provided examples to 
represent the strength of the reported associations. Underlying calculations 
were based on: i) percent change in the outcome for every one-unit change in 
the predictor, where only the outcome was log-transformed, ii) unit change in 
the outcome for every 1% change in the predictor, where only the predictor was 
log-transformed, iii) percent change in the outcome for every 1% change in the 
predictor, where both the predictor and outcome were log-transformed (269). 
For complete models, I additionally presented the results graphically. However 
here, for linear regression analyses, I used standardised coefficients to allow 
visual comparisons across different predictors of interest.  
4.3 Results and discussion 
I identified 8391 participants with a self-reported history of stroke or TIA. Table 
4-1 presents descriptive statistics for variables relevant to both studies: baseline 
characteristics of the participant sample, incorporated in conducted analyses as 
covariates, and measures of cognitive performance, constituting study 
outcomes.  
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Table 4-1 Baseline characteristics of study sample and descriptive statistics 
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Table 4-1 Baseline characteristics of study sample and descriptive statistics 
for performance on cognitive tasks. Continued 
Variables 
Lifestyle factors 
Alcohol intake frequency 
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Cognitive task performance  






Verbal-numerical reasoning, points (range 0 to 13) 
Mean (SD) 











Correct response on first attempt 




BMI indicates body mass index; SD, standard deviation; TIA, transient ischaemic attack. 
92 
4.3.1 Study A results 
Descriptive statistics for predictors of interest in Study A, relating to self-
reported duration of physical activities and sedentary behaviours on a typical 
day, are presented in Table 4-2. Across all conducted models, sample sizes 
ranged from 1571 to 7927 participants. Given multiple analyses, producing a high 
volume of results, I have focused on describing only key findings. Associations for 
all variables of interest are included in Appendix 4, Supplemental Tables 1 to 8. 
4.3.1.1 Predictors of reaction time in Study A 
In unadjusted models, faster reaction times were associated with longer 
reported daily duration of: walking (beta = −0.011, 99.7% CI: −0.019 to −0.003), 
vigorous physical activity (beta = −0.006, 99.7% CI: −0.012 to −0.001), driving 
(beta = −0.032, 99.7% CI: −0.047 to −0.017), and computer use (beta = −0.035, 
99.7% CI: −0.048 to −0.023), as well as total physical activity (beta = −0.012, 
99.7% CI: −0.018 to −0.005). Time spent watching TV was the only factor 
associated with slower reaction times (beta = 0.008, 99.7% CI: 0.005 to 0.012). 
After adjusting for demographics, vigorous physical activity was no longer a 
predictor of reaction time, while associations remained similar for: walking 
(beta = −0.011, 99.7% CI: −0.019 to −0.003), driving (beta = −0.020, 99.7% CI: 
−0.035 to −0.005), computer use (beta = −0.028, 99.7% CI: −0.040 to −0.015), 
watching TV (beta = 0.006, 99.7% CI: 0.002 to 0.009), and total physical activity 
duration (beta = −0.011, 99.7% CI: −0.018 to −0.005). 
In fully adjusted models, additionally accounting for health-, lifestyle- and 
stroke-related factors, computer use was the only significant predictor of task 
performance (beta = −0.023, 99.7% CI: −0.039 to −0.008). To illustrate the 
magnitude of this association, with every 50.0% increase in computer use 
duration, reaction time decreased by 0.9%. In the complete model (Figure 4-1), 
simultaneously including all types of activities/behaviours and covariates, the 
results were similar – only computer use showed a weak, significant association 
with reaction time (beta = −0.024, 99.7% CI: −0.042 to −0.006). Across all 
models, I found no associations between task performance and either moderate 
physical activity or total sedentary time (Figure 4-5 A presents complete model). 
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Table 4-2 Descriptive statistics for self-reported duration of physical activities 
and sedentary behaviours, performed during a typical day. 
Variables 


































































IQR indicates interquartile range; SD, standard deviation. 
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4.3.1.2 Predictors of verbal-numerical reasoning in Study A 
In unadjusted models, better verbal-numerical reasoning task performance was 
associated with longer daily computer use (beta = 0.546, 99.7% CI: 0.342 
to 0.749), while worse performance was associated with watching TV (beta = 
−0.191, 99.7% CI: −0.248 to −0.133) and total duration of sedentary behaviour 
(beta = −0.068, 99.7% CI: −0.113 to −0.022).  Although reduced in magnitude, 
these associations remained significant after adjusting for demographics:  beta = 
0.396, 99.7% CI: 0.192 to 0.599, for computer use; beta = −0.133, 99.7% CI: 
−0.191 to −0.075, for watching TV; and beta = −0.048, 99.7% CI: −0.092 
to −0.003, for total sedentary time. 
In fully adjusted models, computer use and watching TV were the only 
behaviours that predicted task performance. On average, for every 50% increase 
in computer use duration, the task score increased by 0.1 of a point (beta = 
0.336, 99.7% CI: 0.108 to 0.564), while the score decreased by a similar amount 
with every 1-hour increase in watching TV (beta = −0.100, 99.7% CI: −0.169 
to −0.032). Associations were comparable in the complete model (Figure 4-2): 
beta = 0.275, 99.7% CI: 0.018 to 0.533, for computer use; and beta = −0.116, 
99.7% CI: −0.194 to −0.038, for watching TV. 
Regarding total sedentary behaviour duration, after adjusting for all covariates, 
the initial association with verbal-numerical reasoning task scores was no longer 
significant. However, in the complete model (Figure 4-5 B), additionally including 
total physical activity duration among predictors, the association approached 
the adopted significance threshold (beta = −0.056, 99.7% CI: −0.115 to 0.003, p = 
0.005), suggesting that with an increase in time spent sedentary throughout an 
average day, task performance may have marginally worsened. Across all 
conducted models, physical activity did not predict task scores – neither when 
considering particular types of activities nor total daily active time.   
4.3.1.3 Predictors of visual memory in Study A 
In unadjusted models, I found associations between the number of errors in the 
visual memory task and moderate physical activity duration and total physical 
activity duration, nearing the significance threshold (p = 0.003 and p = 0.004, 
respectively). In both cases, longer activity duration was weakly associated with 
95 
more errors: beta = 0.019, 99.7% CI: 0.000 to 0.037, for moderate physical 
activity; and beta = 0.020, 99.7% CI: −0.001 to 0.040, for total activity.  
After adjusting for demographics, my only finding was a trend for an association 
between task performance and watching TV, where more TV time predicted less 
errors (beta = −0.011, 99.7% CI: −0.022 to <0.001, p = 0.004).  In the fully 
adjusted and complete models (Figure 4-3 and Figure 4-5 C), there were no 
significant associations between predictors of interest and visual memory task 
performance.  
4.3.1.4 Predictors of prospective memory in Study A 
In unadjusted models, I observed that a correct response on first attempt in the 
prospective memory task was more likely with longer daily computer use (OR = 
1.316, 99.7% CI: 1.066 to 1.625), and less likely with more time spent watching 
TV (OR = 0.908, 99.7% CI: 0.857 to 0.962).  Associations with task performance 
remained similar after adjusting for demographics: OR = 1.251, 99.7% CI: 1.005 
to 1.557, for computer use; and OR = 0.939, 99.7% CI: 0.884 to 0.996, for 
watching TV. However, none of the sedentary behaviours, nor their total 
duration, predicted the likelihood of a correct response in the fully adjusted and 
complete models (Figure 4-4 and Figure 4-5 D). Physical activity, considered both 
in terms of distinct types and total duration, was not associated with task 




Figure 4-1 Associations of log reaction time with daily duration of physical activity 
and sedentary behaviour according to type in a complete model, with 99.7% CI. 
Notes: Apart from watching TV, reported duration for predictors was log-transformed; 
*p < 0.003.  
 
Figure 4-2 Associations of verbal-numerical reasoning task scores with daily 
duration of physical activity and sedentary behaviour according to type in a 
complete model, with 99.7% CI. 
Notes: Apart from watching TV, reported duration for predictors was log-transformed; 
*p < 0.003.  































Figure 4-3 Associations of log errors in the visual memory task scores with daily 
duration of physical activity and sedentary behaviour according to type in a 
complete model, with 99.7% CI.  
Notes: Apart from watching TV, reported duration for predictors was log-transformed. 
 
Figure 4-4 Associations of a correct response on the prospective memory task with 
daily duration of physical activity and sedentary behaviour according to type in a 
complete model, with 99.7% CI.  
Notes: Apart from watching TV, reported duration for predictors was log-transformed. 































Figure 4-5 Associations of log reaction time (A), verbal-numerical reasoning scores 
(B), log errors in the visual memory task (C), and a correct response on the 
prospective memory task (D) with log of total daily physical activity duration and 
total daily sedentary behaviour duration in complete models, with 99.7% CI. 
-0.6 -0.4 -0.2 0 0.2 0.4 0.6
Standardised coefficients
Log reaction time
Total daily physical 
activity duration







-0.6 -0.4 -0.2 0 0.2 0.4 0.6
Standardised coefficients
Verbal-numerical reasoning score 
Total daily physical 
activity duration







-0.6 -0.4 -0.2 0 0.2 0.4 0.6
Standardised coefficients
Log errors in the visual memory task 
Total daily physical 
activity duration







0.4 0.6 0.8 1 1.2 1.4 1.6
Odds ratios
Correct response on the prospective memory task 
Total daily physical 
activity duration








4.3.2 Study A discussion 
In this cross-sectional study in a sample of stroke survivors from the UK Biobank, 
I found few significant task-specific associations between cognitive performance 
and measures of physical activity and sedentary behaviour, all of which were 
very weak. The most consistently demonstrated effects were for computer use 
and watching TV. Some of the findings seem to oppose expectations arising from 
previous research, including a similar study conducted in the whole UK Biobank 
population (270). 
In that study, with a main focus on sedentary behaviour, the authors reported an 
inverse association between driving time and cognitive performance across all 
considered tasks, which my results did not reflect. A plausible explanation 
relates to the characteristics of my participant sample. Following stroke, many 
people discontinue driving due to motor, perceptual and/or cognitive deficits, or 
even low confidence (271-273). As follows, participants who reported regular 
driving in my study may also be individuals who on average experienced less 
severe post-stroke impairments, including less affected cognition.  
Regarding the remaining two types of sedentary behaviour, conclusions from our 
studies generally seem to align. I found that watching TV was modestly 
associated with worse performance on reaction time, prospective memory and 
verbal-numerical reasoning tasks. Yet, only in case of the latter the effect 
remained significant after adjusting for all covariates. There are two potential 
explanation for this: i) in part, sedentary behaviour detrimentally affects 
cognition through impairing health overall, ii) people in poor health/feeling 
unwell tend to spend more time sedentary. Thus, once health-related factors 
are controlled for, some association may no longer be apparent. 
Research on sedentary behaviour and its effects has long focused on watching TV 
as a central activity of interest. Many studies have demonstrated the negative 
impact of extensive TV viewing on health outcomes, with evidence also 
expanding for a deleterious association with cognition and mood (274-277). 
These findings may have encouraged the supposition that all forms of sedentary 
behaviour are uniformly detrimental across outcomes. However, this may not be 
necessarily the case, as demonstrated for the unselected UK Biobank population 
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and here, where computer use was associated with better cognitive performance 
in most conducted models (none relating to visual memory).  
My results are in line with conclusions from a different area of research, focusing 
on behaviours that help preserve cognitive function in older age. Multiple 
reports suggest a protective effect of engaging in mentally stimulating activities, 
many of which are performed while being sedentary (e.g. playing cards, doing 
puzzles, reading books, sewing) (278-280). Moreover, in research on sedentary 
behaviour, a recent overview of systematic reviews indicated that a favourable 
association of computer and internet use with cognitive function in older adults 
was one of the key and novel findings (205).  
However, in the current state of knowledge, it is important to interpret these 
observations with caution. There is some evidence from randomised controlled 
trials in healthy older adults to support a causal relationship between computer 
training and improved cognitive performance; yet, in a meta-analysis the overall 
effect size was small, while associations were found to differ depending on the 
form of intervention (281). Namely, unsupervised home-based training was 
concluded to be ineffective.  
It therefore seems that at least in part the positive association between 
computer use and cognition could be attributed to individuals with a higher level 
of cognitive function being more likely to engage in this activity. In the case of 
my study, it is also possible that participants who used a computer more 
frequently had greater ease in completing cognitive tasks on a touchscreen – an 
advantage that would not have been present if the assessment were paper-
based.  
In view of the above arguments and discussed evidence, it is perhaps the 
findings on physical activity that are more surprising here, with hardly any 
support for the well-documented positive effect on cognitive performance. The 
only such observation related to faster reaction times being associated with 
longer duration of daily walking, vigorous activity and total physical activity. 
These effects seem consistent with conclusions from the previously described 
meta-analysis, where participation in structured physical activity training 
increased processing speed (233).  
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However, in my study, none of the associations remained significant after 
adjusting for all covariates. It is therefore plausible that the effects of physical 
activity were driven by more active participants being in better health, which in 
turn translated to faster processing speed. This interpretation would not yet 
account for the null results across other cognitive tasks, or the even more 
unexpected finding that moderate and total daily physical activity were weakly 
associated with more errors in the unadjusted model for visual memory. 
One explanation that aligns with these collective observations relates to 
occupation, particularly in light of physical activity being reported for a whole, 
typical day, and not just regarding leisure time. Previous studies have found that 
in contrast to jobs characterised by high intellectual demands, and human 
interaction and communication, occupations based on physical activity are 
associated with poorer cognitive function (282-285). This effect appears to be 
independent of education and deprivation, and so sociodemographic factors 
included in my adjusted models would not have controlled for it. As follows, it is 
possible that the opposing effects of occupational and leisure time physical 
activity jointly manifested as a neutral association with cognitive performance. 
Another important consideration relates to use of self-reported measures. Being 
prone to recall and social desirability bias, it is difficult to ascertain how closely 
they reflected actual energy expenditure, particularly as studies comparing 
subjectively and objectively assessed physical activity indicate correlations 
differing not only in strength, but also in direction (286).  
Lastly, the association between physical activity and poorer visual memory 
performance brings attention to the fact that all findings for this task diverged 
from the overall pattern of results. This may be due to the test’s specific 
properties. Studies describing the UK Biobank cognitive assessment found that 
the visual memory task had: poor test-retest reliability; compared to other 
tasks, had one of the weakest associations with a general cognitive ability score; 
and after adjusting for age, only a weak association with a validated reference 
test (257, 258).  
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4.3.2.1 Clinical implications 
As noted above, although I observed relatively consistent associations with 
cognitive performance for computer use and watching TV, these effects were 
very weak. Thus, if considered in isolation, my results are insufficient to 
conclude that the average daily duration of these behaviours is linked to 
clinically meaningful differences in cognitive function. However, cumulatively 
interpreting the available evidence, it seems that reducing mentally passive 
sedentary behaviour by replacing it with mentally active behaviour and some 
form of physical activity is plausibly of therapeutic value and can be 
recommended (279, 287, 288).  
In relation to breaking-up sedentary time, it seems that at least some gains can 
be expected in terms of physical health and mood (205, 289), which are in turn 
associated with cognitive function. As a group, stroke survivors also seem to be 
among the more likely to benefit from such a change to habits, as the positive 
effects of interrupting prolonged periods of sitting with light-intensity physical 
activity are found to be more pronounced in physically inactive individuals (236). 
Moreover, as a potential intervention, introducing mentally and physically active 
behaviours to break up mentally passive sedentary time is worth considering in 
view of its practical advantages. Strategies based on this approach could be 
easily tailored to suit individual likes and interests, functional status, and living 
conditions, and subsequently be implemented by stroke survivors without the 
need for professional supervision, purchasing specialist equipment or travel.  
Many of the presented arguments in favour of breaking-up sedentary behaviour 
have also been advocated by investigators involved in the RECREATE study 
(REduCing sedentaRy bEhaviour After sTrokE ) (290). Insights gained from this 
project, beginning from systematic reviews and ending on a multicentre cluster 
randomised controlled trial, may indeed find a place in future stroke-specific 
clinical guidelines. Presently, however, there is no indication that assessed 
outcomes will encompass cognitive function (291), and so it seems that the need 
for studies addressing the role of sedentary behaviour in shaping post-stroke 
cognitive outcomes has not yet been met. 
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4.3.2.2 Research implications 
Results of the analyses partially supported my initial assumptions, which may 
have a direct application to future research. Firstly, it seems that sedentary 
behaviour is associated with cognitive performance independently of physical 
activity. As follows, both categories of activity patterns should be accounted for 
in prediction model studies, and both can be considered as potential targets for 
intervention.  
Secondly, distinguishing between different types of sedentary behaviour is a 
valid approach, particularly regarding whether their nature is mentally passive 
or active, as this could entail opposing effects on cognition. However, 
implementing this notion into research practice can present a considerable 
challenge, as behaviours plausibly exist on a continuum, and accurately 
classifying some of them will require a high level of detail. For example, social 
media can be accessed to participate in discussion forums or to watch short 
videos for entertainment purposes. Arguably, the former is more cognitively 
stimulating than the latter, yet both behaviours would fall under the broad 
category of mobile device use.  
Fortunately, in the same review where the distinction between the two types of 
sedentary behaviour was first proposed, an assessment framework was also 
presented (193). The authors suggested considering sedentary behaviour across 
three different contexts – occupation, leisure and transport – and provided 
mentally active and passive examples relevant to each. Conceptually, this novel 
approach seems highly useful in the context of identifying modifiable predictors 
of cognitive function, although its feasibility, validity and reliability are yet to 
be determined in future studies.  
4.3.2.3 Limitations 
One of the main limitations of my study was the aforementioned use of self-
reported measures for key predictors of interest, which introduces concerns 
around estimate accuracy. Ideally, physical activity would be assessed using an 
accelerometer, however, for the UK Biobank such data was not collected until 
seven years after recruitment had begun and involved only a fifth of the sample 
(292). A similar issue relates to identifying eligible participants for my study. 
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Compared to an objective source (e.g. hospital records), relying on self-reported 
history of stroke or TIA may increase the risk of both missing relevant cases, as 
well as including false positives. In a systematic review of the accuracy of 
participant self-report of stroke, the latter problem was indicated as being of 
particular concern for large prospective studies, such as the UK Biobank, where 
healthy individuals are overrepresented, and stroke prevalence is likely to be 
low (293). At the same time, however, based on national stroke prevalence data 
and allowing for the “healthy cohort effect”, the authors of the review 
estimated that the true prevalence of stroke in the UK Biobank is plausibly under 
2%. This aligns with the 1.4% stroke prevalence recorded for the cohort based on 
self-report. 
Due to sample characteristics, there are also potential concerns around 
generalisability, as with many UK Biobank-based studies. Participants in my 
study were on average younger, had a higher education and a lower comorbidity 
burden than an unselected stroke population (for comparison see 294). Yet, both 
inactivity and cognitive problems are likely to be more prevalent in a ‘real 
world’ group of stroke survivors, and the associations observed here may be 
exacerbated in a dedicated stroke cohort.  
A further, related limitation is that I did not have access to data regarding 
stroke-related factors, recognised as predictors of cognitive outcome, including: 
stroke type, acute symptoms, acute physiology and, most importantly, stroke 
severity (23). I attempted to partially adjust for the latter by including disability 
among model covariates, serving as a proxy for post-stroke functional deficits 
(295). In hindsight, as discussed previously, I also acknowledge the relevance of 
controlling for occupation type. However, given the coding of this variable, an 
intention to include it in the analyses would have introduced a high level of 
additional complexity to my study.  
In view of characterising the relationship between activity patterns and post-
stroke cognitive function, it is moreover important to note that I had not 
comprehensively addressed the issue of time elapsed between index stroke or 
TIA and baseline assessment. While I controlled for this factor in the fully 
adjusted and complete models, I did not determine whether it moderated the 
associations between physical activity, sedentary behaviour and cognitive 
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outcomes. Identifying in what period following stroke activity patterns are 
particularly relevant to cognitive performance may significantly contribute to 
planning interventions based on modifying habitual behaviour.   
Another, crucial limitation to understanding the nature of studied relationships 
stems from the cross-sectional design of my study, precluding causal inference. 
Although repeat assessments for the UK Biobank were conducted between 2012 
and 2013 (approximately 20300 participants), data on variables of interest were 
available for only a small percentage of my study sample (e.g. 290 stroke 
survivors completed the verbal-numerical reasoning task at follow-up). As these 
attrition rates may have introduced considerable bias, it did not seem feasible 
to conduct a longitudinal analysis.  
Even with the adopted approach, the extent of missing data was a pronounced 
issue in my study, affecting even 2/3 of participants for some of the variables. 
This was, however, for the most part due to certain baseline assessment tasks 
and questions added at later stages of UK Biobank recruitment. Thus, I assumed 
that most of these data were likely missing completely at random, i.e. that 
there were no systematic differences between the missing values and the 
observed values (296).  
Finally, use of the UK Biobank repository entailed relying on results of bespoke 
cognitive tasks as measures of cognitive performance, designed to allow brief 
assessment on a large scale, without the need for examiner supervision. This 
approach, although having practical advantages, poses a considerable challenge 
to comparing the developed tests with standard cognitive measures, routinely 
administered in research and clinical practice. It also introduces some 
uncertainty regarding what cognitive functions are engaged in task completion.  
4.3.2.4 Strengths 
Alongside inherent limitations, use of the UK Biobank resource presented 
important advantages. I had access to data from a relatively large sample of 
stroke survivors – several times larger than most dedicated stroke cohorts. 
Further, the wealth of available variables made it possible to control for many 
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key factors simultaneously relevant to physical activity, sedentary behaviour and 
cognitive function.  
It was also the variety of collected information that allowed me to adopt a 
relatively novel approach to considering effects of activity patterns – accounting 
for both physical activity and sedentary behaviour, and distinguishing between 
their different types. To my knowledge, this is the first study to address these 
aspects of routine behaviour in relation to cognitive function among stroke 
survivors, who as a group are at greater risk of both inactivity and cognitive 
impairment. 
4.3.2.5 Future directions 
The relationship of post-stroke cognition with habitual physical activity and 
sedentary behaviour appears far from unravelled, considering: the scarcity of 
existing evidence on this specific topic; the limitations of the present study; and 
the complexity of associations, with multiple potential paths of influence, 
originating even prior to index stroke (232). As follows, there is a need for 
bespoke cohort studies in stroke populations, combining objective measures of 
physical activity and sedentary behaviour with self-report to classify types of the 
latter, and employing sensitive and widely recognised cognitive assessment 
tools. These studies will also need to account for a number of sociodemographic, 
health and lifestyle-related factors. 
Regarding approaches to analysis, additional insights might be gained by 
accounting for mediation effects. Specifically, it could be determined how much 
of the overall effect of physical activity and sedentary behaviour on post-stroke 
cognition is explained by associations with physical health (e.g. insulin 
resistance or risk of recurrent stroke) and mood; and whether there is evidence 
for a more direct impact of activity patterns on neurological function.    
A better understanding of the considered associations could in turn inform the 
design of future interventions. Here, it will be essential to maintain a balance 
between the potential to produce clinically meaningful cognitive gains and 
feasibility. The efficacy of any intervention will be of little value if in the long 
term it cannot be embedded in everyday lives of predominantly older 
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individuals, many of whom experience functional disability, comorbidity, fatigue 
and apathy. 
Developing such studies as I suggest will undoubtedly require considerable 
resources, and consequently, funding constitutes a key issue. One route that 
could increase the likelihood of securing financial support could lead through 
broadening the scope of this research. As outlined at the beginning of the 
chapter, physical activity and sedentary behaviour affect health and well-being 
in many ways. If alongside cognition multiple other outcomes were to be 
assessed (e.g. mortality, non-fatal adverse events, functional independence, 
depression or fatigue), this could expand the range of organisations willing to 
fund projects on post-stroke physical activity and sedentary behaviour, 
particularly, as so far RECREATE appears as a single large-scale trial in this 
specific research landscape.  
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4.3.3 Study B results 
The distribution among categories of the six considered social engagement 
proxies is presented in Table 4-3. Across all models I conducted for Study B, 
sample sizes ranged from 1873 to 8266 participants. Similarly as for Study A, in 
this chapter I summarised key findings from my analyses, while complete results 
are included in Appendix 5, Supplemental Tables 9 to 12. 
4.3.3.1 Reaction time 
In unadjusted models, faster reaction times were associated with monthly (beta 
= −0.052, 99.7% CI: −0.095 to −0.009) and weekly (beta = −0.046, 99.7% CI: 
−0.086 to −0.006) family/friend visits as compared to no visits, and participation 
in sports as compared to no reported social activities (beta = −0.031, 99.7% CI: 
−0.058 to −0.003). Slower reaction times were associated with loneliness (beta = 
0.024, 99.7% CI: 0.008 to 0.041) and participation in religious group activity 
(beta = 0.055, 99.7% CI: 0.026 to 0.085).  
After adjusting for demographics, associations with weekly family/friend visits 
(beta = −0.043, 99.7% CI: −0.083 to −0.003), loneliness (beta = 0.020, 99.7% CI: 
0.003 to 0.037), and religious group activity remained significant (beta = 0.048, 
99.7% CI: 0.019 to 0.077). In addition, faster reaction times were predicted by 
satisfaction with family relationships (beta = −0.051, 99.7% CI: −0.095 
to −0.007). 
In fully adjusted models, I found only two proxies of social engagement to be 
significant predictors of task performance. Monthly family/friend visits were 
associated with 6.5% faster reaction times (beta = −0.063, 99.7% CI: −0.119 
to −0.007), while religious group activity – with 4.8% slower times (beta = 0.047, 
99.7% CI: 0.011 to 0.084). However, in the complete model (Figure 4-6), I 
observed no significant associations between any proxies of social engagement 
and reaction time. Satisfaction with friendships and frequency of opportunities 
to confide in someone were the only variables that did not predict task 
performance in any of the models. 
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4.3.3.2 Verbal-numerical reasoning 
In unadjusted models, I found that better verbal-numerical reasoning task scores 
were associated with engagement in multiple social activities (beta = 0.530, 
99.7% CI: 0.200 to 0.861), while worse scores were associated with reported 
loneliness (beta = −0.654, 99.7% CI: −0.938 to −0.370). In partially and fully 
adjusted models, loneliness remained as the only significant predictor of task 
performance, associated with an approximately 0.4-point decrease in scores 
(beta = −0.417, 99.7% CI: −0.697 to −0.136, and beta = −0.412, 99.7% CI: −0.750 
to −0.074, respectively).  
However, having combined all proxies of social engagement in the complete 
model (Figure 4-7), the association with loneliness was no longer significant, 
although close to the set threshold (beta = −0.345, 99.7% CI: −0.704 to 0.013, p = 
0.004). Across all models, I observed no significant associations between verbal-
numerical reasoning scores and family/friend visits, satisfaction with 
relationships, and frequency of opportunities to confide in someone. 
4.3.3.3 Visual memory 
Across all models, none of the studied proxies of social engagement significantly 
predicted the number of errors in the visual memory task. Figure 4-8 presents 
associations with variables of interest in the complete model. 
4.3.3.4 Prospective memory 
Across all models including individual proxies of social engagement, my results 
indicated that loneliness was the only significant predictor of performance on 
the prospective memory task. With reported loneliness, odds of a correct 
response on first attempt were lower by 30.5% (OR = 0.695, 99.7% CI: 0.532 
to 0.907) in the unadjusted model, lower by 28.0% (OR = 0.720, 99.7% CI: 0.543 
to 0.955) in the partially adjusted model, and lower by 33.9% (OR = 0.661, 99.7% 
CI: 0.461 to 0.947) in the fully adjusted model. However, in the complete model 





Figure 4-6 Associations of log reaction time with proxies of social engagement in a 
complete model, with 99.7% CI.  
 
Figure 4-7 Associations of verbal-numerical reasoning task scores with proxies of 
social engagement in a complete model, with 99.7% CI. 
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Figure 4-8 Associations of log errors in the visual memory task with proxies of 
social engagement in a complete model, with 99.7% CI.  
 
Figure 4-9 Associations of a correct response on the prospective memory task with 
proxies of social engagement in a complete model, with 99.7% CI. 
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4.3.4 Study B discussion 
Based on cumulative findings from studies involving animal models, non-stroke 
populations and stroke survivors, I hypothesised that proxies of social 
engagement would predict post-stroke cognitive performance. My findings 
partially supported this assumption, indicating relatively modest task-specific 
associations for some predictors of interest, not all of which remained significant 
after adjusting for covariates. The experience of loneliness was the only proxy of 
social engagement to be associated with most tasks, consistently predicting 
poorer performance. 
Many studies have reported an association between loneliness and health-related 
outcomes, independent even of objective measures of social engagement (297-
300). Similar findings have been reported in relation to cognitive function (301). 
Longitudinal studies in the general older adult population indicated that 
loneliness is associated with an increased risk of incident dementia and cognitive 
decline, and an increased rate of the latter (302, 303).  
Considering loneliness in a broader sense, as a subjective measure of social 
engagement, it also seems relevant that perceived social support has been 
previously identified as a predictor of better performance on word recall and a 
measure of executive function (304). The cognitive abilities required for 
completion of these tasks were plausibly similar as for the prospective memory 
and verbal-numerical reasoning tests here, performance on which was inversely 
associated with loneliness.  
Finding that a subjective measure of social engagement predicted performance 
on a memory-based task is also the one similarity between my results and those 
obtained in a previous study investigating cognitive outcomes among stroke 
survivors, described in the Introduction (245). Beyond that, a comparison of 
observations is rendered difficult by the difference in chosen social engagement 
proxies and cognitive tasks. Despite this, there is one conclusion that may be 
particularly relevant to my findings. The authors reported that social ties and 
emotional support were positively associated with a cognitive summary score, 
yet when individual tasks were considered, only performance on one of seven 
(word recall) was predicted by social factors.  
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In view of this, it seems possible that I would have found significant associations 
for more proxies of social engagement or observed greater effect sizes if I had 
used a global measure of cognitive function. Considering my results on a task-
specific level, it is also noteworthy that none of my predictors of interest were 
associated with visual memory in any of the models. This is consistent with 
findings in Study A, where the emerging pattern of results appeared to diverge 
for this particular task, indicating a possible source in psychometric properties. 
Regarding reaction time, evidence on its predictors seems to be overall 
inconclusive, with some studies supporting my findings (305, 306), and others – 
not (304, 307). Perhaps most surprising is the observed association between 
religious activity and slower reaction times, with a number of existing reports 
suggesting a positive relationship between religious engagement and cognition 
(308). An accurate interpretation of this discrepancy seems however to exceed 
the scope of my analysis, with potentially multiple factors contributing to the 
obtained results (309), e.g. relating to used measures of cognitive performance 
and religious involvement, uncontrolled relevant variables, and residual 
confounding from included covariates. 
In addition to unexpected associations, what seems interesting is that the 
findings did not support certain expected ones. Specifically, in adjusted models, 
participation in social activities did not predict better performance on any of the 
cognitive tasks, despite favourable associations being relatively well-
documented at least for sports and adult education (310-314). Regarding the 
former, the only finding related to faster reaction times in an unadjusted model 
(consistently with results of Study A), which may reflect that the effect was 
driven by younger and healthier participants engaging in sports. Thus, once 
these factors were controlled for, the association was no longer significant. 
Moreover, the “sports” category would not account for non-occupational 
physical activities that could be more commonly engaged in by this population, 
such as gardening or walking. In relation to adult education, on the other hand, 
it may be relevant that very few stroke survivors reported participation in such 
an activity (under 2%). 
There are also several other explanations to consider, which apply to my findings 
more broadly. Firstly, many assumptions arise from studies in the general 
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population, and not all may be directly transferable to the context of stroke. 
Some proxies of social engagement could also be specifically associated with 
cognitive change over time, which given the cross-sectional nature of my data, I 
was unable to investigate. The complexity of associations between social 
engagement and cognition may further exceed the limits of regression analysis, 
with some variables potentially mediating the effects of others (298, 315). 
Moreover, my finding that no proxies of social engagement significantly 
predicted cognitive performance when combined into one, complete model, may 
indicate model overfitting.  
4.3.4.1 Clinical implications 
From a person-centred perspective, a particularly concerning finding was that a 
quarter of my sample experienced loneliness. Taking into account the risk of 
participation bias, as well as a recent report of national survey data (316), this is 
likely an underestimation of true prevalence in an unselected stroke population. 
Although a negative impact on cognition requires further confirmation, it seems 
clear that loneliness is a common problem that can severely compromise an 
individual’s well-being. In recognition of this, in 2018 a United Kingdom 
government press release announced a planned £20 million investment to help 
socially isolated and lonely people (317).  
Evidence from studies conducted in the general adult population suggest that 
interventions for alleviating feelings of loneliness may indeed be successful (318, 
319), yet plausibly there are unique aspects to the experience of loneliness in 
stroke, as well as particular considerations regarding intervention delivery (e.g. 
overcoming communication difficulties). One research team has indicated plans 
to trial an intervention – LISTEN (Loneliness Intervention using Story Theory to 
Enhance Nursing-sensitive outcomes) – with stroke survivors, however, result of 
this study seem so far unpublished (320, 321). 
Until bespoke interventions for diminishing loneliness following stroke are 
available, potential avenues of support may be sought within existing resources. 
A first step would be to identify stroke survivors who experience loneliness – 
asking even just a single question, which could be done at any point of contact 
with health services. If flagged as an important issue to the individual, at its 
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basic level, provision of help could simply involve informing about local 
befriending services and peer support groups, as contact with people who have 
similar experiences seems to be of particular merit (322, 323). 
4.3.4.2 Research implications 
The value of including loneliness as a candidate predictor in prognostic models 
seems so far to have gone unrecognised; while my findings, combined with the 
reviewed literature, suggest this factor could indeed contribute to explaining 
variance in post-stroke outcomes, independently of demographics, health status, 
lifestyle factors and depression. There are also practical advantages worth 
considering. Loneliness is a variable that can be easily assessed and despite 
being subjective, or perhaps because of it, its meaning seems relatively 
unambiguous.  
In comparison, interpreting what objective proxies of social engagement truly 
represent can be more challenging. Regarding frequency of family/friend visits, 
unlike those monthly and weekly, I found that daily visits did not predict faster 
reaction times compared to having no visits in any of the models. In part, this 
could be due to receiving frequent visits as a result of an individual’s greater 
need for external assistance with activities of daily living. In turn, more frequent 
visits may reflect less/no support within the household and/or greater functional 
and cognitive difficulties.  
These findings further prompt the notion that more is not always better, as 
social interactions can also be negative. Opposite to the proposed stress-
buffering role of social support, negative social interaction can itself be a source 
of stress, including e.g. experiences of hostility, discouragement, shaming, 
deceit or violation of boundaries; and has been linked to an increased risk of 
disease (324, 325). Moreover, in the specific context of post-stroke recovery, 
even support can have its negative aspects, as extending to overprotectiveness, 
it may limit opportunities for stroke survivors to engage in certain activities 
(326-328). These combined arguments indicate the importance of applying 
measures that account for the nature of social interactions, in addition to their 




Many of the limitations discussed for Study A also apply here: employing a cross-
sectional design, identification of eligible participants based on self-reported 
medical history, concerns regarding representativeness of the study sample, high 
volume of missing data, use of bespoke measures of cognitive function, and 
inability to control for certain relevant variables (particularly stroke-related 
factors). A further limitation, unique to this study, relates to a lack of 
information on basic features of the participants’ social networks, specifically, 
their marital status and number of people they live with. Unfortunately, access 
to these variables was not covered under the current UK Biobank application. 
4.3.4.4 Strengths 
My study is one of the few to focus on proxies of social engagement as predictors 
of post-stroke cognitive performance. Similarly as in the case of Study A, 
important strengths lie in the relatively large sample size and opportunity to 
control for multiple variables, plausibly associated with both social engagement 
and cognitive performance. Regarding the latter, history of depression 
constituted a key covariate, accounting for which allowed to demonstrate that 
the effect of some aspects of poor social integration likely extend beyond a 
deleterious association with mood. A further strength relates to investigating 
different types of social engagement proxies, representing both ends of the 
objective-subjective continuum.  
4.3.4.5 Future directions 
The associations between post-stroke cognition and social engagement are 
undoubtedly complex, likely involving bidirectional effects. Our understanding of 
them can be improved through longitudinal studies that not only assess the key 
predictors and outcome of interest, but also factors that may explain the 
mechanisms underlying these associations, such as differences in physiological 
stress markers or likelihood of engaging in behaviours that impact health. 
However, it is interventional studies that are ultimately needed to demonstrate 
whether improving aspects of social engagement translates to improved post-
stroke cognitive outcome.  
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As discussed above, the transferability of interventions that were developed in 
the general population to this context may be poor. Thus, before the stage of 
bespoke intervention development and implementation is reached, it is 
important to identify what factors contribute to limited social engagement 
following stroke and which of these stroke survivors find important to address 
(as some may result from personal preference). This in turn emphasizes the need 
for qualitative studies. The few available publications on this topic seem to 
prove how informative such insights can be, having identified issues around: loss 
of shared activities with friends, being unable to contribute to one’s 
environment, communication barriers, embarrassment around disabilities, and 
lack of access to transportation (322, 329, 330).  
4.4 Summary 
Physical activity, sedentary behaviour and social engagement have so far not 
been in the focus of prognostic research in stroke. It is unknown whether the 
accuracy of existing prediction models for post-stroke cognitive outcomes would 
meaningfully improve after adding such predictors, particularly given their close 
link to demographics and health-related factors, which are already commonly 
incorporated. Regardless, the value of continuing research in this direction 
seems to predominantly lie in identifying novel targets for intervention. 
Modifying aspects of habitual activity patterns and social engagement could 
potentially be achieved through means feasible and acceptable to stroke 
survivors, and improve more outcomes following stroke than just cognition.  
Although I conducted two independent studies, this was not in support of an 
outlook that these factors of interest should be addressed separately. On the 
contrary, there is evidence indicating that targeting them simultaneously could 
be of particular benefit. A systematic review of studies in stroke populations 
concluded that social support is an important motivator for engaging in physical 
activity (234); while in the general population, findings suggest a bidirectional 
relationship, where loneliness may reduce the probability of being physically 
active, and physical activity decreases feelings of loneliness (331).  
Regarding which specific aspects of physical activity, sedentary behaviour and 
social engagement are important to target, my most consistent observations 
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indicated that cognitive performance was positively associated with computer 
use (a mentally active sedentary behaviour), and negatively associated with 
watching TV (a mentally passive behaviour) and experiencing loneliness. 
However, given multiple study limitations, these results should be viewed as 
hypothesis-generating rather than definitive. Unfortunately, until bespoke 
studies addressing these topics are conducted, future research is likely to face 
similar challenges. 
Large population-based general-purpose cohort studies have many key strengths. 
However, when focusing on a particular condition (such as stroke, here), the 
available sample size considerably decreases and information specific to that 
condition is often lacking, and thus cannot be accounted for. Conversely, 
datasets from clinical sources are likely to include such information and also 
offer greater certainty regarding sample representativeness. Yet, apart from 
data on commonly recognised risk factors, such as smoking and alcohol intake, 
little or no insight is provided regarding individuals’ everyday life activities and 
experiences.  
Fortunately, this does not imply that existing clinical datasets have no 
application to investigating potentially modifiable predictors of post-stroke 
cognition. Given that: i) at least part of the effect of lifestyle factors and life 
experiences on cognitive impairment and decline is driven by detrimental 
changes to health, and ii) some diseases can be alleviated or even reversed; one 
avenue for using clinical data to its best advantage may be through determining 
the associations between post-stroke cognition and comorbid conditions.
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Chapter 5 Cardiovascular risk factors as 
predictors of acute post-stroke cognitive function: 
Are there two sides to this story? 
In the previous chapter, I presented two studies investigating the relevance of 
potentially modifiable factors to cognitive function following stroke, with a 
specific focus on habitual physical activity, sedentary behaviour, and social 
engagement. In the section on Routes to affecting cognition that formed part of 
my introduction, I indicated that the impact of these factors is considered as at 
least partially driven by modifying cardiovascular risk burden (particularly in 
relation to physical activity patterns). Interestingly, however, findings from 
observational studies and trials of interventions to alleviate cardiovascular 
diseases are not consistent in supporting a link between variation in such risk 
factors and post-stroke cognitive outcomes.  
In this chapter, I argue that (to some extent) neutral results could be due to the 
complexity of these associations, which may involve differing paths of influence 
and interactions between comorbid conditions. To test my assumptions, I 
developed a moderated mediation model, using data from a hyper-acute stroke 
unit setting. This chapter is an adaptation of my published work (332), with 
edited and expanded Methods, Results and Discussion sections. 
5.1 Introduction 
Many studies have investigated the effects of prevalent cardiovascular risk 
factors on post-stroke cognition (23, 25, 333). This interest seems unsurprising 
given the high comorbidity burden among stroke survivors, encompassing 
conditions recognised as predictors of age-related cognitive decline and 
dementia, such as: diabetes mellitus, hypertension, coronary and peripheral 
vascular disease, atrial fibrillation, and previous stroke (334-337). Interestingly, 
despite a strong premise to assume the relevance of cardiovascular risk factors 
to post-stroke cognition, only two of eleven prognostic rules described in 
Chapter 3 included a predictor of this type. In part, this could be due to actual 
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evidence on the associations between comorbid conditions and post-stroke 
cognitive function appearing inconclusive or conflicting (e.g. see 23, 145).  
One possible explanation for the inconsistency of observations relates to the 
complexity of this relationship. Cardiovascular conditions often pre-date 
incident stroke and so it seems plausible that to some degree post-stroke 
cognitive impairment is a manifestation of precursory vascular 
neurodegenerative processes (338, 339). However, the effect of cardiovascular 
risk factors on post-stroke cognition is likely not only driven by gradual 
neurodegeneration. Certain conditions are associated with stroke severity, which 
is in turn a major determinant of cognitive outcome.  
Intuitively, it seems that the presence of cardiovascular diseases should be 
consistently detrimental across outcomes. Indeed, this seems to be the case for 
atrial fibrillation, which is associated with both higher incidence of dementia 
and the most severe ischaemic stroke subtype – cardioembolic infarction (17, 
340, 341). However, the effects of other cardiovascular risk factors on cognitive 
function may be more equivocal, particularly where the pathophysiological 
processes they contribute to trigger endogenous adaptive mechanisms. For 
example, transient ischaemia has been reported to induce a state of “ischaemic 
tolerance” or “preconditioning“ that temporarily protects tissue from 
subsequent, persistent ischaemia (342). Evidence from observational studies 
suggests that this phenomenon, which is consistently demonstrated in animal 
models, may also occur in clinical practice. In cases of stroke, prodromal TIA has 
been associated with less severe symptoms, smaller infarct volumes, and better 
functional outcomes (343-345). 
A similar example relates to vascular disease. Its most common forms involve 
build-up of atherosclerotic plaque, leading to narrowing of vessels and thus 
reduction of blood flow (346). Although this is a progressive pathological 
process, it may support the advantageous development of collateral circulation. 
In the event of arterial occlusion, robust collaterals sustain perfusion, helping to 
maintain nutritive tissue needs (347, 348). Following stroke specifically, 
efficient collateral circulation has been associated with favourable clinical 
outcomes, including an improved response to thrombolytic and recanalisation 
therapy (349, 350).  
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To add further complexity, manifestation of the described putative protective 
mechanisms may be affected by comorbidity. Observations from clinical and 
preclinical models suggest that both hypertension and diabetes may impair the 
development of collaterals (346, 351-355), while diabetes also precludes 
ischaemic tolerance (356, 357). These findings, therefore, highlight that 
cardiovascular risk factors may not only co-occur but also interact. 
In this context, it seems that the traditional approach to data analysis, involving 
use of multivariable regression models, may have been insufficient to capture 
the true nature of associations between cardiovascular diseases and post-stroke 
cognition. In its basic form, the method can only identify those factors directly 
associated with an outcome, while remaining factors are held constant. As such, 
it does not allow us to explore the potential for multiple routes of predictor 
impact, nor the interaction between co-occurring diseases. It is therefore 
possible that neutral results, reported from some of the previous studies, stem 
from the duality or conditionality of considered effects. 
In my study, I aimed to investigate how cardiovascular risk factors can affect 
cognitive function in the acute phase after stroke, through influence on stroke 
severity and prior cognitive impairment. I specifically hypothesised that: 
• previous TIA and vascular disease may have differential effects on acute 
post-stroke cognitive function depending on the path of influence, 
possibly predicting poorer performance through an increased risk of 
prevalent dementia, while predicting better performance through an 
association with reduced stroke severity;   
• a favourable effect of vascular disease on stroke severity, and in turn on 
acute cognitive performance, may be conditional on the absence of 
hypertension and diabetes; 
• a favourable effect of previous TIA on stroke severity, and in turn on 




The dataset used for my analyses is part of a larger research database. The West 
of Scotland Research Ethics Committee approved the primary project on the 4th 
of February 2016 (16/WS/0001). As data collection was embedded in routine 
clinical care, and patient information was fully anonymised prior to archiving, 
obtaining written informed consent from participants was not required. I based 
the design and conduct of the present study on recommendations from recent 
works, summarising theoretical and practical approaches to development of 
mediation and moderation models with an emphasis on best practice (358, 359).     
5.2.1 Study setting and participants 
Participants were consecutive patients admitted to the hyper-acute stroke unit 
of Glasgow Royal Infirmary. The unit provides high dependency level clinical 
care, accepting all cases of suspected stroke and TIA, regardless of preadmission 
physical and cognitive function. Collection of anonymised data took place in four 
waves: May 2016 to February 2017, April to June 2017, October to December 
2017, and July to August 2018. For the purposes of this study, I excluded 
patients for whom a diagnosis of stroke or TIA had been ruled out by the clinical 
team.  
5.2.2 Data collection 
Together with four other trained researchers, we used medical records and data 
collected by the clinical team during acute admission to extract information on 
basic demographics, pre-existing medical conditions, and findings from 
neurological examinations. We additionally acquired cognitive data through 
directly administering a cognitive screening test, which I describe in detail in 
a subsequent section. 
5.2.2.1 Predictors  
Based on indications from previous research, I included cardiovascular risk 
factors with a plausible association with post-stroke cognitive function: vascular 
disease (peripheral and coronary), atrial fibrillation, hypertension, diabetes 
mellitus, previous stroke, and previous TIA. The clinical process in the stroke 
service is for these data to be confirmed from at least two sources, and includes 
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information from both primary and secondary care records. I coded all risk 
factors as either present or absent. I additionally accounted for basic 
demographics of sex and age, the latter treated as a continuous variable (years). 
5.2.2.2 Mediators 
The first mediator I included in the model was stroke severity, assessed using 
the NIHSS (71, 72). Where a specific NIHSS score had not been documented by 
the clinical team, the researcher responsible for data collection would 
retrospectively derive a score based on findings from acute neurological 
examinations, described in patient notes (360). As per emergency department 
triage policy, examination is performed immediately upon hospital admission 
and then confirmed in the hyper-acute stroke unit, noting any changes in initial 
signs (resolution or progression). For inclusion in the analysis, I categorised 
NIHSS into four groups: no stroke signs (score of 0), minor stroke (score of 1 to 
4), moderate stroke (score of 5 to 15), and severe stroke (score of 16 to 42) 
(361). 
The second mediator was a formal diagnosis of dementia prior to incident stroke 
or TIA. This information was obtained from primary or secondary care medical 
records, including reports from mental health services. In the United Kingdom, 
dementia is diagnosed by specialist (secondary) care providers, based on the 
International Classification of Diseases (ICD) criteria (362). 
5.2.2.3 Cognitive performance 
Our research team assessed cognitive performance within a week of stroke or 
TIA, using a test battery of 13 items, comprising Hodkinson’s Abbreviated Mental 
Test (AMT-10) (363, 364) and a short-form version of the MoCA (77). The 
following tasks were included: stating one’s age, current time to the nearest 
hour, date, place, recognition of two people, date of birth, year World War I 
began, name of current Prime Minister, months of the year listed in a backwards 
order, five-word recall, clock draw, recent news item, and verbal fluency (words 
beginning with “f”). Clock draw was the only task to be scored out of 3 points 
(face, number, hands), with remaining items assigned a single point, summing up 
to a maximum total of 15. 
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For the purpose of this study, I considered outcome data to be missing under 
three conditions: (i) the patient refused to participate; (ii) the patient was 
discharged prior to assessment; (iii) the assessment was initiated but could not 
be completed due to external circumstances, e.g. to avoid disruption to work 
carried out by the clinical team. If a patient was unable to complete a particular 
task due to an existing impairment (e.g. aphasia or limb weakness), I assigned a 
score of zero for that item, including it in the sum score (365).  
In cases where the severity of the patient’s condition (e.g. altered level of 
consciousness, agitation) precluded from attempting the assessment altogether, 
I entered a total score of -1. This approach, where an untestable status is 
assigned the lowest possible score, mimics the scoring system applied in delirium 
screening (66, 67). It allowed me to minimise missing data and avoid exclusion of 
participants with the most severe presentation. For inclusion in the analysis, I 
divided cognitive scores of all participants into quintiles, creating the following 
groups: (i) scores from -1 to 2, (ii) scores from 3 to 8, (iii) scores from 9 to 11, 
(iv) scores of 12 and 13, and (v) scores of 14 and 15.  
5.2.3 Statistical analysis 
I developed a first stage dual moderated mediation model for prediction of 
cognitive performance, with two parallel mediators – stroke severity and 
previous diagnosis of dementia (Figure 5-1). Although it was possible to model a 
number of different moderation effects, I focused on three interactions most 
consistently demonstrated by existing evidence (346, 351-357). Namely, I 
hypothesised that mediation of the effect of vascular disease and previous TIA 
on the outcome through stroke severity may be moderated by the presence of 
diabetes (in both cases) and hypertension (for vascular disease only). 
Given that mediation analyses assume causal relationships, I aimed to build a 
model the structure of which would reflect the actual temporal order of 
occurrences. This order was definite for paths mediated by stroke severity (with 
cardiovascular risk factors present before the index stroke/TIA, and the 
cognitive assessment taking place after) and appeared plausible for paths 
mediated by dementia, with evidence suggesting that cardiovascular diseases 
would have likely developed in earlier stages of life. 
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Figure 5-1 Conceptual diagram of the proposed dual moderated mediation model 
with two parallel mediators for acute cognitive performance. 
I analysed the data within a path analysis framework, using structural equation 
modelling (SEM) software, Mplus version 8.3 (366). As the outcome of interest 
was an ordinal variable, I estimated associations with predictors and mediators 
based on a probit regression, using a robust weighted least squares mean and 
variance-adjusted estimator (WLSMV). Missing data were handled as per software 
default, that is, cases with missing data on predictors were removed from the 
analysis, while missing outcome and mediator data were estimated as a function 
of the observed predictors (367).  
The moderated mediation analysis involved regressing cognitive performance on 
both mediators and the eight predictors, while regressing each mediator on the 
eight predictors. In line with my hypothesis, I also regressed stroke severity on 
three interaction terms (TIA x diabetes mellitus, vascular disease x diabetes 
mellitus, vascular disease x hypertension). As I based decisions regarding 




















model overfitting, I intended to retain all predictors and both mediators, 
regardless of path significance. However, in order to achieve a more 
parsimonious model, I planned to remove nonsignificant interaction terms (368). 
I used estimates obtained through the regression analysis to calculate indirect 
effects, applying a product of coefficients approach (359, 369).  
For significant interaction terms, I quantified the indices of partial mediated 
moderation. Using the more complex case of vascular disease as an example, 
this entailed estimating how much the mediated effect of this factor on 
cognitive performance changed depending on the following: firstly, the presence 
or absence of diabetes mellitus, assuming absence of hypertension (held fixed, 
as all other predictors); secondly, the presence or absence of hypertension, 
assuming absence of diabetes mellitus (370). I then probed the partial 
moderated mediation effects to establish for what specific combination of 
factors (four options based on presence vs absence of diabetes and 
hypertension) vascular disease had a significant conditional indirect effect on 
cognitive performance. Based on the same principles, I planned to apply a 
simplified version of this procedure to estimate the conditional indirect effect of 
TIA, depending on the presence or absence of diabetes. 
I determined the significance of individual paths and indirect effects through 
constructing bias-corrected bootstrap confidence intervals, based on drawing 
1000 bootstrap samples. This method is recommended as one that does not 
assume normal sampling distribution and offers greater precision for calculating 
confidence intervals compared to alternatives (371, 372). There are currently no 
consensus guidelines regarding sample size requirements in SEM. However, 
previous simulation studies applying bootstrapping have determined that to 
detect small mediation and moderated mediation effects (estimate = 0.14) with 
80% power, a sample of nearly 500 participants is required (373, 374). 
To provide information on the magnitude of mediated effects, I calculated the 
proportion-mediated effect size – a ratio of the specific indirect effect to the 
total effect of a predictor (375). This is considered an intuitive measure and is 
easily extrapolated from a simple to a multi-mediator model (358). Expecting 
that the direct and indirect effects of a single predictor may be of opposite 
signs, I planned to use absolute coefficient values (376). 
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5.2.4 Additional analyses 
Recognising the potential bias from assumptions about missing data, I repeated 
the described procedures in a sensitivity analysis, using a more conservative 
approach. Namely, I excluded participants who due to an existing impairment 
did not complete particular tasks within the cognitive assessment.  
Further, to examine how use of different analysis strategies may impact 
findings, I additionally conducted a basic multivariable regression, as commonly 
employed in previous studies. Specifically, I entered stroke severity and prior 
dementia into the model alongside all other predictors, thus regressing cognitive 
performance on a total of 10 variables (Figure 5-2).  
 
Figure 5-2 Conceptual diagram of a basic multivariable regression model with acute 




















5.3 Results  
A total of 703 patients were screened during the study recruitment waves. From 
this sample, 109 were given a final diagnosis other than stroke or TIA, leaving 
594 participants fulfilling my inclusion criteria. Table 5-1 presents characteristics 
of the study sample. A correlation matrix for variables incorporated in the model 
is provided in Appendix 6. As seven patients had missing data on predictor 
variables, 587 participants were included in the final analysis. 
Table 5-1 Characteristics of study sample. 
Variables 





























































Stroke severity (NIHSS score, range: 0 – 42) 
Range for sample 
Median (IQR) 
Categories 
No stroke signs, N (%) 
Mild, N (%) 
Moderate, N (%) 
Severe, N (%) 
Missing 
 
0 to 31 







Cognitive test score (range: 0 – 15) 
Range for testable participants 
Median for testable participants (IQR) 
Untestable participants, N (%) 
Missing 
 
0 to 15 
11.0 (8 – 13) 
101 (17.0%) 
22 
IQR indicates interquartile range; NIHSS, National Institutes of Health Stroke Scale; TIA, transient 
ischaemic attack.  
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5.3.1 Final model structure and properties 
As described in the Methods section, the initial model included three interaction 
terms. However, preliminary results indicated that the interaction term of TIA 
and diabetes mellitus was not significantly associated with stroke severity (p = 
0.560) and, therefore, I removed it from the model. Subsequent findings 
suggested a trend for the remaining two interaction terms, between vascular 
disease and diabetes mellitus (p = 0.057) and vascular disease and hypertension 
(p = 0.056), and so I opted to retain them. Consequently, the final model 
differed from that presented in Figure 5-1 in only one aspect, namely, I did not 
consider diabetes as a moderator for the effect of TIA on stroke severity (Figure 
5-3). 
 
Figure 5-3 Conceptual diagram of the final moderated mediation model with two 
parallel mediators for acute cognitive performance. 
For this model, the chi-square statistic indicated no significant discrepancy 
between the observed and model-estimated covariance matrices: Χ2 = 6.580, 




















Mean Square Error of Approximation (RMSEA) = 0.023, Comparative Fit Index 
(CFI) = 0.995, and Standardised Root Mean Square Residual (SRMR) = 0.030 (377). 
Overall, my model explained R2 = 62.10% of variance in cognitive test scores. 
5.3.2 Associations between predictors and mediators 
More severe strokes were associated with age and atrial fibrillation, while 
severity decreased with a history of previous TIA (Table 5-2). The observed 
associations with interactions terms, just above the threshold of statistical 
significance, suggested opposing effects of vascular disease, depending on the 
presence of diabetes mellitus and hypertension. Co-occurring with the former, it 
appeared potentially associated with greater stroke severity, while co-occurring 
with the latter – with less severe presentation. Predictors of prior dementia 
included age and previous stroke. I also observed a trend for an association 
between dementia and history of vascular disease (p = 0.054).  
Table 5-2 Direct associations between predictors and stroke severity, dementia 
and cognitive performance. 
 Unstandardised coefficients (95% bias-corrected CI) 
 Stroke severity Prior dementia Cognitive performance 
Age 0.012 (0.004, 0.019)* 0.059 (0.039, 0.078)* 0.003 (-0.016, 0.027) 
Sex (female) -0.031 (-0.210, 0.180) -0.098 (-0.458, 0.248) -0.264 (-0.588, 0.046) 
Previous stroke 0.008 (-0.217, 0.222) 0.538 (0.176, 0.932)* 0.230 (-0.129, 0.649) 
Previous TIA -0.512 (-0.934, 0.147)* -0.342 (-3.886, 0.279) -0.141 (-2.136, 0.510) 
Atrial fibrillation 0.355 (0.075, 0.609)* 0.145 (-0.270, 0.554) -0.092 (-0.464, 0.279) 
Diabetes -0.025 (-0.274, 0.209) -0.028 (-0.636, 0.535) -0.041 (-0.604, 0.508) 
Hypertension 0.076 (-0.146, 0.301) -0.133 (-0.571, 0.377) -0.065 (-0.502, 0.364) 
Vascular disease 0.002 (-0.405, 0.374) 0.611 (-0.051, 1.246) 0.390 (-0.178, 1.127) 
Vascular disease 
x diabetes 
0.466 (-0.031, 0.924)   
Vascular disease 
x hypertension  
-0.486 (-0.971, 0.016)   
*Significant at p < 0.05  
CI indicates confidence interval; TIA, transient ischaemic attack. 
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5.3.3 Direct effects on cognitive performance  
The results indicated that both mediators were associated with acute post-
stroke cognitive performance: coefficient = -0.748, 95% bias-corrected CI: -0.963 
to -0.572 for stroke severity; coefficient = -0.720, 95% bias-corrected CI: -1.096 
to -0.444 for dementia. However, I observed no significant direct effects of 
included predictors on cognitive performance. 
5.3.4 Indirect effects on cognitive performance 
5.3.4.1 Effects mediated through stroke severity  
I found that age had a negative specific indirect effect on cognitive performance 
(Table 5-3), with 16.36% of the absolute overall effect of age on cognition 
mediated by stroke severity. Poorer cognitive outcome was also indirectly 
associated with a history of atrial fibrillation, with a proportion-mediated effect 
size of 57.45%. Conversely, I observed improved cognitive performance through a 
specific indirect effect of previous TIA, which constituted 49.68% of the absolute 
overall effect.  
The indices of partial mediated moderation suggested a trend for both estimated 
conditional indirect effects of vascular disease on cognition through stroke 
severity (p = 0.077 for both diabetes mellitus and hypertension). Through 
probing, I found that vascular disease produced a significant positive effect on 
performance under only one condition – where there was a history 
of hypertension without diabetes mellitus (estimate = 0.362, 95% bias-corrected 
CI: 0.032 to 0.675; p = 0.024). The proportion-mediated effect size was 30.37%. 
5.3.4.2 Effects mediated through prior dementia 
In relation to the second mediator, dementia, I observed that previous stroke 
had a negative specific indirect effect on cognition, constituting 62.12% of the 
absolute overall effect. Despite the noted trend for an association between 
dementia and vascular disease, the specific indirect effect of this risk factor on 
cognitive performance did not reach statistical significance (p = 0.089). Age, 
therefore, was the only predictor to exert a significant negative indirect effect 
on cognition through both mediators. Compared to stroke severity, dementia 
conveyed a considerably larger portion of its overall absolute effect – 78.18%. 
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Table 5-3 Indirect associations between predictors and cognitive performance. 
 Unstandardised coefficients (95% bias-corrected CI) 
 Effects mediated 
through stroke severity 
Effects mediated 
through prior dementia 
Age -0.009 (-0.015, -0.003)* -0.043 (-0.069, -0.024)* 
Sex (female) 0.023 (-0.145, 0.172) 0.071 (-0.186, 0.349) 
Previous stroke -0.006 (-0.175, 0.168) -0.387 (-0.753, -0.130)* 
Previous TIA 0.383 (0.083, 0.745)* 0.247 (-0.218, 2.152) 
Atrial fibrillation -0.266 (-0.493, -0.052)* -0.105 (-0.479, 0.202) 
Diabetes 0.019 (-0.161, 0.207) 0.020 (-0.398, 0.516) 
Hypertension -0.057 (-0.244, 0.109) 0.096 (-0.278, 0.476) 
Vascular disease -0.002 (-0.297, 0.322) -0.440 (-0.981, 0.064) 
Vascular disease 
x diabetes 
-0.349 (-0.748, 0.030)  
Vascular disease 
x hypertension  
0.363 (-0.032 – 0.759)  
*Significant at p < 0.05  
CI indicates confidence interval; TIA, transient ischaemic attack. 
5.3.5 Results of additional analyses 
For the sensitivity analysis, I excluded 38 participants who due to existing 
impairments were not able to complete particular cognitive tasks. Estimates of 
direct and indirect effects are presented in Appendix 7, Supplemental Tables 13 
and 14. Overall, the findings were similar to those obtained through the main 
analysis, with differences specifically relating to associations with dementia. 
Namely, I found a reversed pattern for dementia predictors, where here the 
association with vascular disease was statistically significant and with previous 
stroke – at trend level (p = 0.056). Moreover, the indirect effect of previous 
stroke on cognition did not reach statistical significance (p = 0.080).  
Results of the alternative, basic regression model resembled the direct 
associations I observed for the moderated mediation analysis, although here 
three variables were significantly associated with poorer cognitive performance. 
These included: stroke severity (estimate = -0.753, 95% bias-corrected CI: -0.875 
to -0.626; p < 0.001), dementia (estimate = -0.995, 95% bias-corrected CI: -1.321 
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to -0.685; p < 0.001) and age (estimate = -0.028, 95% bias-corrected CI: -0.037 
to -0.021; p < 0.001). The model explained R2 = 45.10% of variance in cognitive 
performance. 
5.4 Discussion 
The results of my study provide evidence for the role of stroke severity and prior 
cognitive impairment in mediating the effects of specific cardiovascular risk 
factors on acute cognition. Some of my findings were in line with previously 
reported associations and seem intuitively correct. Poorer cognitive performance 
was associated with: atrial fibrillation through increased stroke severity; 
previous stroke through increased risk of prevalent dementia; and with age 
through both mediators. Importantly, however, I also obtained results which 
contradict the concept that comorbidities have consistently adverse effects on 
outcome. Specifically, I found that previous TIA and vascular disease – 
considered risk factors for cognitive impairment – may be related to better acute 
cognitive performance through alleviating stroke severity.  
At the same time, not all findings supported my hypotheses. Perhaps most 
interestingly, I observed that the likely positive effect of vascular diseases on 
cognition was conditional on the simultaneous absence of diabetes and history of 
hypertension. I assumed that the latter would be detrimental, with previous 
studies showing that high acute blood pressure, a state often seen in patients 
with chronic hypertension (378), is associated with poorer prognosis after stroke 
(379).  
It seems, therefore, that the relationship between hypertension and post-stroke 
outcomes may be indeed more complex than previously suggested, as 
demonstrated in a recent clinical study (380). The authors found that in cases of 
major stroke reperfusion, acute high blood pressure was associated with better 
collateral flow and thus decreased infarct growth and better clinical outcomes, 
while the opposite was observed for patients without reperfusion. Yet, in 
relation to my results, it is important to note that the indices of partial 
mediated moderation did not reach statistical significance, and so I cannot 
conclude that there is indeed a difference in the effect of vascular disease on 
cognition between patients with and without diabetes and hypertension.  
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5.4.1 Clinical implications 
As concluded in Chapter 3, at present none of the existing prognostic rules for 
post-stroke cognitive impairment can be recommended for clinical use. 
Nonetheless, the conducted model development studies provide important 
insight into what factors are most relevant to post-stroke cognitive function. My 
findings add to this knowledge, highlighting the need to account for comorbidity 
and the potential for risk factors not only to co-occur, but also interact. 
Although further confirmation is necessary, it seems plausible that for patients 
with a history of TIA and vascular disease with hypertension, the risk of cognitive 
impairment could be underestimated. Such individuals are more likely to present 
with less severe strokes, while still being prone to the progressive 
neurodegenerative effects of these conditions, demonstrated in previous studies. 
5.4.2 Research implications 
The findings indicate that the prevalent use of basic multivariable regression 
models to determine predictors of post-stroke cognitive function may be overly 
reductionist. Results of the additional analysis showed that if I were to rely on 
the same approach, I would not have observed any significant associations 
between cardiovascular risk factors and acute cognitive performance. Taking 
into account that effects may differ in direction depending on the path of 
influence is an important consideration for future studies. The aims would be to 
improve outcome prognosis and investigate the detrimental role of comorbidity, 
or the benefits of endogenous adaptive mechanisms and disease management.  
5.4.3 Strengths and limitations 
The study sample was representative of a real-world stroke population. My 
method of scoring and coding performance on the cognitive screen allowed to 
avoid exclusion of patients with the most severe impairments, thus reducing risk 
of bias. At the same time, I conducted a sensitivity analysis in a subgroup of 
participants with complete cognitive data to reflect a more conservative 
approach. Further, in the conduct of this research, I strove to adhere to current 
best practice guidelines for mediation and moderated mediation analysis. 
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The data collection protocol, however, was not specifically designed for this 
work and, in turn, not all relevant information was accessible. This was the case 
for education – an important covariate to consider, given associations with both 
cognitive performance and cardiovascular risk factor prevalence and outcomes 
(381). There was also limited data describing participant index stroke. While I as 
was able to include stroke severity as an essential component of my model, I 
could not account for other plausibly relevant features, such as infarct location, 
volume, or the stroke mechanism (e.g. cardioembolic or small vessel occlusion). 
Further, although the idea for the study was inspired by concepts around 
endogenous adaptations, processes underlying analysed associations cannot be 
investigated without accounting for additional variables, for example, the extent 
of cerebral collateral development, or time elapsed between previous TIA and 
subsequent stroke. However, even with information regarding the latter, it 
would be very difficult to assess in an observational study whether ischaemic 
preconditioning indeed occurs (382). While a number of publications have 
reported that TIA reduces the impact of subsequent ischaemia (as I described in 
the Introduction to this Chapter), some have found no such association, or even 
observed a trend toward greater disability following strokes preceded by TIA 
(382-384). Individual heterogeneity among stroke survivors, and the specific 
aetiology of cerebral infarction, are likely to influence the apparent relationship 
between prior TIA and short and long-term post-stroke outcomes (385).   
In view of the above, it is important to also consider alternative explanations for 
the effects of TIA and vascular disease on alleviating stroke severity, which I 
observed in my study. The role of treatment, which I was not able to control for, 
seems of particular relevance here. Specifically, research findings suggest that 
aspirin, routinely administered following TIA, reduces the severity of early 
subsequent stroke (386), while statins, prescribed in cases of vascular disease, 
enhance collateral circulation (387, 388). 
Further study limitations relate to a retrospective assessment of risk factors 
from medical case records, as it is possible that relevant conditions had not been 
noted or even diagnosed. Of particular concern is correct identification of prior 
TIA cases. Low public awareness of TIA symptoms and significance (253), coupled 
with a transient nature, may result in omitting to seek professional help, and so 
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having no record of the event. Multiple factors may have also contributed to 
underdiagnosis of dementia, which according to research evidence is a common 
issue (389); while milder forms of cognitive impairment prior to incident stroke 
were not captured through data collection at all. Dichotomisation based on a 
formal diagnosis of dementia imposes an assumption that people are either 
cognitively intact or have a severe form of cognitive impairment, which does not 
reflect the true, gradual nature of cognitive deterioration.  
Finally, the focus and thus conclusions of this study are restricted to acute 
cognitive outcome. In this context, it is important to note that longitudinal 
studies have demonstrated considerable individual changes in cognitive status 
between the acute and chronic stages following stroke (29, 390, 391). 
Nonetheless, early post-stroke cognitive impairment has been shown to be a 
predictor of future outcomes, both cognitive and functional (392). Moreover, in 
healthcare settings, for many stroke survivors, the only opportunity to undergo a 
cognitive screen may be during hospital admission.  
5.4.4 Future directions 
Ideas and the motivation for future research on this topic largely stem from the 
study limitations discussed above. A better understanding of the associations 
between cardiovascular diseases and post-stroke cognition could be achieved by 
accounting for variables relevant to the presence of pathology-driven protective 
adaptations and treatment effects. Capturing milder forms of prior cognitive 
impairment, on the other hand, could render more precise estimates for the 
strength of mediated effects, which here could have been underestimated.  
Further, it seems important to explore how the role of comorbidity in shaping 
cognitive outcomes may differ across time. It is possible that some factors, for 
which I found no evidence of an unconditional, independent effect on acute 
cognition (e.g. diabetes), are more relevant to longer-term outcome. Similarly, 
observed associations might vary depending on whether cognitive function is 
considered at a single timepoint or in terms of changes in status over time. It is 
these issues that will be the focus of my final study.     
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5.5 Summary 
In this study, I found that the effects of specific cardiovascular risk factors on 
acute post-stroke cognitive function are partially mediated through stroke 
severity and prior dementia. Not all of these effects were detrimental. Vascular 
disease, conditional on the presence of hypertension and absence of diabetes, 
and previous TIA seemed associated with better cognitive performance through 
reduced stroke severity. My observations highlight the complexity of associations 
between cardiovascular risk factors and post-stroke cognition. In this context, 
basic multivariable regression models may be overly reductionist, leading to the 
misidentification of important, potentially casual relationships.
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Chapter 6 The Assessing Post-stroke 
Psychology Longitudinal Evaluation (APPLE) 
study: Design, participants, and data collection 
In light of limitations affecting my two previous studies, I have mentioned the 
important advantages the availability of a bespoke stroke cohort, with 
longitudinal cognitive follow-up, could have to progressing prognosis research on 
post-stroke cognitive change. The next three chapters of my thesis are founded 
in my opportunity to contribute to developing such a resource – the Assessing 
Post-stroke Psychology Longitudinal Evaluation (APPLE) dataset. From recruiting 
participants and conducting assessments, to quality control of documents 
received from multiple, external research sites, to resolving queries generated 
by an independent clinical statistics service – work on APPLE constituted the 
single greatest task during my PhD studentship. Before reporting on my use of 
this dataset to address my specific thesis aims, I give an overview of the APPLE 
project, with a particular focus on inclusion criteria, the consent process, and 
participant assessments.   
6.1 Key features  
APPLE was a multicentre, prospective cohort study, developed with an 
overarching aim to improve our assessment and understanding of the short and 
longer-term neuropsychological consequences of stroke. Specifically, by 
following participating stroke survivors from the acute or subacute phase for an 
18-month period, the project sought to:  
1. assess the prevalence of mood and cognitive disorders prior to index 
stroke; 
2. assess the accuracy and utility of brief cognitive tests and questionnaires 
addressing mood and subjective experiences post-stroke;  
3. describe change in post-stroke cognitive function and mood over time.  
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APPLE was embedded within the NHS, with Ethics Committee and local Research 
& Development department approvals for all involved hospital sites (Research 
Ethics Committee number: 16/SS/0105). The project was funded by a joint grant 
from the Stroke Association and Chief Scientist Office of Scotland (funding 
reference: PPA 2015/01_CSO). The study protocol was registered on Research 
Registry (www.researchregistry.com; ID: researchregistry1018). 
6.2 Participants and setting 
Study participants were recruited from acute stroke units and outpatient stroke 
clinics of 11 hospital sites across the UK, including: the Glasgow Royal Infirmary 
(NHS Greater Glasgow & Clyde [NHS GGC]), Queen Elizabeth University Hospital 
(NHS GGC), Royal Alexandra Hospital (NHS GGC), University Hospital Monklands 
(NHS Lanarkshire), University Hospital Hairmyres (NHS Lanarkshire), Forth Valley 
Royal Hospital (NHS Forth Valley), Queen Margaret Hospital (NHS Fife), Perth 
Royal Infirmary (NHS Tayside), Aberdeen Royal Infirmary (NHS Grampian), 
Morriston Hospital (NHS Wales), and Charing Cross Hospital (Imperial College 
Healthcare NHS Trust). Participating sites admitted all adult cases of suspected 
stroke or TIA, regardless of premorbid physical and cognitive function.  
Recruitment for APPLE took place between November 2016 and February 2019, 
involving both stroke survivors and informants. The Glasgow Royal Infirmary was 
the only site to be open throughout the whole recruitment period, with other 
sites opened at later stages. The last site to initiate recruitment was Charing 
Cross Hospital, beginning in January 2019. 
Stroke participant selection criteria were intentionally broad, allowing to 
include any person over the age of 18 with a clinical diagnosis of stroke or TIA, 
provided they could converse in English prior to the event, they were not 
prisoners, and the responsible clinical team had no objection to their 
participation in the study. Stroke and TIA were defined as a focal, neurological 
event of presumed vascular cause, with the diagnosis made by a stroke 
specialist. All potential participants were also assessed for capacity to provide 
informed consent.  
Patients who were eligible and willing to consider taking part in the study were 
given a Participant Information Sheet (PIS). After at least 24 hours, they would 
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be revisited by a member of the research team to discuss the study further, with 
an opportunity to ask questions and, if wishing to participate, would then sign a 
consent form. In addition to the core study, patients had the option to consent 
to future linkage of their data to clinical, electronic databases, and to provide 
blood and urine samples for biobanking (for NHS GGC sites only).  
In cases where an eligible patient did not have the capacity to provide informed, 
written consent, consent was sought from a suitable proxy (a close relative or 
welfare guardian), while still involving the patient in the decision-making 
process as much as possible. Although the research team aimed to recruit 
patients within a week of their index stroke/TIA, following a protocol 
amendment, no specific cut-off timepoint was applied.  
As well as direct assessments of stroke survivors, the APPLE study also involved 
collecting collateral information from suitable informants. Potential informants 
were indicated by patients, with an understanding that the former should know 
them and aspects of their day-to-day life well (e.g. spouse, child or carer). 
Similarly as in the case of patients, potential informants were given an 
appropriate PIS version, and if wishing to participate in APPLE – would sign a 
consent form on a separate occasion. According to the study protocol, 
recruitment of an informant for a patient was not conditional on the latter’s 
participation in the study. In instances where an informant alone was consented, 
no data were collected through direct assessment of the patient, nor from the 
patient’s medical records. 
6.3 Assessments 
The APPLE study involved 5 assessment timepoints – baseline, 1 month, 6 
months, 12 months, and 18 months following recruitment. After the baseline 
assessment, subsequent follow-ups were scheduled within a two-week time 
window, either side of the initially intended completion date. For all visits, 
attendance was optional, meaning that participants could choose to skip any of 
the planned follow-ups, without withdrawing from the study overall. 
Investigators from all sites received relevant instructional materials and training 
(face-to-face or remote, depending on the site location) for use of assessment 
measures. Baseline and 1-month assessments were conducted by research team 
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members from the site to which the stroke participant had been admitted. With 
the exclusion of participants from NHS Grampian and some from NHS Fife, later 
follow-up assessments (at 6, 12 and 18-months) were performed by our Glasgow 
team, including myself and three other researchers.  
The assessment location was determined based on participant preferences. In 
the first instance, we would generally propose meeting at the local hospital site, 
where the assessment would take place in a private office. For this option, the 
stroke participant could make use of an arranged taxi service, and travel 
accompanied by the informant or another chosen person. In cases where travel 
did not suit the participant, following a risk assessment by the research team, 
we offered to arrange a home visit.  
For the 6, 12 and 18-month follow-ups, a third alternative was to conduct the 
assessment over the telephone. This option was the only one available where a 
face-to-face follow-up was precluded by extensive travel distance. Towards the 
end of the APPLE study, with only 18-month follow-ups outstanding, conducting 
all assessments over the telephone became a necessity due to the COVID-19 
pandemic.   
All five stroke participant assessments involved a combination of cognitive tests 
and questionnaires regarding daily functioning, mood, and subjective 
experiences, while in the case of informants - only completion of questionnaires 
applied. The assessments were designed with an aim to ensure a thorough 
investigation of all aspects relevant to the study, while at the same time not 
overburdening participants. With the assumption that stroke participants’ 
tolerance to length of assessments will improve alongside a gradual recovery 
after the acute phase of stroke, the baseline visit was made shortest, with the 
number of test and questionnaire items increasing over consecutive follow-ups 
until the 12-month assessment (the 18-month being identical). 
6.3.1 Assessment materials 
In relation to cognitive function, all stroke participant assessments incorporated 
a test very similar to the outcome measure described in Chapter 5 – a 
combination of items from the AMT-10 (364) and a short-form MoCA (77). The 
version used for the APPLE study differed by including one additional item 
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(counting down from 20), and in terms of scoring. Specifically, the question 
regarding date was scored out of three points instead of one (a separate point 
for each: day of the month, month and year), and the question regarding place 
was scored out of two points instead of one (one point for the exact location, 
e.g. name of hospital, street name and number of participant’s home, and one 
for the name of the city). Consequently, the maximum total score for the test 
was 19 points. In the following text, I refer to this measure as the AMT-plus. 
Table 6-1 presents the test items and scoring system. 
Table 6-1 Items and scoring for the AMT-Plus. 
Item Scoring 
1. Age 1 
2. Current time 1 
3. Date: day, month, year 3 
4. Place: location, city 2 
5. Two-person recognition 1 
6. Date of birth 1 
7. Year World War I (or II) began   1 
8. Current Prime Minister 1 
9. Countdown from 20 1 
10. Five-word delayed recall 1* 
11. Clock draw: face, numbers, hands 3 
12. Current news item 1 
13. Months of the year in a reverse order 1 
14. Verbal fluency (words beginning with “F”) 1 
 Sum: 19 
*A point was assigned for the correct recall of at least four words. 
To account for differences between assessments in inclusion of other measures, 
below I briefly describe the content of each assessment according to timepoint 
and version. A complete list of measures incorporated into each face-to-face 
assessment is presented in   Table 6-2.  
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  Table 6-2 Measures included in full-length and short stroke participant assessments. 
 Assessments 
 Full-length versions Short versions 
 Baseline 1-month 6-month 12/18-month 6-month 12/18-month 
Objective measures of cognition 
Abbreviated Mental Test – plus (AMT-plus) ✓ ✓ ✓ ✓ ✓ ✓ 
Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) (68) ✓ ✓     
Oxford Cognitive Screen (OCS) (89)  ✓     
Montreal Cognitive Assessment (MoCA) (77)     ✓ ✓ 
Animal Naming Test (393)   ✓ ✓   
Controlled Oral Word Association Task (COWAT) (394)   ✓ ✓   
Letter-Digit Substitution Test (LDST) (395)   ✓ ✓   
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) Word List 
Memory Task, recall and recognition (396) 
  ✓ ✓   
Trail Making Test Parts A and B (397-399)   ✓ ✓   
CERAD Modified Boston Naming Test (396, 400)    ✓   







Table 6-2 Measures included in full-length and short stroke participant assessments. Continued  
 Full-length versions Short versions 
 Baseline 1-month 6-month 12/18-month 6-month 12/18-month 
Measures of function and activity 
Modified Rankin Scale (mRS) (171) ✓ ✓ ✓ ✓ ✓ ✓ 
Barthel Index of Activities of Daily Living (404) ✓  ✓    
Lawton Extended Activities of Daily Living ✓  ✓    
“Frail Non-Disabled” (FiND) Instrument (405) ✓  ✓ ✓ ✓ ✓ 
Brief Fatigue Inventory (BFI) (406)  ✓ ✓ ✓   
Brief Physical Activity Assessment  (407) ✓   ✓  ✓ 
Stroke Impact Scale Short Form (SF-SIS) (408)    ✓   
Measures of mood and subjective experience       
The Depression Intensity Scale Circles (DISCs) (409) ✓      
Patient Health Questionnaire - 2 (PHQ-2) (410) ✓ ✓     
Generalised Anxiety Disorder Scale 2-item (GAD-2) (411) ✓ ✓     
PHQ – Somatic, Anxiety and Depressive Symptom Scales (PHQ-SADS) (412-415)  ✓     
Centre for Epidemiologic Studies Depression Scale Revised (CESD-R) (416)   ✓ ✓ ✓ ✓ 
EuroQol – 5 Dimension (EQ-5D) (417)   ✓ ✓ ✓ ✓ 
Medical Outcomes Study Social Support Survey (MOS-SSS), 4-item (418) ✓   ✓  ✓ 
Patient Reported Evaluation of Cognitive Status (PRECiS) (419)    ✓   
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6.3.1.1 Full-length stroke participant assessments 
For the baseline visit, alongside AMT-plus the only other measure assessing for 
incident cognitive disorder was the CAM-ICU – a screening test for delirium (68). 
Included questionnaires, on the other hand, addressed the participants’ pre-
stroke state, encompassing brief measures of functional independence, frailty, 
anxiety and depression. At baseline, we additionally collected data on patient 
demographics, medical history, findings from acute clinical examinations, 
including stroke-related features, and laboratory test results. Appendix 8 
presents the case report form (CRF) that we used to record most of this 
information.  
Stroke subtype was defined using the Oxfordshire Community Stroke Project 
(OCSP) classification (420), based on a diagnosis made by the leading stroke 
physician. Stroke severity was determined based on the NIHSS (72); where the 
assessment had not been conducted by a clinician and recorded in the patient 
notes, the NIHSS was scored by an adequately trained member of the research 
team.  
Unlike the baseline and all subsequent assessments, the 1-month visit included 
the Oxford Cognitive Screen (OCS; https://www.ocs-test.org/) as an additional 
measure of cognitive function (89). The OCS is a domain-specific tool, developed 
particularly to screen for cognitive impairment following stroke. As such, it was 
designed to be “aphasia and neglect-friendly”, with an option to use a multiple-
choice question format, and with test stimuli centred on a page. Domains 
assessed by the OCS include: language, attention, numerical skills, memory and 
praxis. In relation to questionnaires, measures included at 1 month referred to 
the participants’ post-stroke condition, as was the case for all subsequent 
follow-ups. Compared to baseline, there were fewer scales related to activities 
of daily living, while additionally included were a measure of fatigue and a more 
comprehensive mood questionnaire.  
At the 6-month follow-up, the OCS was replaced by a set of widely-used and 
validated domain-specific tasks, selected based on the National Institute for 
Neurological Disorders and Stroke (NINDS) and Canadian Stroke Network (CSN) 
recommendations for the assessment of vascular cognitive impairment (85). 
These task pertained to: semantic and phonemic verbal fluency, processing 
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speed, learning memory and executive functioning. Regarding questionnaires, 
the addressed aspects of the participants’ condition and daily life were similar 
as for both the baseline and 1-month assessments, although in some instances 
different scales were used. Moreover, a quality of life measure was included. 
Further additions were made in the 12 and 18-month assessments, incorporating: 
word-retrieval and visuospatial ability and visuospatial memory tasks, as well as 
a stroke-specific measure of disability and health-related quality of life, and a 
questionnaire on the subjective experience of cognitive impairment and its 
impact. 
6.3.1.2 Short versions of stroke participant assessments 
Short versions were available as an alternative to 6, 12 and 18-month full-length 
assessments. They were administered at the request of the participant or at the 
researcher’s discretion, in consideration of the participant’s best interest, e.g. 
where completion of test and questionnaire items was associated with 
significant difficulty for the participant due to aphasia, fatigue, or poor general 
health. As presented in   Table 6-2, short assessments included only a subset of 
measures used in the equivalent full-length version, while additionally 
comprising the MoCA. Tasks that overlapped between the AMT-plus and MoCA 
(e.g. clock draw, letter fluency) were assessed only once per visit, with an 
identical score recorded for both tests.  
6.3.1.3 Telephone versions of stroke participant assessments 
As described above, telephone versions were available as an alternative to 6, 12 
and 18-month face-to-face visits. While the set of incorporated measures of 
function and mood matched that of the short versions, important adjustments 
were made for the assessment of cognition, with some AMT-plus items being 
omitted, and the inclusion of the modified Telephone Interview for Cognitive 
Status (TICS-M) (421, 422). In comparison to face-to-face follow-ups, the 
telephone assessments excluded the two-person recognition, clock draw, and 
five-word recall tasks, with the two former having no equivalent, and the latter 
being substituted by recall of a different, ten-word list. 
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6.3.1.4 Relevant amendments to stroke participant assessments 
During preparation and design of my Biobank studies (Chapter 4), I proposed 
including measures of physical activity and social support as factors with 
plausible, yet understudied associations with post-stroke cognitive function. 
Wanting to avoid any significant increase in participant burden, after 
consultation with my Supervisor, we selected very brief scales. The 
questionnaires were added to the baseline, 12 and 18-month assessments for all 
versions in February 2018.  
The included Brief Physical Activity Assessment is a two-item self-report 
measure, designed for use with adults in a primary healthcare setting (407). 
Through asking about the frequency of engaging in moderate and vigorous 
physical activity during a usual week, the tool’s objective is to identify 
individuals who are insufficiently active in view of current recommendations. For 
assessment of social support, we used an abbreviated, 4-item version of The 
Medical Outcomes Study Social Support Survey (MOS-SSS) (418). The 
questionnaire addresses how often four types of social support are available to 
an individual, including: tangible support (material aid or assistance), positive 
social interaction (doing fun, enjoyable things with someone), emotional-
informational support (emotional support and guidance or advice), and 
affectionate support (expression of love and affection).  
6.3.1.5 Informant assessments 
In many ways, informant assessments reflected those of the stroke participants. 
Administered at all timepoints apart from the 1-month follow-up, they could be 
posted, completed over the telephone, or face-to-face during the scheduled 
stroke participant visit. The assessments incorporated measures regarding 
changes in the stroke survivor’s cognitive function, their functional status in 
view of activities of daily living, neuropsychiatric symptoms, mood, and quality 
of life. Questionnaires included in the baseline assessment referred to pre-stroke 
condition. Subsequent follow-ups additionally included one measure with 
questions about the informant, assessing caregiver burden. A full list of 
measures included at each informant assessment timepoint is presented in Table 
6-3. 
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Table 6-3 Measures included in informant assessments. 
 Assessments 
 Baseline 6-month 12/18-month 
Questionnaire on Cognitive Decline in the Elderly 
(IQCODE) Short Form (423) 
✓  ✓ 
Aging and Dementia-8 (AD8) (424) ✓  ✓ 
Modified Rankin Scale (mRS) (171) ✓ ✓ ✓ 
Barthel Index of Activities of Daily Living (404) ✓ ✓ ✓ 
Lawton Extended Activities of Daily Living ✓ ✓ ✓ 
“Frail Non-Disabled” (FiND) Instrument (405) ✓ ✓ ✓ 
Stroke Aphasic Depression Questionnaire for patients 
in hospital, 10-item (SADQ-H 10) (425) 
✓  ✓ 
Geriatric Depression Scale, 15 item (GDS-15) (426) ✓  ✓ 
EuroQol – 5 Dimension (EQ-5D) (417)  ✓ ✓ 
Neuropsychiatric Inventory Questionnaire (NPI-Q) (427)   ✓ 
The Zarit Burden Interview (428)  ✓ ✓ 
 
6.4 Study dropout 
We recorded four reasons for study dropout: withdrawal of consent, loss to 
follow-up, death and “other”, with the latter cause being specified by the 
researcher. Participant withdrawal mirrored the consent process. Specifically, 
participants who withdrew consent for future contact and follow-ups could (if 
applicable) additionally withdraw consent for data storage, linkage and access to 
medical records, and for storage of their samples in the biobank. The “other” 
option was typically selected in situations where we were unable to directly 
contact a participant, yet were aware of their current circumstances and felt 
that arranging future follow-ups would be inappropriate, e.g. end of life care 
situations. The same four dropout reasons were distinguished for informants. As 
a rule, if a participant dropped out of the study, we would withdraw their 
informant from APPLE as well. Such cases would be recorded as “other”, with 
the exact cause documented.   
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6.5 Data processing 
All CRFs were collated at the Academic Section of Geriatric Medicine in the 
Glasgow Royal Infirmary. Our team cross-checked CRFs completed by researchers 
from other sites and prepared all participant documents for transferral to the 
Robertson Centre for Biostatistics. The Centre, which designed the CRFs, was 
responsible for raising queries in case of suspected errors, data entry, and 
creating bespoke datasets, tailored to the requirements of our individual 
studies.  
6.6 Recruitment outcome and follow-up completion 
A total of 354 stroke participants and 151 informants were consented to APPLE, 
the majority being recruited from the Glasgow Royal Infirmary. The contribution 
of each site to stroke participant recruitment is presented in Figure 6-1.  
 
Figure 6-1 Percentage of stroke participants recruited to the APPLE study by each 
of 11 involved hospital sites. 
Notes:  NHS GGC sites are represented in green, NHS Lanarkshire in orange, NHS Forth Valley 
in yellow, NHS Fife in red, NHS Tayside in purple, NHS Grampian in blue, NHS Wales in black, 


































6.6.1 Baseline study sample representativeness 
I had access to patient screening logs from two participating sites – the Glasgow 
Royal Infirmary and the Royal Alexandra Hospital – to provide at least a partial 
indication of study sample representativeness. According to these records, 
during the period from November 2016 to February 2019, 352 patients were 
assessed for study eligibility at the Glasgow Royal Infirmary, of whom 149 (43%) 
consented to take part in APPLE (Figure 6-2). At the Royal Alexandra Hospital, 
open for recruitment between May 2018 and February 2019, 197 patients were 
assessed for eligibility, of whom 24 (12%) consented to study participation 
(Figure 6-3). 
 
Figure 6-2 Patient screening and enrolment for the Glasgow Royal Infirmary. 
Recruited, 
N = 149 (43%)
Refused, 
N = 85 (25%)
Uncertain/non-
stroke diagnosis, 










N = 3 (1%)
Non-English 
speaker,
N = 3 (1%)
Excluded, 
N = 195 (57%)
Total N assessed for eligibility = 352 
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Figure 6-3 Patient screening and enrolment for the Royal Alexandra Hospital. 
 
Table 6-4 includes selected characteristics of the APPLE baseline study sample. 
To allow further insight regarding participant representativeness, I present this 
information alongside data reported from the Sentinel Stroke National Audit 
Programme (SSNAP) (429), for the period between April 2017 and March 2018 
(294). The clinical audit collects a minimum dataset for stroke patients admitted 
to every acute hospital in England, Wales, and Northern Ireland. Annually, 
information from approximately 85000 patients is submitted to the audit, 
representing over 90% of all stroke hospital admissions in the NHS (429). For the 
comparison of patient characteristics, it is important to note that SSNAP does 
not encompass cases of TIA. 
Recruited, 
N = 24 (12%)
Refused,
N = 45 (23%)
Uncertain/non-
stroke diagnosis, 










N = 9 (5%)
Lack of capacity 
to consent with 
no suitable proxy, 
N = 26 (13%)
Excluded, 
N = 173 (88%)
Total N assessed for eligibility = 197 
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Table 6-4 Characteristics of the APPLE baseline study sample presented for 
comparison with a national case mix of stroke patients, admitted to hospital 
between April 2017 and March 2018, as reported by the Sentinel Stroke National 
Audit Programme (SSNAP). 
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IQR indicates interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of 
Health Stroke Scale; TIA, transient ischaemic attack. 
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6.6.2 Follow-up completion 
Focusing on participation rates at individual assessment timepoints, 269 (76.0%) 
stroke survivors took part in the 1-month follow-up, 220 (62.1%) in the 6-month 
follow-up, 185 (52.3%) in the 12-month follow-up, and 171 (48.3%) in the 18-
month follow-up. We recorded that 158 stroke participants formally dropped out 
of the study, including 75 who withdrew consent (either directly or by proxy), 50 
lost to follow-up, 24 who died, and 9 for whom the reason for dropout was 
“other” – in all cases related to a significant decline in health and/or end of life 
care.  
6.7 Summary  
APPLE was a multicentre, prospective cohort study, designed with an overall aim 
to improve our understanding of the neuropsychological sequalae of stroke. It 
involved a longitudinal 18-month follow-up of stroke survivors and their 
informants, with a focus on assessing cognition, mood, subjective experiences, 
and daily functioning. The work I conducted on APPLE constituted a central part 
of my doctoral training. Over the next two chapters, I describe how I used the 
data we collected to address the third of APPLE‘s work packages – describing 
change in post-stroke cognitive function.
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Chapter 7 Trajectories of post-stroke cognitive 
change following stroke: A pilot study using the 
APPLE dataset. Part I: Rationale and methods 
In the previous chapter, I described the design and assessment methods of a 
prospective inception cohort, involving longitudinal cognitive follow-up – the 
APPLE project. In this chapter, I present how I used the APPLE dataset to model 
the natural history of cognitive change following stroke. I devoted a separate 
part of my thesis to the methods of this study to allow a comprehensive and 
precise account of the extensive decision-making process that led to the final 
results. The methodological considerations I describe are important to the 
immediate interpretation of the study findings and, moreover, may serve to 
inform the design of future longitudinal research into post-stroke cognition.  
7.1 Introduction 
A common procedure employed in research aiming to identify predictors of post-
stroke cognitive function relies on average-based estimates of associations 
between a factor of interest and a cognitive outcome, assessed at one specific 
timepoint. The uptake of this strategy was also evident across the prognostic 
model development studies I described in my systematic review (Chapter 3). The 
core characteristic of this approach is that it is “variable-centred”, as the focus 
is on the relationships among variables (430). Alongside practical advantages and 
relative ease in interpretation of results, there is, however, an important 
limitation to this popular strategy when applied to post-stroke cognition - it does 
not reflect the heterogeneity in the process of cognitive change.  
Clinical observations and research findings suggest a dynamic and varied pattern 
of cognitive change following stroke. Although many stroke survivors will 
experience an initial period of cognitive recovery, only some will continue to 
improve in the longer-term, while for others this process will reach a plateau or 
even shift towards a declining trend (431-434). This suggests heterogeneity at 
both a between- and within-individual level. Regarding the former, even where 
at a specific timepoint the same outcome has been apparently achieved by two 
individuals, the path to it may have differed.  
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For example, as illustrated in Figure 7-1, a person may be diagnosed with 
cognitive impairment one year after a stroke either as a result of declining from 
a previous state of having no cognitive impairment (Person A), or following a 
significant but incomplete recovery from severe initial deficits (Person B). 
Despite being categorised into the same outcome group, arguably individuals 
representing these different patterns of change are also likely to differ in terms 
of characteristics relevant to post-stroke cognitive function, and possibly in how 
their condition will progress.  
 
Figure 7-1 Hypothetical trajectories of cognitive change for two individuals classed 
as having cognitive impairment 12 months following stroke. 
Concurrently, on a within-individual level, cognitive change is unlikely to follow 
a constant trajectory over time, with potential for variability in rate and, in 
some cases, even shift in direction. Indeed, observations from longitudinal 
follow-up studies in stroke cohorts indicated that for some participants the 
cognitive status identified (impaired or intact) switched up to two times within a 
three-year period (435, 436). In a similar study, the authors even reported 
instances of reversion from a vascular dementia diagnosis to milder forms of 
impairment, and for one person - to unimpaired cognition (391). These 
observations illustrate what additional insights can be gained through 
investigating individual trajectories of cognitive change.  





















Cut-off score indicating 
cognitive impairment
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However, despite the advantages of the approach used in these studies, it still 
does not allow to capture the full complexity of the subject matter. As a 
consequence of defining the outcome as binary (cognitive impairment vs no 
cognitive impairment) (435, 436), any changes that do not result in crossing a 
diagnostic threshold are missed. A second, partially connected issue relates to 
applying a priori simplifications to classifying participants based on cognitive 
change. This was reflected in basing the decision about categorisation solely on 
change over two chosen timepoints (391, 435, 436). As a result, two individuals 
may be grouped together, for example, as “improvers”, despite presenting 
meaningful differences in severity of initial cognitive impairment, level of 
residual difficulties at follow-up, or rate and specific pattern of change in 
between those timepoints (Figure 7-2).    
 
Figure 7-2 Hypothetical trajectories of cognitive change following stroke for two 
individuals classed as “improvers” (change in status from impaired to intact 
cognition) through a comparison of baseline and 12-month cognitive test scores. 
Such challenges, present in many areas of research focusing on processes and 
change in condition over time, have contributed to increasing interest in 
integrating variable-centred analyses with a person-centred approach (430). This 
goal can be achieved through use of novel analytical strategies, for example 
latent growth modelling techniques, such as growth mixture modelling (GMM) 
(437, 438) and latent class growth analysis (LCGA) (439). Based on recognition of 
a population’s heterogeneity, these methods are applied to identify distinct, 
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homogenous subpopulations (classes) within it.  This allows interindividual 
differences in intraindividual change over time to be captured (440). In addition 
to visualising the unique features of distinguished trajectory shapes, it is then 
also possible to determine what factors are uniquely associated with exhibiting a 
particular pattern of change. 
The aim of this study was to explore the application of a latent growth modelling 
approach to identify meaningful trajectories of post-stroke cognitive change in 
the APPLE dataset. At present, data entry, cleaning, and quality control are still 
ongoing, with information we had collected at the 18-months assessments not 
yet released by the clinical trials unit (the Robertson Centre for Biostatics) for 
APPLE. Therefore, the results of the following analyses, involving data from 
baseline to the 12-month follow-up, will serve to inform the design and choice of 
specific statistical solutions for a subsequent, full-scale study, utilising 
information from all five APPLE assessment timepoints.  
7.2 Methods 
The conduct of the present study compromised of four main sections: i) a factor 
analysis to derive a latent cognitive variable based on raw cognitive scores, to 
serve as the outcome; ii) the selection and implementation of an approach for 
handling missing outcome data; iii) the application of a latent growth modelling 
technique to identify distinct trajectories of cognitive change over time; and iv) 
the investigation of predictors of trajectory class membership. Below I provide a 
detailed description of the rationale and steps involved in each study section, 
with special consideration to Guidelines for Reporting on Latent Trajectory 
Studies (GRoLTS) (441). I begin by presenting my choice of a latent growth 
modelling technique - although this issue specifically pertains to a later stage of 
my study, it was a primary decision, affecting methodological considerations 
from the outset.  
7.2.1 Choice of modelling approach 
Given the pilot nature of the study, I chose to perform a LCGA. This approach is 
recommended as a first step prior to attempting the more complex GMM (440). 
Through utilising SEM techniques, the goal of both methods is to identify 
trajectory-based classes within a sample, where individuals within one class are 
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most similar to one another, while at the same time being most different from 
individuals in all other classes (442). However, the difference is that LCGA 
entails an assumption that growth trajectories (here, counterintuitively 
signifying any pattern, not only an increasing function) are homogenous within a 
class, while GMM allows to account for within-class variation.  
The greater flexibility offered by GMM comes at a cost of increased 
computational demand, more frequent convergence issues (i.e. inability to 
generate an admissible model solution), and need of greater statistical power. 
Nonetheless, this approach may result in a more accurate reflection of real-
world patterns of change where within-class heterogeneity exists, which in most 
contexts cannot be ruled out. Therefore, I intend to test the use of GMM in the 
full-scale study, for which the inclusion of an additional assessment timepoint 
would translate to an increase in power. 
7.2.2 Participants 
The study sample comprised APPLE participants. I applied no selection criteria 
based on individual characteristics. However, I considered that to develop an 
accurate model using LCGA it is key that assessment timepoints are similar 
across participants, relative to an objective, study-independent starting point 
(443). Given the design of APPLE, described in the previous chapter, a particular 
concern was that, relative to index stroke, the baseline assessment of some 
participants would be closer in time to the 1-month assessment of the majority.  
Conversely, introducing strict selection criteria based on recruitment time could 
have led to increased sample bias, as plausibly informing stroke survivors and 
their relatives about APPLE may have been delayed where the patient was very 
unwell in the acute phase. Therefore, I decided to apply a cut-off for inclusion 
of baseline data collected four weeks post-stroke or less. As a result, I included 
343 stroke participants in the present study, equivalent to 96.9% of the original 
APPLE sample.  
As indicated in Chapter 5, there are no consensus guidelines regarding sample 
size requirements for statistical approaches based on SEM. Multiple factors 
affect this issue, including the study design, number of parameters to be 
estimated, distribution of variables, missing data, and effect sizes of tested 
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associations (444). However, based on previous research, it seems that for a 
dataset including four assessment timepoints, a sample of 200 participants is 
sufficient for generating unbiased model estimates using LCGA (443, 445, 446).  
The appropriateness of the sample size for investigating predictors of class 
membership was a separate issue, which could not be addressed before 
determining the number of distinct trajectories. Overall, in view of the 
exploratory objective of this research, I decided to attempt all planned 
analyses, regardless of the associated statistical power. However, where 
appropriate, I would introduce adjustments to compensate for sample size 
limitations.  
7.2.3 Cognitive data 
I used the AMT-plus as a measure of cognitive outcome. Although scores from 
the neuropsychological battery used in APPLE would have offered greater insight 
into the participants’ cognitive function, the AMT-plus was the only test 
repeated across all face-to-face assessments, satisfying an essential requirement 
for LCGA. Moreover, as described in Chapter 6, most of original AMT-plus items 
(14 of 19) were included in the telephone versions of 6, 12, and 18-month 
assessments. Here, the lack of data on unincluded items could have been 
plausibly assumed as missing completely at random (no systematic differences 
between missing and observed values) or missing at random (where any 
systematic differences can be explained by observed data, e.g. if a telephone 
assessment was opted for due to the participant’s functional status) (296). 
Therefore, I considered that in this case the use of an imputation procedure 
would be appropriate.  
This was one of two main arguments for computing factor scores rather than 
using AMT-plus sum scores for the LCGA. A factor score can be estimated for a 
participant with missing values on specific test items based on observations 
available in the dataset. The second argument related to weighting of items. For 
sum scores, items are assigned equal weight, that is, they are assumed to 
contribute an equal amount of information to the measured construct (447). 
However, from a clinical perspective, this seems to be unlikely for the AMT-plus. 
For example, not knowing the city one is in or the current month is likely more 
indicative of a cognitive disorder than not knowing the exact date (448).   
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I describe the process of obtaining factor scores to represent cognitive function 
in the section below. The dataset I used contained information on all 19 AMT-
plus items, coded as separate, binary variables (correct vs incorrect). I included 
every assessment type – full-length, short and telephone versions. Similarly as in 
my study described in Chapter 5, in cases where a participant could not respond 
to a test item due to an existing impairment (e.g. aphasia or limb weakness), I 
assigned a score of 0 for that item. 
7.2.4 Transforming raw cognitive scores into the outcome 
variable: a factor analysis approach 
7.2.4.1 Factor analysis procedure 
An inspection of relationships between the 19 cognitive test items revealed 
extremely high correlations (above 0.9) and instances where no participant 
presented a specific combination of responses for a pair of variables. For 
example, at the 1-month assessment, there were no cases where providing an 
incorrect date of birth cooccurred with correct responses regarding age, time, 
date, or place. Consequently, it was not possible to produce factor scores based 
on a model simultaneously including all items.  
Aiming to find a solution that retained as much information as possible, I 
followed the iterative process described below. After each step (with the 
exclusion of the first one), I verified whether an admissible model solution could 
be found, or whether further adjustments were necessary. 
1. Combining all items from the clock draw task, creating a new, four-level 
item (range: 0 to 3). 
2. Combining items that could be justifiably grouped together based on both 
high intercorrelations and clinical interpretation: 
a) Eight items used in the assessment of consciousness (e.g. GCS and 
NIHSS) and/or relevant to orientation – age, date of birth, time, date, 
month, year, place and city (range: 0 to 8); 
b) Two items relevant to assessing attention – counting down from 20 and 
listing months of the year backwards (range: 0 to 2). 
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3. Collapsing orientation and attention scores to create binary items, with 
cut-offs based on sample distributions;  
a) For orientation – one assigned for sum scores of seven and eight, zero 
for scores below seven; as a result, across the four assessment timepoints, 
the percentage of participants who were assigned a point ranged from 
81.8% to 90.9%; 
b) For attention – one assigned for a sum score of two, zero for scores 
below two; the percentage of participants who were assigned a point 
ranged from 77.7% to 84.9%. 
4. Removing item on recognition of two people. 
5. Removing item on naming current prime minister.  
The last two steps were necessary as the high correlations between these items 
and the orientation item, pertaining to at least one assessment timepoint, 
precluded from their simultaneous inclusion in a single model. Consequently, the 
final model structure incorporated seven items: orientation, attention, recent 
news item, five-word recall, year WWI began, clock draw, and verbal fluency.  
7.2.4.2 Assessing properties of the derived cognitive latent variable 
As all test items (indicators) were categorical, I used a robust weighted least 
squares estimator (WLSMV). With this estimator, missing data are handled based 
on a pairwise present analysis, where all available observations are used to 
estimate correlations between each pair of items (367). I assessed model fit 
based on the chi-square statistic (good fit indicated by non-significance), Root 
Mean Square Error of Approximation (RMSEA; good fit: ≤ 0.06), Comparative Fit 
Index (CFI; good fit: ≥ 0.95), and Tucker-Lewis Index (TLI; good fit: ≥ 0.95).  
Given the longitudinal nature of the data, it was further necessary to examine 
measurement invariance. This is to ensure that the relationship between test 
items and the latent construct that underlies them (here, cognitive function) 
remains unchanged across timepoints or, in other words, that the meaning of the 
investigated construct is the same for each assessment occasion (449, 450). 
Without satisfying this condition, changes in factor scores over time cannot be 
reliably attributed to actual changes in the construct. 
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For categorical indicators, assessing measurement invariance involves comparing 
a configural model to a scalar model (366). For the configural model, I specified 
the same latent factor structure (involving the same seven items) for each 
timepoint, while allowing for loadings and thresholds of indicators to be freely 
estimated. For the scalar model, I constrained loadings and thresholds to be 
equal for corresponding items across timepoints. Invariance is considered to be 
achieved if the chi-square statistic for the scalar model is not significantly worse 
than for the configural model, relative to the change in degrees of freedom. I 
conducted the factor analysis using Mplus version 8.3. The code I developed for 
both models is presented in Appendix 9. 
7.2.4.3 Factor analysis results 
For the configural model, including seven cognitive test items, considered 
indices suggested good model fit: Χ2 = 325.91, p = 0.16; RMSEA = 0.02; CFI = 
0.99; TLI = 0.99. After applying additional equality constraints for the scalar 
model, model fit did not significantly deteriorate (chi-square difference: 8.5, 
degrees of freedom: 15, p = 0.90), indicating that measurement invariance had 
been achieved. Table 7-1 presents estimated factor loadings in a descending 
order, while Table 7-2 includes descriptive statistics for computed factor scores. 
Table 7-1 Unstandardised loadings for the cognitive function latent construct. 
Item Unstandardised loading 
Attention 1.01 
Orientation 1.00 
News item 0.74 
Word recall 0.65 
Clock draw 0.60 
Verbal fluency 0.55 
World War I 0.47 
Table 7-2 Descriptive statistics for estimated factor scores across assessment 
timepoints. 
 Baseline 1-month 6-month 12-month 
Range −2.55 to 1.60 −2.36 to 1.92 −2.03 to 1.54 −1.39 to 1.34 
Mean (SD) −0.08 (0.78) 0.22 (0.84) 0.25 (0.64) 0.40 (0.47) 
Missing 2 81 128 162 
SD indicates standard deviation. 
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7.2.5 Missing outcome data due to study dropout 
7.2.5.1 Considering strategies for handling missing outcome data 
For the purpose of this study, I defined “dropout” as any case, where once an 
assessment had been missed, no subsequent follow-up was completed. This 
included instances of participants repeatedly requesting to skip visits, without 
formally withdrawing from the study.  
In latent growth modelling research, the most popular approach to handling 
missing data due to dropout is full information maximum likelihood estimation 
(FIML) (441). This method involves parameter estimation using all the data that 
are available, without imputing specific missing values (451, 452). A key 
advantage of applying FIML is that each participant, regardless of whether they 
completed the study, is assigned to a latent class. However, unbiased estimates 
can only be produced where data are missing completely at random or at 
random.  
Missingness at random tends to be assumed on the basis that lack of follow-up 
data for a participant is conditional on outcome information collected at 
previous, completed assessment(s) (441). However, it is becoming increasingly 
recognised that at least for certain outcomes and populations, this assumption is 
unlikely to hold (453-455). Dropout may indeed relate to deterioration from 
previous status, which would not be accurately reflected using FIML. 
This concern seems highly relevant to investigating post-stroke outcomes. It 
seems that what has the greatest possibility of being captured in participant 
data, is the initial improvement in function, typically seen in the acute and 
subacute phase of stroke. If after that stage it is mainly stroke survivors with 
better and/or improving cognitive function who remain in the study, estimated 
trajectories may present an overoptimistic view of post-stroke cognitive change 
over time, as compared to patterns occurring within a real-world, unselected 
stroke population.   
There is no direct method to test whether data are missing at random or not. 
However, comparing characteristics of participants who remained in a study to 
those who dropped out may clarify whether the latter were indeed at greater 
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risk of outcome deterioration. The results of such a comparison may also depend 
on the reason for dropout (456). In view of this, I utilised available APPLE 
records to distinguish between cases lost to follow-up due to death or end of life 
care, and cases lost for other reasons.  
I compared the three participant groups (study completers and two groups with 
lost to follow-up) based on factors considered as relevant to cognitive decline. 
Regarding demographics, I accounted for age, sex, and education (in years). For 
health-related factors, I included: BMI (kg/m2), medical conditions (diabetes 
mellitus, vascular disease, heart failure, atrial fibrillation, previous stroke or 
TIA, renal disease, prior cognitive impairment, history of mood disorders, and 
history of substance abuse, including alcohol and illicit drug use), pre-stroke 
functional dependency as indicated by a mRS score of above two (171), and 
lifestyle factors (smoking status and self-reported physical activity). In terms of 
pre-stroke status, I additionally considered the subjective level of received 
social support (based on the MOS-SSS questionnaire). Finally, accounting for 
acute presentation, I included stroke severity as measured by the NIHSS (71, 72), 
and baseline cognitive function (both raw AMT-plus sum scores and factor 
scores).  
To test for potential differences, I used chi-squared and Fisher’s exact tests for 
categorical variables, and the Mann-Whitney U test for continuous ones. I noted 
whether group differences were significant at p < 0.05, as well as after 
accounting for multiple comparisons, using the Holm-Bonferroni technique 
(Holm, 1979). Results indicating that dropout was associated with risk factors for 
cognitive decline would support complementing a latent trajectory analysis using 
FIML with an alternative approach to handling missing data, to reflect poorer 
outcome in lost cases.  
Given the pilot nature of this study, I intended to adapt a computationally 
nondemanding method, described in a publication on trajectories of functional 
limitations in later life (453). There, for participants who died during the study 
follow-up, the authors assigned (with random noise) functional limitations 
greater by one standard deviation (1 SD) from the timepoint-specific sample 
mean, for every missed assessment until death.  
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For the APPLE sample, I assumed it was likely for both dropout groups to appear 
at higher risk of cognitive decline, however, with the difference from study-
completers being greater for participants who died/were in terminal care. If my 
assumption were confirmed, I planned to assign a cognitive function score lower 
by 2 SD from the timepoint-specific sample mean for dropout due to 
death/terminal care, and lower by 1 SD for dropout due to other reasons. 
7.2.5.2 Results of group comparisons according to dropout status 
Descriptive statistics for the total study sample and participant groups 
distinguished based on study dropout are presented in Table 7-3. Results of the 
univariable analyses indicated that both dropout groups differed from 
participants who completed APPLE assessments, even after adjusting for 
multiple comparisons. However, there was little overlap between groups 
regarding variables to which these differences applied to.  
Summarising results significant at least at p < 0.05, participants who dropped 
out due to death or end of life care were on average older than study-
completers, were more frequently diagnosed with heart failure, atrial 
fibrillation and previous stroke/TIA, less physically active, and less likely to be 
functionally independent. Although the latter also applied to the group with 
dropout due to other reasons, remaining differences included a higher 
proportion of female participants, lower average education, more cases of prior 
cognitive impairment and mood disorders, and poorer baseline cognitive 
function. 
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Table 7-3 Descriptive statistics for study sample and group comparison by dropout status. 
 
Total sample           
(N = 343) 
Group comparison by dropout status 
Study-completers 
(N = 199) 
Dropout due to 
death/terminal care 
(N = 25) 
Dropout due to other 
reasons 
(N = 119) 































<18.5 (underweight), N (%) 
18.5 to 24.9 (normal), N (%) 
25.0 to 29.9 (overweight), N (%) 





















Smoking status  
Never, N (%) 
Former, N (%) 

















History of substance abuse, N (%) 37/341 (10.9%) 20/198 (10.1%) 1/25 (4.0%) 16/118 (13.6%) 
Diabetes, N (%) 85/343 (24.8%) 46/199 (23.1%) 8/25 (32.0%) 31/119 (26.1%) 
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Table 7-3 Descriptive statistics for study sample and group comparison by dropout status. Continued 
 
Total sample 
(N = 343) 
Group comparison by dropout status 
Study-completers 
(N = 199) 
Dropout due to 
death/terminal care 
(N = 25) 
Dropout due to other 
reasons 
(N = 119) 
Hypertension, N (%) 183/342 (53.5%) 102/199 (51.3%) 14/25 (56.0%) 67/118 (56.8%) 
Vascular disease, N (%) 98/343 (28.6%) 56/199 (28.1%) 11/25 (44.0%) 31/119 (26.1%) 
Heart failure, N (%) 26/343 (7.6%) 9/199 (4.5%) 7/25 (28.0%)** 10/119 (8.4%) 
Atrial fibrillation, N (%) 56/343 (16.3%) 25/199 (12.6%) 9/25 (36.0%)** 22/119 (18.5%) 
Previous stroke/TIA, N (%) 85/343 (24.8%) 41/199 (20.6%) 12/25 (48.0%)** 32/119 (26.9%) 
Renal disease, N (%) 41/343 (12.0%) 23/199 (11.6%) 6/25 (24.0%) 12/119 (10.1%) 
Prior cognitive impairment, N (%) 26/343 (7.6%) 10/199 (5.0%) 1/25 (4.0%) 15/119 (12.6%)* 
History of mood disorders, N (%) 91/343 (26.5%) 44/199 (22.1%) 8/25 (32.0%) 39/119 (32.8%)* 
Pre-stroke mRS 








































Table 7-3 Descriptive statistics for study sample and group comparison by dropout status. Continued 
 
Total sample 
(N = 343) 
Group comparison by dropout status 
Study-completers 
(N = 199) 
Dropout due to 
death/terminal care 
(N = 25) 
Dropout due to other 
reasons 
(N = 119) 




No stroke signs, N (%) 
Mild, N (%) 
Moderate, N (%) 


































Sum score (range: 0 – 19), Mean (SD) 
Missing 






















Note: Univariable comparisons were made between the two dropout groups and the group of study-completers. 
*significant at p < 0.05; **significant after applying Holm-Bonferroni correction for multiple comparisons 
BMI indicates body mass index; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation; TIA, transient ischaemic attack. 
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7.2.5.3 Finalising the approach for handling missingness 
I had initially considered assigning a lower cognitive score for drop out due to 
death (or end of life care) compared to drop out due to other reasons. However, 
based on my findings, an assumption that one dropout group was at greater risk 
of cognitive decline than the other seemed arbitrary. Moreover, it was possible 
that not all participants had been correctly classified according to dropout 
status. Particularly, where participants withdrew consent or were lost to follow-
up at earlier timepoints, deaths occurring later during the study period may not 
have been recorded. For these reasons, I decided to substitute missing outcome 
values to represent a similar level of cognitive function for both groups. Initially, 
this was around two standard deviations below the sample mean (−2 SD) for a 
specific assessment timepoint. To reduce the artificiality of a dataset generated 
in this way, I added a component of random gaussian noise. Consequently, 
participants with missing outcome data due to dropout would be randomly 
assigned a score from approximately −2.5 SD to −1.5 SD, with most values being 
close to −2 SD, and fewest at either extreme. 
However, an attempt to apply this method proved that for many participants 
who dropped out, it would fail to reflect a realistic decline in cognitive function. 
This was due to the relatively high variability in cognitive function factor scores. 
As such, value substitution for participants with high cognitive function, as 
measured at previous, completed assessments, would indicate a drastic decline, 
while for participants with poor cognitive function – an improvement. I therefore 
opted to divide the participants according to baseline factor scores, forming 
three groups: with scores within ±1 SD (N = 232), with scores below −1 SD (N = 
55), and with scores above 1 SD (N = 56). I then generated values to use for 
substitution based on the timepoint-specific mean of the group the subject had 
been assigned to.  
A final consideration was which missed assessment values should be substituted. 
From a clinical perspective, it seemed that replacing values for each timepoint 
from dropout to either death or the end of follow-up would lead to implausible 
patterns of cognitive change over time. This was partially due to decreasing 
dispersion of values across time, meaning that with each timepoint, a 
subtraction of around −2 SD resulted in a smaller difference from the group 
mean. To illustrate the implications of this with an example, if a participant 
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withdrew from the study after baseline, and every subsequent missing outcome 
value were substituted, their cognitive function would be found to decline at 1-
month as compared to baseline, reaching its lowest point, after which it would 
consistently improve. 
At the same time, given the exploratory nature of this study, it seemed 
uncertain what patterns post-stroke cognitive change would be likely to follow, 
and whether more than one pattern occurred. I therefore decided to apply an 
approach where missing value substitution could not dictate the whole shape of 
a participant’s trajectory, yet rather would steer it towards a direction 
indicating cognitive decline. Specifically, for participants who according to 
APPLE records were still alive at the 12-month assessment, I only substituted 
missing values for this last follow-up, while for participants who died within the 
duration of the study – I substituted the missing value for the timepoint at which 
their death had been noted. All remaining missingness was handled based on 
FIML.  
 
7.2.6 Main analyses 
The main analyses comprised of modelling trajectory classes of cognitive change 
over time and identifying predictors of class membership. I carried out this part 
of my research applying a standard three-step method, as specified in the 
GRoLTS publication (441):  
1. I determined the number of latent trajectory classes without potential 
predictors of class membership;  
2. I saved the most likely class membership for each participant as a new 
variable, adding it to the original dataset;  
3. I investigated predictors of class membership in separate analyses, 
involving logistic regression and mediation models.  
  
173 
7.2.6.1 Identification of latent trajectory classes 
In this key part of the study, I firstly gave special consideration to differences in 
timing of assessments across participants. Despite excluding subjects who were 
recruited to APPLE more than four weeks following stroke, there was still non-
negligible variability in when participants completed study visits. This seemed 
particularly relevant for early assessment, occurring over a period when changes 
in cognitive function would likely be most dynamic.  
For example, the average length of time from index stroke to baseline 
assessment was approximately one week, and ranged from one to twenty-eight 
days, with a standard deviation of five days. For the 1-month follow-up, the 
interval from stroke onset ranged from 24 to 69 days (M = 41, SD = 8). If 
unaccounted for, individual differences in assessment timepoints are likely to 
lead to misestimation of model parameters, and may hinder successful model 
convergence (443). Therefore, I conducted a time-unstructured analysis, where 
individual assessment timepoints are recorded for each participant and included 
as variables in the model (here, an additional four variables) (457).  
A second central issue related to the functional form of trajectories, capturing 
cognitive change over time. In studies using LCGA, the most commonly 
implemented approaches are polynomial functions – linear (straight line), 
quadratic (one curve), cubic (two curves), and incorporating more curves. The 
type of growth function that can be modelled is influenced by the number of 
assessment timepoints (444). With four timepoints, it was possible to specify 
either a linear or quadratic pattern of change. In selecting the optimal solution, 
I followed a similar approach as for deciding on the final number of latent 
trajectory classes.   
I investigated models including from one to six trajectories, assuming that a 
higher number would pose a challenge in view of the available sample size. In 
line with current recommendations, I compared the models on multiple aspects. 
Firstly, I assessed model fit indices: the Akaike information criterion (AIC) (458), 
the Bayesian information criterion (BIC) (459), and the sample size-adjusted BIC 
(SSA-BIC) (460). For these statistics, a lower value indicates better model fit. I 
then considered classification accuracy. Entropy is a summary measure 
reflecting how well classes are separated from one another, and the confidence 
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with which participants are assigned to a specific class (441, 461, 462). 
Estimates range from 0.00 to 1.00; values approaching 1.00 are preferred, with a 
widely applied acceptability threshold of 0.80 (463). Classification accuracy is 
also estimated for individual classes, according to model-based (posterior) 
probabilities (440). I presented this measure as a percentage, where values 
approaching 100% are favoured. It is important to note that for every participant 
a probability is estimated for belonging to each identified class – the class with 
the highest probability is the one the person will be assigned to.  
Another aspect relevant to model comparison includes the number of individuals 
assigned to a particular latent trajectory class. Generally, solutions where less 
than 1% of the study sample represents any given class are rejected in favour of 
a model with fewer trajectories (440). A similar approach is taken where 
identified trajectories highly resemble one another in shape, and any 
distinguishing features are difficult to identify. This also relates to the final 
assessment component, focusing on clinical plausibility and interpretation.  
An example of a Mplus code I developed for a three-class solution is provided in 
Appendix 10. An important feature of the code is the specified number of 
random sets of starting values and the number of final optimisations (two values 
for STARTS), i.e. iterations based on maximum likelihood parameter estimation, 
which I increased from default settings (specifically, from STARTS = 10 2 to 
STARTS = 100 10) (464). This allowed for a more thorough investigation of 
multiple solutions, and in turn increased the probability of obtaining an optimal 
one rather than a solution based on local maxima. Ideally, the iteration is to 
result from successful convergence on the global maximum solution (440). Once I 
selected the most favourable model from considered alternatives, I verified this 
condition by testing whether the parameter estimates would be replicated for 
the two best obtained loglikelihood values (440, 444).  
7.2.6.2 Prediction of class membership 
This part of the study involved a logistic regression analysis, with latent 
trajectory class membership constituting the outcome. As follows, the type of 
developed model – binary or multinomial – depended on the number of classes in 
the final solution. The predictors I considered largely overlapped with the 
variables I had used for comparing groups based on study completion (dropout) 
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status. For this analysis, however, I did not include a global measure of pre-
stroke functional independence, as reflected by the mRS score, assuming that 
this construct would be jointly captured by the many variables relevant to 
medical history. Moreover, I did not investigate associations with measures of 
physical activity and social support due to the very high proportion of missing 
values, exceeding what is considered appropriate for imputation (267). Instead, I 
conducted a separate analysis with these variables in a subsample of 
participants, described in detail in the next section.  
There were also differences in how I coded particular variables of interest, as 
alongside retaining maximum information, I aimed to accommodate modelling 
challenges, related to value distributions diverging far from normal (e.g. zero-
inflated) and the presence of outliers. Specifically, for this analysis, I 
categorised education into four groups, in accordance with the UK schooling 
system: category 1 – under 11 years, which is below the current compulsory 
minimum for full-time education; category 2 – 11 years, reflecting compulsory 
duration at a General Certificates of Secondary Education (GCSE) level; category 
3 – 12 and 13 years, reflecting education at Advanced Levels (A-Levels); and 
category 4 – above 13 years, reflecting progressing into higher education.  
Further, for stroke severity as measured by the NIHSS score, I applied the 
categorisation presented in Table 7-3, distinguishing: no stroke signs (score 
of 0), minor stroke (score of 1 to 4), moderate (score of 5 to 15), and severe 
(score of 16 to 42) (361). Conversely, instead of implementing the clinically 
recognised cut-off values for BMI, I included this factor in the model as a 
centred, continuous variable. This was to allow more accurate modelling of a 
potentially non-linear relationship, with evidence suggesting that, in older age, 
poorer cognitive function may be associated with both low and very high BMI 
values (465-467). As follows, alongside a linear term, I included a quadratic term 
for BMI in the analysis (BMI2).  
After selecting and coding predictors for inclusion in the model, I conducted a 
missing value analysis, using IBM SPSS Statistics 27. I found that missing values 
constituted 0.8% of all values in the dataset, and related to six variables 
(education, BMI, history of substance abuse, smoking status, and stroke 
severity). A graphical inspection of the pattern of missingness indicated that the 
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data were likely missing completely at random. It is generally considered that in 
cases such as this – completely random missingness, affecting below 5% of 
datapoints – missing values can be ignored (267), and a complete-case analysis 
approach applied. However, in this study, this would have led to the exclusion of 
40 participants, and thus a substantial loss of statistical power. I therefore 
decided to employ a multiple imputation procedure, using Bayesian analysis in 
Mplus (468, 469).  
Multiple imputation is recommended as a method that accounts for uncertainty 
about the right value to impute, producing unbiased parameter estimates in a 
variety of missing data situations (470). A missing value is not substituted with a 
single value, but instead is replaced by a set of plausible values, representing a 
distribution of possibilities (471). Consequently, multiple datasets are generated 
for use in subsequent analyses, the results of which are combined for inference. 
For all analyses predicting class membership, I generated ten imputed datasets.  
7.2.7 Additional analyses 
7.2.7.1 Physical activity and social support as predictors of class 
membership 
I included these two predictors in a multivariable analysis involving a subsample 
of study participants, who completed the relevant questionnaires at baseline. 
Given the relatively small sample size, I decided to limit the covariates to 
factors that seemed most essential to account for, including age, sex, education, 
and stroke severity. I intended to also add any variables found significant in the 
main logistic regression. Further, assuming that many health-related factors 
would likely be omitted, for this analysis I decided to account for pre-stroke mRS 
(as an ordinal variable with five categories). Given far from normal distributions, 
I categorised scores from measures of physical activity and social support based 
on tertiles.  
7.2.7.2 Mediation analyses 
An additional aim of this study was to verify whether the effects of 
cardiovascular risk factors described in Chapter 5 would be reproduced after 
redefining the outcome from “acute post-stroke cognitive function” to “pattern 
of longer-term cognitive change”. For this purpose, I intended to replicate the 
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previously developed moderated-mediation model as accurately as possible to 
predict class membership.  
Overall, I performed all relevant statistical procedures as outlined for the 
previous study, with the exception of using multiple imputed datasets. As a 
consequence of the latter, computing bias-corrected bootstrap confidence 
intervals was not possible. Another important limitation was that, for APPLE, 
data regarding previous stroke and previous TIA had been recorded as a single 
variable, and therefore I could not test the individual associations of these 
factors with the outcome.  
In summary, the structure of the investigated model would be as follows: i) 
latent trajectory class membership regressed on two mediators – stroke severity 
and prior cognitive impairment, and seven predictors – age, sex, diabetes, 
hypertension, vascular disease, atrial fibrillation, and previous stroke/TIA; ii) 
stroke severity regressed on the seven predictors and two interaction terms – 
between vascular disease and hypertension, and vascular disease and diabetes; 
iii) prior cognitive impairment regressed on the seven predictors. 
Following this replication analysis, I also sought to expand the developed model. 
Of particular interest was inclusion of education as a predictor, the effect of 
which I could not account for in the previous study. Moreover, I planned to 
introduce any additional variables that were significantly associated with latent 
trajectory class membership in the main logistic regression analysis. Finally, with 
the model being redefined, I intended to remove potentially nonsignificant 
interaction terms for the prediction of stroke severity, to achieve a more 
parsimonious solution (368). 
7.3 Summary 
In this chapter, I presented the methods I had applied to explore heterogeneity 
in the natural history of cognitive change following stroke in the APPLE dataset.  
The core component of this study is the LCGA that allows to identify distinct 
trajectory classes within a studied population. In preparation for this stage of 
analysis, I: i) conducted a factor analysis to derive a latent cognitive variable 
based on participants’ AMT-plus scores, verifying that measurement invariance 
had been achieved; and ii) implemented two alternative approaches for handling 
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missing outcome data due to dropout – based on FIML alone, and coupling FIML 
with selective substitution of missing values.  
The end of this chapter on study methods does not mark the conclusion of a 
decision chain regarding approaches to analysing the APPLE data. Similarly as for 
the procedures I described above, selecting an optimal latent class model 
involves an iterative process. Its result in turn informs the specific choice of 
strategies in a subsequent part of the study, investigating predictors of latent 
class membership. Findings from these two linked investigation components are 
the focus of my next chapter.  
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Chapter 8 Trajectories of post-stroke cognitive 
change following stroke: A pilot study using the 
APPLE dataset. Part II: Results and discussion. 
In the first section of this chapter, I present the results of the main and 
additional analyses I conducted in the APPLE dataset. As I described in Part I, 
this included specifying an optimal growth model based on LCGA, using a latent 
cognitive factor as the outcome variable, followed by identifying predictors of 
distinguished trajectory classes. In the second section, I discuss the clinical and 
research implications of recognising heterogeneity within a stroke population, 
with special consideration to how cognitive outcomes are understood and 
captured. Further, based on my experience of applying LCGA in the context of 
post-stroke cognition, I make recommendations for future research.    
8.1 Results 
8.1.1 Model selection and description of identified trajectories 
8.1.1.1 Default FIML approach for handling missing outcome data 
Individual trajectories of cognitive change over time are presented in Appendix 
11. I initially developed linear growth models with one to six latent classes, 
using the default FIML approach. Table 8-1 presents characteristics relevant to 
optimal model selection. As a next step, I assessed the alternative quadratic 
growth models. The one and two-class models had poorer fit indices compared 
to equivalent linear growth models (BIC of 3558.7 and 3287.1, respectively), 
with the two-class model also presenting lower entropy (0.75). For models with 
three or more classes, meaningful estimates could not be obtained for all 
parameters (model nonidentification). Therefore, I narrowed my selection 
process to three linear growth models with the most favourable characteristics – 
with three, four and six classes. I excluded the five-class model as model fit 
indices were only modestly better than for the four-class alternative and, 
overall, out of all models classification accuracy was poorest.  
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At this stage, I predominantly focused on the types of distinguished trajectories, 
discussing the possible clinical interpretation of alternative model solutions with 
physicians specialising in stroke. Compared to the three-class model (Figure 8-1), 
the four-class model (Figure 8-2) allowed to distinguish a unique trajectory shape 
– latent Class 4. Unlike for the three remaining classes, in this case change over 
time appeared relatively constant, without a steeper period of improvement 
between baseline and the 1-month follow-up. In the six-class model (Figure 8-3), 
however, no additional, unique trajectory type was identified, with little 
difference in trajectory shape between Classes 1 and 2, and Classes 4 and 5. 
Moreover, there were relatively few participants representing Classes 1 and 6 
(under 20 cases). On this basis, I selected the four-class model as the most 
optimal solution. Following replication of the best loglikelihood values, I 
concluded that local maxima had been successfully avoided.   
Table 8-1 Linear growth model comparison for models developed using default 
FIML approach. 
Model AIC BIC SSA-BIC Entropy 
Proportion of 
sample per class 
Classification 
accuracy 
1 class 1980.7 2003.7 1984.7    
2 classes 1590.4 1624.9 1596.4 0.80 59.2%, 40.8% 93.9%, 95.0% 























90.2%, 97.1%  
AIC indicates Akaike information criterion (AIC); BIC, Bayesian information criterion; SSA-BIC,  
sample size-adjusted Bayesian information criterion. 
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Figure 8-1 Trajectories of post-stroke cognitive change for a three-class model 
based on observed means, estimated using a default FIML approach. 
 
Figure 8-2 Trajectories of post-stroke cognitive change for a four-class model 
based on observed means, estimated using a default FIML approach. 
 
Figure 8-3 Trajectories of post-stroke cognitive change for a six-class model based 



































Class 1 (80 participants)
Class 2 (182 participants)



































Class 1 (83 participants)
Class 2 (149 participants)
Class 3 (86 participants)



































Class 1 (19 participants)
Class 2 (73 participants)
Class 3 (112 participants)
Class 4 (70 participants)
Class 5 (52 participants)
Class 6 (17 participants)
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8.1.1.2 FIML with selective substitution for handling missing outcome 
data 
Given little support for a quadratic solution, I only developed linear growth 
models using the alternative approach to handling missing outcome data, 
combining FIML with selective substitution of missing values due to study 
dropout. Based on model characteristics presented in Table 8-2, the three, four, 
and five-class options seemed most favourable, where here it was the 6-class 
model for which classification accuracy was poorest. 
Graphical examination indicated that the types of identified trajectories were 
very similar for both approaches to handling missing data. As previously, 
compared to the three-class model (Figure 8-4), the four-class model (Figure 
8-5) led to the detection of a unique trajectory shape. For the five-class model 
(Figure 8-6), on the other hand, I found that despite different intercepts, the 
key features of trajectory shape were difficult to distinguish between Classes 1 
and 2. Therefore, once again, the four-class model appeared to represent an 
optimal solution, which – as I verified – was not based on local maxima.  
Table 8-2 Linear growth model comparison for models developed using a combined 
approach to handling missing outcome data. 
Model AIC BIC SSA-BIC Entropy 
Proportion of 
sample per class 
Classification 
accuracy 
1 class 2343.6 2366.6 2347.6    
2 classes 1871.0 1905.6 1877.0 0.78 41.7%, 58.3% 93.0%, 93.3% 
























AIC indicates Akaike information criterion (AIC); BIC, Bayesian information criterion; SSA-BIC,  
sample size-adjusted Bayesian information criterion. 
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Figure 8-4 Trajectories of post-stroke cognitive change for a three-class model based on 
observed means, estimated using a combined approach. 
 
Figure 8-5 Trajectories of post-stroke cognitive change for a four-class model based on 
observed means, estimated using a combined approach. 
 
Figure 8-6 Trajectories of post-stroke cognitive change for a five-class model based on 
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Class 1 (20 participants)
Class 2 (82 participants)
Class 3 (136 participants)
Class 4 (78 participants)
Class 5 (27 participants)
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8.1.1.3 Comparison of results from alternative approaches to handling 
missing outcome data 
Table 8-3 presents the estimated intercept and slope for each class for both 
approaches to handling missing outcome data. Depending on the sign, a 
significant slope indicates either an overall improvement or decline in cognitive 
function. However, it is important to note that this estimate represents an 
average across all timepoints, and as such, cannot fully reflect a trajectory 
shape where change is not relatively constant. This was particularly relevant in 
case of Class 1, where the direction of slope changed. In view of this, in my 
description of identified trajectories, I considered both estimated parameters 
and graphical representations, assuming that real values were likely to lie at an 
intermediate point between results obtained using the two different approaches 
to handling missing outcome data.  
Table 8-3 Estimated class characteristics for four-class models by approach to 
handling missing outcome data. 





































*significant at p < 0.05 
FIML indicates full information maximum likelihood. 
As follows, I concluded that Class 1 was characterised by high cognitive function 
soon after stroke, which improved over following weeks, and thereafter 
declined. Class 2 presented with some cognitive problems soon after stroke, 
followed by a period of improvement, after which cognitive function remained 
relatively stable. Class 3 was characterised by comparatively poor initial 
cognitive function, which after a stage of steeper improvement, continued to 
improve at a slower rate. Class 4 experienced severe cognitive impairment soon 
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after stroke, which was followed by improvement in cognitive function at a 
relatively constant rate.  
Although in my interpretation of the selected four-class solution I considered 
results from both models, only one model could be chosen for assigning final 
class membership. For this purpose, I selected the model I developed by 
combining FIML with selective substitution of missing outcome values. This 
decision was guided by two considerations. Firstly, using the default approach, 
from the 6-month timepoint trajectories of all classes showed a positive change 
– slower decline for Class 1 and greater improvement for the three remaining 
classes (see Figure 8-2). From a clinical perspective, it seemed implausible that 
this reflected a real change in cognitive function and, as follows, it could be 
suspected that this effect resulted from increased sample bias after participants 
with poorer cognition (relative to their assigned class) dropped out of the study. 
Secondly, for the default approach, classification accuracy was slightly poorer.  
8.1.2 Prediction of class membership 
Descriptive statistics for predictors of interest by assigned latent class 
membership are provided in Table 8-4. I presented the variables to reflect how 
they were entered in the analyses (as binary, categorical or continuous), with 
the exception of BMI, which while remaining continuous, I centred for inclusion 
in developed models. To facilitate conveying of results, I designated the 
trajectory classes based on the represented overall, relative level of cognitive 
function and unique trajectory features: Class 1 – high – declining, Class 2 – mid-
high – stable, Class 3 – mid-low – slowing improvement, Class 4 – low – constant 
improvement.   
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(N = 79) 
Mid-high – 
stable 








(N = 28) 
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<11 years     
11 years      

































Never, N (%) 
Former, N (%) 

















History of substance 
abuse, N (%) 
8/79 (10.1%) 20/145 (13.8%) 7/89 (7.9%) 2/28 (7.1%) 
Diabetes, N (%) 20/79 (25.3%) 35/147 (23.8%) 21/89 (23.6%) 9/28 (32.1%) 
Hypertension, N (%) 41/79 (51.9%) 78/147 (53.1%) 48/89 (53.9%) 16/27 (59.3%) 
Vascular disease, N (%) 19/79 (24.1%) 45/147 (30.6%) 21/89 (23.6%) 13/28 (46.4%) 
Heart failure, N (%) 5/79 (6.3%) 10/137 (6.8%) 7/89 (7.9%) 4/28 (14.3%) 
Atrial fibrillation, N (%) 9/79 (11.4%) 24/147 (16.3%) 16/89 (18.0%) 7/28 (25.0%) 
Previous stroke/TIA, 
N (%) 
13/79 (16.5%) 37/147 (25.2%) 23/89 (25.8%) 12/28 (42.9%) 
Renal disease, N (%) 7/79 (8.9%) 16/147 (10.9%) 12/89 (13.5%) 6/28 (21.4%) 
Prior cognitive 
impairment, N (%) 
2/79 (2.5%) 4/147 (2.7%) 9/89 (10.1%) 11/28 (39.3%) 
History of mood 
disorder, N (%) 
19/79 (24.1%) 39/147 (26.5%) 25/89 (28.1%) 8/28 (28.6%) 
Physical activity  
1st tertile, N (%) 
2nd tertile, N (%) 


















1st tertile, N (%) 
2nd tertile, N (%) 

















Stroke severity (NIHSS) 
No stroke signs, N (%) 
Mild, N (%) 
Moderate, N (%) 





















BMI indicates body mass index; SD, standard deviation; TIA, transient ischaemic attack.
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8.1.2.1 Results of multinomial logistic regression analysis 
The results of this analysis, central to the prognostic objective of this study, are 
presented in Table 8-5. I chose the mid-high – stable class as an initial point of 
reference for all remaining latent trajectory classes, as one that: included most 
participants, had an intermediate intercept estimate, showed relatively limited 
change in cognitive function over time, and appeared closest to the post-stroke 
recovery pattern traditionally described in existing literature – initial 
(spontaneous) improvement, followed by a plateau period (472-474).   
Compared to this class, I found that representing the high – declining trajectory 
was nearly two times more likely by moving up one category of education, which 
constituted the only significant finding for this comparison. Conversely, with 
moving up one education category, the likelihood of representing the mid-low – 
slowing improvement class decreased by over a third. Compared to the mid-high 
stable class, participants here were also 3.5 times less likely to have a history of 
substance abuse, while being nearly 5 times more likely to have a history of 
cognitive impairment.  
Further, associations with BMI suggested a possible non-linear relationship, 
where the likelihood of being in the mid-low – slowing improvement class 
decreased with rising BMI until approximately a value of 34.5 (obesity), after 
which it began to increase. In other words, participants in this class were more 
likely to have both relatively low and very high BMI, while high-mid-range values 
were associated with the mid-high stable class. I moreover observed a trend 
(p = 0.056), suggesting that as stroke increased in severity from one category to 
the next, participants were around 50% more likely to represent the mid-low – 
slowing improvement trajectory.  
For the third comparison with the mid-high – stable class as a reference, the 
likelihood of representing the low – constant improvement trajectory increased 
nearly by one-tenth with every one-year increase in age, increased 27 times with 
a history of prior cognitive impairment, and 12 times with moving up a category 
of stroke severity. I also noted a trend (p = 0.055), indicating that participants 
were around two times less likely to belong to this class with the overall poorest 
level of cognitive function as education increased by one category.
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Table 8-5 Results of multinomial logistic regression analysis identifying predictors of latent trajectory class membership. 
 
Mid-high - stablea 
vs. high - declining 
Mid-high - stablea vs. 
mid-low – slowing 
improvement 
Mid-high – stablea 
vs. low – constant 
improvement 
High – declininga vs. 
mid-low – slowing 
improvement 
High – declininga vs. 
low – constant 
improvement 
Mid-low – slowing 
improvementa vs. low – 
constant improvement 
Age 0.99 (0.96, 1.02) 1.01 (0.98, 1.04) 1.08 (1.01, 1.15)* 1.02 (0.99, 1.05) 1.09 (1.02, 1.16)** 1.06 (1.00, 1.13)* 
Sex  1.02 (0.53, 1.98) 1.32 (0.71, 2.42) 1.53 (0.51, 4.61) 1.29 (0.59, 2.81) 1.50 (0.45, 5.03) 1.16 (0.40, 3.43) 
Education 1.90 (1.38, 2.61)** 0.64 (0.46, 0.88)** 0.47 (0.22, 1.02) 0.34 (0.23, 0.50)** 0.25 (0.11, 0.56)** 0.74 (0.34, 1.60) 
BMI 
BMI2 
0.99 (0.93, 1.06) 
1.00 (1.00, 1.01) 
0.92 (0.87, 0.98)* 
1.01 (1.00, 1.01)* 
0.98 (0.86, 1.11) 
0.99 (0.98, 1.01) 
0.93 (0.87, 1.00)* 
1.00 (1.00, 1.01) 
0.99 (0.87, 1.12) 
0.99 (0.98, 1.01) 
1.06 (0.93, 1.20) 
0.99 (0.97, 1.00) 
Smoking status 0.75 (0.45, 1.23) 1.15 (0.76, 1.74) 1.26 (0.61, 2.59) 1.54 (0.89, 2.66) 1.69 (0.74, 3.83) 1.10 (0.54, 2.23) 
History of 
substance abuse 
1.05 (0.34, 3.22) 0.28 (0.10, 0.79)* 0.30 (0.04, 2.54) 0.27 (0.07, 0.96)* 0.28 (0.03, 2.80) 1.06 (0.13, 8.75) 
Diabetes 1.31 (0.64, 2.69) 1.02 (0.49, 2.10) 1.32 (0.37, 4.68) 0.78 (0.34, 1.77) 1.00 (0.26, 3.86) 1.29 (0.37, 4.51) 
Hypertension 0.98 (0.53, 1.80) 1.10 (0.60, 2.02) 1.13 (0.41, 3.14) 1.12 (0.55, 2.31) 1.16 (0.39, 3.47) 1.03 (0.38, 2.80) 
Vascular disease 0.92 (0.45, 1.88) 0.62 (0.29, 1.32) 1.00 (0.30, 3.41) 0.68 (0.27, 1.68) 1.09 (0.29, 4.16) 1.62 (0.49, 5.36) 
Heart failure 1.51 (0.41, 5.53) 1.27 (0.37, 4.34) 1.83 (0.34, 9.87) 0.84 (0.18, 3.97) 1.22 (0.19, 7.83) 1.44 (0.27, 7.67) 
Atrial fibrillation 1.00 (0.39, 2.61) 0.90 (0.42, 1.93) 0.43 (0.10, 1.90) 0.90 (0.31, 2.56) 0.42 (0.08, 2.23) 0.47 (0.11, 2.04) 
Previous stroke/TIA 0.58 (0.26, 1.29) 0.95 (0.46, 1.96) 1.83 (0.64, 5.23) 1.63 (0.63, 4.22) 3.16 (0.95, 10.50) 1.93 (0.69. 5.41) 
Renal disease 0.92 (0.28, 2.98) 1.13 (0.47, 2.74) 1.05 (0.32, 3.45) 1.24 (0.32, 4.82) 1.14 (0.23, 5.62) 0.93 (0.28, 3.05) 
Prior cognitive 
impairment 
1.07 (0.20, 5.89) 4.85 (1.24, 18.92)* 26.8 (5.39, 133.02)** 4.51 (0.79, 25.85) 
24.94 (3.53, 
176.05)** 
5.53 (1.35, 22.71)* 
History of mood 
disorder 
1.01 (0.46, 2.24) 1.21 (0.62, 2.38) 0.53 (0.10, 2.67) 1.20 (0.51, 2.84) 0.52 (0.09, 2.98) 0.43 (0.09, 2.10) 
Stroke severity 0.75 (0.48, 1.16) 1.51 (0.99, 2.31) 11.94 (4.64, 30.7)** 2.02 (1.21, 3.38)** 15.96 (5.99, 42.5)** 7.90 (3.07, 20.35)** 
areference class; *significant at p < 0.05; **significant at p < 0.01 
BMI indicates body mass index; TIA, transient ischaemic attack. 
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With the high – declining class as a reference, findings were in most part similar.  
Representing the mid-low – slowing improvement class was approximately three 
times less likely for both education higher by one category and a history of 
substance abuse. I also observed an association where for every 1 unit increase 
in BMI, the likelihood for cognitive change to follow this trajectory decreased by 
7%. At the same time, belonging to the mid-low – slowing improvement class was 
two times more likely for every one-category increase in stroke severity.   
On comparing the high -declining to the low – constant improvement class, I 
observed that representing the latter trajectory was more likely by nearly one-
tenth with every one-year increase in age, 25 times more likely with a history of 
cognitive impairment, and 16 times with moving up a category of stroke 
severity. Conversely, moving up one category of education was associated with 
being four times less likely to belong to the low – constant improvement class. I 
moreover observed a trend (p = 0.061), suggesting the participants in this class 
were approximately three times more likely to have had a previous stroke or 
TIA.  
In the final comparison, with the mid-low – slowing improvement class serving as 
a reference, I found that the likelihood of representing the low – constant 
improvement trajectory increased 0.06 times with every one-year increase in 
age, 5.5 times with a history of cognitive impairment, and nearly 8 times with a 
one-category increase in stroke severity.    
8.1.3 Results of additional analyses 
8.1.3.1 Associations of latent class membership with physical activity 
and social support 
This analysis involved a subsample of 165 participants with data on self-reported 
physical activity and social support, including: 38 participants in the high – 
declining class, 79 in the mid-high – stable class, 39 in the mid-low – slowing 
improvement class, and 9 in the low – constant improvement class. Considering 
results of the main analysis alongside my initial assumptions, I accounted for the 
following predictors: age, sex, education, BMI (linear and quadratic term), pre-
stroke mRS, history of substance abuse, previous stroke/TIA, prior cognitive 
impairment, and stroke severity.  
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However, even with a limited number of variables, I recognised that low 
statistical power would present a major issue for this analysis. To at least 
partially ameliorate this limitation, I decided to combine the two higher-
function classes and the two lower-function classes. In addition to relative 
similarity in the overall level of cognitive function, this seemed justified by the 
observed pattern of change, with the lower-function classes presenting 
continuing improvement, unlike the other two class. Consequently, for this part 
of the study I conducted a binary logistic regression. 
I found no association between measures of physical activity and social support 
and assignment to a lower-function class (OR = 1.02, 95% CI: 0.73 to 1.42; and 
OR = 1.02, 95% CI: 0.76 to 1.36, respectively). Among significant predictors were 
only education (OR = 0.66, 95% CI: 0.52 to 0.85) and stroke severity (OR = 1.48, 
95% CI:1.05 to 2.09). 
8.1.3.2 Mediation analyses 
Similarly as described above, in view of low statistical power, I used a binary 
outcome, differentiating between the two higher-function latent classes and two 
lower-function classes. The first analysis was aimed at replicating the moderated 
mediation model described in Chapter 5. Here, however, obtained estimates 
suggested poor model fit. Following modification recommendations, which can 
be requested as part of the software output, I therefore included an additional 
path, with stroke severity regressed on prior cognitive impairment. The resulting 
mean fit index estimates suggested very good model fit: CFI = 1.00, TLI = 1.23, 
RMSEA < 0.01, SRMR = 0.03.   
For class membership, I found a direct association only with the two mediators: 
stroke severity (coefficient = 0.218, 95% CI: 0.001 to 0.435) and prior cognitive 
impairment (coefficient = 0.580, 95% CI: 0.241 to 0.918). In relation to mediator 
predictors, stroke severity was inversely associated with age (coefficient = 
−0.019, 95% CI: −0.036 to −0.002), and positively associated with atrial 
fibrillation (coefficient = 0.515, 95% CI: 0.129 to 0.902) and prior cognitive 
impairment (coefficient = 0.354, 95% CI: 0.143 to 0.566). Prior cognitive 
impairment was significantly predicted only by age (coefficient = 0.036, 95% CI: 
0.006 to 0.066). Although, there also appeared to be a trend for an association 
with diabetes (coefficient = 0.601, 95% CI: −0.091 to 1.293, p = 0.089). 
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In view of the observed direct associations, as a next step, I tested plausible 
indirect effects. Of these, only two were significant. Representing a lower-
function class was associated with prior cognitive impairment through greater 
stroke severity (coefficient = 0.077, 95% CI: 0.013 to 0.142); and with age, 
through increased likelihood of prior cognitive impairment (coefficient = 0.021, 
95% CI: 0.001 to 0.041). I further found a trend for two additional indirect 
effects, where age decreased the likelihood of belonging to a lower-function 
class through reduced stroke severity (coefficient = −0.004, 95% CI: −0.009 to 
0.001, p = 0.086), while atrial fibrillation increased this likelihood through 
greater stroke severity (coefficient = 0.112, 95% CI: −0.016 to 0.241, p = 0.087).   
In the second analysis, I additionally included education, BMI, and history of 
substance abuse among predictors. To develop a final model, I removed 
insignificant interaction terms one by one in order of descending p-value, which 
here also related to a quadratic term for BMI. However, removing the latter as a 
predictor of class membership resulted in a deterioration of model fit, and 
therefore I retained this term. Fit indices for the resulting final model, 
presented in Figure 8-7, indicated very good model fit: CFI = 1.00, TLI = 1.20, 



















Latent trajectory class 
membership: higher vs 
lower overall cognitive 
function 
Figure 8-7 Conceptual diagram of the final mediation model with two parallel mediators for prediction of latent trajectory class membership. 
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Direct associations between predictors, mediators and class membership are 
presented in Table 8-6. As in the previous analysis, representing a lower-function 
class was more likely with greater stroke severity and prior cognitive 
impairment. This likelihood decreased, however, with education and history of 
substance abuse. I further observed a trend for an inverse association between 
BMI and lower cognitive function (p = 0.054). Although, if the estimate for the 
quadratic term of BMI indeed represented a true effect (p = 0.113), this would 
indicate a change in the direction of the association for very high BMI values – 
the likelihood of belonging to a lower-function class would start to increase from 
a BMI of approximately 36.5.  
The effects of predictors on mediators mostly replicated findings from the 
previous analysis. Reduced stroke severity was associated with age, while 
greater severity – with atrial fibrillation and prior cognitive impairment. The 
latter was significantly associated with age only, although I also observed a 
trend for an association with history of substance abuse (p = 0.082). 
Table 8-6 Direct associations between predictors of interest and stroke severity, 
prior cognitive impairment, and class membership; comparing combined two 
higher-function classes (reference) with two lower-function classes. 






Stroke severity   0.264 (0.047, 0.482)* 
Prior cognitive 
impairment 
0.330 (0.120, 0.506)**  0.594 (0.295, 0.893)** 
Age -0.021 (-0.042, -0.001)* 0.048 (0.006, 0.090)* -0.013 (-0.042, 0.016) 
Sex -0.125 (-0.427, 0.176) -0.132 (-0.668, 0.404) 0.223 (-0.224, 0.669) 
Education 0.068 (-0.086, 0.222) -0.094 (-0.393, 0.205) -0.404 (-0.642, -0.204)** 
BMI 
BMI2 
-0.023 (-0.057, 0.011) 
 
0.009 (-0.058, 0.075) 
 
-0.052 (-0.104, 0.001) 
0.003 (-0.001, 0.006) 
History of 
substance abuse 
0.077 (-0.450, 0.605) 0.859 (-0.110, 1.828) -1.162 (-2.030, -0.294)** 
Diabetes 0.143 (-0.250, 0.535) 0.426 (-0.167, 1.019) -0.200 (-0.705, 0.305) 
Hypertension 0.100 (-0.219, 0.420) -0.090 (-0.715, 0.535) 0.109 (-0.367, 0.585) 
Vascular disease -0.179 (-0.527, 170) 0.381 (-0.176, 0.938) -0.345 (-0.824, 0.134) 
Atrial fibrillation 0.571 (0.187, 0.955)** -0.590 (-1.371, 0.192) 0.221 (-0.391, 0.833) 
Previous 
stroke/TIA 
0.187 (-0.171, 0.544) 0.140 (-0.380, 0.659) 0.080 (-0.392, 0.552) 
*significant at p < 0.05; significant at p < 0.01 
BMI indicates body mass index; CI, confidence interval; TIA, transient ischaemic attack.  
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Regarding indirect effects, I found that representing a lower-function class was 
significantly associated with atrial fibrillation and prior cognitive impairment 
through greater stroke severity (coefficient = 0.151, 95% CI: 0.005 to 0.297; and 
coefficient = 0.087, 95% CI: 0.023 to 0.151, respectively), as well as with age 
through increased risk of prior cognitive impairment. There was also some 
indication for possible opposing effects of age through stroke severity. As age 
was associated with reduced stroke severity, it in turn appeared to decrease the 
likelihood of belonging to a lower-function class (coefficient = −0.006, 95% CI: 
−0.012 to 0.001, p = 0.073). At the same time, age was associated with an 
increased risk of prior cognitive impairment, in turn linked to greater stroke 
severity, and ultimately – with lower cognitive function (coefficient = 0.004, 95% 
CI: 0.000 to 0.009, p = 0.079). Finally, I noted a potential indirect effect of 
history of substance abuse on lower-function class membership through an 
increased risk of prior cognitive impairment (coefficient = 0.510, 95% CI: −0.080 
to 1.100, p = 0.090). 
8.2 Discussion 
Findings from my study confirm existing concepts. Following stroke, most 
individuals experience an initial period of cognitive improvement, after which 
function may either continue to improve, remain relatively stable or decline. 
However, with improvement associated with overall more severe impairment, 
and decline with high cognitive function, an interpretation of what constitutes 
‘good’ post-stroke cognitive outcome remains uncertain.  
Based on the APPLE dataset, I identified four distinct trajectory classes for post-
stroke cognitive change over a one-year period. Key distinguishing features of 
trajectory shape related to the intercepts and direction of change following the 
1-month assessment. Although regarding the latter, it is relevant to note that 
the uniqueness of the mid-high – stable class was rather due to the relative lack 
of change. The low – constant improvement class can also be set apart on 
account of a feature indicated in its designation – having the only trajectory 
representing nearly linear growth. This may be due to an initially slower 
recovery rate, which has been previously associated with particularly severe 
acute post-stroke impairment (475-477). Considering how trajectories related to 
one another, it is moreover important to highlight that none crossed over, that 
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is, the order of classes according to level of cognitive performance prevailed 
throughout the duration of follow-up.  
Through investigating what factors characterised the identified trajectory 
classes, I obtained some unexpected results. Firstly, higher overall cognitive 
function, as represented by the first two trajectory classes, was associated with 
a history of substance abuse. This is in contrast to an extensive body of evidence 
indicating that alcohol and drug abuse increase the risk of neuropathology and 
cognitive deficits, with some detrimental effects likely to persist even after 
prolonged abstinence (478-481). Interestingly, results of the mediation analysis 
provided some support for such an association – I observed a trend, where 
history of substance abuse appeared to increase the risk of prior cognitive 
impairment. In view of this, it seems plausible that substance abuse was 
identified as a distinctive profile feature of participants with overall higher 
cognitive function not on the basis of a causal relationship, but rather due to 
covariation. 
On one hand, substance abuse may have been one of the crucial predisposing 
factors for stroke among individuals who were comparatively young and had low 
comorbidity burden, and thus in some ways were less likely to present with 
cognitive impairment at this stage (482). On the other, substance abuse is 
associated with even several times higher mortality rates compared to the age-
matched general population (483, 484). Recognising death as a competing risk 
for cognitive impairment may explain why fewer participants with a history of 
substance abuse represented the two lower-function trajectory classes, 
characterised by older age, higher prevalence of most diseases, and more severe 
strokes.  
Another controversial finding relates to the potential duality of the indirect 
effect of age, increasing the likelihood of belonging to a lower-function class 
through increased risk of prior cognitive impairment, while decreasing this 
likelihood through reduced stroke severity. What was more, it seemed that age 
could also indirectly contribute to increased stroke severity through its effect on 
prior cognitive impairment. Given limitations of the analysis, and the discussed 
associations appearing as trends, these findings should be interpreted with 
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caution. Nonetheless, it seems worth considering why age could be associated 
with reduced stroke severity.  
One interpretation of this effect, which I mentioned above in the context of 
alcohol abuse, relates to the presence of survival bias. Older people may be 
more likely to die following a severe stroke, and therefore as a group will be 
underrepresented in research such as this (485). As an alternative explanation, 
studies suggest that stroke at a younger age is associated with a greater risk of 
developing space occupying oedema, including malignant middle cerebral artery 
infarction, which is associated with severe presentation and increased fatality 
(486, 487). Older people are less susceptible to this condition, argued to be due 
to more advanced cerebral atrophy, which affords potential compensatory space 
within the intracranial cavity.  
This phenomenon adds to other examples described in Chapter 5, indicating that 
in specific circumstances pathological processes can lead to more favourable 
outcomes. In this study, however, I did not observe a significant effect of 
vascular disease on reduced stroke severity (either conditional or unconditional), 
while an association with previous TIA alone could not be assessed. It is yet 
possible that, to some extent, the observed effect of age on stroke severity 
captured the cumulative influence of endogenous adaptive mechanisms, 
potentially developing with age-related progression of cardiovascular diseases. 
The conclusions from Chapter 5 also allowed me to anticipate the overall lack of 
direct effects of cardiovascular risk factors on cognitive trajectories in the 
present analyses. One exception was a trend for participants with the poorest 
overall level of cognitive function to be more likely to have had a previous 
stroke or TIA as compared to the high – declining class. This is in line with 
existing research evidence, similarly as the observed associations between 
representing one of the two lower-function classes and older age, lower 
education, greater stroke severity, prior cognitive impairment, and both lower 
and very high BMI values (23, 145, 465, 467).  
What is, however, puzzling, is that these factors would also typically be 
associated with cognitive decline, whereas the two classes characterised by 
them showed improvement over time. Conversely, it was the class with the 
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highest education and lowest prevalence of clinical risk factors (with the 
exception of history of alcohol abuse) that showed a decline in cognitive 
function after the 1-month assessment. 
One explanation for this may be that trajectories of post-stroke cognitive change 
are influenced by two co-occurring processes, exerting opposing effects. The 
first involves ongoing neurodegeneration, while the second entails recovery from 
stroke-induced damage. For participants who had less severe strokes and were 
relatively unaffected by acute cognitive impairment, the scope for longer-term 
recovery would have been limited. This in turn could have allowed for a more 
pronounced effect of a neurodegenerative process, resulting from pre-existing 
risk factors that predisposed to stroke, as well as neuropathological sequala of 
the stroke itself. Given the comparatively overall high level of cognitive function 
of participants who represented this trajectory, it seems that this process was 
captured at an early stage, or at least the manifestation of it was. The latter 
could have been delayed through the impact of cognitive reserve (488), 
presumably associated with the high level of education characterising this class.  
The opposite would apply to participants with overall poor cognitive function, 
for whom the trajectory slope appeared to predominantly reflect recovery. 
Nonetheless, the impact of neurodegeneration seems also apparent in this case, 
particularly on account of the intercept. Although poor initial cognitive function 
could in part be accounted for by on average greater stroke severity, findings 
based on medical history suggest that prior cognitive impairment was also a key 
contributing factor here.  
In understanding the meaning of distinct trajectory shapes, it seems moreover 
important to emphasise that the present study offers only a “snapshot” of 
cognitive changes occurring over a lifespan. Trajectory class membership is 
plausibly to some degree fluid and dependent on the point in time at which an 
individual is observed. To illustrate this argument, it is possible that with age 
and the consequent accumulation of health-related risk factors, a person who 
once represented the mid-high – stable class will experience a subsequent 
stroke, initiating change along a low – constant improvement trajectory. 
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8.2.1 Clinical implications 
A similar message can be emphasised as in Chapter 5 – for some stroke survivors, 
the risk of cognitive decline and potential future impairment may be easily 
underestimated. Based on my findings, this concern particularly relates to 
individuals representing a high - declining trajectory of cognitive change. 
Compared to other stroke survivors, this group’s profile seems to be 
characterised by younger age, higher education, fewer comorbidities, a less 
severe index stroke, and high acute cognition. As follows, they can 
understandably be assumed to make a very good recovery and maintain high 
cognitive function. However, even where gradual decline does not amount to a 
diagnosis of cognitive impairment, it can be experienced by the individual as a 
severe loss, compromising quality of life.  
Although in line with current clinical guidelines (489), all stroke survivors are to 
be supported in management of cardiovascular risk factors, there remains a key 
issue of whether anything more can be done to promote cognitive resilience and 
improvement. In this context, recognising distinct subpopulations among stroke 
survivors and understanding their characteristics may be an important step 
towards tailoring effective interventions to best suit individual profiles.  
8.2.2 Research implications 
Insights from this study encourage a revaluation of the currently dominant 
approach to how post-stroke cognitive outcome is defined and measured. Unlike, 
for example, recurrent stroke or death, cognitive function is not inherently 
binary, nor does it constitute a single event. Yet, in many studies in this area of 
research, it is treated as such. This does not imply that categorising individuals 
at a specific point in time following stroke into cognitively intact and cognitively 
impaired lacks real-world meaning or implications, or that this approach will not 
allow identification of relevant determinants of cognitive status. It is, however, 
undeniably leading to a loss of important information. 
In a clinical context, the aim of prediction research is to identify individuals at 
risk of an unfavourable outcome so that risk can be addressed – either in the 
present, or in the future, for example, once an intervention can be implemented 
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in routine practice following successful trials (96). However, with a binary 
outcome assessed at one timepoint, the risk of cognitive decline cannot be 
recognised, and thus addressed in those whose deficits have not yet reached the 
threshold for diagnosis of cognitive impairment. Similarly, it will not be possible 
to identify, and thus attempt to influence factors that differentiate between 
stroke survivors who partially recover from severe cognitive impairment and 
those who either maintain the same poor level of function or even deteriorate.  
Regardless of design, one adjustment that can be easily introduced to many 
studies is use of a continuous cognitive outcome. Understandably, both 
researchers and clinicians may consider interpretation of findings in relation to a 
formal diagnosis, such as mild cognitive impairment and dementia, more 
intuitive and useful. This, however, does not preclude from conducting an 
additional analysis with a continuous cognitive score for comparison of results, 
to verify whether any relevant effects have been missed.  
Another option worth considering, although entailing a higher level of 
complexity, is latent class analysis, where unlike in this study, subpopulations 
are distinguished based on co-occurrence of certain individual characteristics 
(demographics, medical conditions, lifestyle factors) (490). This allows to 
determine distinct profiles within a heterogenous population, such as that of 
stroke survivors, which can then be introduced in a model to predict cognitive 
outcome. Yet preferably, where resources permit, future research into post-
stroke cognitive outcomes should focus on longitudinal study designs with 
multiple assessment timepoints.  
In this context, it is important to discuss one of the key challenges of 
longitudinal research – handling of missing outcome data due to dropout. 
Similarly as reported by other researchers (e.g., 168, 491, 492), on comparing 
participants who remained in the study to those who dropped out, I found that 
the latter presented more risk factors for cognitive decline. As follows, it seems 
that this type of missingness is likely not to be random. Such comparisons are, 
however, rarely conducted and most studies adopt a complete-case analysis 
approach. As individuals with more severe difficulties are likely to be 
underrepresented, this can lead to biased estimates.  
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Once missing data appear, there is no ideal method for handling this issue, 
although some techniques are considered more favourable than others (493). 
With this in mind, it is recommended to test more than one approach, using 
different assumptions about missingness, and compare the obtained results (i.e. 
conduct a sensitivity analysis). Observations from this comparison can then be 
considered for the interpretation of findings and overall study conclusions, 
offering a more realistic view of the investigated effects themselves, or at least 
the likely degree of bias that should be taken into account. 
8.2.3 Strengths and limitations 
The broad inclusion criteria for recruitment into APPLE, as well as the option to 
obtain consent through proxy, constituted key prerequisites for the participant 
sample to be representative of a real-world stroke case-mix. I aimed to preserve 
this advantage in the present study, by excluding very few (N = 11) participants 
from conducted analyses. However, unlike in research utilising data from routine 
care registries, participation bias could not have been avoided. The extent of 
this bias is difficult to assess.  
As I described in Chapter 6, patient screening logs were available for only 2 of 11 
participating hospital sites, indicating a considerable disparity in enrolment 
rates (43% for the Glasgow Royal Infirmary vs 12% for the Royal Alexandra 
Hospital). The differences in characteristics between the APPLE and SSNAP 
cohorts (as can be seen in Table 6-4) are also difficult to interpret, as the latter 
did not include patients with a diagnosis of TIA. Nonetheless, it seems that the 
APPLE sample underrepresents survivors of severe stroke.  
In all decisions related to the study design and statistical analyses, I aimed to 
follow current recommendations as outlined in GRoLTS (441), PROBAST (95) and 
relevant materials on SEM (494, 495). Even so, the strengths of chosen strategies 
were frequently accompanied by certain drawbacks. Conducting factor analysis 
to obtain a latent variable representing cognitive function allowed me to handle 
missing data from telephone assessments, account for differing contributions of 
test items, and verify measurement invariance throughout follow-up.  
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At the same time, however, to ensure success of the procedure, I applied a 
data-driven approach for exclusion and collapsing of specific AMT-plus questions. 
The need for such adjustments suggests a certain level of redundancy across test 
items, and reminds that there is no evidence regarding the psychometric 
properties of this particular cognitive screening tool (a hybrid between the AMT-
10 and a short-form MoCA). Moreover, the meaning of the individual factor 
scores that I derived is only relative. As such, estimates of cognitive function 
cannot be directly translated to scores from standardised assessment measures, 
including thresholds for diagnosis of cognitive impairment.  
On a similar note, through accounting for differences in assessment timepoints 
across participants, I increased the probability of successful model convergence 
and good model fit (443). Unfortunately, not all preferred software output 
features were available for more complex models such as the one developed. 
This specifically relates to plotting estimated factor score means against 
observed means for identified trajectories. Figures included in the Results 
section only present observed means. Adding estimated means is recommended 
to aid the selection of an optimal solution from considered alternatives, 
differing in terms of number of classes and type of growth function, and for 
assessing overall model fit (441).  
Further, I accounted for the possibility of non-random missingness in outcome 
data – an issue frequently ignored in studies involving use of LCGA. To attenuate 
potential bias, I initially planned to apply a method that had been tested in a 
previous study (453). However, emerging challenges seemed to justify 
introducing modifications, ultimately resulting in the use of a somewhat 
experimental approach. Nonetheless, compared to results of the default analysis 
using FIML alone, from a clinical perspective the adjusted trajectory shapes 
seemed more plausible, while the overall effect on the final model was limited.   
Regarding additional analyses, the study sample was too small to provide 
sufficient power for an outcome dividing participants into four classes. While the 
solution to combine subgroups may have increased the likelihood of detecting 
significant effects, it also led to a loss of information, relevant to the uniqueness 
of each class. To some extent, this could have contributed to the observed lack 
of association between trajectory membership and measures of physical activity 
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and social support. Plausibly, there were also other relevant limitations, 
including reliance on self-report for the assessment of physical activity, and for 
both variables – the briefness of chosen questionnaires. Although ensuring 
minimal participant burden, the restricted number of incorporated items may 
have been insufficient to reflect interindividual variability in measured 
constructs.    
I also experienced challenges to replicating the final model from Chapter 5. At 
the variable level, the effects of previous stroke and TIA could not be separated. 
At the path level, ensuring good model fit required specifying prior cognitive 
impairment as a predictor for stroke severity. As a result, it is difficult to 
interpret any differences in findings across the two studies. Nonetheless, the 
relevance of including a path from prior cognitive impairment to stroke severity 
is in itself an important finding, and is supported by previous research, 
indicating more severe strokes in patients with dementia (496, 497). 
8.2.4 Future directions  
As indicated in the Introduction, an immediate next step will be to repeat this 
analysis with inclusion of data from the 18-month assessment timepoint. This 
will provide an opportunity to further develop conducted procedures. Perhaps 
the most important planned modification relates to specifying a different type of 
growth function. With the exception of the low – constant improvement class, 
graphical representations clearly indicated that for the remaining three 
trajectories a single linear function could not capture observed differences in 
rate and/or direction of change over time. Availability of five assessment 
timepoints will allow to apply what seems to be a more suitable solution – 
modelling of piecewise trajectories (444). This involves breaking growth into 
specific segments. For the APPLE dataset, a better fitting model could likely be 
achieved through specifying one linear function for the period from baseline to 
the 1-month assessment, and another for the remaining duration of follow-up.  
Increasing model complexity may also be advantageous in relation to three 
further study aspects. Firstly, I will additionally specify a model based on GMM, 
to enable accounting for potential within-class heterogeneity. Secondly, I will 
explore the use of more advanced techniques to handling missing outcome data, 
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allowing for explicit modelling of dropout (454). Thirdly, for variables of interest 
that were reassessed during follow-up (alongside cognitive performance), I will 
consider effects at different stages of trajectory progression rather than 
exclusively at baseline.  
This final aspect seems of particular interest in view of identifying potential 
targets for intervention and, here specifically, will offer an opportunity to 
readdress the role of physical activity and social support (notwithstanding 
limitations discussed above). Two publications point to the latter as an indeed 
promising focus of investigation, as over a six-month period following stroke, 
high social support was associated with a considerable increase in functional 
improvement (246, 247). In one of the studies (246), the authors also found that 
after an initial period of recovery, participants with the lowest level of social 
support were likely to show a decline in functional status, beginning at around 
two months post-stroke. Moreover, compared to survivors of severe and 
moderate stroke, those with mild stroke were at highest risk of low support.  
These findings appear particularly relevant in view of how trajectory shape 
changed after the 1-month assessment for APPLE participants in the two higher-
function classes. On a broader perspective, they also point to another potential 
explanation for why overall better post-stroke cognitive function could be 
coupled with a less favourable pattern of change, that is, differences in 
treatment, available services, opportunities, and experiences across stroke 
survivors, depending on their initial presentation.  
Having conducted repeated literature searches for the purpose of my thesis, I 
have not yet found a publication describing the use of latent growth modelling 
techniques for identifying trajectories of post-stroke cognitive change. This adds 
further merit to expanding this field of research by repeating similar studies in 
different datasets. Preferably, these will involve larger sample sizes and more 
assessment timepoints, and will offer a broad scope of investigation for 
modifiable determinants of outcome, the targeting of which could promote 
cognitive improvement and long-term preservation of high cognitive function.   
204 
8.3 Summary 
This study represents a pioneer attempt to capture post-stroke cognitive changes 
using a latent growth modelling technique. My results speak to the heterogeneity 
of the investigated process. This was reflected in the identification of four 
cognitive trajectories, with distinct features regarding the initial severity of 
deficits, and the rate and pattern of changes occurring over a one-year period. 
In the wider context of my thesis, this research reinforces earlier conclusions 
regarding the complexity of the cognitive sequalae of stroke and their 
associations with individual characteristics. As I discuss in my final chapter, 
underestimating this complexity may create a gap between the potential and 
actual impact of prognosis research on improving post-stroke cognitive function.
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Chapter 9 Discussion 
Improving cognitive function is a priority objective for individuals affected by 
stroke (37). Prognosis research has the potential to play an important role in 
achieving this goal, through informing the development and implementation of 
appropriate interventions (96). The first pivotal steps involve gaining a better 
understanding of the cognitive changes that occur following stroke, and the 
factors that are associated with their course. In recent years, much research has 
been conducted to this end, with attention now turning towards applying the 
obtained findings to allow accurate prognosis of post-stroke cognitive outcome 
at an individual level, based on selected characteristics.  
Through examining the existing literature with a focus on post-stroke cognitive 
function, I identified three under-investigated topics, where further evidence 
could meaningfully contribute to the foundations for this next stage of research. 
This included assessing the relevance of: i) potentially modifiable factors, ii) 
differential effects of risk factors, depending on paths of influence and co-
occurrence, and iii) interindividual differences in intraindividual cognitive 
change over time.   
9.1 Relevance of potentially modifiable factors  
The unique value of identifying modifiable factors lies in their potential to serve 
as targets for intervention. In addressing this topic, I focused on two domains of 
everyday life that have received much research interest as prognostic (and 
possibly causal) factors for cognitive function in the general population – 
physical activity patterns and social engagement. In relation to the former, the 
associations that I observed most consistently related to the daily duration of 
two types of sedentary behaviour, where computer use had a positive effect on 
cognitive performance, and the opposite was indicated for watching TV. At the 
same time, I found very little evidence to support the anticipated relationship 
between increased physical activity and better cognitive function. As discussed 
in Chapter 4, based on these findings I reached two main conclusions: 1) it is 
possible for sedentary behaviour to be associated with post-stroke cognitive 
function independently of physical activity, and 2) sedentary behaviour may 
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have opposing effects on cognitive function depending on whether it is mentally 
passive or active.  
In relation to social engagement, from a number of measures representing both 
ends on the objective-subjective continuum, I found that cognitive task 
performance was most consistently associated with loneliness. Importantly, 
feeling lonely was reported by one in four stroke survivors in the study sample – 
a concerning observation given the distressing nature of the experience itself, as 
well as previous evidence suggesting its detrimental relationship with not just 
cognition (301-303), but also many other individual outcomes, such as 
depression, diminished immunity, cardiovascular disease, and mortality (297, 
298, 300, 498).  
For the interpretation of my results from both studies, it is important to note 
that the associations I observed between cognitive performance and predictors 
of interest overall were weak, and there was some heterogeneity in findings 
across different tasks. Moreover, as discussed in sections 4.3.2.3 and 4.3.4.3, 
both studies had considerable methodological limitations, many of which related 
to use of data from a general-purpose cohort (UK Biobank). One, involving the 
use of suboptimal measures of physical activity and social support, also posed an 
issue in the APPLE study. Here, this specifically related to the briefness of both 
chosen questionnaires, and for the assessment of physical activity – reliance on 
self-report. Coupled with a relatively small sample size, this may explain my 
neutral results, where neither of these factors predicted the course of post-
stroke cognitive change over a one-year period.  
In view of this, my findings from the UK Biobank analyses on the associations 
between habitual physical activity, sedentary behaviour, and social engagement 
on post-stroke cognitive function cannot be considered as definitive. However, 
they provide grounds for instigating further focussed studies in this area. 
Investigating the impact of breaking up mentally passive sedentary behaviour 
with cognitive and light-intensity physical activity seems of particular interest, 
as a more feasible and sustainable alternative strategy to structured, supervised 
exercise sessions for stroke survivors with greater activity limitations and 
participation restrictions. Promoting social support, on the other hand, may be 
considered as an additional interventional component, having the potential to 
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improve adherence to treatment programmes (499-501), alongside a possible, 
more direct effect on cognitive function. 
9.2 Differential effects of risk factors 
The potential for risk modification was also a key consideration that motivated 
me to focus on the cognitive consequences of cardiovascular diseases. While 
there is a strong premise to assume their relevance to post-stroke cognitive 
function, existing evidence on this topic appeared inconclusive or conflicting 
(23, 145). I recognised that this may be due to the complex nature of these 
associations, with some effects on cognition preceding index stroke, interactions 
between diseases, and multiple paths of influence (direct and indirect). In 
relation to the latter, I further assumed that the effects of cardiovascular risk 
factors may not be unequivocally detrimental, as pathological processes can 
trigger endogenous adaptive mechanisms; for example the theory around  TIA 
inducing ischaemic tolerance (343), and large vessel cerebrovascular disease 
leading to the development of collateral circulation (347, 348). This inspired me 
to develop a model, allowing me to test the indirect effects of cardiovascular 
risk factors on acute post-stroke cognitive function, as mediated through stroke 
severity and a history of dementia, and to assess moderation effects due to 
comorbidity.  
As I describe in Chapter 5, my results indicated that poorer cognitive 
performance was associated with: atrial fibrillation through increased stroke 
severity, previous stroke through an increased risk of prevalent dementia, as 
well as age through both mediators. Importantly, my findings also supported the 
hypothesis that some indirect effects of cardiovascular risk factors may be 
favourable. Specifically, vascular disease in the presence of hypertension and 
absence of diabetes, as well as previous TIA seemed to be associated with better 
acute cognitive performance through reduced stroke severity.  
I conducted a similar analysis in the APPLE dataset, which I described in 
Chapters 7 and 8, using an alternative outcome – the pattern of post-stroke 
cognitive change over one year, dichotomised to reflect an overall higher and 
overall lower level of cognitive function. In addition to confirming the relevance 
of stroke severity and prior cognitive impairment, the main comparable finding 
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related to an indirect association between atrial fibrillation and lower overall 
cognitive function, through increased stroke severity. Conversely, one of my 
most unique observations concerned the possible opposing effects of age – 
associated with higher cognitive function through reduced stroke severity, and 
with lower function through an increased risk of prior cognitive impairment. To 
add further complexity, prior cognitive impairment was in turn linked to greater 
stroke severity.  
The differences in findings across the two studies are difficult to account for, as 
I was unable to precisely replicate the first model in the APPLE dataset. This was 
only one of many challenges associated with conducting these analyses and the 
interpretation of results. Another significant limitation related to uncertainty in 
the measurement of variables of interest, particularly regarding pre-stroke 
cognitive function. Similar to most predictors, coding of this factor relied on the 
presence of information in medical records, while evidence suggests that 
underdiagnosis and/or under-recording of cognitive impairment, even in its 
severe form, is a common issue (389).  
Moreover, I did not have access to data relevant to verifying my initial 
assumptions, regarding the possible impact of previous TIA and vascular disease 
on alleviating stroke severity, and thus better acute cognitive performance. 
While I developed my hypotheses based on an assumed role of endogenous 
protective adaptations, treatment effects (e.g. from prescribed medication) 
provide a highly plausible alternative explanation for my findings (386, 387).  
Overall, the results of my analyses still leave much uncertainty. Nonetheless, 
they are not without research implications. My findings suggest that commonly 
applied basic multivariable models constitute an overly reductionist approach to 
investigating the associations between cardiovascular diseases and post-stroke 
cognitive function. Consequently, the importance of the former may be easily 
underestimated. This conclusion is also likely to apply to assessing the relevance 
of lifestyle factors, as their effect on cognition is plausibly (at least in part) 
exerted through modifying cardiovascular risk.  
In view of this, I would recommend future application of moderated mediation 
analyses for studying the associations between modifiable factors and post-
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stroke cognitive function, considering multiple putative paths of influence and 
interaction effects. To gain a better understanding of the mechanisms that 
underly investigated relationships, it moreover seems necessary to account for 
neuroimaging evidence of structural, metabolic, and/or functional brain 
abnormalities. Inclusion of such variables in statistical models as mediators could 
contribute to explaining how modifiable factors affect post-stroke cognition 
through their impact on progression of neuropathological processes.  
My findings regarding the complexity of between-predictor and predictor-
outcome relationships may also have clinical implications. Assuming observed 
associations reflected true effects, stroke survivors with a history of TIA and 
vascular disease with hypertension could be considered as having a relatively low 
risk of future post-stroke cognitive disorders on account of less severe index 
strokes. However, the presence of these conditions is likely associated with 
progressive neurological damage, occurring long-term. The conclusion that for 
specific subgroups of stroke survivors the actual risk of cognitive deterioration 
may be underappreciated was also implied by my findings from the APPLE study.  
9.3 Trajectories of post-stroke cognitive change 
As I emphasised in Chapter 2 in the section on stratified medicine, while sharing 
certain characteristics, clinically defined populations are in many ways 
heterogeneous. This can manifest in variability in the clinical course of a 
condition or - expanding this notion beyond the context of disease – in the 
change that occurs in individual status over time. In relation to cognitive 
function following stroke, it is moreover apparent that in addition to differences 
between individuals, there is also heterogeneity in the pattern of change on a 
within-individual level. Latent growth modelling techniques were developed to 
capture these aspects – the interindividual differences in intraindividual change 
over time (440). Yet, it appears they have not been previously employed to 
investigate the topic of post-stroke cognition. 
Through applying LCGA in the APPLE dataset, I identified four distinct trajectory 
classes reflecting cognitive change during the first year following stroke: i) a 
high – declining class, with high cognitive function soon after stroke, improving 
over following weeks, and thereafter declining; ii) a mid-high – stable class, with  
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some cognitive problems soon after stroke, followed by a period of 
improvement, after which cognitive function remained relatively stable; iii) a 
mid-low – slowing improvement class, with comparatively poor initial cognitive 
function, which after a stage of steeper improvement, continued to improve at a 
slower rate; and iv) a low – constant improvement class, with severe cognitive 
impairment soon after stroke, followed by improvement in cognitive function at 
a relatively constant rate. During the follow-up period, the order of classes 
according to level of cognitive performance prevailed, meaning that at no point 
did a class with poorer initial cognitive function exceed in performance a class 
with higher initial function. In general, study participants representing the two 
classes with lower overall cognitive function were characterised by older age, 
lower education, greater stroke severity, and pre-stroke cognitive impairment. 
Given the pilot nature of this research, similar analyses need to firstly be 
conducted in the full APPLE dataset (including an 18-month assessment), 
followed by testing in independent participant samples, before confidence in my 
findings will seem justifiable. Nonetheless, I consider that the particular merit 
of this study does not lie in closing, but rather opening questions. These apply to 
some of the basic, widespread assumptions made in prognosis research into post-
stroke cognition: Is the absence of diagnosed cognitive impairment at a specific 
point in time equivalent to a good outcome? Is prognostic accuracy achievable 
assuming direct, unconditional predictor-outcome associations? How applicable 
are average estimates to any individual, given such heterogeneity within a 
stroke population? These questions, together with my initial conclusions from 
reviewing the existing literature, and findings from my earlier studies, evoked 
reflections on the role and direction of development for this area of research.  
9.4 Appraisal of prognosis research into post-stroke 
cognition: a pause before deciding on future 
directions 
Viewing my thesis as a whole, it may seem that the existing research work I 
described across the first three chapters called for a different direction of 
investigations. In accordance with the PROGRESS framework (96), which was the 
focus of Chapter 2, I inferred that prognosis research into post-stroke cognition 
has presently reached the beginning of the third theme, related to the 
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development of prognostic models. Conversely, the three topics I chose to 
address in my studies can be classed as pertaining to the two preceding themes 
of fundamental prognosis research and prognostic factor research. This gives rise 
to an unavoidable question: why look back instead of moving forward? 
The reason for this was that I considered the next obvious steps – external 
validation and potential updating of existing prognostic rules – premature, with 
two crucial issues remaining open to debate:  
1. is accurate prognosis of individual post-stroke cognitive outcomes viable?     
2. is the ability to predict individual post-stroke cognitive outcomes 
valuable? 
As I found, the results of my studies only added fuel to these uncertainties, 
particularly in relation to viability. 
9.4.1 Examining the viability of individual outcome prognosis 
9.4.1.1 Post-stroke cognitive impairment 
As I described in Chapter 3, to date only one prognostic rule for predicting post-
stroke cognitive impairment has been externally validated – the CHANGE score 
(164). It presented only fair discriminatory power (AUROC of 0.75), despite the 
prediction being relatively short-term, with the outcome assessed between 
three to six months post-stroke. While this is the result of only one study, and 
comparable data are unavailable for other identified prognostic rules, this 
observation is not singular in suggesting limited potential for such tools to have 
good accuracy (AUROC of at least 0.80). Further support is gained from a 
systematic review of 61 prognostic models for predicting dementia in the 
general population, where good performance in an independent dataset was 
rarely reported (152), followed by several deductive arguments.  
One issue has been repeatedly emphasised across all my studies – the nature of 
the matter is extremely complex. Cognitive function is shaped by multiple 
interlinked experiences and exposures, with influences present throughout the 
entire lifespan (502). Even when just focusing on selected prognostic factors, 
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appearing most relevant to post-stroke cognition either based on temporal 
proximity or putative underlying causal mechanisms, modelling their effects is a 
challenging task. As I demonstrated, this relates to the possibility of differential 
associations for a given predictor with post-stroke cognition, stemming from 
varying paths of influence, between-variable interactions, and the heterogeneity 
of the population. 
In stark contrast to this complexity, is the relative simplicity of prognostic rules. 
Indeed, maximising simplicity is an intentionally sought property in the design of 
prognostic rules to ensure feasibility of use. Arguably, for the purpose of 
outcome prognosis, where the effect of a variable is indirect, conditional, or 
non-universal, it can be recognised as having poor prognostic value, and thus to 
not merit attention. This approach does not seem unreasonable, given that there 
are alternative predictors, such as age, stroke severity, and cerebral atrophy, 
which have a strong, consistently proven association with post-stroke cognition.  
Nonetheless, to some extent, relativity of effects will also apply to such factors, 
and while ignoring this issue will not negate their prognostic utility, it may 
diminish it. For example, it is worth considering whether performance of the 
CHANGE score could be improved by incorporating interaction effects between 
some of the predictors it already includes, namely, between education and both 
white matter hyperintensities and global cortical atrophy. Indeed, many studies 
in the field of cognitive reserve have indicated that education attenuates the 
effects of neuropathological changes on cognitive function (503, 504)  
Alongside a reductionist approach to modelling the effects of predictors, 
perhaps the greatest commonly applied simplification relates to capturing the 
outcome, with post-stroke cognition forced to fit the dimensions of a single, 
binary event. Importantly, however, estimating that an individual is at low risk 
of post-stroke cognitive impairment at a specific point in time gives no 
assurance that they are at low risk of cognitive decline. Findings from my latent 
class growth analysis support the notion of such duality, indicating declining 
performance in individuals with fewest cognitive deficits, who at the same time 
were younger, more educated, had fewer comorbidities, and had less severe 
index strokes than participants representing classes with overall lower, albeit 
improving function.  
213 
Overlooking the direction of cognitive change over time is also likely to entail a 
certain short-sightedness of predictions. Despite decline in cognitive function, a 
prognostic rule may correctly predict that according to standard criteria an 
individual will be classed as cognitively intact at six months; but will this still 
apply at one year if changes continue along the same trajectory?  
9.4.1.2 Post-stroke delirium 
The above concerns seem of lesser relevance to prognosis of delirium in acute 
stroke. Intrinsically, the aim of a prognostic rule in this context is to predict an 
outcome typically occurring within a matter of days. The sudden onset and 
transient nature of delirium is also more akin to the concept of a single event. 
For similar reasons, there is merit in prioritising factors that are affecting the 
individual in the acute phase of stroke, such as existing comorbidities, sensory 
impairments, infection, or dehydration, rather than life-course influences.  
Nonetheless, external validations of prognostic rules for predicting delirium in 
older adult inpatients indicate that in most cases performance is also only fair 
(153). This seems to remind us that as in relation to mild cognitive impairment 
and dementia, the development, progression and determining factors of delirium 
are not yet fully understood. Whether accurate prognosis of individual outcomes 
is possible without such an understanding is debatable.   
9.4.2 Examining the value of individual outcome prognosis     
The issues of viability and value of applying prognostic rules to predict individual 
post-stroke cognitive outcome are intertwined. At a minimum, produced 
estimates can only be considered of value if they are better than chance. 
Conversely, even excellent discrimination and calibration cannot ensure that an 
estimated risk is worth knowing. Assuming that satisfactory prognostic accuracy 
is achievable, below I consider the potential importance and implications of 
applying prognostic rules from individual, research, and policy perspectives.  
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9.4.2.1 A clinical and personal perspective 
Individual prognosis of post-stroke cognitive impairment 
A qualitative study investigating the views of stroke survivors, carers and 
clinicians on use of prognostic tools for predicting post-stroke dementia in 
routine practice highlighted a shared, paramount concern (175): is knowledge of 
the risk worth the entailed psychological burden, given there is currently no 
established treatment to change the outcome? Familiarity with the seven 
existing prognostic rules addressing post-stroke cognitive impairment seems to 
only reinforce a sense of inevitability.  
As I presented in the Results section of Chapter 3, nearly all the considered 
predictors were non-modifiable. Moreover, they relied on information collected 
around the time of index stroke. This is naturally understandable, and even 
ideal, in view of an intention to apply a prognostic rule in the acute phase. 
However, confidence in such predictions would also imply that regardless of 
what an individual does after a stroke (e.g. close adherence to prescribed 
medications or lifestyle changes), this will not have a meaningful impact on their 
risk of cognitive impairment. From this perspective, contentiously, it seems we 
should hope that existing rules would not perform well in external validation.  
Appropriate initiation of preventive interventions, however, is not the only aim 
of estimating the individual probability of an unfavourable outcome. In the same 
qualitative study (175), participants expressed that awareness of the risk of 
dementia could help in planning for the future and finding useful coping 
strategies. This view does not yet seem to explicitly support the use of 
prognostic tools, at least in their present form.  
Two of the existing rules aimed to predict cognitive impairment up to one year 
following stroke, while the five remaining ones focused on the outcome 
occurring after three to six months. Given this relatively short time span, it is 
questionable whether a prognostic rule is indeed useful in alerting a stroke 
survivor and/or carer to the prospect of severe cognitive difficulties, and the 
consequent need for preparation. Plausibly, many of the deficits informing the 
diagnosis of dementia, e.g. at 6 months, would have already been present in the 
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acute phase of stroke. Assuming these impairments were recognised through 
routine cognitive screening or personal observations, practical adjustments to 
daily lives of the stroke survivor and their family/carers could have been made 
regardless of the prognosis.   
Another issue relates to whether it is ever truly appropriate to assume that 
deterioration of cognitive function is of no concern to a stroke survivor, even if 
the risk estimated by a prognostic rule is low. A recent study reported that one 
year following a severe stroke, the risk of dementia is a staggering 50 times 
higher than in the age and sex-matched population (20). In this context, 
however, it is particularly noteworthy that the incidence of dementia was found 
to be comparatively 3.5 times higher just after TIA, increasing to approximately 
6 times for minor stroke (NIHSS score < 3). Further supporting this argument are 
my findings regarding trajectories of cognitive change, presented in Chapter 8. 
Improvement was coupled with relatively poor cognitive function, while high 
function – with decline. As such, it is questionable whether representing any 
subgroup constitutes a satisfying outcome, with the answer likely depending on 
individual point of view.    
Individual prognosis of post-stroke delirium 
As in the case of viability, the evaluation of prognostic rules for predicting 
delirium takes a somewhat different course. On one hand, there are 
recommended interventions for delirium (64). On the other, recognition of this 
condition in the context of stroke can often be difficult (147, 505). Identifying 
high risk individuals could encourage closer and more frequent monitoring of 
behaviour and cognitive function, reducing the likelihood of delirium being 
missed, and thus remaining untreated. Yet, perhaps even more importantly, risk 
awareness could contribute to delirium prevention.  
A Cochrane review (506) concluded there was strong evidence supporting multi-
component interventions to prevent delirium in general, geriatric, and surgical 
ward settings. While the specific content of considered interventions varied, 
some elements were shared across multiple studies, including: provision of 
individualised care, reorientation (repeatedly informing a patient about the 
environment/circumstances they are in), avoidance of sensory deprivation, 
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maintaining appropriate nutrition and hydration, mobilisation, and promoting 
sleep hygiene. Since the publication of the review, one study (N = 108) has 
further tested a multi-component intervention specifically in an acute stroke 
setting, indicating a reduction in the incidence rate of delirium by 16.7% (507).  
However, despite the possibility of preventing or treating post-stroke delirium, 
there still seems to be insufficient justification for estimating the individual risk 
of its development in clinical practice. Looking at the intervention components 
listed above, it can be argued that all acute stroke patients should be entitled to 
such care; particularly, as the absolute risk of delirium in this group is high, 
being at approximately 25% (21). 
9.4.2.2 A research perspective 
The value of applying prognostic rules in a research context is typically indicated 
in relation to clinical trials. Due to heterogeneity within a clinical population, 
the average benefit of a tested intervention reported for a study sample may in 
many cases be a poor representation of the likely treatment effect in a 
particular individual (508). Exploring differences in treatment effects by 
employing conventional subgroup analysis, where participants are repeatedly 
categorised based on one variable at a time (e.g. sex or history of hypertension), 
is recognised as having significant limitations (509). Specifically, an increased 
risk of false positive findings due to multiple testing is coupled with a reduced 
ability to detect real heterogeneity in treatment effects (510). The latter results 
from any single variable likely having only a small influence on treatment effect, 
as well as from possible similarities across analysed subgroups regarding many 
other pertinent characteristics.  
By simultaneously accounting for multiple factors, prognostic rules overcome 
these limitations. Importantly, the single property they capture - the risk of an 
unfavourable outcome – is considered highly relevant to explaining variation in 
treatment effect (509). As I described in Chapter 2 in the section on stratified 
medicine, where the relative effect of a treatment is found to be similar across 
individuals, those with the highest initial risk of an unfavourable outcome will 
experience the greatest absolute benefit. This is a key consideration for clinical 
decision-making. Given that most interventions are associated with some 
217 
adverse effects, for a person whose probability of an unfavourable outcome is 
low, the estimated benefit from the treatment may be too low to outweigh the 
potential risks.  
The relevance of the individual risk of a future outcome to treatment effect is 
recognised as practically universal (509). As follows, prognostic rules for 
predicting cognitive disorders may indeed contribute to clinical trials of 
interventions targeting cognitive function following stroke. The extent of their 
application, however, may depend on intervention content. Arguably, the 
potential impact of some treatments may by limited by the presence of factors 
that contribute to the overall increased probability of a future cognitive 
disorder, thus disrupting the expected association between a higher risk and 
greater absolute benefit. To illustrate this point, I describe an example based on 
prevention - currently considered a priority approach to reducing the high global 
burden of dementia (511, 512).  
Similarly as in the case of delirium, recognition of the multifactorial aetiology of 
dementia has encouraged the development of multi-component interventions for 
risk reduction (512, 513). Focusing on such aspects as physical activity, diet, 
control of cardiovascular risk factors, and cognitive training, these interventions 
heavily rely on self-management, with study participants required to individually 
implement changes in their everyday life (514-517). Following stroke, however, 
individuals with initial cognitive problems may experience challenges to fully 
participating in interventions based on self-management (518, 519). As follows, 
despite likely being at greater risk of future dementia, they may benefit from 
such strategies less than stroke survivors for whom there are no cognitive 
barriers to implementing and maintaining lifestyle recommendations.         
Recognising that there are distinct subpopulations among stroke survivors, 
further draws attention to the possibility of having to address differing 
intervention aims. Reflecting on the trajectories of cognitive change that I 
identified in Chapter 8, for individuals with overall high cognitive function, in 
the sub-acute stage of stroke it could be a priority to maintain the current level 
of performance and avoid cognitive decline. For individuals representing an 
overall low cognitive function trajectory, however, it seems it would be 
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important to focus on improving performance. Whether one type of intervention 
could address both aims with equal success is open to question.  
9.4.2.3 A healthcare policy perspective  
An increasing burden of cognitive disorders has major implications for health and 
social services (520, 521). The current prioritisation of prevention for strategic 
policy-making has been coupled with a desire to identify high-risk individuals for 
targeting interventions (511, 512, 522). Interestingly, in “From evidence into 
action: opportunities to protect and improve the nation’s health” released in 
2014 by Public Health England, one of the stated aims in relation to dementia 
prevention was to develop a personalised risk assessment calculator for 
incorporation into the NHS Health Check (523). However, a rationale for this 
decision had not been described.  
In general, health policies aimed at dementia prevention focus on improving 
public and professional awareness of the disorder, and promoting behaviours 
that can lead to the reduction of modifiable risk factors, such as physical 
activity, a healthy diet, smoking cessation, and limited alcohol consumption 
(511). Importantly, such recommendations appear to be universally beneficial, 
and to entail a low risk of adverse effects. Moreover, the relative risk of 
cognitive impairment and decline for stroke survivors is already high compared 
to the general population. Therefore, a similar question arises as for 
implementation of multicomponent interventions for preventing delirium – why 
should such strategies be targeted only at a specific subgroup of stroke 
survivors, who are at highest risk of dementia?  
This is not to say that prognosis research has not and will not be crucial to the 
development of effective healthcare policies for the prevention of post-stroke 
cognitive disorders. Based on indications from the PROGRESS series, key 
contributions may include (96, 99): i) estimating average prognosis to model the 
population burden of cognitive disorders and associated service requirements, ii) 
comparisons of different healthcare systems to inform how variation in standard 
care influences cognitive outcomes, iii) identifying modifiable risk factors to 
target in preventive, policy-level interventions, and iv) assessing the impact of 
such interventions.  
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9.5 Conclusions 
To date, there is no specific, recommended intervention to improve cognitive 
function following stroke. A seemingly clear path through which prognosis 
research may contribute to changing this reality involves identifying modifiable 
prognostic factors, causally associated with post-stroke cognition, to serve as 
treatment targets. In this context, findings from my UK Biobank studies provided 
preliminary evidence to support further investigation of three factors – mentally 
passive sedentary behaviour and loneliness as associated with poorer cognitive 
function, and mentally active sedentary behaviour as associated with better 
function.  
These observations already highlight one important challenge to understanding 
predictor-outcome relationships – what could be considered a single variable, 
such as the level of habitual physical activity or social engagement, may have a 
number of different components, each characterised by distinct properties. 
Without recognising their unique relevance, true and important associations 
could be easily missed, misrepresented or misinterpreted. 
It is yet perhaps the next step that seems to be the hardest based on previous 
research endeavours – translating findings from observational studies (as the 
ones I conducted) to successful interventions, improving individual outcomes in a 
clinically meaningful way. The results of my subsequent studies seem to provide 
insight on why this gap is so difficult to bridge, as well as suggestions for how 
this issue could be addressed.   
Firstly, it is important to consider how and when a potentially causal factor can 
affect post-stroke cognitive outcome. As I found through my moderated 
mediation analyses, a lack of evidence-based assumptions regarding these 
aspects to inform the development of a statistical model may also lead to 
misidentification of relevant associations. This shortcoming is then likely to have 
implications at the stage of intervention design, with accurate answers to “how” 
and “when” crucial to ensuring applicability of a considered approach.  
For example, there has been much controversy regarding active blood pressure 
lowering in acute stroke, with studies reporting mixed results on the impact of 
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this strategy on early and long-term outcomes (including, e.g. neurological 
deterioration, death, and dependency) (524, 525). Findings from a recent study, 
which I described in Chapter 5, indicated a possible explanation for such 
inconsistencies - the impact of blood pressure on clinical outcomes is highly 
dependent on reperfusion (380). With a favourable effect of higher blood 
pressure in patients with reperfusion, and the opposite observed for patients 
without it, the authors suggested that active blood-pressure lowering should not 
be considered prior to reperfusion treatment. 
Secondly, stroke survivors constitute a heterogenous population, which can 
manifest in differential patterns of cognitive change over time, and varying 
relevance of specific prognostic factors. This observation undermines the 
possibility of developing an effective one-size-fits-all intervention. While risk-
stratification based on prognostic rule estimates may account for some of the 
variation in treatment effects, it seems that a more holistic and in-depth 
understanding of individual profiles may be necessary to appropriately tailor 
future interventions (526). In addition to factors that I addressed in my thesis, 
neuroimaging findings may play an important role in gaining this understanding, 
allowing to account for interindividual differences in the extent of 
neuropathological changes, their type, including whether they are reversible 
(e.g. metabolic abnormalities) or irreversible, and their manifestation.  
In summary, I believe that in the present context of prognosis research in post-
stroke cognition, fundamental and prognostic factor investigations still have a 
priority role to play in advancing the search for ways to improve individual 
outcomes. For contributions to be meaningful, however, it seems important to 
reconsider our approach to capturing cognitive changes following stroke and 
their associations with individual characteristics. Overlooking information that 
speaks to the complexity of the subject matter can significantly limit the real-
world application of research findings. It is then, when the practical advantages 
of conceptual simplifications come at too high a cost.     
 




Appendix 1: Chapter 3, PRISMA checklist  
Section/topic  # Checklist item  
Reported on 
page # 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  52 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
N/A 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  52, 53 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
53 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
53 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
54, 55 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
54 




Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
54, 55 
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Section/topic  # Checklist item  
Reported on 
page #  
METHODS   
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
53, 55; RP 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
55, 56 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
56 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  56 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
N/A 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
N/A 
RESULTS  
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
57, 58 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
59-69 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  60, 61, 70 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
66-68 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
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Section/topic  # Checklist item  
Reported on 
page #  
RESULTS  
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 




Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
71-74 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
72-74 




Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders 
for the systematic review.  
N/A 
RP indicates Review Protocol (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020170428). 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA 
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
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Appendix 2: Chapter 3, search strategy 
Medline (via OVID) search strategy 
1. cerebrovascular disorders/ OR exp basal ganglia cerebrovascular disease/ 
OR exp brain ischemia/ OR exp intracranial arterial diseases/ OR exp 
"intracranial embolism and thrombosis"/ OR exp intracranial 
hemorrhages/ OR stroke/ OR exp brain infarction/ OR vasospasm, 
intracranial/  
2. (stroke OR post?stroke OR cerebrovasc$ OR brain vasc$ OR cerebral vasc$ 
OR cva$ OR apoplex$ OR SAH).ti,ab. 
3. ((brain$ OR cerebr$ OR cerebell$ OR intracran$ OR intracerebral) adj5 
(isch?emi$ OR infarct$ OR thrombo$ OR emboli$ OR occlus$)).ti,ab.  
4. ((brain$ OR cerebr$ OR cerebell$ OR intracerebral OR intracranial OR 
subarachnoid) adj5 (h?emorrhage$ OR h?ematoma$ OR bleed$)).ti,ab.  
5. ((transi$ adj3 isch?em$ adj3 attack$) OR TIA$1).ti,ab. 
6. 1 OR 2 OR 3 OR 4 OR 5 
7.  ((validat$ OR predict$ OR prognos$ OR rule$) adj3 (outcome$ OR risk$ OR 
model$)).ti,ab. 
8. (prognos$ AND (method$ OR history OR variable$ OR criteria OR scor$ OR 
characteristic$ OR finding$ OR factor$ OR model$)).ti,ab. 
9. ((history OR variable$ OR criteria OR scor$ OR characteristic$ OR finding$ 
OR factor$) adj3 (predict$ OR model$ OR decision$ OR identif$ OR 
prognos$)).ti,ab. 
10. (decision$ adj3 (model$ OR clinical$)).ti,ab. 
11. (stratification OR discriminat$ OR calibration).ti,ab. 
12. ROC curve/ 
13. (c-statistic OR c statistic OR area under the curve OR AUC).ti,ab. 
14. (indices OR algorithm OR multivariable).ti,ab. 
15. 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 
16. exp dementia/ 
17. delirium/ 
18. delirium, dementia, amnestic, cognitive disorders/ 
19. exp cognition disorders/ 




23. (Alzheimer$ OR AD).ti,ab. 
24. deliri$.ti,ab.  
25. ((cognit$ OR memory OR mental OR brain) adj3 (func$ OR perform$ OR 
abilit$ OR declin$ OR reduc$ OR impair$ OR disorder$ OR fail$ OR los$ OR 
deficit$ OR stop$ OR progress$ OR improve$)).ti,ab. 
26. mental perform$.ti,ab. 
27. (memory adj3 (complain$ or declin$ or function$)).ti,ab. 
28. 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 
29. 6 AND 15 AND 28 
Embase (via OVID) search strategy 
1. cerebrovascular disease/ OR exp basal ganglion hemorrhage/ OR exp brain 
hematoma/ OR exp brain hemorrhage/ OR exp brain infarction/ OR exp 
brain ischemia/ OR cerebral artery disease/ OR exp cerebrovascular 
accident/ OR exp occlusive cerebrovascular disease/ OR vertebrobasilar 
insufficiency/ OR stroke/ OR stroke patient/ OR stroke unit/ 
2. (stroke OR post?stroke OR cerebrovasc$ OR brain vasc$ OR cerebral vasc$ 
OR cva$ OR apoplex$ OR SAH).ti,ab. 
3. ((brain$ OR cerebr$ OR cerebell$ OR intracran$ OR intracerebral) adj5 
(isch?emi$ OR infarct$ OR thrombo$ OR emboli$ OR occlus$)).ti,ab.  
4. ((brain$ OR cerebr$ OR cerebell$ OR intracerebral OR intracranial OR 
subarachnoid) adj5 (h?emorrhage$ OR h?ematoma$ OR bleed$)).ti,ab.  
5. ((transi$ adj3 isch?em$ adj3 attack$) OR TIA$1).ti,ab. 
6. 1 OR 2 OR 3 OR 4 OR 5 
7.  ((validat$ OR predict$ OR prognos$ OR rule$) adj3 (outcome$ OR risk$ OR 
model$)).ti,ab. 
8. (prognos$ AND (method$ OR history OR variable$ OR criteria OR scor$ OR 
characteristic$ OR finding$ OR factor$ OR model$)).ti,ab. 
9.  ((history OR variable$ OR criteria OR scor$ OR characteristic$ OR finding$ 
OR factor$) adj3 (predict$ OR model$ OR decision$ OR identif$ OR 
prognos$)).ti,ab. 
10. (decision$ adj3 (model$ OR clinical$)).ti,ab. 
11. (stratification OR discriminat$ OR calibration).ti,ab. 
12. receiver operating characteristic/ 
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13. (c-statistic OR c statistic OR area under the curve OR AUC).ti,ab. 
14. (indices OR algorithm OR multivariable).ti,ab. 
15. 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 
16. exp dementia/ 
17. delirium/ 
18. exp cognitive defect/ 
19. exp cognition/ 
20. memory/ 
21. dement$.ti,ab. 
22. (Alzheimer$ OR AD).ti,ab. 
23. deliri$.ti,ab.  
24. ((cognit$ OR memory OR mental OR brain) adj3 (func$ OR perform$ OR 
abilit$ OR declin$ OR reduc$ OR impair$ OR disorder$ OR fail$ OR los$ OR 
deficit$ OR stop$ OR progress$ OR improve$)).ti,ab. 
25. mental perform$.ti,ab. 
26. (memory adj3 (complain$ or declin$ or function$)).ti,ab. 
27. 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 
28. 6 AND 15 AND 27 
PsycINFO (via EBSCO) search strategy 
S1 DE "Cerebrovascular Disorders" OR DE "Cerebral Arteriosclerosis" OR DE 
"Cerebral Hemorrhage" OR DE "Cerebral Ischemia" OR DE "Cerebrovascular 
Accidents" OR DE "Subarachnoid Hemorrhage"  
S2 TI (stroke OR post#stroke OR cerebrovasc* OR "brain vasc*" OR "cerebral 
vasc*" OR cva* OR apoplexy OR SAH) OR AB (stroke OR post#stroke OR 
cerebrovasc* OR "brain vasc*" OR "cerebral vasc*" OR cva* OR apoplexy OR 
SAH) 
S3 TI ((brain* OR cerebr* OR cerebell* OR intracran* OR intracerebral) N5 
(isch#emi$ OR infarct* OR thrombo* OR emboli* OR occlus*)) OR AB 
((brain* OR cerebr* OR cerebell* OR intracran* OR intracerebral) N5 
(isch#emi$ OR infarct* OR thrombo* OR emboli* OR occlus*))  
S4 TI ((brain* OR cerebr* OR cerebell* OR intracerebral OR intracranial OR 
subarachnoid) N5 (h#emorrhage* OR h#ematoma* OR bleed*)) OR AB 
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((brain* OR cerebr* OR cerebell* OR intracerebral OR intracranial OR 
subarachnoid) N5 (h#emorrhage* OR h#ematoma* OR bleed*))  
S5 TI ((transi* N3 isch#em* N3 attack*) OR TIA) OR AB ((transi* N3 isch#em* N3 
attack*) OR TIA) 
S6 S1 OR S2 OR S3 OR S4 OR S5 
S7 TI ((validat* OR predict* OR prognos* OR rule*) N3 (outcome* OR risk* OR 
model*)) OR AB ((validat* OR predict* OR prognos* OR rule*) N3 (outcome* 
OR risk* OR model*)) 
S8 TI (prognos* AND (method* OR history OR variable* OR criteria OR scor* OR 
characteristic* OR finding* OR factor* OR model*)) OR AB (prognos* AND 
(method* OR history OR variable* OR criteria OR scor* OR characteristic* 
OR finding* OR factor* OR model*)) 
S9 TI ((history OR variable* OR criteria OR scor* OR characteristic* OR finding* 
OR factor*) N3 (predict* OR model* OR decision* OR identif* OR prognos*)) 
OR AB ((history OR variable* OR criteria OR scor* OR characteristic* OR 
finding* OR factor*) N3 (predict* OR model* OR decision* OR identif* OR 
prognos*)) 
S10 TI (decision* N3 (model* OR clinical*)) OR AB (decision* N3 (model* OR 
clinical*)) 
S11 TI (stratification OR discriminat* OR calibration) OR AB (stratification OR 
discriminat* OR calibration) 
S12 TI ("c-statistic" OR "c statistic" OR "area under the curve" OR AUC) OR AB 
("c-statistic" OR "c statistic" OR "area under the curve" OR AUC) 
S13 TI (indices OR algorithm OR multivariable) OR AB (indices OR algorithm 
OR multivariable) 
S14 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 
S15 DE "Dementia" OR DE "Presenile Dementia" OR DE "Pseudodementia" OR 
DE "Semantic Dementia" OR DE "Senile Dementia" OR DE "Vascular 
Dementia"  
S16 DE "Neurocognitive Disorders" OR DE "Delirium" OR DE "Memory Disorders" 
OR DE "Cognitive Impairment"  
S17 DE "Memory" OR DE "Memory Decay" 
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S18 DE "Cognition"  
S19 TI dement* OR AB dement*  
S20 TI (alzheimer* OR AD) OR AB (alzheimer* OR AD)  
S21 TI deliri* OR AB deliri*  
S22 TI (((cognit* OR memory OR mental OR brain) N3 (func* OR perform* OR 
ability* OR declin* OR reduc* OR impair* OR disorder* OR fail* OR los* OR 
deficit* OR stop* OR progress* OR improve*))) OR AB (((cognit* OR 
memory OR mental OR brain) N3 (func* OR perform* OR ability* OR 
declin* OR reduc* OR impair* OR disorder* OR fail* OR los* OR deficit* OR 
stop* OR progress* OR improve*)))  
S23 TI "mental perform*" OR AB "mental perform*"  
S24 TI ((memory N3 (complain* or declin* or function*))) OR AB ((memory N3 
(complain* or declin* or function*))) 
S25 S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR 24 
S26 S6 AND S14 AND S25 
CINAHL (via EBSCO) search strategy 
S1 (MH "Cerebrovascular Disorders") OR (MH "Basal Ganglia Cerebrovascular 
Disease+") OR (MH "Cerebral Ischemia+") OR (MH "Intracranial Arterial 
Diseases+") OR (MH “Intracranial Embolism and Thrombosis+”) OR (MH 
“Intracranial Hemorrhage+") OR (MH “Stroke+) OR (MH “Cerebral 
Vasospasm”)  
S2 TI (stroke OR post#stroke OR cerebrovasc* OR "brain vasc*" OR "cerebral 
vasc*" OR cva* OR apoplexy OR SAH) OR AB (stroke OR post#stroke OR 
cerebrovasc* OR "brain vasc*" OR "cerebral vasc*" OR cva* OR apoplexy OR 
SAH) 
S3 TI ((brain* OR cerebr* OR cerebell* OR intracran* OR intracerebral) N5 
(isch#emi$ OR infarct* OR thrombo* OR emboli* OR occlus*)) OR AB 
((brain* OR cerebr* OR cerebell* OR intracran* OR intracerebral) N5 
(isch#emi$ OR infarct* OR thrombo* OR emboli* OR occlus*))  
S4 TI ((brain* OR cerebr* OR cerebell* OR intracerebral OR intracranial OR 
subarachnoid) N5 (h#emorrhage* OR h#ematoma* OR bleed*)) OR AB 
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((brain* OR cerebr* OR cerebell* OR intracerebral OR intracranial OR 
subarachnoid) N5 (h#emorrhage* OR h#ematoma* OR bleed*))  
S5 TI ((transi* N3 isch#em* N3 attack*) OR TIA) OR AB ((transi* N3 isch#em* N3 
attack*) OR TIA) 
S6 S1 OR S2 OR S3 OR S4 OR S5 
S7 TI ((validat* OR predict* OR prognos* OR rule*) N3 (outcome* OR risk* OR 
model*)) OR AB ((validat* OR predict* OR prognos* OR rule*) N3 (outcome* 
OR risk* OR model*)) 
S8 TI (prognos* AND (method* OR history OR variable* OR criteria OR scor* OR 
characteristic* OR finding* OR factor* OR model*)) OR AB (prognos* AND 
(method* OR history OR variable* OR criteria OR scor* OR characteristic* 
OR finding* OR factor* OR model*)) 
S9 TI ((history OR variable* OR criteria OR scor* OR characteristic* OR finding* 
OR factor*) N3 (predict* OR model* OR decision* OR identif* OR prognos*)) 
OR AB ((history OR variable* OR criteria OR scor* OR characteristic* OR 
finding* OR factor*) N3 (predict* OR model* OR decision* OR identif* OR 
prognos*)) 
S10 TI (decision* N3 (model* OR clinical*)) OR AB (decision* N3 (model* OR 
clinical*)) 
S11 TI (stratification OR discriminat* OR calibration) OR AB (stratification OR 
discriminat* OR calibration) 
S12 (MH “ROC Curve”) 
S13 TI (("c-statistic" OR "c statistic" OR "area under the curve" OR AUC)) OR 
AB (("c-statistic" OR "c statistic" OR "area under the curve" OR AUC)) 
S14 TI (indices OR algorithm OR multivariable) OR AB (indices OR algorithm 
OR multivariable) 
S15 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 
S16 (MH "Dementia+")  
S17 (MH "Delirium")  
S18 (MH “Delirium, Dementia, Amnestic, Cognitive Disorders”) 
S19 (MH “Cognition Disorders+”) 
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S20 (MH “Cognition”) 
S21 (MH “Memory”) OR (MH “Memory Disorders”) 
S22 TI dement* OR AB dement*  
S23 TI (alzheimer* OR AD) OR AB (alzheimer* OR AD)  
S24 TI deliri* OR AB deliri*  
S25 TI (((cognit* OR memory OR mental OR brain) N3 (func* OR perform* OR 
ability* OR declin* OR reduc* OR impair* OR disorder* OR fail* OR los* OR 
deficit* OR stop* OR progress* OR improve*))) OR AB (((cognit* OR 
memory OR mental OR brain) N3 (func* OR perform* OR ability* OR 
declin* OR reduc* OR impair* OR disorder* OR fail* OR los* OR deficit* OR 
stop* OR progress* OR improve*)))  
S26 TI "mental perform*" OR AB "mental perform*"  
S27 TI ((memory N3 (complain* or declin* or function*))) OR AB ((memory N3 
(complain* or declin* or function*))) 
S28 S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 
OR S26 OR S27 











Appendix 3: Chapter 3, completed PROBAST forms 
for included studies 
First part of PROBAST form, applicable to all included 
studies 
(Prediction model study Risk Of Bias Assessment Tool) 
 
Published in Annals of Internal Medicine (freely available): 
1. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction 
Model Studies 
2. PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction 




What does PROBAST assess? 
PROBAST assesses both the risk of bias and concerns regarding applicability of 
a study that evaluates (develops, validates or updates) a multivariable 
diagnostic or prognostic prediction model. It is designed to assess primary 
studies included in a systematic review. 
 
Bias occurs if systematic flaws or limitations in the design, conduct or analysis 
of a primary study distort the results. For the purpose of prediction modelling 
studies, we have defined risk of bias to occur when shortcomings in the study 
design, conduct or analysis lead to systematically distorted estimates of a 
model’s predictive performance or to an inadequate model to address the 
research question. Model predictive performance is typically evaluated using 
calibration, discrimination and sometimes classification measures, and these 
are likely inaccurately estimated in studies with high risk of bias. Applicability 
refers to the extent to which the prediction model from the primary study 
matches your systematic review question, for example in terms of the 
participants, predictors or outcome of interest. 
 
A primary study may include the development and/or validation or update of 
more than one prediction model. A PROBAST assessment should be completed 
for each distinct model that is developed, validated or updated (extended) for 
making individualised predictions. Where a publication assesses multiple 
prediction models, only complete a PROBAST assessment for those models that 
meet the inclusion criteria for your systematic review. Please note that 
subsequent use of the term “model” includes derivatives of models, such as 
simplified risk scores, nomograms, or recalibrations of models. 
 
PROBAST is not designed for all multivariable diagnostic or prognostic studies. 
For example, studies using multivariable models to identify predictors 
associated with an outcome but not attempting to develop a model for making 





PROBAST includes four steps. 
Step Task When to complete 
1 Specify your systematic 
review question(s) 
Once per systematic review 
2 Classify the type of 
prediction model evaluation 
Once for each model of interest in each 
publication being assessed, for each 
relevant outcome 
3 Assess risk of bias and 
applicability 
Once for each development and 
validation of each distinct prediction 
model in a publication 
4 Overall judgment Once for each development and 
validation of each distinct prediction 
model in a publication 
 
If this is your first time using PROBAST, we strongly recommend reading the 
detailed explanation and elaboration (E&E, see link above) paper and to check 
the examples on www.probast.org 
 
Step 1: Specify your systematic review question 
State your systematic review question to facilitate the assessment of the 
applicability of the evaluated models to your question. The following table 
should be completed once per systematic review. 
 
Criteria Specify your systematic review question 
Intended use of 
model:  
 
Prognosis of cognitive outcome following stroke 
Participants 
including selection 
criteria and setting: 
Adults with ischaemic stroke, haemorrhagic stroke, or 
TIA 
Predictors (used in 
prediction 
modelling), including 
types of predictors 
(e.g. history, clinical 
examination, 
biochemical markers, 
imaging tests), time 
of measurement, 
specific measurement 





Demographics, medical history, lifestyle factors, 
clinical examination, biochemical markers, imaging 
data. All predictors should be collected or refer to a 
point in time preceding the occurrence of the 
cognitive outcome. 
Outcome to be 
predicted:  
 
Any cognitive outcome, including cognitive change, 




Second part of PROBAST form, completed individually 
for each included study 
Chander et al., 2017; CHANGE score 
Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, 
model validation or model update, or combination. Different signalling 
questions apply for different types of prediction model evaluation. If the 
evaluation does not fit one of these classifications then PROBAST should not be 
used. 
 









Definition for type of 
prediction model study 
Development 
only 
Development X Prediction model 
development without external 
validation. These studies may 
include internal validation 







✓ Prediction model 
development combined with 
external validation in other 




Validation X External validation of existing 
(previously developed) model 
in other participants. 
 
This table should be completed once for each publication being assessed and 
for each relevant outcome in your review. 
Publication 
reference 
Chander, R. J. et al.; Development and validation of 
a risk score (CHANGE) for cognitive impairment after 
ischemic stroke; 2017 
Models of 
interest 
CHANGE score based on demographics and imaging variables 
Outcome of 
interest 
Post-stroke cognitive impairment 
 
 
Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of 
bias (low, high or unclear) and includes signalling questions to help make 
judgements. Signalling questions are rated as yes (Y), probably yes (PY), 
probably no (PN), no (N) or no information (NI). All signalling questions are 
phrased so that “yes” indicates absence of bias. Any signalling question rated 
as “no” or “probably no” flags the potential for bias; you will need to use your 
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judgement to determine whether the domain should be rated as “high”, “low” 
or “unclear” risk of bias. The guidance document contains further instructions 
and examples on rating signalling questions and risk of bias for each domain. 
The first three domains are also rated for concerns regarding applicability 
(low/ high/ unclear) to your review question defined above.  
Complete all domains separately for each evaluation of a distinct model. 
Shaded boxes indicate where signalling questions do not apply and should not 
be answered. 
 
DOMAIN 1:  Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
Development: 
Retrospective cohort 
Participants: diagnosis of ischaemic stroke; exclusion criteria: Discharge mRS 
>2; Subjects with pre-stroke cognitive impairment, neurological or psychiatric 
comorbidities, presented outside of the window period, or were unable to 
undergo cognitive assessments due to severe communication or visual 
disturbances as a result of the stroke, were excluded. Subjects with 
significant depression, screened via the 9-point Patient Health Questionnaire 
(PHQ-9) were also excluded. 
Patients who were assessed by the clinical teams as being at risk for 
developing PSCI were scheduled for outpatient follow-up within 3–6 months 
after incident stroke. 
Validation: 
Retrospective cohort (STRIDE study); participants: inclusion criteria were: 
Chinese ethnicity, fluency in Cantonese, ability to participate in cognitive 
assessments, and provision of signed informed consent. Exclusion criteria for 
this study were: severe language impairment precluding cognitive assessment, 
presence of terminal illness, clinically significant psychiatric comorbidity, or 
known history of dementia before the index stroke. Severe language 
impairment was defined as a score of 3 points (i.e., mute) in the language 
score of the National Institute of Health Stroke Scale (NIHSS). All patients 
with stroke/TIA were invited to return for a neuropsychological assessment at 
3 to 6 months after the index event. 
 Dev Val 
1.1 Were appropriate data sources used, e.g. cohort, RCT or nested 
case-control study data? 
PY PY 
1.2 Were all inclusions and exclusions of participants appropriate? N Y 







Rationale of bias rating: 
Development: 
It seems that all data for the study was collected at a single time-point, using 
admission records, which indicates that some predictors were not recorded 
for the purpose of research but routine clinical care - it is difficult to 
determine the quality of the data. However, medical records are overall 
considered a reliable source of information on general health-related 
variables. This is also not a factor that would necessarily overestimate the 
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performance of the model/lead to overoptimistic results. Moreover, routine 
clinical data is what would most likely be used if the model were applied in 
practice. 
Exclusion criteria may have led to a non-representative patient sample, as 
stroke is likely to lead to disability (particularly as many patients may have 
had prior disability) and impairments impeding cognitive assessments, 
however, authors have stated that they wanted to focus on non-disabling 
strokes; excluding participants with depression may have lead to 
overestimation of prognostic accuracy, as it might be particularly difficult to 
distinguish between symptoms of depression and cognitive impairment, 
leading to an increase of false positives. High risk of bias due to enrolment 
being based on the clinical team’s decision about who is at highest risk of 
PSCI, with no indication of how this decision was reached. 
Validation: 
As above, there are potential issues related to admission data not being 
recorded for research purposes, however this does not likely introduce a high 
risk of bias. This study was overall more inclusive, if exclusion criteria mainly 
applied where cognitive assessment would not be appropriate or possible, or 
where findings could be contributed to other significant medical conditions. 
B. Applicability 
Describe included participants, setting and dates:  
Development: 
Participants with non-disabling stroke who were found by the clinical team to 
be at risk of developing PSCI,  recruitment from a tertiary centre in Singapore 
from Jan 2008 to Dec 2012 
Validation: 
Participant selection criteria as described above, recruitment from acute 
stroke unit in Hong Kong from Jan 2009 and Dec 2010 
Concern that the included participants and 





Rationale of applicability rating: 
Development: 
Sample may not be representative due to narrowing to patients assessed as 
likely to develop PSCI and selection criteria excluding disabled and depressed 
participants, with both disability and depression being relatively common in 
stroke populations; also potential cultural, geographical and healthcare 
differences, most obvious issue related to education – in western countries 
education <6 years would be an uncommon occurrence. However, the only 
criterium regarding participants was being an adult, diagnosed with stroke, so 
study population matches review question. 
Validation: 
Included participants match the review question, although potential cultural, 
geographical and healthcare differences, most obvious issue related to 
education – in western countries education <6 years would be an uncommon 
occurrence 
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DOMAIN 2:  Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and 
timing of assessment: 
Predictors: Chronic lacunes, white matter hyperintensities, age, non-lacunar 
acute cortical infarcts, global cortical atrophy, education. 
Development: demographic, clinical and risk factor data were obtained from 
admission records, clinical MR images obtained at the time of stroke 
appraised by neurologist and neuroradiologist, and visually rated by blinded 
raters. 
Validation: demographic and clinical data collected during acute 
hospitalisation, MRI performed within first week of admission, appraised by 3 
trained neurologists 
 Dev Val 
2.1 Were predictors defined and assessed in a similar way for all 
participants? 
Y Y 
2.2 Were predictor assessments made without knowledge of 
outcome data?  
PY NI 
2.3 Are all predictors available at the time the model is intended 
to be used? 
Y Y 






Rationale of bias rating: 
In development study, MR image raters were blinded and trained specialists, 
no information regarding blinding when assessing demographics, however 
these predictors do not involve subjective judgement. 
In validation study, MR images were appraised by trained specialists; blinding 
was not explicitly stated, however predictors were assessed prior to outcome. 
B. Applicability 
Concern that the definition, assessment or 
timing of predictors in the model do not match 





Rationale of applicability rating: 
There are potential issues with access to MRI, trained specialists using the 
assessment tools and subjectivity in rating MR images. However, everything 
matches review question and the setting for use was not specifically defined, 
e.g. these methods would still be highly applicable to research settings 
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DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time 
interval between predictor assessment and outcome determination: 
Development: 
“Cognitive status was assessed by clinical team via structured clinical 
interview and the Mini-Mental State Examination (MMSE). If further 
confirmation was required, the Singaporean version of the Montreal Cognitive 
Assessment (MoCA) was conducted. Subjects were classified as having PSCI if 
they had an MRI-confirmed infarct, met criteria for vascular cognitive 
impairment, and had MMSE ≤ 25 or MoCA ≤ 22. Remaining subjects were 
classified as having no cognitive impairment (NCI).” 
Validation: 
“All patients with stroke/TIA were invited to return for a neuropsychological 
assessment at 3 to 6 months after the index event. Trained psychologists 
administered the Clinical Dementia Rating (CDR), Cantonese Mini-Mental State 
Examination (MMSE), and Hong Kong version of the Montreal Cognitive 
Assessment to evaluate patients’ cognitive functions while blinded to 
neuroimaging findings. The Chinese Geriatric Depression Scale was used to 
assess the extent of depressive symptoms. When grading using the CDR, care 
was taken particularly to grade only those impairments that were attributed 
to cognitive symptoms, not to motor/mood disturbances. Patients suspected 
of having dementia as defined by a CDR rating of 1 point or more at 
screening, and their caregivers, were invited for a detailed clinical 
assessment by neurologists specialized in dementia (V.C.T.M. and L.A.), who 
then confirmed a diagnosis of dementia according to the Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition. During this clinical 
assessment, the neurologists also inquired about patients’ cognitive function 
before the index event to exclude patients with dementia before the index 
event.” 
 Dev Val 
3.1 Was the outcome determined appropriately? Y Y 
3.2 Was a pre-specified or standard outcome definition used? PY Y 
3.3 Were predictors excluded from the outcome definition? PN Y 
3.4 Was the outcome defined and determined in a similar way for 
all participants? 
N N? 
3.5 Was the outcome determined without knowledge of predictor 
information? 
PN Y 
3.6 Was the time interval between predictor assessment and 
outcome determination appropriate? 
Y Y 
Risk of bias introduced by the outcome or 





Rationale of bias rating: 
Development: 
3.1 MMSE is considered to not have sufficient sensitivity to capture MCI in 
stroke populations, however it is nonetheless a standard, accepted, widely-
used measure of cognition, 3.2 Not clear how criteria for VCI were applied 
(were definite, probable and possible all treated the same?), 3.3 Imaging 
variables (potentially predictors) are used to assess VCI, 3.4 some participants 
were additionally assessed with the MoCA without an objective indication of 
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who needed to be (seems to be based on subjective call), also there was a 
relatively big difference in assessment times (between 3 to 6 months) 3.5 
given the diagnosing of VCI, it appears likely that assessors had some 
knowledge of imaging results. 
Validation: 
Seems that all participants were assessed using the same 3 standard 
measures, although not quite clear (possibly MoCA and MMSE were not always 
used in combination) and once again there was a relatively big difference in 
assessment times - 3 to 6 months (but does this go under 3.4 or 3.6?), CDR 
criteria are pre-specified and clear compared to what criteria might have 
been applied to diagnose VCI and also do not require knowledge of imaging 
findings, assessors were blinded to the latter. 
B. Applicability 
At what time point was the outcome determined:  
Between 3 to 6 months 
 
If a composite outcome was used, describe the relative 
frequency/distribution of each contributing outcome:  
N/A 
Concern that the outcome, its definition, 






Rationale of applicability rating: 
The time interval was appropriate to capture PSCI and the review question did 
not impose and specific time restrictions regarding outcome assessment.  
The review focuses on any cognitive outcome assessed using a recognised 
measure, and therefore the chosen outcome matches the review question. 
 
DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors, outcome 
events and events per candidate predictor: 
Development: 209 participants, 26 candidate predictors (intracranial stenosis 
was not mentioned in the table, but was in the text), 78 events, 3.0 events 
per predictor 
Validation: 693 participants, 352 with PSCI 
Describe how the model was developed (for example in regards to modelling 
technique (e.g. survival or logistic modelling), predictor selection, and risk 
group definition): 
Logistic regression 
Variables were deemed eligible for inclusion in the initial stage of model 
building if they were: 1) statistically significant at the univariate level after 
operationalization, 2) found in the literature to be relevant, and 3) were 
deemed by the study team that the variables were common enough to be 
available to existing stroke workflows 
“Statistically significant continuous variables were operationalized into 
categorical variables based on clinically relevant cutoffs and retested for 
statistical significance.” 
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Describe whether and how the model was validated, either internally (e.g. 
bootstrapping, cross validation, random split sample) or externally (e.g. 
temporal validation, geographical validation, different setting, different 
type of participants): 
Apparent and temporal with stability assessed using 10-fold cross-validation; 
external 
Describe the performance measures of the model, e.g. (re)calibration, 
discrimination, (re)classification, net benefit, and whether they were 
adjusted for optimism: 
Discrimination, classification abilities, calibration, cross-validation to assess 
stability of AUROC estimates 
Describe any participants who were excluded from the analysis: 
Development: 34 excluded – 6 presented outside of 3-6 months, 28 had 
incomplete investigative data 
Validation: 314 subjects were excluded - 71 with hemorrhagic stroke, 140 
with TIA, 86 with non-stroke or unknown etiologies, and 17 with history of 
intracranial hemorrhage); also participants with incomplete data were 
excluded from the STRIDE study itself 
Describe missing data on predictors and outcomes as well as methods used 
for missing data: 
Information on missing data was not presented, participants with missing data 
were excluded from the analysis 
 Dev Val 
4.1 Were there a reasonable number of participants with the 
outcome? 
N Y 
4.2 Were continuous and categorical predictors handled 
appropriately? 
NI PY 
4.3 Were all enrolled participants included in the analysis? N N 
4.4 Were participants with missing data handled appropriately? N N 
4.5 Was selection of predictors based on univariable analysis 
avoided?  
N  
4.6 Were complexities in the data (e.g. censoring, competing 
risks, sampling of controls) accounted for appropriately? 
PN N 
4.7 Were relevant model performance measures evaluated 
appropriately? 
Y Y 
4.8 Were model overfitting and optimism in model performance 
accounted for? 
Y  
4.9 Do predictors and their assigned weights in the final model 
correspond to the results from multivariable analysis?  
N  




Rationale of bias rating: 
Development:  
Too few participants with event relative to candidate predictors, exclusion of 
participants with missing data, selection of predictors based on univariable 
analysis, global cortical atrophy and white matter hyperintensities were 
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included in the risk score despite not being significant in multivariable 
regression – inconsistency in approach 
Validation: 
Issues due to missing data and exclusion of participants lost to follow-
up/dead. 
 
Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and 
concerns regarding applicability of the prediction model evaluation 
(development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model 
evaluation 
Low risk of 
bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external 
validation, and it was rated as low risk of bias for all 
domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the 
development was based on a very large data set and included 
some form of internal validation. 
High risk of 
bias  
If at least one domain is judged to be at high risk of bias.  
Unclear risk 
of bias 
If an unclear risk of bias was noted in at least one domain and 
it was low risk for all other domains.  
 





If low concerns regarding applicability for all domains, 
the prediction model evaluation is judged to have low 




If high concerns regarding applicability for at least one 
domain, the prediction model evaluation is judged to 




If unclear concerns (but no “high concern”) regarding 
applicability for at least one domain, the prediction 
model evaluation is judged to have unclear concerns 




Overall judgement about risk of bias and applicability of the prediction 
model evaluation 




Summary of sources of potential bias:  
Assessment of outcome associated with knowledge of predictors and differing 
across subject; issues with model development, including type of analysis, 
selection of predictors and handling missing data 




Summary of applicability concerns: selection criteria that exclude 
participants with common sequalae of stroke, including depression and any 
disability resulting in dependence, however the study population nonetheless 




Ding et al., 2019 
Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, 
model validation or model update, or combination. Different signalling 
questions apply for different types of prediction model evaluation. If the 
evaluation does not fit one of these classifications then PROBAST should not be 
used. 
 









Definition for type of 
prediction model study 
Development 
only 
Development ✓ Prediction model 
development without external 
validation. These studies may 
include internal validation 







X Prediction model 
development combined with 
external validation in other 




Validation X External validation of existing 
(previously developed) model 




This table should be completed once for each publication being assessed and 
for each relevant outcome in your review. 
Publication 
reference 
Ding, M. Y. et al. Predictors of Cognitive Impairment 
after Stroke: A Prospective Stroke Cohort Study. 2019 
Models of 
interest 




Post-stroke cognitive impairment diagnosed based on MMSE, 
MoCA, CDR and DSM-4 criteria 
 
Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of 
bias (low, high or unclear) and includes signalling questions to help make 
judgements. Signalling questions are rated as yes (Y), probably yes (PY), 
probably no (PN), no (N) or no information (NI). All signalling questions are 
phrased so that “yes” indicates absence of bias. Any signalling question rated 
as “no” or “probably no” flags the potential for bias; you will need to use your 
judgement to determine whether the domain should be rated as “high”, “low” 
or “unclear” risk of bias. The guidance document contains further instructions 
and examples on rating signalling questions and risk of bias for each domain. 
The first three domains are also rated for concerns regarding applicability 
(low/ high/ unclear) to your review question defined above.  
Complete all domains separately for each evaluation of a distinct model. 
Shaded boxes indicate where signalling questions do not apply and should not 
be answered. 
 
DOMAIN 1:  Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
Prospective cohort; Inclusion criteria: diagnosis of stroke, stroke onset within 
last 7 days, adult, willingness to undergo assessments and data collection 
procedures; Exclusion criteria: pregnancy, severe vital organ failure, major 
mental illness, history of dementia, participation in other trials 
 Dev Val 
1.3 Were appropriate data sources used, e.g. cohort, RCT or nested 
case-control study data? 
Y  
1.4 Were all inclusions and exclusions of participants appropriate? Y  







Rationale of bias rating: 
Exclusion criteria seem appropriate as future cognitive outcomes are less of a 
priority where patient’s condition may be terminal and are less likely to be 
assessed in a real-world healthcare setting, inclusion of patients with 
dementia may have led to overoptimistic model estimations, outcomes of 
patients taking part in other trials may be affected by interventions. 
B. Applicability 
Describe included participants, setting and dates:  
Tertiary care centre in China, patients diagnosed with acute ischaemic stroke; 
data collection: June 2017 to May 2018 
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Concern that the included participants and 





Rationale of applicability rating: 
Although applicability may be affected by cultural, geographical and 
healthcare settings, the study sample seems representative of stroke 
population of interest 
 
DOMAIN 2:  Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and 
timing of assessment: 
Age, years of education, periventricular hyperintensity grading (PVH), 
diabetes mellitus (DM), number of acute nonlacunar infarcts. DM was defined 
by fasting plasma glucose, 2h postprandial glucose or treatment with insulin 
or oral hypoglycemic medication. Acute nonlacunar infarct defined as lesion 
greater than 20mm. PVH assessed based on Fazekas scale.   
 Dev Val 
2.4 Were predictors defined and assessed in a similar way for all 
participants? 
N  
2.5 Were predictor assessments made without knowledge of 
outcome data?  
NI  
2.6 Are all predictors available at the time the model is intended 
to be used? 
Y  






Rationale of bias rating: 
Although different measures were used to determine DM, all seem valid, 
particularly that lab findings might not indicate disease in patients taking 
medication, while some patients might be undiagnosed or not take medication 
for other reasons; as the study is prospective it can be inferred the predictors 
were assessed without knowledge of the outcome; it is not stated whether MR 
image raters had similar levels of expertise and assessment of these 
predictors allows for subjectivity, however the included predictors were well-
defined and based on recognised, standard tool. 
B. Applicability 
Concern that the definition, assessment or 
timing of predictors in the model do not match 





Rationale of applicability rating: 
Definition, assessment and timing match our broad review question 
  
244 
DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time 
interval between predictor assessment and outcome determination: 
All patients were asked to complete the MMSE, MoCA, a neuropsychological 
assessment battery and were assessed based on CDR and DSM-4 criteria. PSCI 
identified if both MMSE and MoCA scores were lower than cut-off or a 
neuropsychological battery with more than one affected domain if the MMSE 
and MoCA were discordant and the CDR rating was greater than 0 points. Post-
stroke dementia was diagnosed based on DSM-4 criteria. Follow-up was 
between 6 and 12 months 
 Dev Val 
3.7 Was the outcome determined appropriately? PY  
3.8 Was a pre-specified or standard outcome definition used? Y  
3.9 Were predictors excluded from the outcome definition? Y  
3.10 Was the outcome defined and determined in a similar way 
for all participants? 
N?  
3.11 Was the outcome determined without knowledge of 
predictor information? 
NI  
3.12 Was the time interval between predictor assessment and 
outcome determination appropriate? 
Y  
Risk of bias introduced by the outcome or 





Rationale of bias rating: 
This is difficult to assess without knowing whether assessors had knowledge of 
predictor information, as assessment based on CDR and DSM-4 allows for 
subjective judgement, while examiner may influence test results with their 
behaviour, potentially large difference in follow-up time between participants 
(6 to 12 months); the level of assessor expertise is also unclear. 
B. Applicability 
At what time point was the outcome determined:  
Between 6 to 12 months 
 
If a composite outcome was used, describe the relative 
frequency/distribution of each contributing outcome:  
N/A 
Concern that the outcome, its definition, 






Rationale of applicability rating: 
Although it is unlikely that cognition will be routinely assessed using a method 
as complex as described in this study, it seems credible (likely to correctly 
identify cases of PSCI); all aspects of the outcome match the review question. 
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DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors, outcome 
events and events per candidate predictor: 
145, 77 outcome events, number of candidate predictors is unclear but seems 
like 52, and at least 45, so EPV at most 1.7 
Describe how the model was developed (for example in regards to modelling 
technique (e.g. survival or logistic modelling), predictor selection, and risk 
group definition): 
Logistic regression, predictors selected based on results of univariable analysis 
Describe whether and how the model was validated, either internally (e.g. 
bootstrapping, cross validation, random split sample) or externally (e.g. 
temporal validation, geographical validation, different setting, different 
type of participants): 
Paper mentions bootstrap in estimating predictor ORs, but doesn’t seem to 
have been applied to AUROC estimate, also unclear on number of replications, 
seems like only apparent validation was done. 
Describe the performance measures of the model, e.g. (re)calibration, 
discrimination, (re)classification, net benefit, and whether they were 
adjusted for optimism: 
Discrimination with AUROC, calibration, but only based on Hosmer-Lemeshow 
test 
Describe any participants who were excluded from the analysis: 
34 subjects did not participate in follow-up visit due to rehabilitation in 
admission, not in Shanghai, refusal. 
Describe missing data on predictors and outcomes as well as methods used for 
missing data: 
No indication of any missing data 
 Dev Val 
4.10 Were there a reasonable number of participants with the 
outcome? 
N  
4.11 Were continuous and categorical predictors handled 
appropriately? 
Y  
4.12 Were all enrolled participants included in the analysis? N  
4.13 Were participants with missing data handled appropriately? NI  
4.14 Was selection of predictors based on univariable analysis 
avoided?  
PN  
4.15 Were complexities in the data (e.g. censoring, competing 
risks, sampling of controls) accounted for appropriately? 
N  
4.16 Were relevant model performance measures evaluated 
appropriately? 
N  
4.17 Were model overfitting and optimism in model 
performance accounted for? 
N  
4.18 Do predictors and their assigned weights in the final model 
correspond to the results from multivariable analysis?  
NI  





Rationale of bias rating: 
Too few participants relative to number of candidate predictors, participants 
lost to follow-up were excluded, method of handling missing data not 
explicitly stated, predictors assessed based on univariable associations, no 
appropriate measure of calibration, only apparent validation with AUROC no 
corrected for optimism, also authors didn’t report on results of logistic 
regression models or even what exact variables were included in them, 
therefore it is not possible to assess 4.9. 
 
Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and 
concerns regarding applicability of the prediction model evaluation 
(development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model 
evaluation 
Low risk of 
bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external 
validation, and it was rated as low risk of bias for all 
domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the 
development was based on a very large data set and included 
some form of internal validation. 
High risk of 
bias  
If at least one domain is judged to be at high risk of bias.  
Unclear risk 
of bias 
If an unclear risk of bias was noted in at least one domain and 
it was low risk for all other domains.  
 





If low concerns regarding applicability for all domains, 
the prediction model evaluation is judged to have low 




If high concerns regarding applicability for at least one 
domain, the prediction model evaluation is judged to 




If unclear concerns (but no “high concern”) regarding 
applicability for at least one domain, the prediction 
model evaluation is judged to have unclear concerns 





Overall judgement about risk of bias and applicability of the prediction 
model evaluation 




Summary of sources of potential bias: 
High risk of bias in terms of analysis due to exclusion of participants lost to 
follow-up, type of analysis, selection of predictors, and estimation of model 
performance; also unclear whether outcome was assessed with blinding to 
predictors 




Summary of applicability concerns: 
Study sample seems likely to be representative of stroke population in which 
cognitive outcome is recognised as relevant/important (not terminally ill or 
with level of functional disability requiring full-time care), all aspects match 
review question. 
 
Gong et al., 2019 
Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, 
model validation or model update, or combination. Different signalling 
questions apply for different types of prediction model evaluation. If the 
evaluation does not fit one of these classifications then PROBAST should not be 
used. 
 









Definition for type of 
prediction model study 
Development 
only 
Development ✓ Prediction model 
development without external 
validation. These studies may 
include internal validation 







X Prediction model 
development combined with 
external validation in other 




Validation X External validation of existing 
(previously developed) model 
in other participants. 
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This table should be completed once for each publication being assessed and 
for each relevant outcome in your review. 
Publication 
reference 
Gong, K. A nomogram to predict cognitive impairment after 
supratentorial spontaneous intracranial hematoma in adult 
patients: A retrospective cohort study. 2019 
Models of 
interest 
Nomogram based on Glasgow Coma Scale, bleeding volume 
and presence of intraventricular haemorrhage 
Outcome of 
interest 
Cognitive impairment after supratentorial haemorrhage 
 
Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of 
bias (low, high or unclear) and includes signalling questions to help make 
judgements. Signalling questions are rated as yes (Y), probably yes (PY), 
probably no (PN), no (N) or no information (NI). All signalling questions are 
phrased so that “yes” indicates absence of bias. Any signalling question rated 
as “no” or “probably no” flags the potential for bias; you will need to use your 
judgement to determine whether the domain should be rated as “high”, “low” 
or “unclear” risk of bias. The guidance document contains further instructions 
and examples on rating signalling questions and risk of bias for each domain. 
The first three domains are also rated for concerns regarding applicability 
(low/ high/ unclear) to your review question defined above.  
Complete all domains separately for each evaluation of a distinct model. 
Shaded boxes indicate where signalling questions do not apply and should not 
be answered. 
 
DOMAIN 1:  Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
Retrospective cohort 
170 consecutive patients with intracranial hematoma were enrolled in this 
study. All participants were admitted in rehabilitation department and had 
received initial treatment at the onset of stroke in 1 hospital in southeast 
area of China. Eleven patients were excluded due to dementia past history. 
Nineteen patients with stroke history before and 23 patients with subtentorial 
hematoma were also excluded. We divided the remaining 127 patients into 2 
datasets according their admission time, 92 patients who were admitted 
before 2018 were enrolled in development dataset. 
 Dev Val 
1.5 Were appropriate data sources used, e.g. cohort, RCT or nested 
case-control study data? 
Y  
1.6 Were all inclusions and exclusions of participants appropriate? Y  







Rationale of bias rating: 
Participants with previous stroke are often excluded due to potential 
confounding from pre-existing disability and cognitive impairment, inclusion 
of patients with dementia may lead to overoptimistic model estimations, the 
aim of the study was to focus only on patients with haemorrhage. 
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B. Applicability 
Describe included participants, setting and dates:  
Patients with intracranial hematoma, 1 hospital in southeast area of China; 
January 1, 2016 to October 31, 2018 
Concern that the included participants and 





Rationale of applicability rating: 
Study limited to one particular stroke type, however this was the specified 
aim and still fits with the review question, applicability may be affected by 
cultural, geographical and healthcare settings 
 
DOMAIN 2:  Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and 
timing of assessment: 
Bleeding volume and intraventricular haemorrhage evaluated independently 
by 2 neurosurgeons. 
GCS assessed at stroke onset by clinicians in charge of patient care. 
 Dev Val 
2.7 Were predictors defined and assessed in a similar way for all 
participants? 
Y  
2.8 Were predictor assessments made without knowledge of 
outcome data?  
NI  
2.9 Are all predictors available at the time the model is intended 
to be used? 
Y  






Rationale of bias rating: 
2.2 is unclear, assessment of CT images allows for some subjectivity, however 
predictors seem well-defined and 2 independent raters were involved. 
B. Applicability 
Concern that the definition, assessment or 
timing of predictors in the model do not match 





Rationale of applicability rating: 
All aspects related to predictors match the review question. 
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DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time 
interval between predictor assessment and outcome determination: 
Mini-mental State Examination (MMSE) score was evaluated after 3 months 
from the onset of the disease by 1 qualified rehabilitation physician. MMSE ≤ 
24 was considered as cognitive impairment. 
 Dev Val 
3.13 Was the outcome determined appropriately? Y  
3.14 Was a pre-specified or standard outcome definition used? Y  
3.15 Were predictors excluded from the outcome definition? Y  
3.16 Was the outcome defined and determined in a similar way 
for all participants? 
Y  
3.17 Was the outcome determined without knowledge of 
predictor information? 
NI  
3.18 Was the time interval between predictor assessment and 
outcome determination appropriate? 
Y  
Risk of bias introduced by the outcome or 





Rationale of bias rating: 
MMSE is not as sensitive as e.g. MoCA that is recommended for stroke 
populations, yet it is nonetheless a recognised, validated and widely-used 
measure of cognitive function, 3.5 is unclear and test scores may be to a 
certain extent influenced by examiner behaviour, yet given the binary nature 
of the outcome, this would likely only affect participants with actual scores 
near the cut off, also the examiner seems qualified to carry out the 
assessment appropriately 
B. Applicability 
At what time point was the outcome determined:  
3 months after stroke onset 
 
If a composite outcome was used, describe the relative 
frequency/distribution of each contributing outcome:  
N/A 
Concern that the outcome, its definition, 






Rationale of applicability rating: 
All aspects of the outcome match the review question. 
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DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors, outcome 
events and events per candidate predictor: 
92 participants, 13 candidate predictors, 69 outcome events in development 
and validation datasets (unknown for development set alone), even if all 69 
were in development set, EPV = 5.3 
Describe how the model was developed (for example in regards to modelling 
technique (e.g. survival or logistic modelling), predictor selection, and risk 
group definition): 
We used logistic regression to build models on the development dataset. 
Cognitive impairment was chosen to be the response variable. Age, gender, 
hemorrhage sites, bleeding volume, GCS, IVH, DM, hypertension, 
hyperlipidemia were potential risk factors. We classified GCS into 3 
categories: GCS ≥ 12, 9 ≤ GCS < 12 and GCS ≤ 8. Bleeding volume was also 
divided into ordered categorical factors as volume  < 10 ml, 10 ml ≤ 
volume < 20 ml, 20 ml ≤ volume < 30 ml, 30 ml ≤ volume < 40 ml, 40 ml ≤ 
volume < 50 ml, 50 ml ≤ volume < 60 ml and volume ≥ 60 ml. Risk factors which 
showed statistically significant in univariate logistic analysis would be 
enrolled in multiple logistic regression. Akaike Information Criterion (AIC) was 
used to determine which factors should be enrolled in the final model. 
Describe whether and how the model was validated, either internally (e.g. 
bootstrapping, cross validation, random split sample) or externally (e.g. 
temporal validation, geographical validation, different setting, different 
type of participants): 
We divided the remaining 127 patients into 2 datasets according their 
admission time, 92 patients who were admitted before 2018 were enrolled in 
development dataset. The other 35 patients were in validation dataset. 
Describe the performance measures of the model, e.g. (re)calibration, 
discrimination, (re)classification, net benefit, and whether they were 
adjusted for optimism: 
A nomogram was drawn according to the final logistic regression model. 
Receiver operating characteristic (ROC) curve and calibration curve on 
development and validation datasets were drawn separately. 
Describe any participants who were excluded from the analysis: 
Participants excluded as described in Domain A, apparently no loss to follow 
up 
Describe missing data on predictors and outcomes as well as methods used 
for missing data: 
No mention of missing data 
 Dev Val 
4.19 Were there a reasonable number of participants with the 
outcome? 
N  
4.20 Were continuous and categorical predictors handled 
appropriately? 
PN  
4.21 Were all enrolled participants included in the analysis? Y  
4.22 Were participants with missing data handled appropriately? NI  




4.24 Were complexities in the data (e.g. censoring, competing 
risks, sampling of controls) accounted for appropriately? 
NI  
4.25 Were relevant model performance measures evaluated 
appropriately? 
Y  
4.26 Were model overfitting and optimism in model 
performance accounted for? 
N  
4.27 Do predictors and their assigned weights in the final model 
correspond to the results from multivariable analysis?  
PY  




Rationale of bias rating: 
Too few participants for model development and validation, GCS categorised 
differently than recommended (score of 12 should be treated as more severe) 
and uncertain how many patients with what variability In volume were 
grouped in bleeding volume >60, seletion of predictors based on univariable 
associations, inappropriate method of internal validation. 
 
Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and 
concerns regarding applicability of the prediction model evaluation 
(development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model 
evaluation 
Low risk of 
bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external 
validation, and it was rated as low risk of bias for all 
domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the 
development was based on a very large data set and included 
some form of internal validation. 
High risk of 
bias  
If at least one domain is judged to be at high risk of bias.  
Unclear risk 
of bias 
If an unclear risk of bias was noted in at least one domain and 
it was low risk for all other domains.  
 





If low concerns regarding applicability for all domains, 
the prediction model evaluation is judged to have low 




If high concerns regarding applicability for at least one 
domain, the prediction model evaluation is judged to 




If unclear concerns (but no “high concern”) regarding 
applicability for at least one domain, the prediction 
model evaluation is judged to have unclear concerns 
regarding applicability overall. 
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Overall judgement about risk of bias and applicability of the prediction 
model evaluation 




Summary of sources of potential bias: 
Source of bias stems from model development and validation issues, including 
insufficient sample size, predictor selection and use of split-sample 
validation. 




Summary of applicability concerns: 
All domains match review question, few exclusion criteria so sample likely to 
be representative. 
 
Kandiah et al., 2016; SIGNAL2 
Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, 
model validation or model update, or combination. Different signalling 
questions apply for different types of prediction model evaluation. If the 
evaluation does not fit one of these classifications then PROBAST should not be 
used. 
 









Definition for type of 
prediction model study 
Development 
only 
Development ✓ Prediction model 
development without external 
validation. These studies may 
include internal validation 







X Prediction model 
development combined with 
external validation in other 




Validation X External validation of existing 
(previously developed) model 
in other participants. 
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This table should be completed once for each publication being assessed and 
for each relevant outcome in your review. 
Publication 
reference 
Kandiah, N. et al. Cognitive Impairment after Mild Stroke: 








Post-stroke cognitive impairment 
 
 
Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of 
bias (low, high or unclear) and includes signalling questions to help make 
judgements. Signalling questions are rated as yes (Y), probably yes (PY), 
probably no (PN), no (N) or no information (NI). All signalling questions are 
phrased so that “yes” indicates absence of bias. Any signalling question rated 
as “no” or “probably no” flags the potential for bias; you will need to use your 
judgement to determine whether the domain should be rated as “high”, “low” 
or “unclear” risk of bias. The guidance document contains further instructions 
and examples on rating signalling questions and risk of bias for each domain. 
The first three domains are also rated for concerns regarding applicability 
(low/ high/ unclear) to your review question defined above.  
Complete all domains separately for each evaluation of a distinct model. 
Shaded boxes indicate where signalling questions do not apply and should not 
be answered. 
 
DOMAIN 1:  Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
Retrospective cohort;  
“From this database, we included patients with mild ischemic stroke, defined 
as having a modified Rankin scale of ≤2 with an MR-confirmed acute infarct. 
Exclusion criteria included presence of pre-stroke cognitive impairment, 
absence of MRI performed during acute stroke work-up, presentation to 
outpatient clinic outside 3–6 months, neurological or psychiatric 
comorbidities, unable to undergo cognitive assessments due to severe 
communication or visual disturbances as a result of the stroke. Subjects with 
significant depression, screened via the 9-point Patient Health Questionnaire 
(PHQ-9) were also excluded.” 
“Patients who were assessed by the clinical teams as being at risk for 
developing PSCI were scheduled for outpatient follow-up within 3–6 months 
after incident stroke.” 
 Dev Val 
1.7 Were appropriate data sources used, e.g. cohort, RCT or nested 
case-control study data? 
Y  
1.8 Were all inclusions and exclusions of participants appropriate? N  








Rationale of bias rating: 
It seems that all data for the study was collected at a single time-point, using 
admission records, which indicates that some predictors were not recorded 
for the purpose of research but routine clinical care - it is difficult to 
determine the quality of the data. However, medical records are overall 
considered a reliable source of information on general health-related 
variables. This is also not a factor that would necessarily overestimate the 
performance of the model/lead to overoptimistic results. Moreover, routine 
clinical data is what would most likely be used if the model were applied in 
practice. 
Exclusion criteria may have led to a non-representative patient sample, as 
stroke is likely to lead to disability (particularly as many patients may have 
had prior disability) and impairments impeding cognitive assessments, 
however, authors have stated that they wanted to focus on non-disabling 
strokes; excluding participants with depression may have led to 
overestimation of prognostic accuracy, as it might be particularly difficult to 
distinguish between symptoms of depression and cognitive impairment, 
leading to an increase of false positives. High risk of bias due to enrolment 
being based on the clinical team’s decision about who is at highest risk of 
PSCI, with no indication of how this decision was reached. 
B. Applicability 
Describe included participants, setting and dates:  
Participants with non-disabling stroke who were found by the clinical team to 
be at risk of developing PSCI, recruitment from a tertiary centre in Singapore 
from Jan 2008 to Dec 2012 
Concern that the included participants and 





Rationale of applicability rating: 
Sample may not be representative due to narrowing to patients assessed as 
likely to develop PSCI and selection criteria excluding those disabled and 
depressed, with both disability and depression being relatively common in 
stroke populations (issues with model generalisability); also potential cultural, 
geographical and healthcare differences, most obvious issue related to 
education – in western countries education <6 years would be an unlikely 
occurrence. However, the only criterium regarding participants was being an 
adult, diagnosed with stroke, so study population matches review question. 
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DOMAIN 2:  Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and 
timing of assessment: 
Age, education <6 years, global cortical atrophy stages, fazekas stages, 
nonlacunar cortical infarct stages, chronic lacunes >=2, intracranial stenosis. 
“Data on demographic factors and vascular risk factors were collected from 
admission records. MR images were reviewed independently by a neurologist 
and a neuroradiologist. Acute infarcts were quantified based on the number 
and location of lacunar and non-lacunar infarcts. T2 sequences were used to 
quantify white matter hyperintensity (WMH) using the Fazekas scale. Chronic 
lacunes were quantified by number and location. Gradient-echo sequences 
were used to rate microhemorrhages using the Microbleeds Anatomical Rating 
Scale. MRA images were rated for presence and severity of intracranial large 
vessel stenosis. T1 sequences were also assessed for global cortical atrophy 
(GCA). Any differences in ratings between raters were resolved by 
consensus.” 
 Dev Val 
2.10 Were predictors defined and assessed in a similar way for all 
participants? 
Y  
2.11 Were predictor assessments made without knowledge of 
outcome data?  
NI  
2.12 Are all predictors available at the time the model is 
intended to be used? 
Y  






Rationale of bias rating: 
It is unclear from this paper whether raters had knowledge of outcome data, 
however subsequent publication suggests that they were blinded. Also having 
two independent, well-qualified raters reduces risk of bias for assessing 
imaging variables, particularly as recognised and validated tools were applied. 
B. Applicability 
Concern that the definition, assessment or 
timing of predictors in the model do not match 





Rationale of applicability rating: 
There are potential issues with access to MRI, trained specialists using the 
assessment tools and subjectivity in rating MR images. However, everything 
matches review question and the setting for use was not specifically defined, 
e.g. these methods would still be highly applicable to research settings. 
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DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time 
interval between predictor assessment and outcome determination: 
“During outpatient care, patients were assessed for progression of risk factors 
and for cognitive status using the Mini-Mental State Exam (MMSE). Where 
clinically indicated or further confirmation of cognitive status was required, 
the Montreal Cognitive Assessment (MoCA) was carried out as well. 
Subjects in the development dataset were classified as PSCI if there were any 
cognitive symptoms during the clinical visit, and scored either MMSE ≤25 or 
MoCA ≤22, following validated local cutoffs. PSCI patients did not meet 
criteria for dementia. Patients who did not meet criteria for PSCI or dementia 
were categorized as “No Cognitive Impairment (NCI)”.” 
 Dev Val 
3.19 Was the outcome determined appropriately? PY  
3.20 Was a pre-specified or standard outcome definition used? PY  
3.21 Were predictors excluded from the outcome definition? NI  
3.22 Was the outcome defined and determined in a similar way 
for all participants? 
N  
3.23 Was the outcome determined without knowledge of 
predictor information? 
NI  
3.24 Was the time interval between predictor assessment and 
outcome determination appropriate? 
Y  
Risk of bias introduced by the outcome or 





Rationale of bias rating: 
The statement “if there were any cognitive symptoms during the clinical visit” 
does not allow to determine how these symptoms were assessed and what was 
considered sufficient to provide evidence of PSCI, there is no information 
regarding whether the outcome was determined without knowledge of 
predictors, however information from the subsequent paper suggests that 
predictors could have even actually considered in the process; some 
participants additionally completed the MoCA (a more sensitive measure) with 
selection criteria remaining unclear. Also, there was relatively big variability 
in the interval from index stroke to follow-up. 
B. Applicability 
At what time point was the outcome determined:  
3 to 6 months post-stroke 
 
If a composite outcome was used, describe the relative 
frequency/distribution of each contributing outcome:  
N/A 
Concern that the outcome, its definition, 






Rationale of applicability rating: 
Despite the relatively big variability in assessment timing, all aspects of the 
outcome match the review question. 
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DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors, outcome 
events and events per candidate predictor: 
209 participants, 43 candidate predictors, 78 outcome events, EPV = 1.8 
Describe how the model was developed (for example in regards to modelling 
technique (e.g. survival or logistic modelling), predictor selection, and risk 
group definition): 
“Potential variables for the predictive model were identified by comparing 
PSCI and NCI patients and tested for significance using independent sample 
ttest or Wilcoxon-Mann-Whitney test for continuous data, and χ2 test or 
Fisher’s Exact test for categorical data. Statistically significant continuous 
variables were converted into categorical variables based on clinical cutoffs 
and retested using χ2 test or Fisher’s Exact test. All variables significant at 
univariate level were put into multivariate logistic regression models as 
predictor variables, with PSCI status as the outcome variable. A point system 
was developed based on the beta coefficients from the final model.” 
Describe whether and how the model was validated, either internally (e.g. 
bootstrapping, cross validation, random split sample) or externally (e.g. 
temporal validation, geographical validation, different setting, different 
type of participants): 
Apparent and temporal with stability assessed using 10-fold cross-validation 
Describe the performance measures of the model, e.g. (re)calibration, 
discrimination, (re)classification, net benefit, and whether they were 
adjusted for optimism: 
Discrimination, calibration, and classification measures 
Describe any participants who were excluded from the analysis: 
“We excluded 34 patients (six presented outside of 3 to 6 months and 28 had 
incomplete clinical or investigative data).” 
Describe missing data on predictors and outcomes as well as methods used for 
missing data: 
Participants with missing data were excluded from the analysis. 
 Dev Val 
4.28 Were there a reasonable number of participants with the 
outcome? 
N  
4.29 Were continuous and categorical predictors handled 
appropriately? 
NI  
4.30 Were all enrolled participants included in the analysis? N  
4.31 Were participants with missing data handled appropriately? N  
4.32 Was selection of predictors based on univariable analysis 
avoided?  
N  
4.33 Were complexities in the data (e.g. censoring, competing 
risks, sampling of controls) accounted for appropriately? 
PN  
4.34 Were relevant model performance measures evaluated 
appropriately? 
Y  
4.35 Were model overfitting and optimism in model 
performance accounted for? 
Y  
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4.36 Do predictors and their assigned weights in the final model 
correspond to the results from multivariable analysis?  
N  




Rationale of bias rating: 
Too few participants relative to number of candidate predictors, continuous 
predictors apparently categorised based on clinical cut-offs, but no references 
provided, also unclear whether cut-offs were specified prior to analysis, 
predictors selected based on univariable analysis, participants with missing 
data excluded from analysis, based on how scores were assigned to age, 
education <6 should have been assigned 4 points. 
 
Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and 
concerns regarding applicability of the prediction model evaluation 
(development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model 
evaluation 
Low risk of 
bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external 
validation, and it was rated as low risk of bias for all 
domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the 
development was based on a very large data set and included 
some form of internal validation. 
High risk of 
bias  
If at least one domain is judged to be at high risk of bias.  
Unclear risk 
of bias 
If an unclear risk of bias was noted in at least one domain and 
it was low risk for all other domains.  
 





If low concerns regarding applicability for all domains, 
the prediction model evaluation is judged to have low 




If high concerns regarding applicability for at least one 
domain, the prediction model evaluation is judged to 




If unclear concerns (but no “high concern”) regarding 
applicability for at least one domain, the prediction 
model evaluation is judged to have unclear concerns 




Overall judgement about risk of bias and applicability of the prediction 
model evaluation 




Summary of sources of potential bias: 
Unrepresentative study sample with participants with no post-stroke 
dependency or depression, yet deemed likely to experience PSCI without clear 
indication of how this was decided, outcome assessed with use of MoCA for 
some participants but not for others’ and most likely with knowledge of 
predictor information, issues with analysis from sample size, to selection of 
predictors, dealing with missing data, to scoring system. 




Summary of applicability concerns: 
Due to selection criteria, it is likely that there will be issues with model 
generalisability, however the study population nonetheless matches the 
review question. 
 
Lin et al., 2003 
Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, 
model validation or model update, or combination. Different signalling 
questions apply for different types of prediction model evaluation. If the 
evaluation does not fit one of these classifications then PROBAST should not be 
used. 
 









Definition for type of 
prediction model study 
Development 
only 
Development ✓ Prediction model 
development without external 
validation. These studies may 
include internal validation 







X Prediction model 
development combined with 
external validation in other 




Validation X External validation of existing 
(previously developed) model 
in other participants. 
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This table should be completed once for each publication being assessed and 
for each relevant outcome in your review. 
Publication 
reference 
Lin, L.-H. et al. Prediction of post-stroke dementia. 2003 
Models of 
interest 







Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of 
bias (low, high or unclear) and includes signalling questions to help make 
judgements. Signalling questions are rated as yes (Y), probably yes (PY), 
probably no (PN), no (N) or no information (NI). All signalling questions are 
phrased so that “yes” indicates absence of bias. Any signalling question rated 
as “no” or “probably no” flags the potential for bias; you will need to use your 
judgement to determine whether the domain should be rated as “high”, “low” 
or “unclear” risk of bias. The guidance document contains further instructions 
and examples on rating signalling questions and risk of bias for each domain. 
The first three domains are also rated for concerns regarding applicability 
(low/ high/ unclear) to your review question defined above.  
Complete all domains separately for each evaluation of a distinct model. 
Shaded boxes indicate where signalling questions do not apply and should not 
be answered. 
 
DOMAIN 1:  Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
Prospective cohort. 
“All of the participants were recruited from patients with acute ischemic 
stroke admitted consecutively to the neurology department from November 1, 
1995, to October 31, 1999. Stroke was defined as a rapidly developing clinical 
manifestation of a focal loss of cerebral function lasting >24 hours. Diagnosis 
was made by neurologists based on clinical symptoms and confirmed by the 
findings of neuroimaging studies. Patients with prior cerebrovascular events 
were also included, whereas those with TIA were excluded. Additional 
exclusions were those associated with other primary brain lesions (e.g., 
trauma, tumor, and Parkinson’s disease) or severe medical comorbidity (e.g., 
terminal cancer). To investigate the clinical determinants of new-onset 
dementia 3 months after stroke onset, we also excluded patients with 
Alzheimer’s disease and possible dementia resulting from other nonvascular 
etiologies.” 
 Dev Val 
1.9 Were appropriate data sources used, e.g. cohort, RCT or nested 
case-control study data? 
Y  
1.10 Were all inclusions and exclusions of participants 
appropriate? 
Y  








Rationale of bias rating: 
Exclusion criteria seem appropriate as future cognitive outcomes are less of a 
priority where patients condition may be terminal and are less likely to be 
assessed in a real-world healthcare setting, cognitive impairment due to other 
neurological conditions would confound results, and inclusion of patients with 
dementia may have led to overoptimistic model estimations. 
B. Applicability 
Describe included participants, setting and dates:  
“Kaohsiung Medical University Hospital is one of the largest medical centers in 
southern Taiwan, with 23 medical departments and 1,251 beds. It serves the 
citizens of Kaohsiung City (approximately 1.5 million) as well as people 
throughout southern Taiwan. Most stroke patients are admitted through the 
emergency department and then referred to departments such as internal 
medicine, neurology, or neurosurgery wards for subsequent care. 
All of the participants were recruited from patients with acute ischemic 
stroke admitted consecutively to the neurology department from November 1, 
1995, to October 31, 1999.” 
Concern that the included participants and 





Rationale of applicability rating: 
Participants and setting match the review question and the study sample 
seems representative of stroke population of interest, although applicability 
may be affected by cultural, geographical and healthcare settings and 
recruitment time (started 25 years ago). 
 
DOMAIN 2:  Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and 
timing of assessment: 
Age of 65 years or older, previous occupation as a labourer, prior stroke, left 
carotid vascular territory, moderate to severe stroke severity, cognitive 
impairment, poorer functional status at admission.  
“A structured medical history was obtained, and neurologic, functional, 
cognitive, and neuroimaging examinations were performed within 7 to 10 days 
of hospitalization. Stroke severity was assessed with the NIH Stroke Scale 
(NIHSS) administered by the same specially trained nurse. A culturally 
adapted version of the Mini-Mental State Examination (MMSE) to assess 
present cognitive status was performed by a specially trained psychologist. 
Functional status was assessed based on the ability of subjects to perform the 
motor items of the Functional Independence Measure (FIM) instrument by two 
senior physical therapists trained in using this instrument. The neurologists 
and neuroradiologists recorded the MRI findings according to the methods of 
our previous study for the infarct location (cortical or subcortical area), 
vascular lesion territory (left or right carotid or vertebrobasilar artery), single 
or multiple vascular lesion, and stroke mechanism (lacunar, thrombotic, and 
embolic). Major medical data, prior stroke, previous cardiovascular diseases 
(e.g., hypertension, diabetes, heart diseases, and hypercholesterolemia), and 
medical complications were collected from medical records within 1 month 
after discharge.” 
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 Dev Val 
2.13 Were predictors defined and assessed in a similar way for all 
participants? 
Y  
2.14 Were predictor assessments made without knowledge of 
outcome data?  
Y  
2.15 Are all predictors available at the time the model is 
intended to be used? 
PY  






Rationale of bias rating: 
Data on predictors collected by qualified examiners using recognised and 
validated tools prior to outcome assessment. 
B. Applicability 
Concern that the definition, assessment or 
timing of predictors in the model do not match 





Rationale of applicability rating: 
All aspects related to predictors match the review question, chosen 
assessment tools are widely accessible and used. 
 
DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time 
interval between predictor assessment and outcome determination: 
 
“All patients who had survived at 3 months after the stroke were scheduled to 
undergo follow-up. A version of the neuropsychological test battery adapted 
for use in the Taiwanese population was administered by psychologists along 
with the Hamilton Depression Rating Scale (HDRS) as a screen for significant 
mood disorder and the severity rating of current depression. This battery 
included the following measures: MMSE orientation items; verbal memory (the 
Selective Reminding Test); language ability including naming (selected items 
from the Boston Naming Test), verbal fluency (letter and category fluency 
subtest of the Boston Diagnostic Aphasia Examination [BDAE]), comprehension 
(the complex ideation subtest of the BDAE), and repetition (selected items 
from the repetition subtest of the BDAE); visuospatial ability (items selected 
from the Rosen Drawing Test and the matching task of the Benton Visual 
Retention Test); abstractive reasoning (the similarities subtest of the 
Wechsler Adult Intelligence Scale–Revised and the nonverbal identities and 
oddities subtest of the Mattis Dementia Rating Scale); and attention function 
(cancellation tasks using shapes and letters as targets). Senior neurologists 
collected detailed clinical data, performed the neurobehavioral examinations, 
and scored the Hachinski Ischemia Scale and the Clinical Dementia Rating 
Scale (CDR). Furthermore, the NIHSS and the FIM motor scale were 
reassessed.” 
“Clinical diagnosis of dementia of various types or other mental disorders was 
made by senior neurologists and psychologists based on the findings of 
detailed clinical and cognitive evaluations of the patients. Diagnosis of 
dementia made 3 months after the stroke was based on the Neurologic 
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Adaptation of the 10th edition of the International Classification of Disease 
(ICD-10NA) criteria, which require impairment in memory and at least two 
other cognitive domains and which should be severe enough to affect 
activities of daily living. VaD was defined as new onset of dementia after 
stroke using the criteria of the National Institute of Neurologic Disorders and 
Stroke/Association internationale pour la recherche et l’enseignement en 
neurosciences. AD was diagnosed according to the criteria of the National 
Institute of Neurologic and Communicative Disorders and Stroke/Alzheimer’s 
Disease and Related Disorders Association. Other subtypes of dementia were 
diagnosed based on the CERAD dementia assessment package. All available 
data were reviewed at a consensus conference to establish a diagnosis. The 
interrater reliability between two behavioral neurologists involved in the 
collection and assessment of diagnostic data on neurologic and cognitive 
function was high.” 
 Dev Val 
3.25 Was the outcome determined appropriately? Y  
3.26 Was a pre-specified or standard outcome definition used? Y  
3.27 Were predictors excluded from the outcome definition? PN  
3.28 Was the outcome defined and determined in a similar way 
for all participants? 
Y  
3.29 Was the outcome determined without knowledge of 
predictor information? 
PN  
3.30 Was the time interval between predictor assessment and 
outcome determination appropriate? 
Y  
Risk of bias introduced by the outcome or 





Rationale of bias rating: 
Outcome seems to have been determined appropriately in terms of tools and 
criteria used, as well as level of examiner expertise, however a consensus 
meeting and taking into account “all available data”, indicates that predictors 
were considered when making the diagnosis, which introduces risk of 
overestimating the strength of association between predictors and outcome. 
B. Applicability 
At what time point was the outcome determined:  
3 months post-stroke 
 
If a composite outcome was used, describe the relative 
frequency/distribution of each contributing outcome:  
N/A 
Concern that the outcome, its definition, 






Rationale of applicability rating: 
All aspect of the outcome match the review question. 
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DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors, outcome 
events and events per candidate predictor: 
283 participants, 28 candidate predictors, 26 outcome events, EPV = 0.93 
Describe how the model was developed (for example in regards to modelling 
technique (e.g. survival or logistic modelling), predictor selection, and risk 
group definition): 
“Patients were divided into two groups according to the diagnosis of 
dementia. The sociodemographic and clinical data at baseline and 3 months 
after stroke were compared between these two groups. Education was 
dichotomized into low (<=6 years) and high (>6 years). Economic status was 
grouped into low (housewife, unskilled, semiskilled, and skilled trade or craft) 
and high (clerical/office worker, manager business/government, and 
professional/technical) social class levels. Previous primary occupation was 
classified into manual labor and nonmanual labor categories. The severity of 
stroke was classified as mild (NIHSS 0 to 7) and moderate to severe (NIHSS > 
7). Based on our previous study using MMSE to identify subjects with cognitive 
impairment, different cutoff points for three educational levels were used: 
<16 for illiterate, <21 for grade school literate, and <24 for junior high school 
and higher education literate. The functional status by FIM motor score at 
admission was divided into poor to middle (score 13 to 47) and high (score 48 
to 91) score categories. Univariate statistical analysis (chi2 test or Fisher’s 
exact test as appropriate) was carried out to examine the associations 
between the demographic and clinical factors of stroke patients and the 
development of PSD. The factors identified as significant by univariate 
analysis were then applied as prospective predictors to construct a model for 
predicting the likelihood of PSD. Stepwise logistic regression was employed to 
construct a predictive model. Colinearity among potential predictors was 
evaluated using the Spearman rank correlation. Variables with moderate to 
high intercorrelations (Spearman rank correlation coefficient rs >=0.50 or rs 
<=-0.50) were regarded as colinear and consequently not entered together in 
the same regression analysis. All possible combinations were examined to find 
the best model. The final model was selected based on goodness of fit.” 
Describe whether and how the model was validated, either internally (e.g. 
bootstrapping, cross validation, random split sample) or externally (e.g. 
temporal validation, geographical validation, different setting, different 
type of participants):  
Apparent validation only 
Describe the performance measures of the model, e.g. (re)calibration, 
discrimination, (re)classification, net benefit, and whether they were 
adjusted for optimism:  
Classification measure only. 
Describe any participants who were excluded from the analysis: 
69 patients were not interviewed (including 46 who had moved or lost contact 
or refused follow-up, 10 who had incomplete data collection, 8 who had died 
prior to the follow-up at 3 months, and 5 who lived in long-term care 
institutions). Patients who were not examined 3 months after stroke had 
scores showing significantly more impairment than patients who were 
examined on the NIHSS and the FIM motor score administered within 7 to 10 
days of hospitalization. 
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Describe missing data on predictors and outcomes as well as methods used for 
missing data: 
Participants with missing data were excluded from analysis. 
 Dev Val 
4.37 Were there a reasonable number of participants with the 
outcome? 
N  
4.38 Were continuous and categorical predictors handled 
appropriately? 
PN  
4.39 Were all enrolled participants included in the analysis? N  
4.40 Were participants with missing data handled appropriately? N  
4.41 Was selection of predictors based on univariable analysis 
avoided?  
N  
4.42 Were complexities in the data (e.g. censoring, competing 
risks, sampling of controls) accounted for appropriately? 
N  
4.43 Were relevant model performance measures evaluated 
appropriately? 
N  
4.44 Were model overfitting and optimism in model 
performance accounted for? 
N  
4.45 Do predictors and their assigned weights in the final model 
correspond to the results from multivariable analysis?  
Y  




Rationale of bias rating: 
Too few participants relative to candidate predictors, continuous predictors 
were dichotomised with atypical choice of cut-off for NIHSS (usually moderate 
stroke from 5 points onwards), predictors selected based on univariable 
associations, participants with missing data and no follow-up excluded from 
the analysis, but shown to have more severe strokes than included patients, 
no measures of discrimination or calibration, only apparent validation. 
 
Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and 
concerns regarding applicability of the prediction model evaluation 
(development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model 
evaluation 
Low risk of 
bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external 
validation, and it was rated as low risk of bias for all 
domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the 
development was based on a very large data set and included 
some form of internal validation. 
High risk of 
bias  




If an unclear risk of bias was noted in at least one domain and 
it was low risk for all other domains.  
 





If low concerns regarding applicability for all domains, 
the prediction model evaluation is judged to have low 




If high concerns regarding applicability for at least one 
domain, the prediction model evaluation is judged to 




If unclear concerns (but no “high concern”) regarding 
applicability for at least one domain, the prediction 
model evaluation is judged to have unclear concerns 
regarding applicability overall. 
 
 
Overall judgement about risk of bias and applicability of the prediction 
model evaluation 




Summary of sources of potential bias: 
Diagnosis of outcome most likely involving knowledge of predictors, multiple 
issues with analysis from sample size, through predictor categorisation and 
selection, dealing with missing data, to performance estimation and lack of 
appropriate model validation. 




Summary of applicability concerns: 
Participants, predictors and outcome all match review question and 




Munsch et al., 2016 
Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, 
model validation or model update, or combination. Different signalling 
questions apply for different types of prediction model evaluation. If the 
evaluation does not fit one of these classifications then PROBAST should not be 
used. 
 









Definition for type of 
prediction model study 
Development 
only 
Development ✓ Prediction model 
development without external 
validation. These studies may 
include internal validation 







X Prediction model 
development combined with 
external validation in other 




Validation X External validation of existing 
(previously developed) model 
in other participants. 
 
This table should be completed once for each publication being assessed and 
for each relevant outcome in your review. 
Publication 
reference 
Munsch, F. Stroke location is an independent predictor 
of cognitive outcome. 2016 
Models of 
interest 




Good post-stroke cognitive outcome 
 
 
Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of 
bias (low, high or unclear) and includes signalling questions to help make 
judgements. Signalling questions are rated as yes (Y), probably yes (PY), 
probably no (PN), no (N) or no information (NI). All signalling questions are 
phrased so that “yes” indicates absence of bias. Any signalling question rated 
as “no” or “probably no” flags the potential for bias; you will need to use your 
judgement to determine whether the domain should be rated as “high”, “low” 
or “unclear” risk of bias. The guidance document contains further instructions 
and examples on rating signalling questions and risk of bias for each domain. 
The first three domains are also rated for concerns regarding applicability 
(low/ high/ unclear) to your review question defined above.  
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Complete all domains separately for each evaluation of a distinct model. 
Shaded boxes indicate where signalling questions do not apply and should not 
be answered. 
 
DOMAIN 1:  Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
Prospective cohort; 
“Primary inclusion criteria were men and women, older than 18 years old, 
with a clinical diagnosis of minor-to-severe supratentorial cerebral infarct 
(NIHSS between 1 and 25) between 24 and 72 hours after the onset. Exclusion 
criteria were history of symptomatic cerebral infarct with functional deficit 
(prestroke modified Rankin Scale [mRS] score ≥1), infratentorial stroke, 
history of severe cognitive impairment (dementia), or psychiatric troubles 
matching to axis 1 of the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth edition (DSM-4) criteria except for major depression, coma, 
pregnant or breast-feeding women, and contraindications to MRI.” 
 Dev Val 
1.11 Were appropriate data sources used, e.g. cohort, RCT or 
nested case-control study data? 
Y  
1.12 Were all inclusions and exclusions of participants 
appropriate? 
Y  







Rationale of bias rating: 
inclusion of patients with dementia may have led to overoptimistic model 
estimations, as the study also aimed to predict functional outcome, inclusion 
of participants with previous functional disability due to stroke may have 
caused a similar issue, other exclusion criteria based on practical 
considerations, unclear why stroke severity was limited to a score of 25 – this 
may be just the max in the sample, however, this is unlikely to introduce high 
risk of bias, as very severe stroke are relatively uncommon now and in such 
cases prediction of longer-term cognitive outcome is not a high priority. 
B. Applicability 
Describe included participants, setting and dates:  
Most likely conducted in France, 428 consecutive patients presenting a 
suspected supratentorial ischemic stroke from June 2012 to February 2015. 
Concern that the included participants and 





Rationale of applicability rating: 
Information regarding study setting is limited, however review question is 
very broad so it is unlikely that it would not match. 
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DOMAIN 2:  Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and 
timing of assessment: 
NIHSS (continuous variable), Age (continuous variable), Lesion volume 
(continuous in cm3), Log of stroke location (continuous in voxels). 
At baseline, the NIHSS was recorded between 24 and 72 hours after stroke 
onset, at the time of the MRI scan. 
“We used the VLSM method implemented in the nonparametric mapping 
toolbox included in the MRIcron software package (MRIcron, Verion 6.6.2013). 
This method establishes a relationship between the presence or lack of a 
lesion and a behavioral score on a voxel-by-voxel basis. For each voxel, a 
Brunner–Munzel rank order test was performed to determine whether the 
behavioral score is significantly different between the lesioned and 
nonlesioned group. We built maps of functional and cognitive eloquent regions 
using, respectively, mRS and MoCA measured at 3 months as behavioral 
scores. A subanalysis was conducted on a short MoCA (sMOCA) in which the 
items naming and language have been removed. The resulting Z score maps 
were controlled for multiple comparisons using the false discovery rate 
correction to ensure a false-positive rate of P<0.05. The eloquent regions 
were identified using the Automated Anatomic Labeling, Brodmann, and JHU-
WhiteMatterlabels-1mm atlases available in the MRIcron software package. 
The objective was to use the VLSM maps, which showed the eloquent areas in 
terms of mRS and MoCA scores, to predict, respectively, the functional and 
cognitive outcomes at 3 months for a new stroke patient. For that purpose, 
we overlapped the patient’s lesion binary mask on each VLSM map. Then, we 
extracted all significant Z scores (corresponding to eloquent voxels that 
survived a 5% false discovery rate cutoff threshold) contained in the lesion, 
using a home-made program developed in Matlab (Mathworks Natick, 
Massachusetts). Finally, using the R software package (Version 3.0.1), we 
calculated the number of eloquent voxels. This quantitative variable contains 
the information of location and will be referred to as stroke location in the 
following sections.” 
 Dev Val 
2.16 Were predictors defined and assessed in a similar way for all 
participants? 
Y  
2.17 Were predictor assessments made without knowledge of 
outcome data?  
N  
2.18 Are all predictors available at the time the model is 
intended to be used? 
N  






Rationale of bias rating: 
Voxels were identified based on outcome data from the same participants 
who were involved in developing the prognostic model and on whom the 
model’s performance was assessed – high risk of overestimating the strength 
of association between predictors and outcome. 
B. Applicability 
Concern that the definition, assessment or 
timing of predictors in the model do not match 






Rationale of applicability rating: 
To estimate stroke location using this method required use of outcome data, 
the review question specified that information on predictors should be 
collected prior to the occurrence of the outcome; it is unclear how an 
independent researcher/clinician could apply the method of voxel estimation 
themselves – the method does not appear easily accessible in the setting it 
would potentially be applied in. 
 
DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time 
interval between predictor assessment and outcome determination: 
At 3-month follow-up, all patients underwent a standardized battery of 
clinical testing including, among others, … the Montreal Cognitive Assessment 
(MoCA) to assess cognitive deficits.  
A favorable cognitive outcome was defined as a MoCA score >25. 
 Dev Val 
3.31 Was the outcome determined appropriately? Y  
3.32 Was a pre-specified or standard outcome definition used? Y  
3.33 Were predictors excluded from the outcome definition? Y  
3.34 Was the outcome defined and determined in a similar way 
for all participants? 
PY  
3.35 Was the outcome determined without knowledge of 
predictor information? 
NI  
3.36 Was the time interval between predictor assessment and 
outcome determination appropriate? 
Y  
Risk of bias introduced by the outcome or 





Rationale of bias rating: 
It is unclear whether examiners were blinded to predictor information and 
test scores may be to a certain extent influenced by examiner behaviour, yet 
given the binary nature of the outcome, this would likely only affect 
participants with actual scores near the cut off. It is also unclear who carried 
out the assessment, however administering the MoCA does not require 
extensive and/or specialist training.  
B. Applicability 
At what time point was the outcome determined:  
3 months post-stroke  
If a composite outcome was used, describe the relative 
frequency/distribution of each contributing outcome:  
 
N/A 
Concern that the outcome, its definition, 






Rationale of applicability rating: 
All aspects of the outcome match the review question. 
272 
DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors, outcome 
events and events per candidate predictor: 
198 participants, 4 candidate predictors, 77 outcome events, EPV = 19.3 
Describe how the model was developed (for example in regards to modelling 
technique (e.g. survival or logistic modelling), predictor selection, and risk 
group definition): 
Logistic regression, predictors specified before analysis with 2 candidate 
models later compared against one another in terms of discrimination, all 
predictors were left continuous 
Describe whether and how the model was validated, either internally (e.g. 
bootstrapping, cross validation, random split sample) or externally (e.g. 
temporal validation, geographical validation, different setting, different 
type of participants): 
Internal model validation using 10 fold-cross validation and sample splitting 
based on recruitment period. 
Describe the performance measures of the model, e.g. (re)calibration, 
discrimination, (re)classification, net benefit, and whether they were 
adjusted for optimism: 
Discrimination 
Describe any participants who were excluded from the analysis: 
28 excluded due to missing MRI sequences, 23 due to images with insufficient 
quality, 26 lost to follow-up, 13 died, 10 with missing outcome data 
Describe missing data on predictors and outcomes as well as methods used for 
missing data: 
Participants with missing data were excluded from the analysis. 
 Dev Val 
4.46 Were there a reasonable number of participants with the 
outcome? 
PY  
4.47 Were continuous and categorical predictors handled 
appropriately? 
Y  
4.48 Were all enrolled participants included in the analysis? N  
4.49 Were participants with missing data handled appropriately? N  
4.50 Was selection of predictors based on univariable analysis 
avoided?  
Y  
4.51 Were complexities in the data (e.g. censoring, competing 
risks, sampling of controls) accounted for appropriately? 
N  
4.52 Were relevant model performance measures evaluated 
appropriately? 
N  
4.53 Were model overfitting and optimism in model 
performance accounted for? 
Y  
4.54 Do predictors and their assigned weights in the final model 
correspond to the results from multivariable analysis?  
Y  






Rationale of bias rating: 
Data of less than half the enrolled participants (428) were use for model 
development, among other reasons, with some participants assigned to a 
validation set, and participants with missing data or lost to follow-up being 
excluded from the analysis; also no assessment of calibration.  
 
Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and 
concerns regarding applicability of the prediction model evaluation 
(development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model 
evaluation 
Low risk of 
bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external 
validation, and it was rated as low risk of bias for all 
domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the 
development was based on a very large data set and included 
some form of internal validation. 
High risk of 
bias  
If at least one domain is judged to be at high risk of bias.  
Unclear risk 
of bias 
If an unclear risk of bias was noted in at least one domain and 
it was low risk for all other domains.  
 





If low concerns regarding applicability for all domains, 
the prediction model evaluation is judged to have low 




If high concerns regarding applicability for at least one 
domain, the prediction model evaluation is judged to 




If unclear concerns (but no “high concern”) regarding 
applicability for at least one domain, the prediction 
model evaluation is judged to have unclear concerns 
regarding applicability overall. 
 
 
Overall judgement about risk of bias and applicability of the prediction 
model evaluation 




Summary of sources of potential bias: 
Issues relating to one of the main predictors of interest being determined 
based on outcome data and exclusion of participants from the analysis due to 
missing data and loss to follow-up, model calibration was not assessed. 





Summary of applicability concerns: 
Review question specified that information on predictors ought to be known 
prior to outcome occurrence, also the method for estimating stroke location 
would not be accessible in a clinical setting and would likely even be 
challenging to apply in a research setting. 
 
Salihovic et al., 2018 
Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, 
model validation or model update, or combination. Different signalling 
questions apply for different types of prediction model evaluation. If the 
evaluation does not fit one of these classifications then PROBAST should not be 
used. 
 









Definition for type of 
prediction model study 
Development 
only 
Development ✓ Prediction model 
development without external 
validation. These studies may 
include internal validation 







X Prediction model 
development combined with 
external validation in other 




Validation X External validation of existing 
(previously developed) model 
in other participants. 
 
This table should be completed once for each publication being assessed and 
for each relevant outcome in your review. 
Publication 
reference 




Decision tree based on cognitive performance  
Outcome of 
interest 
Dementia/ vascular cognitive syndromes 
 
Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of 
bias (low, high or unclear) and includes signalling questions to help make 
judgements. Signalling questions are rated as yes (Y), probably yes (PY), 
probably no (PN), no (N) or no information (NI). All signalling questions are 
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phrased so that “yes” indicates absence of bias. Any signalling question rated 
as “no” or “probably no” flags the potential for bias; you will need to use your 
judgement to determine whether the domain should be rated as “high”, “low” 
or “unclear” risk of bias. The guidance document contains further instructions 
and examples on rating signalling questions and risk of bias for each domain. 
The first three domains are also rated for concerns regarding applicability 
(low/ high/ unclear) to your review question defined above.  
Complete all domains separately for each evaluation of a distinct model. 
Shaded boxes indicate where signalling questions do not apply and should not 
be answered. 
 
DOMAIN 1:  Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
“The study was prospective and included 275 patients with acute stroke 
(ischemic and hemorrhagic), both sexes and all age groups, who were 
hospitalized at the Department of Neurology, University Clinical Center Tuzla 
(from September 1, 2011, to August 31, 2012.). Excluding criteria were 
subarachnoid hemorrhage, recurrent stroke, or mortality in the first 3 months 
after the patient was included in the study, existence of cognitive impairment 
before the beginning of the study (based on medical records). Also, study did 
not include patients whose bad general somatic state enabled quality testing, 
as well as patients with aphasia who could not do all tests.” 
 Dev Val 
1.13 Were appropriate data sources used, e.g. cohort, RCT or 
nested case-control study data? 
Y  
1.14 Were all inclusions and exclusions of participants 
appropriate? 
Y  







Rationale of bias rating: 
Inclusion of patients with cognitive impairment may lead to overoptimistic 
model estimations; recurrent stroke is likely to affect outcome, yet difficult 
to account for if using baseline predictors; other exclusion criteria based on 
practical considerations; main concern relates to excluding patients who died 
within the first 3 months, yet this will be addressed in the analysis domain 
B. Applicability 
Describe included participants, setting and dates:  
Patients with acute stroke, hospitalized at the Department of Neurology, 
University Clinical Center Tuzla (September 1, 2011 to August 31, 2012) 
Concern that the included participants and 





Rationale of applicability rating: 
Participants and setting match review question 
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DOMAIN 2:  Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and 
timing of assessment: 
“Patients were tested in three occasions; first testing was after 3 months, 
second testing after 6 months, and third after 12 months of stroke. For the 
evaluation of cognitive functions, the following measure scales were used: 
Mini-Mental Status Examination MMSE, Montreal Cognitive Assessment, 
Wechsler’s Intelligence Scale WB-II, Wechsler’s scale of memory, Rey-
Osterrieth complex figure test—RCFT” 
 Dev Val 
2.19 Were predictors defined and assessed in a similar way for all 
participants? 
PY  
2.20 Were predictor assessments made without knowledge of 
outcome data?  
PY  
2.21 Are all predictors available at the time the model is 
intended to be used? 
Y  






Rationale of bias rating: 
Unclear description, however seems that standard tests were used for 
assessment of cognitive performance (predictors), and with a prospective 
study design it can be assumed that predictors were estimated prior to the 
outcome (and therefore without knowledge of if). 
B. Applicability 
Concern that the definition, assessment or 
timing of predictors in the model do not match 





Rationale of applicability rating: 
Unclear description, yet review question is very broad and there is no 
indication that chosen predictors do not match it 
 
DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time 
interval between predictor assessment and outcome determination: 
Patients were divided into following groups: dementia of strategic infarct 
(DSI), cortical dementia (CD), sub cortical dementia (SCD), hemorrhagic 
dementia (HD), and patients without dementia. The VCI diagnosis was based 
on diagnostic criteria (DSM-4 and ICD-10), clinical exams, and 
neuropsychological testing. 
 Dev Val 
3.37 Was the outcome determined appropriately? Y  
3.38 Was a pre-specified or standard outcome definition used? NI  
3.39 Were predictors excluded from the outcome definition? PN  
3.40 Was the outcome defined and determined in a similar way 
for all participants? 
PY  
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3.41 Was the outcome determined without knowledge of 
predictor information? 
PN  
3.42 Was the time interval between predictor assessment and 
outcome determination appropriate? 
NI  
Risk of bias introduced by the outcome or 





Rationale of bias rating: 
Given criteria for VCI, it seems that performance on cognitive tests would 
have been taken into account to make a diagnosis of dementia. 
B. Applicability 
At what time point was the outcome determined:  
12 months post-stroke 
 
If a composite outcome was used, describe the relative 
frequency/distribution of each contributing outcome:  
N/A 
Concern that the outcome, its definition, 






Rationale of applicability rating: 
Outcome definition, timing and assessment match review question. 
 
DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors, outcome 
events and events per candidate predictor: 
275 participants, unclear number of candidate predictors (min. 3), 85 
participants in smaller outcome group, EPV unknown. 
 
Describe how the model was developed (for example in regards to modelling 
technique (e.g. survival or logistic modelling), predictor selection, and risk 
group definition): 
A CHAID algorithm analysis was used to develop the decision tree models. 
CHAID decision trees are nonparametric procedures that make no assumptions 
of the underlying data. This algorithm determines how continuous and/or 
categorical independent variables best combine to predict a binary outcome 
based on “if-then” logic by portioning each independent variable into 
mutually exclusive subsets based on homogeneity of the data. 
Describe whether and how the model was validated, either internally (e.g. 
bootstrapping, cross validation, random split sample) or externally (e.g. 
temporal validation, geographical validation, different setting, different 
type of participants): 
No report on validation. 
Describe the performance measures of the model, e.g. (re)calibration, 
discrimination, (re)classification, net benefit, and whether they were 
adjusted for optimism: 
No performance measures reported 
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Describe any participants who were excluded from the analysis: 
Patients were excluded if they died during the first 3 months after stroke. 
Describe missing data on predictors and outcomes as well as methods used 
for missing data: 
No mention of missing data. 
 Dev Val 
4.55 Were there a reasonable number of participants with the 
outcome? 
PN  
4.56 Were continuous and categorical predictors handled 
appropriately? 
NI  
4.57 Were all enrolled participants included in the analysis? N  
4.58 Were participants with missing data handled appropriately? N  
4.59 Was selection of predictors based on univariable analysis 
avoided?  
PY  
4.60 Were complexities in the data (e.g. censoring, competing 
risks, sampling of controls) accounted for appropriately? 
N  
4.61 Were relevant model performance measures evaluated 
appropriately? 
N  
4.62 Were model overfitting and optimism in model 
performance accounted for? 
N  
4.63 Do predictors and their assigned weights in the final model 
correspond to the results from multivariable analysis?  
N/A  




Rationale of bias rating: 
CHAID analysis requires high sample size, because of the data splitting it 
entails; participants who died within 3 months of index stroke were excluded; 
no mention of how missing data were handled; CHAID is considered an 
exploratory method; no mention of any form of validation. 
 
Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and 
concerns regarding applicability of the prediction model evaluation 
(development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model 
evaluation 
Low risk of 
bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external 
validation, and it was rated as low risk of bias for all 
domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the 
development was based on a very large data set and included 
some form of internal validation. 
High risk of 
bias  




If an unclear risk of bias was noted in at least one domain and 
it was low risk for all other domains.  
 





If low concerns regarding applicability for all domains, 
the prediction model evaluation is judged to have low 




If high concerns regarding applicability for at least one 
domain, the prediction model evaluation is judged to 




If unclear concerns (but no “high concern”) regarding 
applicability for at least one domain, the prediction 
model evaluation is judged to have unclear concerns 
regarding applicability overall. 
 
 
Overall judgement about risk of bias and applicability of the prediction 
model evaluation 




Summary of sources of potential bias: 
Main issues relate to outcome likely being based on predictor information and 
analysis limitations- small sample size, excluding patients who died, no form 
performance estimation/validation. 




Summary of applicability concerns: 
All assessed aspects match review question. 
Kostalova et al., 2012 
Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, 
model validation or model update, or combination. Different signalling 
questions apply for different types of prediction model evaluation. If the 
evaluation does not fit one of these classifications then PROBAST should not be 
used. 
 









Definition for type of 
prediction model study 
Development 
only 
Development ✓ Prediction model 
development without external 
validation. These studies may 
include internal validation 








X Prediction model 
development combined with 
external validation in other 




Validation X External validation of existing 
(previously developed) model 
in other participants. 
 
This table should be completed once for each publication being assessed and 
for each relevant outcome in your review. 
Publication 
reference 
Kostalova, M. et al. Towards a predictive model for post-
stroke delirium. 2012 
Models of 
interest 







Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of 
bias (low, high or unclear) and includes signalling questions to help make 
judgements. Signalling questions are rated as yes (Y), probably yes (PY), 
probably no (PN), no (N) or no information (NI). All signalling questions are 
phrased so that “yes” indicates absence of bias. Any signalling question rated 
as “no” or “probably no” flags the potential for bias; you will need to use your 
judgement to determine whether the domain should be rated as “high”, “low” 
or “unclear” risk of bias. The guidance document contains further instructions 
and examples on rating signalling questions and risk of bias for each domain. 
The first three domains are also rated for concerns regarding applicability 
(low/ high/ unclear) to your review question defined above.  
Complete all domains separately for each evaluation of a distinct model. 
Shaded boxes indicate where signalling questions do not apply and should not 
be answered. 
 
DOMAIN 1:  Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
A prospective observational study in a cohort of consecutive patients with 
ischemic stroke or intracerebral haematoma admitted within 24 hours of 
stroke onset. The inclusion criteria were: admission diagnosis of cerebral 
infarction or intracerebral haemorrhage; that a delirium assessment could be 
carried out within 24 hours of stroke onset; and approval of the patient or 
his/her relatives. A priori exclusion criteria were: duration of stroke 
symptoms and signs < 24 hours, history of severe head trauma or neurosurgery 
at any time before stroke; subarachnoid haemorrhage, venous infarction or 
brain tumour; history of psychosis; patients who did not speak Czech; and 
patients who were comatose or stuporous on admission and did not improve 
during the first week post-stroke, with a Richmond agitation and sedation 
scale (RASS) score <=-4. 
  
281 
 Dev Val 
1.15 Were appropriate data sources used, e.g. cohort, RCT or 
nested case-control study data? 
Y  
1.16 Were all inclusions and exclusions of participants 
appropriate? 
Y  







Rationale of bias rating: 
Selection criteria appropriate as overall are aimed to exclude participants 
who are not within the focus of the study (not stroke patients), for whom an 
assessment would not be appropriate due to severity of condition and who 
may have confounding conditions, leading to spurious results. 
B. Applicability 
Describe included participants, setting and dates:  
The study population was recruited over a 15-month period (between January 
2009 and March 2010) from all stroke patients consecutively admitted to a 6-
bed stroke unit, part of the Department of Neurology of the University 
Hospital. 
Concern that the included participants and 





Rationale of applicability rating: 
Participants and setting match the review question focusing on people 
diagnosed with any type of stroke. 
 
DOMAIN 2:  Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and 
timing of assessment: 
Model 1: age, GGT > 1.02 ukat, bilirubin > 20, ICH, lesion volume > 40 ccm 
Model 2: age, ICH, lesion volume > 40 ccm, SOFA-Max > 2 
Risk factors evaluated prospectively; laboratory markers were estimated 
multiple times within the 7 day follow-up period, using the most abnormal 
value for inclusion in the model. The volume of the infarction was calculated 
from delayed MRI FLAIR 3-D scans performed 4–6 weeks after onset of stroke 
using the volumetric semi-automatic segmentation method. 
 Dev Val 
2.22 Were predictors defined and assessed in a similar way for all 
participants? 
Y  
2.23 Were predictor assessments made without knowledge of 
outcome data?  
NI  
2.24 Are all predictors available at the time the model is 
intended to be used? 
N  








Rationale of bias rating: 
Outcome and many predictors were assessed within the same follow-up 
period, it is therefore possible that a predictor value was recorded after 
occurrence of delirium, also it seems likely that the clinicians/researchers 
involved in the data collection were aware of both patient predictors and 
outcome, however selected predictors seem objective, with lesion volume 
assessed using a validated, semi-automated method.  
B. Applicability 
Concern that the definition, assessment or 
timing of predictors in the model do not match 





Rationale of applicability rating: 
The timing of predictors does not match the review question as we specified 
that predictors need to be recorded/known prior to the occurrence of the 
outcome. 
 
DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time 
interval between predictor assessment and outcome determination: 
“Evaluation of delirium was performed daily by a panel of specialist, delirium 
experts working in the University hospital: two neurologists with over 15 years 
of experience and two neuropsychologists with over 5 years of experience 
with stroke and intensive care patients, a psychiatrist with over 10 years of 
experience in psychiatric intensive care and a speech therapist with over 10 
years of experience with stroke patients . They applied the criteria for 
delirium presented in DSM-4 and based their judgements on interviews with 
family members, information obtained from junior and nursing staff and chart 
reviews. The core clinical criteria for diagnosis are a disturbance of 
consciousness with reduced ability to focus, sustain or shift attention; other 
cognitive or perceptual disturbances; acuity of onset (hours to days) and 
fluctuation over the course of the day; and presence of an underlying cause, 
such as a general medical condition, medication, a combination of aetiologies 
or indeterminate aetiology. With respect to high prevalence of pre-stroke 
dementia or possibility of disturbances of memory, perception or attention 
(such as aphasia or neglect) caused by lesions of certain brain regions, the 
mental status of patients on admission was considered as a new baseline and 
acute onset and fluctuating course was assessed as positive in the event of 
new change from this baseline mental status or fluctuation in it. Each 
evaluation was performed by at least one neurologist and one 
neuropsychologist; the speech therapist who had performed the introductory 
logopedic exam was then brought in, together with a psychiatrist if necessary. 
In parallel with clinical assessment based on DSM-4 criteria, blindly and 
independently CAM-ICU scoring was used and high sensitivity, specificity and 
accuracy of this diagnostic instrument was found. The delirium experts 
standardized their approach to DSM-4 criteria and CAM-ICU scoring over a 3-
month training phase via roundtable discussions with attending neurologists 
and intensive care specialists regarding their approach to standardizing their 
ICU delirium assessment. The expert evaluation, however, was used as a gold 
standard both in this methodological study and in current evaluation of risk 
factors. The first evaluation was made within 24 hours of admission (day 1) 
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and then daily on 7 consecutive days upon which the patient was accessible to 
testing irrespective of the result of the first evaluation. Follow-up was 
stopped in patients who became inaccessible to testing because of worsening 
of consciousness or death.” 
 Dev Val 
3.43 Was the outcome determined appropriately? Y  
3.44 Was a pre-specified or standard outcome definition used? Y  
3.45 Were predictors excluded from the outcome definition? N  
3.46 Was the outcome defined and determined in a similar way 
for all participants? 
Y  
3.47 Was the outcome determined without knowledge of 
predictor information? 
N  
3.48 Was the time interval between predictor assessment and 
outcome determination appropriate? 
N  
Risk of bias introduced by the outcome or 





Rationale of bias rating: 
The method of outcome assessment seems to reach a gold standard, given the 
applied criteria, undergone training and experts involved, however it appears 
that predictors were taken into account in this process and therefore the 
association between predictors and outcome is likely to be overestimated. 
B. Applicability 
At what time point was the outcome determined:  
Within a 7-day period, which was the same as the predictors 
 
If a composite outcome was used, describe the relative 
frequency/distribution of each contributing outcome:  
N/A 
Concern that the outcome, its definition, 






Rationale of applicability rating: 
The issue with timing relates to the assessment of predictors overlapping with 
the assessment of the outcome, however in itself the timing of outcome 
assessment is appropriate given that delirium can develop and recede shortly 
after admission; all other aspects of the outcome match the review question. 
 
DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors, outcome 
events and events per candidate predictor: 
100 participants, 37 candidate predictors, 43 outcome events, EPV = 1.2 
Describe how the model was developed (for example in regards to modelling 
technique (e.g. survival or logistic modelling), predictor selection, and risk 
group definition): 
Where employed, optimal cut-off values of continuous variables were 
optimized on the basis of ROC analysis. “For multivariate analysis the 
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backward stepwise logistic regression model was used, entering all the 
variables with p < 0.10. on univariate analysis. The final set of potential 
predictive factors and interaction terms (coded as binary variables) was 
subjected to a stepwise selection algorithm in multivariate logistic regression 
(driven by maximum likelihood ratio test). Only predictors that were 
significant and mutually uncorrelated were kept in the final model.” 
Describe whether and how the model was validated, either internally (e.g. 
bootstrapping, cross validation, random split sample) or externally (e.g. 
temporal validation, geographical validation, different setting, different 
type of participants): 
“A simple 2-fold cross-validation (randomly assigning database records to two 
data sets of equal size and using them changeably as training and testing set) 
was applied.” 
Describe the performance measures of the model, e.g. (re)calibration, 
discrimination, (re)classification, net benefit, and whether they were 
adjusted for optimism: 
“Proportion of correctly recognized cases was evaluated to assess the 
accuracy of the proposed model equations.” 
Describe any participants who were excluded from the analysis: 
19 incomplete protocols - patients who died or became comatose or stuporous 
during the follow-up. 
Describe missing data on predictors and outcomes as well as methods used 
for missing data: 
No information on missing data. 
 Dev Val 
4.64 Were there a reasonable number of participants with the 
outcome? 
N  
4.65 Were continuous and categorical predictors handled 
appropriately? 
N  
4.66 Were all enrolled participants included in the analysis? N  
4.67 Were participants with missing data handled appropriately? NI  
4.68 Was selection of predictors based on univariable analysis 
avoided?  
N  
4.69 Were complexities in the data (e.g. censoring, competing 
risks, sampling of controls) accounted for appropriately? 
N  
4.70 Were relevant model performance measures evaluated 
appropriately? 
N  
4.71 Were model overfitting and optimism in model 
performance accounted for? 
Y  
4.72 Do predictors and their assigned weights in the final model 
correspond to the results from multivariable analysis?  
Y  




Rationale of bias rating: 
Too few participants, which authors indicated by calling this a “pilot 
attempt”, use of data-driven predictor cut-offs, predictor selection based on 
univariable associations, exclusion of participants lost to follow-up, no 
estimates of model discrimination or calibration. 
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Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and 
concerns regarding applicability of the prediction model evaluation 
(development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model 
evaluation 
Low risk of 
bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external 
validation, and it was rated as low risk of bias for all 
domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the 
development was based on a very large data set and included 
some form of internal validation. 
High risk of 
bias  
If at least one domain is judged to be at high risk of bias.  
Unclear risk 
of bias 
If an unclear risk of bias was noted in at least one domain and 
it was low risk for all other domains.  
 





If low concerns regarding applicability for all domains, 
the prediction model evaluation is judged to have low 




If high concerns regarding applicability for at least one 
domain, the prediction model evaluation is judged to 




If unclear concerns (but no “high concern”) regarding 
applicability for at least one domain, the prediction 
model evaluation is judged to have unclear concerns 
regarding applicability overall. 
 
 
Overall judgement about risk of bias and applicability of the prediction 
model evaluation 




Summary of sources of potential bias: 
Main sources relate to inclusion of predictor information in outcome 
assessment and multiple issues with analysis procedures and estimation of 
model performance. 




Summary of applicability concerns: 
Issues due to assessment of predictor overlapping with outcome assessment, 




Kotfis et al., 2019; DELIAS 
Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, 
model validation or model update, or combination. Different signalling 
questions apply for different types of prediction model evaluation. If the 
evaluation does not fit one of these classifications then PROBAST should not be 
used. 
 









Definition for type of 
prediction model study 
Development 
only 
Development ✓ Prediction model 
development without external 
validation. These studies may 
include internal validation 







X Prediction model 
development combined with 
external validation in other 




Validation X External validation of existing 
(previously developed) model 
in other participants. 
 
This table should be completed once for each publication being assessed and 
for each relevant outcome in your review. 
Publication 
reference 
Kotfis, K. et al. Could neutrophil-to-lymphocyte ratio (NLR) 
serve as a potential marker for delirium prediction in 
patients with acute ischemic stroke? a 
prospective observational study. 2019 
Models of 
interest 






Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of 
bias (low, high or unclear) and includes signalling questions to help make 
judgements. Signalling questions are rated as yes (Y), probably yes (PY), 
probably no (PN), no (N) or no information (NI). All signalling questions are 
phrased so that “yes” indicates absence of bias. Any signalling question rated 
as “no” or “probably no” flags the potential for bias; you will need to use your 
judgement to determine whether the domain should be rated as “high”, “low” 
or “unclear” risk of bias. The guidance document contains further instructions 
and examples on rating signalling questions and risk of bias for each domain. 
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The first three domains are also rated for concerns regarding applicability 
(low/ high/ unclear) to your review question defined above.  
Complete all domains separately for each evaluation of a distinct model. 
Shaded boxes indicate where signalling questions do not apply and should not 
be answered. 
 
DOMAIN 1:  Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
Prospective observational study; Consecutive adult patients (age > 18 years) 
with acute ischemic stroke; “We excluded patients with hematology disorders 
(5 patients), incomplete laboratory testing (6 patients), or no data regarding 
follow-up.”  
 Dev Val 
1.17 Were appropriate data sources used, e.g. cohort, RCT or 
nested case-control study data? 
Y  
1.18 Were all inclusions and exclusions of participants 
appropriate? 
Y  







Rationale of bias rating: 
Excluding patients with incomplete data is a potential source of bias, however 
this will be addressed separately under the analysis domain, other criteria 
seem appropriate 
B. Applicability 
Describe included participants, setting and dates:  
Patients admitted to the neurology department of a busy district general 
hospital in Poland between 30 June 2015 and 31 March 2018. Patients with AIS 
were admitted to the neurology department within 48 hours of symptom 
development. 
Concern that the included participants and 





Rationale of applicability rating: 
Both participants and setting match review question. 
 
DOMAIN 2:  Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and 
timing of assessment: 
Hemianopia, aphasia, age, NIHSS on admission, NLR, Leukocytes, CRP 
The data was collected prospectively by a dedicated member of staff. Blood 
analysis carried out at admission. 
 Dev Val 




2.26 Were predictor assessments made without knowledge of 
outcome data?  
NI  
2.27 Are all predictors available at the time the model is 
intended to be used? 
NI  






Rationale of bias rating: 
As the primary outcome was assessed within 24 hours, it seems possible that 
information on some predictors could have been collected after the outcome 
assessment, which could e.g. affect judgement regarding aphasia, hemianopia 
and/or NIHSS. Also the method of assessing aphasia and hemianopia is 
unclear.  
B. Applicability 
Concern that the definition, assessment or 
timing of predictors in the model do not match 





Rationale of applicability rating: 
Applicability would depend on whether the predictors were all estimated 
prior to the outcome. 
 
DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time 
interval between predictor assessment and outcome determination: 
We used the Polish version of the CAM-ICU assessment tool to screen all 
patients for delirium at admission and on a daily basis after admission to the 
hospital. To aid delirium diagnosis, a review of medical and nursing notes for 
a full evaluation of delirium was performed by one of the investigators. 
Delirium was diagnosed according to the Diagnostic and Statistical Manual of 
Mental Disorders 5th edition. Delirium was defined as “early onset” if it was 
diagnosed within the first 24 hours after admission to the neurology unit due 
to acute ischemic stroke. 
 Dev Val 
3.49 Was the outcome determined appropriately? Y  
3.50 Was a pre-specified or standard outcome definition used? PY  
3.51 Were predictors excluded from the outcome definition? PN  
3.52 Was the outcome defined and determined in a similar way 
for all participants? 
PY  
3.53 Was the outcome determined without knowledge of 
predictor information? 
N  
3.54 Was the time interval between predictor assessment and 
outcome determination appropriate? 
NI  
Risk of bias introduced by the outcome or 





Rationale of bias rating: 
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It is unclear whether the outcome was assessed always after the predictors 
were determined; there are no details regarding the investigators 
experience/qualifications and the description of what criteria were used to 
diagnose delirium beyond use of CAM-ICU seems a bit vague, yet it seems that 
the investigator had knowledge of the predictors and they were used to aid 
judgement, which may have led to overestimation of associations between 
predictors and outcome. 
B. Applicability 
At what time point was the outcome determined:  
At admission and on a daily basis afterwards up to 5 days. 
 
If a composite outcome was used, describe the relative 
frequency/distribution of each contributing outcome:  
N/A 
Concern that the outcome, its definition, 






Rationale of applicability rating: 
The timing of outcome assessment is appropriate given that delirium can 
develop and recede shortly after admission; all other aspects of the outcome 
match the review question with CAM-ICU and DSM-5 criteria being appropriate 
for assessment of delirium. 
 
DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors, outcome 
events and events per candidate predictor:  
1001 participants, seems like 40 candidate predictors?, 172 outcome events, 
EPV = 4.3 
Describe how the model was developed (for example in regards to modelling 
technique (e.g. survival or logistic modelling), predictor selection, and risk 
group definition): 
“The receiver operating characteristic (ROC) curve analysis was performed to 
determine the best cut-off value for predicting the clinical end points. 
Logistic regression analysis was performed, with additional correction for 
potentially interfering variables (age, sex, and body mass index (BMI)). On the 
basis of this regression, the parameters most closely related to the 
occurrence of delirium were sought. Based on a multifactorial model, 
information on the impact of each variable on delirium was obtained. Next, 
the contribution of each analyzed variable was calculated, and the formula 
was presented using elements with which the delirium score was 
calculated. p-value ≤ 0.05 was considered significant.” 
“Because patients with delirium had significantly higher values of NLR at 
admission, we decided to perform a ROC analysis to calculate the best cut-off 
value to predict delirium.” 
“Multivariable logistic regression analysis adjusted according to age, sex, BMI, 
comorbidities, and baseline neurology showed that leucocyte count (p < 
0.001) and neutrophil count (p = 0.012) as well as mean NRL (p = 0.028), NRL 
(p < 0.001), and NLR at the predefined cut-off of >4.86 (p < 0.001) exhibited 
an association with post-stroke delirium after adjustment with baseline 
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characteristics. For NLR > 4.86 adjusted for age, sex, BMI, comorbidities, and 
baseline neurology, the odds ratio (OR) was 1.875 (95% CI 1.314–2.675, p = 
0.001). Similar finding was noted regarding the CRP, with the cut-off >9.10, 
for which the OR adjusted for age, sex, BMI, comorbidities, and baseline 
neurology was even higher with NLR at 2.132 (95% CI 1.482–3.066, p < 0.001). 
The AUC value for NLR as well as its sensitivity and specificity were moderate, 
so we decided to find a combination of markers and clinical parameters that 
would help predict the occurrence of early-onset delirium in AIS. Using 
clinical and laboratory factors, we determined that an index composed of 
age, NIHSS score, neurological findings, leucocyte count, NLR, and CRP was 
better at predicting early-onset delirium after acute ischemic stroke than any 
of the factors alone. To increase the diagnostic value of the laboratory 
markers in the study group, clinical and laboratory variables most associated 
with delirium were determined based on logistic regression.” 
Describe whether and how the model was validated, either internally (e.g. 
bootstrapping, cross validation, random split sample) or externally (e.g. 
temporal validation, geographical validation, different setting, different 
type of participants): 
“To verify the predictability value of the DELIAS score for the diagnosis of 
delirium, we performed an ROC analysis for delirium diagnosed up to the fifth 
day in the same group of patients.” 
Describe the performance measures of the model, e.g. (re)calibration, 
discrimination, (re)classification, net benefit, and whether they were 
adjusted for optimism: 
Discrimination and classification measures. 
Describe any participants who were excluded from the analysis: 
Excluded patients with incomplete laboratory testing (6 patients), or no data 
regarding follow-up. 
Describe missing data on predictors and outcomes as well as methods used 
for missing data: 
Participants with missing data were excluded. 
 Dev Val 
4.73 Were there a reasonable number of participants with the 
outcome? 
N  
4.74 Were continuous and categorical predictors handled 
appropriately? 
N  
4.75 Were all enrolled participants included in the analysis? N  
4.76 Were participants with missing data handled appropriately? N  
4.77 Was selection of predictors based on univariable analysis 
avoided?  
NI  
4.78 Were complexities in the data (e.g. censoring, competing 
risks, sampling of controls) accounted for appropriately? 
N  
4.79 Were relevant model performance measures evaluated 
appropriately? 
N  
4.80 Were model overfitting and optimism in model 
performance accounted for? 
N  
4.81 Do predictors and their assigned weights in the final model 








Rationale of bias rating: 
There were too few outcome events relative to candidate predictors; it is not 
clear how predictors were chosen or which were entered into the 
multivariable logistic model; participants with missing data were excluded, 
although this would most likely not cause a high ROB as this was only 19 from 
1022; data-driven cut-offs for laboratory markers, only apparent validation, 
no information regarding calibration. 
 
Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and 
concerns regarding applicability of the prediction model evaluation 
(development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model 
evaluation 
Low risk of 
bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external 
validation, and it was rated as low risk of bias for all 
domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the 
development was based on a very large data set and included 
some form of internal validation. 
High risk of 
bias  
If at least one domain is judged to be at high risk of bias.  
Unclear risk 
of bias 
If an unclear risk of bias was noted in at least one domain and 
it was low risk for all other domains.  
 





If low concerns regarding applicability for all domains, 
the prediction model evaluation is judged to have low 




If high concerns regarding applicability for at least one 
domain, the prediction model evaluation is judged to 




If unclear concerns (but no “high concern”) regarding 
applicability for at least one domain, the prediction 
model evaluation is judged to have unclear concerns 




Overall judgement about risk of bias and applicability of the prediction 
model evaluation 




Summary of sources of potential bias: 
Quite a lot of study aspects unclear, issues with outcome assessment involving 
knowledge of predictors, issues with analysis, assessment of performance and 
validation 




Summary of applicability concerns: 
Applicability cannot be fully assessed as there is insufficient information to 
determine whether all predictor data was collected prior to the outcome. 
 
Oldenbeuving et al., 2014 
Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, 
model validation or model update, or combination. Different signalling 
questions apply for different types of prediction model evaluation. If the 
evaluation does not fit one of these classifications then PROBAST should not be 
used. 
 









Definition for type of 
prediction model study 
Development 
only 
Development ✓ Prediction model 
development without external 
validation. These studies may 
include internal validation 







X Prediction model 
development combined with 
external validation in other 




Validation X External validation of existing 
(previously developed) model 




This table should be completed once for each publication being assessed and 
for each relevant outcome in your review. 
Publication 
reference 
Oldenbeuving, A. W. et al. An early prediction of delirium 
in the acute phase after stroke. 2014 
Models of 
interest 






Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of 
bias (low, high or unclear) and includes signalling questions to help make 
judgements. Signalling questions are rated as yes (Y), probably yes (PY), 
probably no (PN), no (N) or no information (NI). All signalling questions are 
phrased so that “yes” indicates absence of bias. Any signalling question rated 
as “no” or “probably no” flags the potential for bias; you will need to use your 
judgement to determine whether the domain should be rated as “high”, “low” 
or “unclear” risk of bias. The guidance document contains further instructions 
and examples on rating signalling questions and risk of bias for each domain. 
The first three domains are also rated for concerns regarding applicability 
(low/ high/ unclear) to your review question defined above.  
Complete all domains separately for each evaluation of a distinct model. 
Shaded boxes indicate where signalling questions do not apply and should not 
be answered. 
 
DOMAIN 1:  Participants 
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
Prospective cohort; 
“During 1 year, 630 consecutive patients with stroke admitted to the stroke 
units of the St. Elisabeth and TweeSteden hospitals in Tilburg, the 
Netherlands, were investigated for the presence and risk factors of delirium. 
Criteria for stroke were neurologic deficit of sudden onset lasting longer than 
24 hours. Patients with ischemic and hemorrhagic stroke were included. All 
patients were admitted to a stroke care unit and treated according to 
standard protocols according to international guidelines.  
Exclusion criteria. Patients with subarachnoid hemorrhage and TIA were 
excluded. Patients had to be older than 18 years. Of the 630 consecutive 
patients, 95 were excluded. Forty-four patients were excluded because they 
already died before the first screening or because death appeared imminent. 
One patient was younger than 18 years, 2 had severe mental retardation, 6 
had a severe language barrier, 35 were transferred to another hospital 
because of capacity problems, and 7 patients refused informed consent. Eight 
patients were admitted twice in the same period; only the first admission was 
included in the analyses. Hence, 527 patients were included in the analysis.” 
 Dev Val 
1.19 Were appropriate data sources used, e.g. cohort, RCT or 
nested case-control study data? 
Y  











Rationale of bias rating: 
Overall, broad inclusion criteria mainly excluding participants with other 
conditions than that of interest or those for whom a cognitive assessment was 
inappropriate or not possible.  
B. Applicability 
Describe included participants, setting and dates:  
During 1 year, 630 consecutive patients with stroke admitted to the stroke 
units of the St. Elisabeth and TweeSteden hospitals in Tilburg, the 
Netherlands. 
Concern that the included participants and 





Rationale of applicability rating: 
Dates are unclear, however regardless the participants and setting match the 
review question. 
 
DOMAIN 2:  Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and 
timing of assessment: 
Age, NIHSS , stroke subtype, infection 
“We collected the following baseline data: age, sex, medication at time of 
admission, alcohol use (defined as a mean intake of one or more units every 
day), and auditory and visual impairment. At admission, all patients 
underwent clinical examination and a noncontrast enhanced CT scan with 5-
mm contiguous slices. Stroke subtype was classified with the Oxfordshire 
Community Stroke Project criteria. For the multivariable analysis, partial 
anterior circulation infarction (PACI) and total anterior circulation infarction 
(TACI) were grouped. The severity of the clinical deficits was scored 
according to the NIH Stroke Scale (NIHSS), both at admission and at the first 
screening for delirium. The NIHSS data of the first screening were used in the 
analyses.” 
“Infection was scored at both screening dates using data from the medical 
records from the day of hospitalisation until the day of screening. We used 
the following data: pyrexia, high leucocytosis and/or raised ESR with a 
positive blood, sputum or urine culture and/or infiltrate on chest x-ray, or for 
which antibiotics were prescribed.” 
“CT scans of 484 patients were analyzed for atrophy and white matter 
changes by 2 raters blinded for patient characteristics.” 
 Dev Val 
2.28 Were predictors defined and assessed in a similar way for all 
participants? 
N  
2.29 Were predictor assessments made without knowledge of 
outcome data?  
PN  
2.30 Are all predictors available at the time the model is 
intended to be used? 
N  
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Rationale of bias rating: 
Different variables were used for determining infection, although this seems 
appropriate given potential differences in type and symptoms of infection. 
Instead of using NIHSS from admission, a score that is determined on the same 
occasion as delirium was included, which could have led to overestimation of 
the association between this predictor and the outcome. Also, infection could 
have been recorded after a diagnosis of delirium was made at the first 
screening. 
B. Applicability 
Concern that the definition, assessment or 
timing of predictors in the model do not match 





Rationale of applicability rating: 
Issue due to overlap of predictor and outcome assessment, as stated above. 
 
DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time 
interval between predictor assessment and outcome determination: 
“Every patient was screened for delirium between days 2 and 4 after 
admission, and a second time between days 5 and 7. If the patient was 
discharged before the second delirium screening, only the first screening was 
performed. Delirium was assessed with the Confusion Assessment Method 
(CAM). If the CAM was positive, delirium was diagnosed and the severity of 
delirium was assessed daily with the Delirium Rating Scale (DRS).” 
 Dev Val 
3.55 Was the outcome determined appropriately? N  
3.56 Was a pre-specified or standard outcome definition used? Y  
3.57 Were predictors excluded from the outcome definition? Y  
3.58 Was the outcome defined and determined in a similar way 
for all participants? 
Y  
3.59 Was the outcome determined without knowledge of 
predictor information? 
N  
3.60 Was the time interval between predictor assessment and 
outcome determination appropriate? 
N  
Risk of bias introduced by the outcome or 





Rationale of bias rating: 
The outcome measure itself was appropriate, however the timing of 
assessment could have led to missing occurrence of delirium, particularly as 
the authors reported that it could last just 1 day and some patients were not 
screened till day 4 after the admission, it is also unclear whether the interval 
between the 1st and 2nd screenings was random or predetermined, e.g. could 
one patient be screened at days 4 and 5? NIHSS was assessed at the same time 
as the outcome and infection could have been recorded even after that, 
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which indicates that predictors were known to the person determining the 
outcome; there is also no mention of blinding to any other of the predictors 
collected at admission, this introduces a high ROB as assessment of CAM 
involves some subjectivity. 
B. Applicability 
At what time point was the outcome determined:  
Between days 2 and 4 after admission, and a second time between days 5 and 
7. 
 
If a composite outcome was used, describe the relative 
frequency/distribution of each contributing outcome:  
N/A 
Concern that the outcome, its definition, 






Rationale of applicability rating: 
Despite issues described above, all aspects of the outcome match the review 
question. 
 
DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors, outcome 
events and events per candidate predictor: 
527 participants, 18 candidate predictors, 62 outcome events, EPV = 3.4 
Describe how the model was developed (for example in regards to modelling 
technique (e.g. survival or logistic modelling), predictor selection, and risk 
group definition): 
From preceding study: 
A multivariable logistic regression analysis was performed with delirium as 
dependent variable. Initially, a full model was analyzed including all variables 
with a p value of 0.20 in the univariable analysis. For the multivariable 
analyses, a backward elimination procedure was used to define the final 
independent risk factors. Variables were eliminated from the model if the p 
value was 0.10. 
From current study: 
Age was an independent risk factor if brain atrophy was left out of the model. 
“For the current study, our aim was to develop a risk score that is available 
on the day of admission and that can be easily obtained. Therefore, we used 
age instead of brain atrophy. By means of the β coefficients from the logistic 
regression model, we allocated a score to each risk factor. Three models were 
tested: 1 with all variables found significant in the multivariable analysis in 
the previous study with age instead of atrophy, 2 including only variables 
easily available for clinicians, 3 further simplified with only age and NIHSS” 
Describe whether and how the model was validated, either internally (e.g. 
bootstrapping, cross validation, random split sample) or externally (e.g. 
temporal validation, geographical validation, different setting, different 
type of participants): 
Apparent and temporal validation 
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Describe the performance measures of the model, e.g. (re)calibration, 
discrimination, (re)classification, net benefit, and whether they were 
adjusted for optimism: 
Discrimination and classification measures 
Describe any participants who were excluded from the analysis: 
Forty-four patients were excluded because they already died before the first 
screening or because death appeared imminent, 35 were transferred to 
another hospital because of capacity problems 
Describe missing data on predictors and outcomes as well as methods used 
for missing data: 
No mention of missing data 
 Dev Val 
4.82 Were there a reasonable number of participants with the 
outcome? 
N  
4.83 Were continuous and categorical predictors handled 
appropriately? 
PN  
4.84 Were all enrolled participants included in the analysis? N  
4.85 Were participants with missing data handled appropriately? N  
4.86 Was selection of predictors based on univariable analysis 
avoided?  
N  
4.87 Were complexities in the data (e.g. censoring, competing 
risks, sampling of controls) accounted for appropriately? 
N  
4.88 Were relevant model performance measures evaluated 
appropriately? 
N  
4.89 Were model overfitting and optimism in model 
performance accounted for? 
N  
4.90 Do predictors and their assigned weights in the final model 
correspond to the results from multivariable analysis?  
NI  




Rationale of bias rating: 
Too few participants relative to number of candidate predictors, not clear 
how NIHSS categories were created, as they do not align with typically applied 
cut-offs, participants who died or were lost to follow-up were excluded from 
the study, predictors were initially selected based on univariable analysis, no 
assessment of calibration, apparent validation with no correction for 
optimism, beta coefficients used to create the final score were not presented 
in either publication 
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Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and 
concerns regarding applicability of the prediction model evaluation 
(development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model 
evaluation 
Low risk of 
bias  
If all domains were rated low risk of bias. 
If a prediction model was developed without any external 
validation, and it was rated as low risk of bias for all 
domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the 
development was based on a very large data set and included 
some form of internal validation. 
High risk of 
bias  
If at least one domain is judged to be at high risk of bias.  
Unclear risk 
of bias 
If an unclear risk of bias was noted in at least one domain and 
it was low risk for all other domains.  
 





If low concerns regarding applicability for all domains, 
the prediction model evaluation is judged to have low 




If high concerns regarding applicability for at least one 
domain, the prediction model evaluation is judged to 




If unclear concerns (but no “high concern”) regarding 
applicability for at least one domain, the prediction 
model evaluation is judged to have unclear concerns 
regarding applicability overall. 
 
 
Overall judgement about risk of bias and applicability of the prediction 
model evaluation 




Summary of sources of potential bias: 
Issues in terms of overlap in assessment of predictors and outcome with 
inherent lack of blinding, timing of outcome assessment may have led to 
missing occurrences of delirium, multiple issues regarding model development 
and assessment of performance  




Summary of applicability concerns: 
Review question specifies that predictors should be known prior to the 
occurrence of the outcome, which here was not the case. 
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Appendix 4: Chapter 4, associations between performance on cognitive tasks and 
measures of physical activity and sedentary behaviour in the UK Biobank 
Supplemental Table 1 Associations between log reaction time and daily duration of types of physical activities and sedentary behaviours. 
Variable 
Log reaction time models 







































































Sample  5,739 5,675 3,574 3,535 






















































Sample  7,771 7,673 4,564 3,535 
*Significant at p < 0.003; anatural log of reported duration  




Supplemental Table  2 Associations between log reaction time and total daily physically active and sedentary times. 
Variable 
Log reaction time models 






















































Sample  7,770 7,672 4,564 3,535 
*Significant at p < 0.003; anatural log of reported duration  





Supplemental Table 3 Associations between verbal-numerical reasoning task scores and daily duration of types of physical activities and sedentary 
behaviours. 
Variable 
Verbal-numerical reasoning models 







































































Sample  1,927 1,906 1,583 1,571 






















































Sample  2,530 2,500 1,975 1,571 
*Significant at p < 0.003; anatural log of reported duration  




Supplemental Table 4 Associations between verbal-numerical reasoning task scores and total daily physically active and sedentary times. 
Variable 
Verbal-numerical reasoning models 






















































Sample  2,530 2,500 1,975 1,571 
*Significant at p < 0.003; anatural log of reported duration  




Supplemental Table 5 Associations between log errors in the visual memory task and daily duration of types of physical activities and sedentary behaviours. 
Variable 
Visual memory models (log of errors) 







































































Sample  5,845 5,782 3,626 3,584 






















































Sample  7,927 7,825 4,639 3,584 
*Significant at p < 0.003; anatural log of reported duration  




Supplemental Table 6 Associations between log errors in the visual memory task and total daily physically active and sedentary times. 
Variable 
Visual memory models (log of errors) 






















































Sample  7,926 7,824 4,639 3,584 
*Significant at p < 0.003; anatural log of reported duration  




Supplemental Table 7 Associations between a correct response on the prospective memory task and daily duration of types of physical activities and 
sedentary behaviours. 
Variable 
Prospective memory models 
Unadjusted Partially adjusted Fully adjusted Complete 






































































Sample  2,037 2,014 1,660 1,644 






















































Sample  2,709 2,669 2,081 1,644 
*Significant at p < 0.003; anatural log of reported duration  




Supplemental Table 8 Associations between a correct response on the prospective memory task and total daily physically active and sedentary times. 
Variable 
Prospective memory models 






















































Sample  2,709 2,669 2,081 1,644 
*Significant at p < 0.003; anatural log of reported duration  




Appendix 5: Chapter 4, associations between performance on cognitive tasks and 
proxies of social engagement in the UK Biobank 
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Supplemental Table 9 Associations between log reaction time and proxies of social engagement. 
Variable 
Log reaction time models 





































































Sample  8,052 7,934 4,689 1,954 









































Sample 2,731 2,685 2,085 1,954 


















Sample 8,033 7,847 4,637 1,954 
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Supplemental Table 9 Associations between log reaction time and proxies of social engagement. Continued 
Variable 





































































Sample 7,852 7,674 4,543 1,954 










































































































Sample 8,152 7,968 4,698 1,954 
*Significant at p < 0.003; areference category 
CI indicates confidence interval; std., standardised; unstd., unstandardised. 
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Supplemental Table 10 Associations between verbal-numerical reasoning task scores and proxies of social engagement. 
Variable 
Verbal-numerical reasoning models 





































































Sample  2,611 2,572 2,018 1,873 









































Sample 2,573 2,534 1,995 1,873 















(−0.704, 0.013)  
−0.160 
(−0.326, 0.006) 
Sample 2,582 2,543 1,997 1,873 
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Supplemental Table 10 Associations between verbal-numerical reasoning task scores and proxies of social engagement. Continued 
Variable 





































































Sample 2,525 2,488 1,963 1,873 










































































































Sample 2,614 2,574 2,020 1,873 
*Significant at p < 0.003; areference category 
CI indicates confidence interval; std., standardised; unstd., unstandardised. 
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Supplemental Table 11 Associations between log errors in the visual memory task and proxies of social engagement. 
Variable 
Visual memory models (log of errors) 





































































Sample  8,232 8,108 4,769 1,991 









































Sample 2,804 2,754 2,127 1,991 


















Sample 8,145 8,019 4,716 1,991 
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Supplemental Table 11 Associations between log errors in the visual memory task and proxies of social engagement. Continued.  
Variable 





































































Sample 7,957 7,837 4,615 1,991 










































































































Sample 8,266 8,143 4,778 1,991 
*Significant at p < 0.003; areference category 
CI indicates confidence interval; std., standardised; unstd., unstandardised. 
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Supplemental Table 12 Associations between a correct response on the prospective memory task and proxies of social engagement. 
Variable 
Prospective memory models 





































































Sample  2,810 2,759 2,131 1,973 









































Sample 2,767 2,718 2,106 1,973 


















Sample 2,778 2,727 2,108 1,973 
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Supplemental Table 12 Associations between a correct response on the prospective memory task and proxies of social engagement. Continued.  
 
Variable 





































































Sample 2,706 2,660 2,073 1,973 










































































































Sample 2,815 2,763 2,134 1,973 
*Significant at p < 0.003; areference category 
CI indicates confidence interval; std., standardised; unstd., unstandardised.
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Appendix 6: Chapter 5, correlations between variables included in the model 

















Age  0.276* 0.044 0.159* 0.453* 0.047 0.261* 0.233* 0.175* 0.575* -0.425* 
Sex (female) 0.276*  -0.036 0.093 -0.032 -0.018 0.137* 0.060 0.028 0.104 -0.179* 
Previous stroke 0.044 -0.036  -0.404* 0.087 0.294* 0.192* 0.197* 0.039 0.260* -0.088 
Previous TIA 0.159* 0.093 -0.404*  -0.068 -0.019 0.018 0.147 -0.237* -0.068 0.104 
Atrial fibrillation 0.453* -0.032 0.087 -0.068  0.132 0.228* 0.110 0.243* 0.246* -0.309* 
Diabetes 0.047 -0.018 0.294* -0.019 0.132  0.290* 0.374* 0.079 0.066 -0.087 
Hypertension 0.261* 0.137* 0.192* 0.018 0.228* 0.290*  0.295* 0.060 0.035 -0.087 
Vascular disease 0.233* 0.060 0.197* 0.147 0.110 0.374* 0.295*  -0.031 0.291* -0.021 
Stroke severity 0.175* 0.028 0.039 -0.237* 0.243* 0.079 0.060 -0.031  0.246* -0.550* 
Prior dementia 0.575* 0.104 0.260* -0.068 0.246* 0.066 0.035 0.291* 0.246*  -0.609* 
Cognitive performance -0.425* -0.179* -0.088 0.104 -0.309* -0.087 -0.087 -0.021 -0.550* -0.609  
*Significant at p < 0.05 
TIA indicates transient ischaemic attack. 
Note: Coefficients were obtained from correlations appropriate to each pair of variables: tetrachoric for two dichotomous, biserial for one dichotomous and one 
continuous, polychoric for two ordered categorical and one ordered categorical and one dichotomous, polyserial for one ordered categorical and one continuous. 
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Appendix 7: Chapter 5, results of sensitivity 
analysis 
Supplemental Table 13 Direct associations between predictors and stroke severity, 
dementia and cognitive performance. 
 Unstandardised coefficients (95% bias-corrected CI) 
 Stroke severity Prior dementia Cognitive performance 
Age 0.012 (0.004, 0.020)* 0.061 (0.037, 0.081)* 0.002 (-0.017, 0.025) 
Sex (female) -0.066 (-0.254, 0.141) -0.080 (-0.444, 0.296) -0.188 (-0.526, 0.157) 
Previous stroke 0.033 (-0.184, 0.259) 0.396 (-0.053, 0.773) 0.103 (-0.278, 0.517) 
Previous TIA -0.394 (-0.776, 0.006)* -0.256 (-1.163, 0.305) -0.012 (-0.727, 0.571) 
Atrial fibrillation 0.373 (0.072, 0.641)* 0.053 (-0.427, 0.497) -0.124 (-0.508, 0.351) 
Diabetes -0.035 (-0.307, 0.246) 0.009 (-0.771, 0.556) -0.022 (-0.671, 0.522) 
Hypertension 0.116 (-0.161, 0.328) -0.234 (-0.762, 0.270) -0.081 (-0.554, 0.318) 
Vascular disease 0.047 (-0.382, 0.450) 0.644 (-0.016, 1.265)* 0.339 (-0.246, 1.066) 
Vascular disease 
x diabetes 
0.456 (-0.024, 0.956)   
Vascular disease 
x hypertension  
-0.482 (-0.983, 0.006)   
*significant at p < 0.05 
CI indicates confidence interval; TIA, transient ischaemic attack. 
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Supplemental Table 14 Indirect associations between predictors and cognitive performance. 
 Unstandardised coefficients (95% bias-corrected CI) 
 Effects mediated through 
stroke severity 
Effects mediated through 
prior dementia 
Age -0.008 (-0.015, -0.003)* -0.041 (-0.069, -0.021)* 
Sex (female) 0.048 (-0.104, 0.197) 0.054 (-0.214, 0.307) 
Previous stroke -0.024 (-0.195, 0.138) -0.265 (-0.599, 0.001) 
Previous TIA 0.285 (-0.020, 0.584) 0.171 (-0.217, 0.826) 
Atrial fibrillation -0.269 (-0.492, -0.049)* -0.035 (-0.387, 0.270) 
Diabetes 0.025 (-0.195, 0.234) -0.006 (-0.393, 0.542) 
Hypertension -0.084 (-0.263, 0.110) 0.157 (-0.165, 0.588) 
Vascular disease -0.034 (-0.348, 0.290) -0.432 (-1.017, -0.023) 
Vascular disease 
x diabetes 
-0.330 (-0.741, 0.022)  
Vascular disease 
x hypertension  
0.348 (-0.011, 0.748)  
*significant at p < 0.05 
CI indicates confidence interval; TIA, transient ischaemic attack. 
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Appendix 8: Chapter 6, case report form for 


























Appendix 9: Chapter 7, Mplus code for factor 
analysis models 
Configural model 
TITLE: CFA for AMT data baseline to 12m, configural model; 
DATA:  FILE IS  
C:\Users\Bogna\OneDrive - University of Glasgow\APPLE Trajectories\AMT_raw 
data.dat; 
VARIABLE:  
      NAMES ARE 
          ID_new 
          ori_B ww1_B att_B rec_B clock_B news_B let_B  
          ori_1 ww1_1 att_1 rec_1 clock_1 news_1 let_1 
          ori_6 ww1_6 att_6 rec_6 clock_6 news_6 let_6 
          ori_12 ww1_12 att_12 rec_12 clock_12 news_12 let_12; 
      USEVARIABLES  ARE 
          ori_B ww1_B att_B rec_B clock_B news_B let_B  
          ori_1 ww1_1 att_1 rec_1 clock_1 news_1 let_1 
          ori_6 ww1_6 att_6 rec_6 clock_6 news_6 let_6 
          ori_12 ww1_12 att_12 rec_12 clock_12 news_12 let_12;   
    CATEGORICAL ARE ALL;     
    IDVARIABLE IS ID_new; 
    MISSING ARE ALL (-999);                           
ANALYSIS:  
    ESTIMATOR = WLSMV; 
    PROCESSORS = 2; 
MODEL:  
    AMT0 BY ori_B ww1_B att_B rec_B clock_B news_B let_B; 
    AMT1 BY ori_1 ww1_1 att_1 rec_1 clock_1 news_1 let_1; 
    AMT2 BY ori_6 ww1_6 att_6 rec_6 clock_6 news_6 let_6; 
    AMT3 BY ori_12 ww1_12 att_12 rec_12 clock_12 news_12 let_12; 
    {ori_B@1 ww1_B@1 att_B@1 rec_B@1 clock_B@1 news_B@1 let_B@1  
    ori_1@1 ww1_1@1 att_1@1 rec_1@1 clock_1@1 news_1@1 let_1@1 
    ori_6@1 ww1_6@1 att_6@1 rec_6@1 clock_6@1 news_6@1 let_6@1 
    ori_12@1 ww1_12@1 att_12@1 rec_12@1 clock_12@1 news_12@1 let_12@1}; 
    [AMT0@0 AMT1@0 AMT2@0 AMT3@0]; 
    AMT0 WITH AMT1 AMT2 AMT3; 
    AMT1 WITH AMT2 AMT3; 
    AMT2 WITH AMT3; 
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    ori_B WITH ori_1 ori_6 ori_12; 
    ori_1 WITH ori_6 ori_12; 
    ori_6 WITH ori_12; 
    ww1_B WITH ww1_1 ww1_6 ww1_12; 
    ww1_1 WITH ww1_6 ww1_12; 
    ww1_6 WITH ww1_12;   
    att_B WITH att_1 att_6 att_12; 
    att_1 WITH att_6 att_12; 
    att_6 WITH att_12; 
    rec_B WITH rec_1 rec_6 rec_12; 
    rec_1 WITH rec_6 rec_12; 
    rec_6 WITH rec_12; 
    clock_B WITH clock_1 clock_6 clock_12; 
    clock_1 WITH clock_6 clock_12; 
    clock_6 WITH clock_12; 
    news_B WITH news_1 news_6 news_12; 
    news_1 WITH news_6 news_12; 
    news_6 WITH news_12; 
    let_B WITH let_1 let_6 let_12; 
    let_1 WITH let_6 let_12; 
    let_6 WITH let_12; 
OUTPUT: 
    STANDARDIZED MODINDICES(3.84) PATTERNS RESIDUAL; 
SAVEDATA: 
    DIFFTEST = chidiff.dat; 
Scalar model 
TITLE: CFA for AMT data baseline to 12m, scalar model; 
DATA:  FILE IS  
C:\Users\Bogna\OneDrive - University of Glasgow\APPLE Trajectories\AMT_raw 
data.dat; 
VARIABLE:  
    NAMES ARE 
        ID_new 
        ori_B ww1_B att_B rec_B clock_B news_B let_B  
        ori_1 ww1_1 att_1 rec_1 clock_1 news_1 let_1 
        ori_6 ww1_6 att_6 rec_6 clock_6 news_6 let_6 
        ori_12 ww1_12 att_12 rec_12 clock_12 news_12 let_12; 
   USEVARIABLES  ARE 
        ori_B ww1_B att_B rec_B clock_B news_B let_B  
        ori_1 ww1_1 att_1 rec_1 clock_1 news_1 let_1 
        ori_6 ww1_6 att_6 rec_6 clock_6 news_6 let_6 
        ori_12 ww1_12 att_12 rec_12 clock_12 news_12 let_12; 
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    CATEGORICAL ARE ALL;               
    IDVARIABLE IS ID_new; 
    MISSING ARE ALL (-999);                                  
ANALYSIS:  
    ESTIMATOR = WLSMV; 
    PROCESSORS = 2; 
DIFFTEST = C:\Users\Bogna\OneDrive - University of Glasgow\APPLE 
Trajectories\chidiff.dat;  
MODEL:  
    AMT0 BY ori_B; 
    AMT0 BY ww1_B (cow); 
    AMT0 BY att_B (hen); 
    AMT0 BY rec_B (horse); 
    AMT0 BY clock_B (donkey); 
    AMT0 BY news_B (deer); 
    AMT0 BY let_B (elk); 
    AMT1 BY ori_1; 
    AMT1 BY ww1_1 (cow); 
    AMT1 BY att_1 (hen); 
    AMT1 BY rec_1 (horse); 
    AMT1 BY clock_1 (donkey); 
    AMT1 BY news_1 (deer); 
    AMT1 BY let_1 (elk); 
    AMT2 BY ori_6; 
    AMT2 BY ww1_6 (cow); 
    AMT2 BY att_6 (hen); 
    AMT2 BY rec_6 (horse); 
    AMT2 BY clock_6 (donkey); 
    AMT2 BY news_6 (deer); 
    AMT2 BY let_6 (elk); 
    AMT3 BY ori_12; 
    AMT3 BY ww1_12 (cow); 
    AMT3 BY att_12 (hen); 
    AMT3 BY rec_12 (horse); 
    AMT3 BY clock_12 (donkey); 
    AMT3 BY news_12 (deer); 
    AMT3 BY let_12 (elk); 
    [ori_B$1] (yellow); 
    [ww1_B$1] (black); 
    [att_B$1] (indigo);  
    [rec_B$1] (ochre);  
    [clock_B$2] (turquoise);  
    [news_B$1] (gold);  
    [let_B$1] (magenta); 
    [ori_1$1] (yellow); 
    [ww1_1$1] (black); 
    [att_1$1] (indigo);  
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     [rec_1$1] (ochre);  
     [clock_1$2] (turquoise);  
     [news_1$1] (gold);  
     [let_1$1] (magenta); 
     [ori_6$1] (yellow); 
     [ww1_6$1] (black); 
     [att_6$1] (indigo);  
     [rec_6$1] (ochre);  
     [clock_6$2] (turquoise);  
     [news_6$1] (gold);  
     [let_6$1] (magenta); 
     [ori_12$1] (yellow); 
     [ww1_12$1] (black); 
     [att_12$1] (indigo);  
     [rec_12$1] (ochre);  
     [clock_12$2] (turquoise);  
     [news_12$1] (gold);  
     [let_12$1] (magenta); 
     {ori_B@1 ww1_B@1 att_B@1 rec_B@1 clock_B@1 news_B@1 let_B@1  
     ori_1 ww1_1 att_1 rec_1 clock_1 news_1 let_1 
     ori_6 ww1_6 att_6 rec_6 clock_6 news_6 let_6 
     ori_12 ww1_12 att_12 rec_12 clock_12 news_12 let_12}; 
     [AMT0@0 AMT1* AMT2* AMT3*]; 
     AMT0 WITH AMT1 AMT2 AMT3; 
     AMT1 WITH AMT2 AMT3; 
     AMT2 WITH AMT3; 
     ori_B WITH ori_1 ori_6 ori_12; 
     ori_1 WITH ori_6 ori_12; 
     ori_6 WITH ori_12; 
     ww1_B WITH ww1_1 ww1_6 ww1_12; 
     ww1_1 WITH ww1_6 ww1_12; 
     ww1_6 WITH ww1_12;   
     att_B WITH att_1 att_6 att_12; 
     att_1 WITH att_6 att_12; 
     att_6 WITH att_12; 
     rec_B WITH rec_1 rec_6 rec_12; 
     rec_1 WITH rec_6 rec_12; 
     rec_6 WITH rec_12; 
     clock_B WITH clock_1 clock_6 clock_12; 
     clock_1 WITH clock_6 clock_12; 
     clock_6 WITH clock_12; 
     news_B WITH news_1 news_6 news_12; 
     news_1 WITH news_6 news_12; 
     news_6 WITH news_12; 
     let_B WITH let_1 let_6 let_12; 
     let_1 WITH let_6 let_12; 
     let_6 WITH let_12; 
 
330 
     
OUTPUT: 
    STANDARDIZED MODINDICES(3.84) PATTERNS; 
SAVEDATA: 
    SAVE=FS; 
    FILE IS AMT_fscores_scalar.dat; 
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Appendix 10: Chapter 7, Mplus code for a latent 
class trajectory model with three classes 
TITLE: LCGA with default approach to handling missing outcome data; 
DATA: FILE IS 
C:\Users\Bogna\OneDrive - University of Glasgow\APPLE Trajectories\ 
\LCGA_default\AMT_FS&T_finalN_def.dat; 
VARIABLE: 
    NAMES ARE 
        ID_new 
        AMT0 AMT1 AMT2 AMT3 t0 t1 t2 t3; 
    USEVARIABLES ARE 
        AMT0 AMT1 AMT2 AMT3 t0 t1 t2 t3; 
    TSCORES = t0 t1 t2 t3; 
    MISSING ARE ALL (-999); 
    IDVARIABLE IS ID_new; 
    CLASSES = c(3);     
ANALYSIS: 
    TYPE = MIXTURE RANDOM; 
    ALGORITHM = INTEGRATION; 
    STARTS = 100 10; 
    STITERATIONS = 10; 
    PROCESSORS = 4; 
MODEL: 
    %OVERALL% 
    i s | AMT0-AMT3 AT t0-t3; 
    i@0 s@0;  
PLOT: 
    TYPE = PLOT3;  
    SERIES = AMT0(0) AMT1(1) AMT2(6) AMT3(12);     
OUTPUT: 
    sampstat TECH1 TECH8; 
 





Appendix 11: Chapter 8, individual trajectories of change in cognitive function over a 
12-month period, following recruitment into the APPLE study. 
  
333 
List of References 
 
1. Horn JL, Cattell RB. Refinement and test of the theory of fluid and 
crystallized general intelligences. J Educ Psychol (1966) 57(5):253-70. Epub 
1966/10/01. doi: 10.1037/h0023816. PubMed PMID: 5918295. 
2. Salthouse T. Consequences of age-related cognitive declines. Annu Rev 
Psychol (2012) 63:201-26. Epub 2011/07/12. doi: 10.1146/annurev-psych-
120710-100328. PubMed PMID: 21740223. 
3. Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Clin 
Geriatr Med (2013) 29(4):737-52. Epub 2013/10/08. doi: 
10.1016/j.cger.2013.07.002. PubMed PMID: 24094294. 
4. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. 
Mild cognitive impairment: ten years later. Arch Neurol (2009) 66(12):1447-55. 
Epub 2009/12/17. doi: 10.1001/archneurol.2009.266. PubMed PMID: 20008648; 
PubMed Central PMCID: PMCPMC3081688. 
5. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. 
The diagnosis of mild cognitive impairment due to Alzheimer's disease: 
Recommendations from the National Institute on Aging-Alzheimer's Association 
workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers & 
Dementia (2011) 7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. PubMed PMID: 
WOS:000291239600004. 
6. American Psychiatric Association. Diagnostic and Statistical Manual of 
Mental Disorders (5th ed.). Washington, DC: American Psychiatric Association 
(2013). 
7. Sachs-Ericsson N, Blazer DG. The new DSM-5 diagnosis of mild 
neurocognitive disorder and its relation to research in mild cognitive 
impairment. Aging Ment Health (2015) 19(1):2-12. Epub 2014/06/11. doi: 
10.1080/13607863.2014.920303. PubMed PMID: 24914889. 
8. Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, et al. 
Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol (2014) 
10(11):634-42. Epub 2014/10/01. doi: 10.1038/nrneurol.2014.181. PubMed PMID: 
25266297. 
9. Deckers K, van Boxtel MP, Schiepers OJ, de Vugt M, Munoz Sanchez JL, 
Anstey KJ, et al. Target risk factors for dementia prevention: a systematic 
review and Delphi consensus study on the evidence from observational studies. 
Int J Geriatr Psychiatry (2015) 30(3):234-46. Epub 2014/12/17. doi: 
10.1002/gps.4245. PubMed PMID: 25504093. 
10. Anstey KJ, Ee N, Eramudugolla R, Jagger C, Peters R. A Systematic Review 
of Meta-Analyses that Evaluate Risk Factors for Dementia to Evaluate the 
Quantity, Quality, and Global Representativeness of Evidence. J Alzheimers Dis 
(2019) 70:S165-S86. doi: 10.3233/Jad-190181. PubMed PMID: 
WOS:000481670800014. 
11. Peters R, Booth A, Rockwood K, Peters J, D'Este C, Anstey KJ. Combining 
modifiable risk factors and risk of dementia: a systematic review and meta-
analysis. Bmj Open (2019) 9(1). doi: ARTN e022846 
10.1136/bmjopen-2018-022846. PubMed PMID: WOS:000471116800067. 
334 
12. Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D, et al. 
Global, regional, and national burden of stroke, 1990-2016: a systematic analysis 
for the Global Burden of Disease Study 2016. Lancet Neurol (2019) 18(5):439-58. 
doi: 10.1016/S1474-4422(19)30034-1. PubMed PMID: WOS:000464140400013. 
13. Leys D, Henon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke 
dementia. Lancet Neurol (2005) 4(11):752-9. Epub 2005/10/22. doi: 
10.1016/S1474-4422(05)70221-0. PubMed PMID: 16239182. 
14. WHO MONICA Project Principal Investigators. The World Health 
Organization MONICA Project (monitoring trends and determinants in 
cardiovascular disease): a major international collaboration. . J Clin Epidemiol 
(1988) 41(2):105-14. Epub 1988/01/01. doi: 10.1016/0895-4356(88)90084-4. 
PubMed PMID: 3335877. 
15. National Institute for Health and Care Excellence (NICE). What are strokes 
and transient ischaemic attacks? : NICE  [updated August 2020; cited 2021 March 
2]. Available from: https://cks.nice.org.uk/topics/stroke-tia/background-
information/definition/. 
16. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et 
al. An updated definition of stroke for the 21st century: a statement for 
healthcare professionals from the American Heart Association/American Stroke 
Association. Stroke (2013) 44(7):2064-89. Epub 2013/05/09. doi: 
10.1161/STR.0b013e318296aeca. PubMed PMID: 23652265. 
17. Murphy SJ, Werring DJ. Stroke: causes and clinical features. Medicine 
(Abingdon) (2020) 48(9):561-6. Epub 2020/08/25. doi: 
10.1016/j.mpmed.2020.06.002. PubMed PMID: 32837228. 
18. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et 
al. Definition and evaluation of transient ischemic attack: a scientific statement 
for healthcare professionals from the American Heart Association/American 
Stroke Association Stroke Council; Council on Cardiovascular Surgery and 
Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on 
Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular 
Disease. The American Academy of Neurology affirms the value of this statement 
as an educational tool for neurologists. Stroke (2009) 40(6):2276-93. Epub 
2009/05/09. doi: 10.1161/STROKEAHA.108.192218. PubMed PMID: 19423857. 
19. van Rooij FG, Kessels RP, Richard E, De Leeuw FE, van Dijk EJ. Cognitive 
Impairment in Transient Ischemic Attack Patients: A Systematic Review. 
Cerebrovasc Dis (2016) 42(1-2):1-9. Epub 2016/02/18. doi: 10.1159/000444282. 
PubMed PMID: 26886189. 
20. Pendlebury ST, Rothwell PM, Oxford Vascular S. Incidence and prevalence 
of dementia associated with transient ischaemic attack and stroke: analysis of 
the population-based Oxford Vascular Study. Lancet Neurol (2019) 18(3):248-58. 
Epub 2019/02/21. doi: 10.1016/S1474-4422(18)30442-3. PubMed PMID: 
30784556. 
21. Shaw RC, Walker G, Elliott E, Quinn TJ. Occurrence Rate of Delirium in 
Acute Stroke Settings Systematic Review and Meta-Analysis. Stroke (2019) 
50(11):3028-36. doi: 10.1161/Strokeaha.119.025015. PubMed PMID: 
WOS:000492999300032. 
335 
22. Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, 
prevention and treatment. Nature Reviews Neurology (2009) 5(4):210-20. doi: 
10.1038/nrneurol.2009.24. PubMed PMID: WOS:000265854600008. 
23. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors 
associated with pre-stroke and post-stroke dementia: a systematic review and 
meta-analysis. Lancet Neurol (2009) 8(11):1006-18. Epub 2009/09/29. doi: 
10.1016/S1474-4422(09)70236-4. PubMed PMID: 19782001. 
24. Melkas S, Jokinen H, Hietanen M, Erkinjuntti T. Poststroke cognitive 
impairment and dementia: prevalence, diagnosis, and treatment. Degener 
Neurol Neuromuscul Dis (2014) 4:21-7. Epub 2014/02/05. doi: 
10.2147/DNND.S37353. PubMed PMID: 32669898. 
25. Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, 
mechanisms and management. Ann Transl Med (2014) 2(8):80. Epub 2014/10/22. 
doi: 10.3978/j.issn.2305-5839.2014.08.05. PubMed PMID: 25333055. 
26. van Rijsbergen MW, Mark RE, de Kort PL, Sitskoorn MM. Subjective 
cognitive complaints after stroke: a systematic review. J Stroke Cerebrovasc Dis 
(2014) 23(3):408-20. Epub 2013/06/27. doi: 
10.1016/j.jstrokecerebrovasdis.2013.05.003. PubMed PMID: 23800498. 
27. Lo JW, Crawford JD, Desmond DW, Godefroy O, Jokinen H, Mahinrad S, et 
al. Profile of and risk factors for poststroke cognitive impairment in diverse 
ethnoregional groups. Neurology (2019) 93(24):e2257-e71. Epub 2019/11/13. 
doi: 10.1212/WNL.0000000000008612. PubMed PMID: 31712368. 
28. Heruti RJ, Lusky A, Dankner R, Ring H, Dolgopiat M, Barell V, et al. 
Rehabilitation outcome of elderly patients after a first stroke: Effect of 
cognitive status at admission on the functional outcome. Arch Phys Med Rehab 
(2002) 83(6):742-9. doi: 10.1053/apmr.2002.32739. PubMed PMID: 
WOS:000176004400002. 
29. Patel MD, Coshall C, Rudd AG, Wolfe CD. Cognitive impairment after 
stroke: clinical determinants and its associations with long-term stroke 
outcomes. J Am Geriatr Soc (2002) 50(4):700-6. Epub 2002/05/02. doi: 
10.1046/j.1532-5415.2002.50165.x. PubMed PMID: 11982671. 
30. Nys GMS, van Zandvoort MJE, van der Worp HB, de Haan EHF, de Kort 
PLM, Jansen BPW, et al. Early cognitive impairment predicts long-term 
depressive symptoms and quality of life after stroke. Journal of the Neurological 
Sciences (2006) 247(2):149-56. doi: 10.1016/j.jns.2006.04.005. 
31. Cumming TB, Brodtmann A, Darby D, Bernhardt J. The importance of 
cognition to quality of life after stroke. Journal of Psychosomatic Research 
(2014) 77(5):374-9. doi: 10.1016/j.jpsychores.2014.08.009. PubMed PMID: 
WOS:000344718200006. 
32. Mole JA, Demeyere N. The relationship between early post-stroke 
cognition and longer term activities and participation: A systematic review. 
Neuropsychological Rehabilitation (2020) 30(2):346-70. doi: 
10.1080/09602011.2018.1464934. PubMed PMID: WOS:000516877900012. 
33. Rigby H, Gubitz G, Phillips S. A systematic review of caregiver burden 
following stroke. Int J Stroke (2009) 4(4):285-92. Epub 2009/08/20. doi: 
10.1111/j.1747-4949.2009.00289.x. PubMed PMID: 19689757. 
336 
34. Rohde D, Gaynor E, Large M, Conway O, Bennett K, Williams DJ, et al. 
Stroke survivor cognitive decline and psychological wellbeing of family 
caregivers five years post-stroke: a cross-sectional analysis. Top Stroke Rehabil 
(2019) 26(3):180-6. Epub 2019/03/26. doi: 10.1080/10749357.2019.1590972. 
PubMed PMID: 30907273. 
35. Tang EYH, Price C, Stephan BCM, Robinson L, Exley C. Impact of Memory 
Problems Post-stroke on Patients and Their Family Carers: A Qualitative Study. 
Front Med-Lausanne (2020) 7. doi: ARTN 267 
10.3389/fmed.2020.00267. PubMed PMID: WOS:000548401400001. 
36. Claesson L, Linden T, Skoog I, Blomstrand C. Cognitive impairment after 
stroke - impact on activities of daily living and costs of care for elderly people. 
The Goteborg 70+ Stroke Study. Cerebrovasc Dis (2005) 19(2):102-9. Epub 
2004/12/21. doi: 10.1159/000082787. PubMed PMID: 15608434. 
37. Pollock A, St George B, Fenton M, Firkins L. Top ten research priorities 
relating to life after stroke. Lancet Neurol (2012) 11(3):209-. doi: Doi 
10.1016/S1474-4422(12)70029-7. PubMed PMID: WOS:000301014900008. 
38. Mijajlovic MD, Pavlovic A, Brainin M, Heiss WD, Quinn TJ, Ihle-Hansen HB, 
et al. Post-stroke dementia - a comprehensive review. BMC Med (2017) 15(1):11. 
Epub 2017/01/18. doi: 10.1186/s12916-017-0779-7. PubMed PMID: 28095900, 
39. Brainin M, Tuomilehto J, Heiss WD, Bornstein NM, Bath PM, Teuschl Y, et 
al. Post-stroke cognitive decline: an update and perspectives for clinical 
research. Eur J Neurol (2015) 22(2):229-38, e13-6. Epub 2014/12/11. doi: 
10.1111/ene.12626. PubMed PMID: 25492161. 
40. Broome LJ, Battle CE, Lawrence M, Evans PA, Dennis MS. Cognitive 
Outcomes following Thrombolysis in Acute Ischemic Stroke: A Systematic 
Review. J Stroke Cerebrovasc Dis (2016) 25(12):2868-75. Epub 2016/08/30. doi: 
10.1016/j.jstrokecerebrovasdis.2016.07.048. PubMed PMID: 27569709. 
41. Strambo D, Bartolini B, Beaud V, Marto JP, Sirimarco G, Dunet V, et al. 
Thrombectomy and Thrombolysis of Isolated Posterior Cerebral Artery Occlusion: 
Cognitive, Visual, and Disability Outcomes. Stroke (2020) 51(1):254-61. Epub 
2019/11/14. doi: 10.1161/STROKEAHA.119.026907. PubMed PMID: 31718503. 
42. Bath PM, Scutt P, Blackburn DJ, Ankolekar S, Krishnan K, Ballard C, et al. 
Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with 
Previous Stroke: Main Results from the Pilot 'Prevention of Decline in Cognition 
after Stroke Trial' (PODCAST) Randomised Controlled Trial. PLoS One (2017) 
12(1):e0164608. Epub 2017/01/18. doi: 10.1371/journal.pone.0164608. PubMed 
PMID: 28095412. 
43. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et 
al. Effects of blood pressure lowering with perindopril and indapamide therapy 
on dementia and cognitive decline in patients with cerebrovascular disease. Arch 
Intern Med (2003) 163(9):1069-75. Epub 2003/05/14. doi: 
10.1001/archinte.163.9.1069. PubMed PMID: 12742805. 
44. Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, et al. 
Effects of long-term blood pressure lowering and dual antiplatelet treatment on 
cognitive function in patients with recent lacunar stroke: a secondary analysis 
from the SPS3 randomised trial. Lancet Neurol (2014) 13(12):1177-85. Epub 
2014/12/03. doi: 10.1016/S1474-4422(14)70224-8. PubMed PMID: 25453457.  
337 
45. Ankolekar S, Geeganage C, Anderton P, Hogg C, Bath PM. Clinical trials for 
preventing post stroke cognitive impairment. J Neurol Sci (2010) 299(1-2):168-
74. Epub 2010/09/22. doi: 10.1016/j.jns.2010.08.052. PubMed PMID: 20855090. 
46. Yang Z, Wang H, Edwards D, Ding C, Yan L, Brayne C, et al. Association of 
blood lipids, atherosclerosis and statin use with dementia and cognitive 
impairment after stroke: A systematic review and meta-analysis. Ageing Res Rev 
(2020) 57:100962. Epub 2019/09/11. doi: 10.1016/j.arr.2019.100962. PubMed 
PMID: 31505259. 
47. Ihle-Hansen H, Thommessen B, Fagerland MW, Oksengard AR, Wyller TB, 
Engedal K, et al. Multifactorial vascular risk factor intervention to prevent 
cognitive impairment after stroke and TIA: a 12-month randomized controlled 
trial. Int J Stroke (2014) 9(7):932-8. Epub 2012/12/05. doi: 10.1111/j.1747-
4949.2012.00928.x. PubMed PMID: 23205666. 
48. Matz K, Teuschl Y, Firlinger B, Dachenhausen A, Keindl M, Seyfang L, et 
al. Multidomain Lifestyle Interventions for the Prevention of Cognitive Decline 
After Ischemic Stroke: Randomized Trial. Stroke (2015) 46(10):2874-80. Epub 
2015/09/17. doi: 10.1161/STROKEAHA.115.009992. PubMed PMID: 26374482. 
49. Merriman NA, Sexton E, McCabe G, Walsh ME, Rohde D, Gorman A, et al. 
Addressing cognitive impairment following stroke: systematic review and meta-
analysis of non-randomised controlled studies of psychological interventions. 
BMJ Open (2019) 9(2):e024429. Epub 2019/03/02. doi: 10.1136/bmjopen-2018-
024429. PubMed PMID: 30819706. 
50. O'Brien JT, Thomas A. Vascular dementia. Lancet (2015) 386(10004):1698-
706. Epub 2015/11/26. doi: 10.1016/S0140-6736(15)00463-8. PubMed PMID: 
26595643. 
51. Desmond DW. The neuropsychology of vascular cognitive impairment: is 
there a specific cognitive deficit? J Neurol Sci (2004) 226(1-2):3-7. Epub 
2004/11/13. doi: 10.1016/j.jns.2004.09.002. PubMed PMID: 15537510. 
52. Stephens S, Kenny RA, Rowan E, Allan L, Kalaria RN, Bradbury M, et al. 
Neuropsychological characteristics of mild vascular cognitive impairment and 
dementia after stroke. Int J Geriatr Psychiatry (2004) 19(11):1053-7. Epub 
2004/10/14. doi: 10.1002/gps.1209. PubMed PMID: 15481073. 
53. O'Brien JT. Vascular cognitive impairment. Am J Geriatr Psychiatry (2006) 
14(9):724-33. Epub 2006/09/01. doi: 10.1097/01.JGP.0000231780.44684.7e. 
PubMed PMID: 16943169. 
54. Gaebel W, Reed GM, Jakob R. Neurocognitive disorders in ICD-11: a new 
proposal and its outcome. World Psychiatry (2019) 18(2):232-3. Epub 
2019/05/07. doi: 10.1002/wps.20634. PubMed PMID: 31059606. 
55. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, et 
al. Cerebral blood flow in dementia. Arch Neurol (1975) 32(9):632-7. Epub 
1975/09/01. doi: 10.1001/archneur.1975.00490510088009. PubMed PMID: 
1164215. 
56. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia 
JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of 
the NINDS-AIREN International Workshop. Neurology (1993) 43(2):250-60. Epub 
1993/02/01. doi: 10.1212/wnl.43.2.250. PubMed PMID: 8094895. 
338 
57. van Straaten EC, Scheltens P, Knol DL, van Buchem MA, van Dijk EJ, 
Hofman PA, et al. Operational definitions for the NINDS-AIREN criteria for 
vascular dementia: an interobserver study. Stroke (2003) 34(8):1907-12. Epub 
2003/07/12. doi: 10.1161/01.STR.0000083050.44441.10. PubMed PMID: 
12855825. 
58. McAleese KE, Alafuzoff I, Charidimou A, De Reuck J, Grinberg LT, 
Hainsworth AH, et al. Post-mortem assessment in vascular dementia: advances 
and aspirations. BMC Med (2016) 14(1):129. Epub 2016/09/08. doi: 
10.1186/s12916-016-0676-5. PubMed PMID: 27600683. 
59. Wiederkehr S, Simard M, Fortin C, van Reekum R. Comparability of the 
clinical diagnostic criteria for vascular dementia: a critical review. Part I. J 
Neuropsychiatry Clin Neurosci (2008) 20(2):150-61. Epub 2008/05/03. doi: 
10.1176/appi.neuropsych.20.2.150. PubMed PMID: 18451186. 
60. Wiederkehr S, Simard M, Fortin C, van Reekum R. Validity of the clinical 
diagnostic criteria for vascular dementia: A critical review. Part II. Journal of 
Neuropsychiatry and Clinical Neurosciences (2008) 20(2):162-77. doi: DOI 
10.1176/appi.neuropsych.20.2.162. PubMed PMID: WOS:000257991900004. 
61. Sachdev PS, Lipnicki DM, Crawford JD, Brodaty H. The Vascular Behavioral 
and Cognitive Disorders criteria for vascular cognitive disorders: a validation 
study. European Journal of Neurology (2019) 26(9):1161-7. doi: 
10.1111/ene.13960. PubMed PMID: WOS:000478748700006. 
62. Quinn TJ, Elliott E, Langhorne P. Cognitive and Mood Assessment Tools for 
Use in Stroke. Stroke (2018) 49(2):483-90. doi: 10.1161/Strokeaha.117.016994. 
PubMed PMID: WOS:000422928000046. 
63. Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, et al. 
Alzheimer's Association recommendations for operationalizing the detection of 
cognitive impairment during the Medicare Annual Wellness Visit in a primary 
care setting. Alzheimer's & dementia : the journal of the Alzheimer's 
Association (2013) 9(2):141-50. Epub 2012/12/26. doi: 
10.1016/j.jalz.2012.09.011. PubMed PMID: 23265826. 
64. National Institute for Health and Care Excellence (NICE). Delirium: 
prevention, diagnosis and management (2010) [updated March 2019; cited 2021 
March 5]. Available from: https://www.nice.org.uk/guidance/cg103/chapter/1-
Guidance#treating-delirium. 
65. Mulkey MA, Olson DM, Hardin SR. Top four evidence-based nursing 
interventions for delirium. Medsurg Nursing (2019) 28(6):357-62. 
66. 4AT rapid clinical test for delirium [cited 2019 October 15]. Available 
from: https://www.the4at.com/. 
67. Bellelli G, Morandi A, Davis DHJ, Mazzola P, Turco R, Gentile S, et al. 
Validation of the 4AT, a new instrument for rapid delirium screening: a study in 
234 hospitalised older people. Age Ageing (2014) 43(4):496-502. doi: 
10.1093/ageing/afu021. 
68. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, et al. Evaluation 
of delirium in critically ill patients: validation of the Confusion Assessment 
Method for the Intensive Care Unit (CAM-ICU). Crit Care Med (2001) 29(7):1370-
9. Epub 2001/07/11. doi: 10.1097/00003246-200107000-00012. PubMed PMID: 
11445689. 
339 
69. Mansutti I, Saiani L, Palese A. Detecting delirium in patients with acute 
stroke: a systematic review of test accuracy. Bmc Neurol (2019) 19(1):310. Epub 
2019/12/04. doi: 10.1186/s12883-019-1547-4. PubMed PMID: 31791260. 
70. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A 
practical scale. Lancet (1974) 2(7872):81-4. Epub 1974/07/13. doi: 
10.1016/s0140-6736(74)91639-0. PubMed PMID: 4136544. 
71. Brott T, Adams HP, Jr., Olinger CP, Marler JR, Barsan WG, Biller J, et al. 
Measurements of acute cerebral infarction: a clinical examination scale. Stroke 
(1989) 20(7):864-70. Epub 1989/07/01. doi: 10.1161/01.str.20.7.864. PubMed 
PMID: 2749846. 
72. Stroke Scales and Related Information: National Institute of Health, 
National Institute of Neurological Disorders and Stroke. [updated March 29, 
2016; cited 2019 September 20]. Available from: 
https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Preventing-
Stroke/Stroke-Scales-and-Related-Information. 
73. Cote R, Hachinski VC, Shurvell BL, Norris JW, Wolfson C. The Canadian 
Neurological Scale: a preliminary study in acute stroke. Stroke (1986) 17(4):731-
7. Epub 1986/07/01. doi: 10.1161/01.str.17.4.731. PubMed PMID: 3738958. 
74. Elliott E, Drozdowska BA, Taylor-Rowan M, Shaw RC, Cuthbertson G, 
Quinn TJ. Who Is Classified as Untestable on Brief Cognitive Screens in an Acute 
Stroke Setting? Diagnostics (Basel) (2019) 9(3). Epub 2019/08/17. doi: 
10.3390/diagnostics9030095. PubMed PMID: 31416176. 
75. Stolwyk RJ, O'Neill MH, McKay AJD, Wong DK. Are Cognitive Screening 
Tools Sensitive and Specific Enough for Use After Stroke? A Systematic Literature 
Review. Stroke (2014) 45(10):3129-+. doi: 10.1161/Strokeaha.114.004232. 
PubMed PMID: WOS:000342794700060. 
76. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical 
method for grading the cognitive state of patients for the clinician. J Psychiatr 
Res (1975) 12(3):189-98. Epub 1975/11/01. doi: 10.1016/0022-3956(75)90026-6. 
PubMed PMID: 1202204. 
77. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, 
Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool 
for mild cognitive impairment. J Am Geriatr Soc (2005) 53(4):695-9. Epub 
2005/04/09. doi: 10.1111/j.1532-5415.2005.53221.x. PubMed PMID: 15817019. 
78. Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state 
examination in the detection of dementia and mild cognitive impairment. J 
Psychiatr Res (2009) 43(4):411-31. Epub 2008/06/27. doi: 
10.1016/j.jpsychires.2008.04.014. PubMed PMID: 18579155. 
79. Lees R, Selvarajah J, Fenton C, Pendlebury ST, Langhorne P, Stott DJ, et 
al. Test accuracy of cognitive screening tests for diagnosis of dementia and 
multidomain cognitive impairment in stroke. Stroke (2014) 45(10):3008-18. Epub 
2014/09/06. doi: 10.1161/STROKEAHA.114.005842. PubMed PMID: 25190446. 
80. Chu K. An introduction to sensitivity, specificity, predictive values and 
likelihood ratios. Emergency Medicine (1999) 11(3):175-81. 
81. Cullen B, O'Neill B, Evans JJ, Coen RF, Lawlor BA. A review of screening 
tests for cognitive impairment. J Neurol Neurosurg Psychiatry (2007) 78(8):790-
9. Epub 2006/12/21. doi: 10.1136/jnnp.2006.095414. PubMed PMID: 17178826. 
340 
82. Swift A, Heale R, Twycross A. What are sensitivity and specificity? Evid 
Based Nurs (2020) 23(1):2-4. Epub 2019/11/14. doi: 10.1136/ebnurs-2019-
103225. PubMed PMID: 31719126. 
83. Roebuck-Spencer TM, Glen T, Puente AE, Denney RL, Ruff RM, Hostetter 
G, et al. Cognitive Screening Tests Versus Comprehensive Neuropsychological 
Test Batteries: A National Academy of Neuropsychology Education Paperdagger. 
Arch Clin Neuropsychol (2017) 32(4):491-8. Epub 2017/03/24. doi: 
10.1093/arclin/acx021. PubMed PMID: 28334244. 
84. National Institute for Health and Care Excellence (NICE). Stroke 
rehabilitation in adults.: NICE (2013) [cited 2021 March 3]. Available from: 
https://www.nice.org.uk/guidance/cg162/chapter/1-
recommendations#cognitive-functioning-2. 
85. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, 
et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke 
Network vascular cognitive impairment harmonization standards. Stroke (2006) 
37(9):2220-41. Epub 2006/08/19. doi: 10.1161/01.STR.0000237236.88823.47. 
PubMed PMID: 16917086. 
86. Ahmed N, Steiner T, Caso V, Wahlgren N, participants E-Ks. 
Recommendations from the ESO-Karolinska Stroke Update Conference, 
Stockholm 13-15 November 2016. Eur Stroke J (2017) 2(2):95-102. Epub 
2018/06/15. doi: 10.1177/2396987317699144. PubMed PMID: 29900406. 
87. Lees R, Fearon P, Harrison JK, Broomfield NM, Quinn TJ. Cognitive and 
mood assessment in stroke research: focused review of contemporary studies. 
Stroke (2012) 43(6):1678-80. Epub 2012/04/27. doi: 
10.1161/STROKEAHA.112.653303. PubMed PMID: 22535271. 
88. Saa JP, Tse T, Baum C, Cumming T, Josman N, Rose M, et al. Longitudinal 
evaluation of cognition after stroke - A systematic scoping review. PLoS One 
(2019) 14(8):e0221735. Epub 2019/08/30. doi: 10.1371/journal.pone.0221735. 
PubMed PMID: 31465492. 
89. Demeyere N, Riddoch MJ, Slavkova ED, Bickerton WL, Humphreys GW. The 
Oxford Cognitive Screen (OCS): validation of a stroke-specific short cognitive 
screening tool. Psychol Assess (2015) 27(3):883-94. Epub 2015/03/03. doi: 
10.1037/pas0000082. PubMed PMID: 25730165. 
90. Crivelli D, Angelillo MT, Grippa E, Colucci A, Nardulli R, Balconi M. When 
is a novel psychometric measure needed? A preliminary analysis regarding the 
Cognitive Assessment for Stroke Patients (CASP) battery compared with MMSE 
and MoCA. Appl Neuropsych-Adul (2018) 25(5):410-6. doi: 
10.1080/23279095.2017.1320556. PubMed PMID: WOS:000436574500004. 
91. Qian L, Ding L, Cheng L, Zhu X, Zhao H, Jin J, et al. Early biomarkers for 
post-stroke cognitive impairment. J Neurol (2012) 259(10):2111-8. Epub 
2012/03/13. doi: 10.1007/s00415-012-6465-y. PubMed PMID: 22407276. 
92. Liu M, Zhou K, Li H, Dong X, Tan G, Chai Y, et al. Potential of serum 
metabolites for diagnosing post-stroke cognitive impairment. Mol Biosyst (2015) 




93. Chen YC, Chou WH, Fang CP, Liu TH, Tsou HH, Wang Y, et al. Serum Level 
and Activity of Butylcholinesterase: A Biomarker for Post-Stroke Dementia. J Clin 
Med (2019) 8(11). Epub 2019/10/28. doi: 10.3390/jcm8111778. PubMed PMID: 
31653081. 
94. Grobbee DE, Hoes AW. Clinical epidemiology: principles, methods, and 
applications for clinical research. Burlington, MA: Jones & Bartlett Publishers 
(2014). 
95. Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et 
al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction 
Model Studies. Ann Intern Med (2019) 170(1):51-8. Epub 2019/01/01. doi: 
10.7326/M18-1376. PubMed PMID: 30596875. 
96. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, et al. 
Prognosis research strategy (PROGRESS) 1: a framework for researching clinical 
outcomes. BMJ (2013) 346:e5595. Epub 2013/02/07. doi: 10.1136/bmj.e5595. 
PubMed PMID: 23386360. 
97. Kent P, Cancelliere C, Boyle E, Cassidy JD, Kongsted A. A conceptual 
framework for prognostic research. BMC Med Res Methodol (2020) 20(1):172. 
Epub 2020/07/01. doi: 10.1186/s12874-020-01050-7. PubMed PMID: 32600262. 
98. University College London. Prognosis research partnership: UCL  [cited 
2021 March 6]. Available from: https://www.ucl.ac.uk/health-
informatics/research/impact-research/prognosis-research-partnership. 
99. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, et 
al. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS 
Med (2013) 10(2):e1001380. Epub 2013/02/09. doi: 
10.1371/journal.pmed.1001380. PubMed PMID: 23393429. 
100. Hughes TF, Ganguli M. Modifiable Midlife Risk Factors for Late-Life 
Cognitive Impairment and Dementia. Curr Psychiatry Rev (2009) 5(2):73-92. Epub 
2009/12/01. doi: 10.2174/157340009788167347. PubMed PMID: 19946443. 
101. Regitz-Zagrosek V, Oertelt-Prigione S, Seeland U, Hetzer R. Sex and 
gender differences in myocardial hypertrophy and heart failure. Circ J (2010) 
74(7):1265-73. Epub 2010/06/19. doi: 10.1253/circj.cj-10-0196. PubMed PMID: 
20558892. 
102. World Health Organization (WHO). Global Health Observatory (GHO) data. 
Female life expectancy.: WHO  [cited 2021 March 2]. Available from: 
https://www.who.int/gho/women_and_health/mortality/life_expectancy_text/
en/. 
103. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and 
prognostic research: what, why, and how? BMJ (2009) 338:b375. Epub 
2009/02/25. doi: 10.1136/bmj.b375. PubMed PMID: 19237405. 
104. Herbert RD. Cohort studies of aetiology and prognosis: they're different. J 
Physiother (2014) 60(4):241-4. Epub 2014/12/03. doi: 
10.1016/j.jphys.2014.07.005. PubMed PMID: 25443537. 
105. Hingorani AD, Windt DA, Riley RD, Abrams K, Moons KG, Steyerberg EW, et 
al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ 
(2013) 346:e5793. Epub 2013/02/07. doi: 10.1136/bmj.e5793. PubMed PMID: 
23386361. 
342 
106. Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, 
Schroter S, et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model 
research. PLoS Med (2013) 10(2):e1001381. Epub 2013/02/09. doi: 
10.1371/journal.pmed.1001381. PubMed PMID: 23393430. 
107. Altman DG, Vergouwe Y, Royston P, Moons KGM. Prognosis and prognostic 
research: validating a prognostic model. Bmj-Brit Med J (2009) 338. doi: ARTN 
b605; 10.1136/bmj.b605. PubMed PMID: WOS:000266502400003. 
108. Ntaios G, Faouzi M, Ferrari J, Lang W, Vemmos K, Michel P. An integer-
based score to predict functional outcome in acute ischemic stroke: the ASTRAL 
score. Neurology (2012) 78(24):1916-22. doi: 10.1212/WNL.0b013e318259e221. 
109. Steyerberg EW. Clinical prediction models: a practical approach to 
development, validation, and updating: Springer Science & Business Media 
(2009). 
110. Pencina MJ, D'Agostino RB, Sr. Evaluating Discrimination of Risk Prediction 
Models: The C Statistic. JAMA (2015) 314(10):1063-4. Epub 2015/09/09. doi: 
10.1001/jama.2015.11082. PubMed PMID: 26348755. 
111. Crowson CS, Atkinson EJ, Therneau TM. Assessing calibration of prognostic 
risk scores. Stat Methods Med Res (2016) 25(4):1692-706. Epub 2013/08/03. doi: 
10.1177/0962280213497434. PubMed PMID: 23907781. 
112. Carter JV, Pan JM, Rai SN, Galandiuk S. ROC-ing along: Evaluation and 
interpretation of receiver operating characteristic curves. Surgery (2016) 
159(6):1638-45. doi: 10.1016/j.surg.2015.12.029. PubMed PMID: 
WOS:000375890400017. 
113. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et 
al. Assessing the performance of prediction models: a framework for traditional 
and novel measures. Epidemiology (2010) 21(1):128-38. Epub 2009/12/17. doi: 
10.1097/EDE.0b013e3181c30fb2. PubMed PMID: 20010215. 
114. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: 
Wiley (2000). xii, 373 p. p. 
115. Minne L, Ludikhuize J, de Rooij SEJA, Abu-Hanna A. Characterizing 
Predictive Models of Mortality for Older Adults and Their Validation for Use in 
Clinical Practice. J Am Geriatr Soc (2011) 59(6):1110-5. doi: 10.1111/j.1532-
5415.2011.03411.x. PubMed PMID: WOS:000291978300020. 
116. Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et 
al. PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model 
Studies: Explanation and Elaboration. Ann Intern Med (2019) 170(1):W1-W33. 
Epub 2019/01/01. doi: 10.7326/M18-1377. PubMed PMID: 30596876. 
117. Steyerberg EW, Harrell FE, Borsboom GJJM, Eijkemans MJC, Vergouwe Y, 
Habbema JDF. Internal validation of predictive models: Efficiency of some 
procedures for logistic regression analysis. J Clin Epidemiol (2001) 54(8):774-81. 
doi: Doi 10.1016/S0895-4356(01)00341-9. PubMed PMID: WOS:000170019900003. 
118. Efron B, Tibshirani R. An introduction to the bootstrap. New York: 
Chapman & Hall (1993). 
119. Altman DG, Royston P. What do we mean by validating a prognostic 
model? Stat Med (2000) 19(4):453-73. doi: Doi 10.1002/(Sici)1097-
0258(20000229)19:4<453::Aid-Sim350>3.3.Co;2-X. PubMed PMID: 
WOS:000085613900005. 
343 
120. Ramspek CL, Jager KJ, Dekker FW, Zoccali C, van Diepen M. External 
validation of prognostic models: what, why, how, when and where? Clinical 
Kidney Journal (2021) 14(1):49-58. doi: 10.1093/ckj/sfaa188. 
121. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of 
prognostic information. Ann Intern Med (1999) 130(6):515-24. Epub 1999/03/13. 
doi: 10.7326/0003-4819-130-6-199903160-00016. PubMed PMID: 10075620. 
122. Austin PC, van Klaveren D, Vergouwe Y, Nieboer D, Lee DS, Steyerberg 
EW. Geographic and temporal validity of prediction models: different 
approaches were useful to examine model performance. J Clin Epidemiol (2016) 
79:76-85. doi: 10.1016/j.jclinepi.2016.05.007. PubMed PMID: 
WOS:000389967700013. 
123. Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, 
Habbema JD. Validation and updating of predictive logistic regression models: a 
study on sample size and shrinkage. Stat Med (2004) 23(16):2567-86. Epub 
2004/08/03. doi: 10.1002/sim.1844. PubMed PMID: 15287085. 
124. Sim J, Teece L, Dennis MS, Roffe C, Team SOSS. Validation and 
Recalibration of Two Multivariable Prognostic Models for Survival and 
Independence in Acute Stroke. PLoS One (2016) 11(5):e0153527. Epub 
2016/05/27. doi: 10.1371/journal.pone.0153527. PubMed PMID: 27227988. 
125. Babyak MA. What you see may not be what you get: a brief, nontechnical 
introduction to overfitting in regression-type models. Psychosomatic medicine 
(2004) 66(3):411-21. 
126. Frisoni GB, Scheltens P, Galluzzi S, Nobili FM, Fox NC, Robert PH, et al. 
Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular 
disease, and regional cerebral blood flow and metabolism: consensus paper of 
the EADC. J Neurol Neurosurg Psychiatry (2003) 74(10):1371-81. Epub 
2003/10/23. doi: 10.1136/jnnp.74.10.1371. PubMed PMID: 14570828. 
127. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic 
research: application and impact of prognostic models in clinical practice. BMJ 
(2009) 338:b606. Epub 2009/06/09. doi: 10.1136/bmj.b606. PubMed PMID: 
19502216. 
128. Reilly BM, Evans AT. Translating clinical research into clinical practice: 
Impact of using prediction rules to make decisions. Annals of Internal Medicine 
(2006) 144(3):201-9. doi: 10.7326/0003-4819-144-3-200602070-00009. PubMed 
PMID: WOS:000235074800007. 
129. Genuis SJ, Genuis SK. Resisting cookbook medicine. Bmj (2004) 
329(7458):179. 
130. How to calculate risk: BMJ  [cited 2021 March 8]. Available from: 
https://bestpractice.bmj.com/info/toolkit/learn-ebm/how-to-calculate-risk/. 
131. National Institute for Health and Care Excellence (NICE). Atrial 
fibrillation: managament: NICE (2014) [updated August 1 2014; cited 2021 March 





132. Seelig J, Pisters R, Hemels ME, Huisman MV, ten Cate H, Alings M. When 
to withhold oral anticoagulation in atrial fibrillation - an overview of frequent 
clinical discussion topics. Vascular Health and Risk Management (2019) 15:399-
408. doi: 10.2147/Vhrm.S187656. PubMed PMID: WOS:000486212500001. 
133. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical 
management. J Autoimmun (2019) 96:1-13. Epub 2018/11/19. doi: 
10.1016/j.jaut.2018.11.001. PubMed PMID: 30448290. 
134. Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician 
(2008) 77(11):1553-60. Epub 2008/06/28. PubMed PMID: 18581835. 
135. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. 
N Engl J Med (2007) 357(1):39-51. Epub 2007/07/06. doi: 
10.1056/NEJMra043186. PubMed PMID: 17611206. 
136. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et 
al. American Society of Clinical Oncology/College of American Pathologists 
guideline recommendations for human epidermal growth factor receptor 2 
testing in breast cancer. Arch Pathol Lab Med (2007) 131(1):18-43. Epub 
2007/01/01. doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2. PubMed 
PMID: 19548375. 
137. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical 
Risk Stratification for Predicting Stroke and Thromboembolism in Atrial 
Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on 
Atrial Fibrillation. Chest (2010) 137(2):263-72. doi: 10.1378/chest.09-1584. 
PubMed PMID: WOS:000274612600006. 
138. Medicines Management and Therapeutics Committee. Atrial fibrillation 
and anticoagulation management. In: Medicines Information Leaflet (2019) 8(5); 
Publisher: Oxford University Hospitals NHS Foundation Trust. 
139. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel 
user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients 
with atrial fibrillation: the Euro Heart Survey. Chest (2010) 138(5):1093-100. 
Epub 2010/03/20. doi: 10.1378/chest.10-0134. PubMed PMID: 20299623. 
140. De Backer O, Arnous S, Ihlemann N, Vejlstrup N, Jorgensen E, Pehrson S, 
et al. Percutaneous left atrial appendage occlusion for stroke prevention in 
atrial fibrillation: an update. Open Heart (2014) 1(1):e000020. Epub 2014/10/22. 
doi: 10.1136/openhrt-2013-000020. PubMed PMID: 25332785. 
141. Zhang X, Bi X. Post-Stroke Cognitive Impairment: A Review Focusing on 
Molecular Biomarkers. J Mol Neurosci (2020) 70(8):1244-54. Epub 2020/03/29. 
doi: 10.1007/s12031-020-01533-8. PubMed PMID: 32219663. 
142. Casolla B, Caparros F, Cordonnier C, Bombois S, Henon H, Bordet R, et al. 
Biological and imaging predictors of cognitive impairment after stroke: a 
systematic review. J Neurol (2019) 266(11):2593-604. Epub 2018/10/24. doi: 
10.1007/s00415-018-9089-z. PubMed PMID: 30350168. 
143. Fong TG, Davis D, Growdon ME, Albuquerque A, Inouye SK. The interface 
between delirium and dementia in elderly adults. Lancet Neurol (2015) 




144. Mansutti I, Saiani L, Palese A. Delirium in patients with ischaemic and 
haemorrhagic stroke: findings from a scoping review. European Journal of 
Cardiovascular Nursing (2019) 18(6):435-48. doi: 10.1177/1474515119846226. 
PubMed PMID: WOS:000477647400002. 
145. Gottesman RF, Hillis AE. Predictors and assessment of cognitive 
dysfunction resulting from ischaemic stroke. Lancet Neurol (2010) 9(9):895-905. 
Epub 2010/08/21. doi: 10.1016/S1474-4422(10)70164-2. PubMed PMID: 
20723846. 
146. Danovska M, Peychinska D. Post-stroke cognitive impairment–
phenomenology and prognostic factors. Journal of IMAB–Annual Proceeding 
Scientific Papers (2012) 18(3):290-7. 
147. Carin-Levy G, Mead GE, Nicol K, Rush R, van Wijck F. Delirium in acute 
stroke: screening tools, incidence rates and predictors: a systematic review. J 
Neurol (2012) 259(8):1590-9. Epub 2012/01/12. doi: 10.1007/s00415-011-6383-4. 
PubMed PMID: 22234842. 
148. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of 
Evidence. In: Oxford Centre for Evidence-Based Medicine, editor. (2011). 
149. Burns PB, Rohrich RJ, Chung KC. The Levels of Evidence and Their Role in 
Evidence-Based Medicine. Plast Reconstr Surg (2011) 128(1):305-10. doi: 
10.1097/PRS.0b013e318219c171. PubMed PMID: WOS:000292499600068. 
150. Tang EYH, Robinson L, Stephan BCM. Risk Prediction Models for Post-
Stroke Dementia. Geriatrics (Basel) (2017) 2(3). Epub 2017/06/22. doi: 
10.3390/geriatrics2030019. PubMed PMID: 31011029. 
151. Drozdowska BA, McGill K, McKay M, Bartlam R, Langhorne P, Quinn TJ. 
Prognostic rules for predicting cognitive syndromes following stroke: A 
systematic review. Eur Stroke J (2021) 6(1):18-27. Epub 2021/04/06. doi: 
10.1177/2396987321997045. PubMed PMID: 33817331. 
152. Hou XH, Feng L, Zhang C, Cao XP, Tan L, Yu JT. Models for predicting risk 
of dementia: a systematic review. J Neurol Neurosurg Psychiatry (2019) 
90(4):373-9. Epub 2018/06/30. doi: 10.1136/jnnp-2018-318212. PubMed PMID: 
29954871. 
153. Lindroth H, Bratzke L, Purvis S, Brown R, Coburn M, Mrkobrada M, et al. 
Systematic review of prediction models for delirium in the older adult inpatient. 
BMJ Open (2018) 8(4):e019223. Epub 2018/05/01. doi: 10.1136/bmjopen-2017-
019223. PubMed PMID: 29705752. 
154. Tang EYH, Price CI, Robinson L, Exley C, Desmond DW, Kohler S, et al. 
Assessing the Predictive Validity of Simple Dementia Risk Models in Harmonized 
Stroke Cohorts. Stroke (2020) 51(7):2095-102. Epub 2020/06/23. doi: 
10.1161/STROKEAHA.120.027473. PubMed PMID: 32568644. 
155. Moons KG, de Groot JA, Bouwmeester W, Vergouwe Y, Mallett S, Altman 
DG, et al. Critical appraisal and data extraction for systematic reviews of 
prediction modelling studies: the CHARMS checklist. PLoS Med (2014) 
11(10):e1001744. Epub 2014/10/15. doi: 10.1371/journal.pmed.1001744. 
PubMed PMID: 25314315. 
  
346 
156. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting 
items for systematic reviews and meta-analyses: the PRISMA statement. Ann 
Intern Med (2009) 151(4):264-9, W64. Epub 2009/07/23. doi: 10.7326/0003-
4819-151-4-200908180-00135. PubMed PMID: 19622511. 
157. Cochrane Stroke. Search Methods for the Cochrane Stroke Group 
Specialised Register. Resources for authors and editors of reviews. [cited 2019 
October 7]. Available from: 
https://apps.ccbs.ed.ac.uk/csrg/entity/searchmethods.pdf. 
158. Geersing GJ, Bouwmeester W, Zuithoff P, Spijker R, Leeflang M, Moons 
KG. Search filters for finding prognostic and diagnostic prediction studies in 
Medline to enhance systematic reviews. PLoS One (2012) 7(2):e32844. Epub 
2012/03/07. doi: 10.1371/journal.pone.0032844. PubMed PMID: 22393453. 
159. Flodgren GM, Berg RC. Primary and secondary prevention interventions for 
cognitive decline and dementia. Oslo: (2016). 
160. National Institute for Health and Care Excellence (NICE). Appendix D: 
Review search strategies. Dementia: assessment, management and support for 
people living with dementia and their carers. (2018) [cited 2019 October 7]. 
Available from: https://www.nice.org.uk/guidance/ng97/documents/search-
strategies. 
161. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and 
mobile app for systematic reviews. Syst Rev (2016) 5(1):210. Epub 2016/12/07. 
doi: 10.1186/s13643-016-0384-4. PubMed PMID: 27919275. 
162. Carter JV, Pan J, Rai SN, Galandiuk S. ROC-ing along: Evaluation and 
interpretation of receiver operating characteristic curves. Surgery (2016) 
159(6):1638-45. Epub 2016/03/11. doi: 10.1016/j.surg.2015.12.029. PubMed 
PMID: 26962006. 
163. Drozdowska BA, Singh S, Quinn TJ. Thinking About the Future: A Review of 
Prognostic Scales Used in Acute Stroke. Frontiers in Neurology (2019) 10. doi: 
ARTN 274; 10.3389/fneur.2019.00274. PubMed PMID: WOS:000461859800001. 
164. Chander RJ, Lam BYK, Lin X, Ng AYT, Wong APL, Mok VCT, et al. 
Development and validation of a risk score (CHANGE) for cognitive impairment 
after ischemic stroke. Sci Rep (2017) 7(1):12441. Epub 2017/10/01. doi: 
10.1038/s41598-017-12755-z. PubMed PMID: 28963553. 
165. Ding MY, Xu Y, Wang YZ, Li PX, Mao YT, Yu JT, et al. Predictors of 
Cognitive Impairment After Stroke: A Prospective Stroke Cohort Study. J 
Alzheimers Dis (2019) 71(4):1139-51. Epub 2019/09/17. doi: 10.3233/JAD-
190382. PubMed PMID: 31524163. 
166. Gong K, Zhao L, Guo J, Wang Z. A nomogram to predict cognitive 
impairment after supratentorial spontaneous intracranial hematoma in adult 
patients: A retrospective cohort study. Medicine (Baltimore) (2019) 
98(42):e17626. Epub 2019/10/19. doi: 10.1097/MD.0000000000017626. PubMed 
PMID: 31626144. 
167. Kandiah N, Chander RJ, Lin X, Ng A, Poh YY, Cheong CY, et al. Cognitive 
Impairment after Mild Stroke: Development and Validation of the SIGNAL2 Risk 
Score. J Alzheimers Dis (2016) 49(4):1169-77. Epub 2015/11/26. doi: 
10.3233/JAD-150736. PubMed PMID: 26599056. 
347 
168. Lin JH, Lin RT, Tai CT, Hsieh CL, Hsiao SF, Liu CK. Prediction of poststroke 
dementia. Neurology (2003) 61(3):343-8. Epub 2003/08/13. doi: 
10.1212/01.wnl.0000078891.27052.10. PubMed PMID: 12913195. 
169. Munsch F, Sagnier S, Asselineau J, Bigourdan A, Guttmann CR, Debruxelles 
S, et al. Stroke Location Is an Independent Predictor of Cognitive Outcome. 
Stroke (2016) 47(1):66-73. doi: 10.1161/Strokeaha.115.011242. PubMed PMID: 
WOS:000367136500011. 
170. Salihovic D, Smajlovic D, Mijajlovic M, Zoletic E, Ibrahimagic OC. 
Cognitive syndromes after the first stroke. Neurological Sciences (2018) 
39(8):1445-51. doi: 10.1007/s10072-018-3447-6. PubMed PMID: 
WOS:000439465800016. 
171. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. 
Interobserver agreement for the assessment of handicap in stroke patients. 
Stroke (1988) 19(5):604-7. Epub 1988/05/01. doi: 10.1161/01.str.19.5.604. 
PubMed PMID: 3363593. 
172. Kostalova M, Bednarik J, Mitasova A, Dusek L, Michalcakova R, Kerkovsky 
M, et al. Towards a predictive model for post-stroke delirium. Brain Injury 
(2012) 26(7-8):962-71. doi: 10.3109/02699052.2012.660510. PubMed PMID: 
WOS:000305135100007. 
173. Kotfis K, Bott-Olejnik M, Szylinska A, Rotter I. Could Neutrophil-to-
Lymphocyte Ratio (NLR) Serve as a Potential Marker for Delirium Prediction in 
Patients with Acute Ischemic Stroke? A Prospective Observational Study. Journal 
of Clinical Medicine (2019) 8(7). doi: ARTN 1075; 10.3390/jcm8071075. PubMed 
PMID: WOS:000479003300157. 
174. Oldenbeuving AW, de Kort PLM, van der Sluijs JFV, Kappelle LJ, Roks G. 
An early prediction of delirium in the acute phase after stroke. J Neurol 
Neurosur Ps (2014) 85(4):431-4. doi: 10.1136/jnnp-2013-304920. PubMed PMID: 
WOS:000332308500016. 
175. Tang E, Exley C, Price C, Stephan B, Robinson L. The views of public and 
clinician stakeholders on risk assessment tools for post-stroke dementia: a 
qualitative study. BMJ Open (2019) 9(3):e025586. Epub 2019/03/29. doi: 
10.1136/bmjopen-2018-025586. PubMed PMID: 30918033. 
176. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et 
al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J 
Epidemiol (2015) 44(3):827-36. Epub 2015/06/08. doi: 10.1093/ije/dyv098. 
PubMed PMID: 26050254. 
177. Riley RD, Ensor J, Snell KIE, Debray TPA, Altman DG, Moons KGM, et al. 
External validation of clinical prediction models using big datasets from e-health 
records or IPD meta-analysis: opportunities and challenges. Bmj-Brit Med J 
(2016) 353. doi: ARTN i3140; 10.1136/bmj.i3140. PubMed PMID: 
WOS:000378723500006. 
178. Brainin M, Tuomilehto J, Heiss WD, Bornstein NM, Bath PMW, Teuschl Y, 
et al. Post-stroke cognitive decline: an update and perspectives for clinical 
research. European Journal of Neurology (2015) 22(2):229. doi: 
10.1111/ene.12626. PubMed PMID: WOS:000347701300004. 
  
348 
179. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to 
screen risk factors for use in multivariable analysis. J Clin Epidemiol (1996) 
49(8):907-16. doi: Doi 10.1016/0895-4356(96)00025-X. PubMed PMID: 
WOS:A1996VB72900014. 
180. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis 
studies in systematic reviews. Ann Intern Med (2006) 144(6):427-37. Epub 
2006/03/22. doi: 10.7326/0003-4819-144-6-200603210-00010. PubMed PMID: 
16549855. 
181. Young RJ. The effect of regular exercise on cognitive functioning and 
personality. Br J Sports Med (1979) 13(3):110-7. Epub 1979/09/01. doi: 
10.1136/bjsm.13.3.110. PubMed PMID: 486882. 
182. Monk A. Aging, Loneliness, and Communications. Am Behav Sci (1988) 
31(5):532-63. doi: Doi 10.1177/000276488031005004. PubMed PMID: 
WOS:A1988N948700003. 
183. Gajewski PD, Falkenstein M. Physical activity and neurocognitive 
functioning in aging - a condensed updated review. Eur Rev Aging Phys A (2016) 
13. doi: ARTN 1; 10.1186/s11556-016-0161-3. PubMed PMID: 
WOS:000369694000001. 
184. Erickson KI, Hillman C, Sullman CM, Ballard RM, Bloodgood B, Conroy DE, 
et al. Physical Activity, Cognition, and Brain Outcomes: A Review of the 2018 
Physical Activity Guidelines. Medicine and Science in Sports and Exercise (2019) 
51(6):1242-51. doi: 10.1249/Mss.0000000000001936. PubMed PMID: 
WOS:000468480400019. 
185. Penninkilampi R, Casey AN, Singh MF, Brodaty H. The Association between 
Social Engagement, Loneliness, and Risk of Dementia: A Systematic Review and 
Meta-Analysis. J Alzheimers Dis (2018) 66(4):1619-33. doi: 10.3233/Jad-180439. 
PubMed PMID: WOS:000457776400027. 
186. Evans IEM, Martyr A, Collins R, Brayne C, Clare L. Social Isolation and 
Cognitive Function in Later Life: A Systematic Review and Meta-Analysis. J 
Alzheimers Dis (2019) 70:S119-S44. doi: 10.3233/Jad-180501. PubMed PMID: 
WOS:000481670800012. 
187. Sommerlad A, Sabia S, Singh-Manoux A, Lewis G, Livingston G. Association 
of social contact with dementia and cognition: 28-year follow-up of the 
Whitehall II cohort study. Plos Medicine (2019) 16(8). doi: ARTN e1002862; 
10.1371/journal.pmed.1002862. PubMed PMID: WOS:000489050500019. 
188. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated 
lifestyle in late life might protect against dementia. Lancet Neurol (2004) 
3(6):343-53. doi: Doi 10.1016/S1474-4422(04)00767-7. PubMed PMID: 
WOS:000221663000016. 
189. Dause TJ, Kirby ED. Aging gracefully: social engagement joins exercise 
and enrichment as a key lifestyle factor in resistance to age-related cognitive 
decline. Neural Regeneration Research (2019) 14(1):39-42. doi: 10.4103/1673-
5374.243698. PubMed PMID: WOS:000451333500006. 
190. Caspersen CJ, Powell KE, Christenson GM. Physical-Activity, Exercise, and 
Physical-Fitness - Definitions and Distinctions for Health-Related Research. 
Public Health Rep (1985) 100(2):126-31. PubMed PMID: WOS:A1985AFX9800005. 
349 
191. National Health Service (NHS). Exercise  [updated 2019 8 Oct; cited 2020 
20 Oct]. Available from: https://www.nhs.uk/live-well/exercise/. 
192. Atkin AJ, Gorely T, Clemes SA, Yates T, Edwardson C, Brage S, et al. 
Methods of Measurement in epidemiology: Sedentary Behaviour. International 
Journal of Epidemiology (2012) 41(5):1460-71. doi: 10.1093/ije/dys118. PubMed 
PMID: WOS:000309922700032. 
193. Hallgren M, Dunstan DW, Owen N. Passive Versus Mentally Active 
Sedentary Behaviors and Depression. Exerc Sport Sci Rev (2020) 48(1):20-7. doi: 
10.1249/Jes.0000000000000211. PubMed PMID: WOS:000502755700005. 
194. Bath PA, Deeg D. Social engagement and health outcomes among older 
people: introduction to a special section. European Journal of Ageing (2005) 
2(1):24-30. doi: 10.1007/s10433-005-0019-4. 
195. Hall A, Wellman B. Social networks and social support.  (1985). 
196. Berkman LF. The relationship of social networks and social support to 
morbidity and mortality.  (1985). 
197. Bowling A, Browne PD. Social Networks, Health, and Emotional Well-Being 
among the Oldest in London. J Gerontol (1991) 46(1):S20-S32. doi: DOI 
10.1093/geronj/46.1.S20. PubMed PMID: WOS:A1991FJ10900014. 
198. Everard KM, Lach HW, Fisher EB, Baum MC. Relationship of activity and 
social support to the functional health of older adults. J Gerontol B-Psychol 
(2000) 55(4):S208-S12. doi: DOI 10.1093/geronb/55.4.S208. PubMed PMID: 
WOS:000088045700008. 
199. Cohen S, Hoberman HM. Positive Events and Social Supports as Buffers of 
Life Change Stress. J Appl Soc Psychol (1983) 13(2):99-125. doi: DOI 
10.1111/j.1559-1816.1983.tb02325.x. PubMed PMID: WOS:A1983RB53800001. 
200. Young FW, Glasgow N. Voluntary social participation and health. Res 
Aging (1998) 20(3):339-62. doi: Doi 10.1177/0164027598203004. PubMed PMID: 
WOS:000073237100004. 
201. Gilmour H. Social participation and the health and well-being of Canadian 
seniors. Health Rep (2012) 23(4):23-32. PubMed PMID: WOS:000312760600003. 
202. Kamiya Y, Whelan B, Timonen V, Kenny RA. The differential impact of 
subjective and objective aspects of social engagement on cardiovascular risk 
factors. Bmc Geriatr (2010) 10. doi: Artn 81; 10.1186/1471-2318-10-81. PubMed 
PMID: WOS:000208731600081. 
203. Rook KS. Research on social support, loneliness, and social isolation: 
Toward an integration. Review of Personality & Social Psychology (1984). 
204. Miles L. Physical activity and health. Nutrition Bulletin (2007) 32(4):314-
63. doi: 10.1111/j.1467-3010.2007.00668.x. 
205. Saunders TJ, McIsaac T, Douillette K, Gaulton N, Hunter S, Rhodes RE, et 
al. Sedentary behaviour and health in adults: an overview of systematic reviews. 
Appl Physiol Nutr Metab (2020) 45(10 (Suppl. 2)):S197-S217. Epub 2020/10/16. 
doi: 10.1139/apnm-2020-0272. PubMed PMID: 33054341. 
206. Saunders TJ, Larouche R, Colley RC, Tremblay MS. Acute sedentary 
behaviour and markers of cardiometabolic risk: a systematic review of 
intervention studies. J Nutr Metab (2012) 2012:712435. Epub 2012/07/04. doi: 
10.1155/2012/712435. PubMed PMID: 22754695. 
350 
207. Stamatakis E, de Rezende LFM, Rey-Lopez JP. Sedentary Behaviour and 
Cardiovascular Disease. Springer Ser Epidemi (2018):215-43. doi: 10.1007/978-3-
319-61552-3_9. PubMed PMID: WOS:000465573600010. 
208. Chan JSY, Liu G, Liang D, Deng K, Wu J, Yan JH. Special Issue - 
Therapeutic Benefits of Physical Activity for Mood: A Systematic Review on the 
Effects of Exercise Intensity, Duration, and Modality. J Psychol (2019) 
153(1):102-25. Epub 2018/10/16. doi: 10.1080/00223980.2018.1470487. PubMed 
PMID: 30321106. 
209. Berkman LF, Krishna A. Social Network Epidemiology. In: Berkman LF, 
Kawachi I, Glymour MM, editors. Social Epidemiology, 2nd Edition. New York: 
Oxford University Press (2014). 
210. Uchino BN, Cacioppo JT, KiecoltGlaser JK. The relationship between 
social support and physiological processes: A review with emphasis on underlying 
mechanisms and implications for health. Psychol Bull (1996) 119(3):488-531. doi: 
Doi 10.1037/0033-2909.119.3.488. PubMed PMID: WOS:A1996UL59200008. 
211. McEwen BS. The neurobiology of stress: from serendipity to clinical 
relevance. Brain Res (2000) 886(1-2):172-89. doi: Doi 10.1016/S0006-
8993(00)02950-4. PubMed PMID: WOS:000166027200014. 
212. Friedler B, Crapser J, McCullough L. One is the deadliest number: the 
detrimental effects of social isolation on cerebrovascular diseases and cognition. 
Acta Neuropathol (2015) 129(4):493-509. doi: 10.1007/s00401-014-1377-9. 
PubMed PMID: WOS:000351517200002. 
213. Cohen S, Doyle WJ, Skoner DP, Rabin BS, Gwaltney JM. Social ties and 
susceptibility to the common cold. Jama-J Am Med Assoc (1997) 277(24):1940-4. 
PubMed PMID: WOS:A1997XF08700038. 
214. Knox SS, Uvnas-Moberg K. Social isolation and cardiovascular disease: an 
atherosclerotic pathway? Psychoneuroendocrinology (1998) 23(8):877-90. 
PubMed PMID: 9924742. 
215. Loucks EB, Berkman LF, Gruenewald TL, Seeman TE. Relation of social 
integration to inflammatory marker concentrations in men and women 70 to 79 
years. Am J Cardiol (2006) 97(7):1010-6. doi: 10.1016/j.amjcard.2005.10.043. 
PubMed PMID: WOS:000236708700017. 
216. Cohen S. Psychosocial stress, social networks and susceptibility to 
infection. The link between religion and health: Psychoneuroimmunology and 
the faith factor (2002):101-23. 
217. Cacioppo JT, Hawkley LC. Social isolation and health, with an emphasis on 
underlying mechanisms. Perspect Biol Med (2003) 46(3):S39-S52. doi: DOI 
10.1353/pbm.2003.0049. PubMed PMID: WOS:000184458500004. 
218. Stuller KA, Jarrett B, DeVries AC. Stress and social isolation increase 
vulnerability to stroke. Exp Neurol (2012) 233(1):33-9. doi: 
10.1016/j.expneurol.2011.01.016. PubMed PMID: WOS:000300123900005. 
219. Akerlind I, Hornquist JO. Loneliness and Alcohol-Abuse - a Review of 
Evidences of an Interplay. Social Science & Medicine (1992) 34(4):405-14. doi: 
Doi 10.1016/0277-9536(92)90300-F. PubMed PMID: WOS:A1992HJ54000007. 
220. Dyal SR, Valente TW. A Systematic Review of Loneliness and Smoking: 
Small Effects, Big Implications. Subst Use Misuse (2015) 50(13):1697-716. doi: 
10.3109/10826084.2015.1027933. PubMed PMID: WOS:000365684100009. 
351 
221. Pritchard ME, Yalch KL. Relationships among loneliness, interpersonal 
dependency, and disordered eating in young adults. Pers Indiv Differ (2009) 
46(3):341-6. doi: 10.1016/j.paid.2008.10.027. PubMed PMID: 
WOS:000263406900016. 
222. Levine MP. Loneliness and Eating Disorders. J Psychol (2012) 146(1-2):243-
57. doi: 10.1080/00223980.2011.606435. PubMed PMID: WOS:000302607900016. 
223. Prang KH, Berecki-Gisolf J, Newnam S. Recovery from musculoskeletal 
injury: the role of social support following a transport accident. Health Qual Life 
Outcomes (2015) 13:97. Epub 2015/07/04. doi: 10.1186/s12955-015-0291-8. 
PubMed PMID: 26138816. 
224. Wu JR, Frazier SK, Rayens MK, Lennie TA, Chung ML, Moser DK. Medication 
Adherence, Social Support, and Event-Free Survival in Patients With Heart 
Failure. Health Psychol (2013) 32(6):637-46. doi: 10.1037/a0028527. PubMed 
PMID: WOS:000319547300004. 
225. Cardoso-Moreno MJ, Tomas-Aragones L. The influence of perceived family 
support on post surgery recovery. Psychol Health Med (2017) 22(1):121-8. Epub 
2016/02/24. doi: 10.1080/13548506.2016.1153680. PubMed PMID: 26899740. 
226. Wylde V, Kunutsor S, Lenguerrand E, Jackson J, Blom AW, Beswick AD. 
Association of social support with patient-reported outcomes after joint 
replacement: a systematic review and meta-analysis. Lancet Rheumatol (2019) 
1(3):E174-E86. doi: 10.1016/S2665-9913(19)30050-5. PubMed PMID: 
WOS:000547827900016. 
227. van Praag H, Kempermann G, Gage FH. Neural consequences of 
environmental enrichment. Nat Rev Neurosci (2000) 1(3):191-8. Epub 
2001/03/22. doi: 10.1038/35044558. PubMed PMID: 11257907. 
228. Volkers KM, Scherder EJ. Impoverished environment, cognition, aging and 
dementia. Rev Neurosci (2011) 22(3):259-66. Epub 2011/05/20. doi: 
10.1515/RNS.2011.026. PubMed PMID: 21591910. 
229. Rosenich E, Hordacre B, Paquet C, Koblar SA, Hillier SL. Cognitive Reserve 
as an Emerging Concept in Stroke Recovery. Neurorehabilitation and Neural 
Repair (2020) 34(3):187-99. doi: Artn 1545968320907071; 
10.1177/1545968320907071. PubMed PMID: WOS:000515468100001. 
230. McDonald MW, Hayward KS, Rosbergen ICM, Jeffers MS, Corbett D. Is 
Environmental Enrichment Ready for Clinical Application in Human Post-stroke 
Rehabilitation? Frontiers in Behavioral Neuroscience (2018) 12. doi: ARTN 135; 
10.3389/fnbeh.2018.00135. PubMed PMID: WOS:000438309100001. 
231. Zhao Z, Sabirzhanov B, Wu J, Faden AI, Stoica BA. Voluntary Exercise 
Preconditioning Activates Multiple Antiapoptotic Mechanisms and Improves 
Neurological Recovery after Experimental Traumatic Brain Injury. J Neurotrauma 
(2015) 32(17):1347-60. Epub 2014/11/25. doi: 10.1089/neu.2014.3739. PubMed 
PMID: 25419789. 
232. Reinholdsson M, Palstam A, Sunnerhagen KS. Prestroke physical activity 
could influence acute stroke severity (part of PAPSIGOT). Neurology (2018) 




233. Oberlin LE, Waiwood AM, Cumming TB, Marsland AL, Bernhardt J, Erickson 
KI. Effects of Physical Activity on Poststroke Cognitive Function A Meta-Analysis 
of Randomized Controlled Trials. Stroke (2017) 48(11):3093-+. doi: 
10.1161/Strokeaha.117.017319. PubMed PMID: WOS:000413496900038. 
234. Nicholson S, Sniehotta FF, van Wijck F, Greig CA, Johnston M, McMurdo 
MET, et al. A systematic review of perceived barriers and motivators to physical 
activity after stroke. International Journal of Stroke (2013) 8(5):357-64. doi: 
10.1111/j.1747-4949.2012.00880.x. PubMed PMID: WOS:000320725200022. 
235. Marzolini S, Fong K, Jagroop D, Neirinckx J, Liu J, Reyes R, et al. 
Eligibility, Enrollment, and Completion of Exercise-Based Cardiac Rehabilitation 
Following Stroke Rehabilitation: What Are the Barriers? Phys Ther (2020) 
100(1):44-56. Epub 2019/10/08. doi: 10.1093/ptj/pzz149. PubMed PMID: 
31588512. 
236. Benatti FB, Ried-Larsen M. The Effects of Breaking up Prolonged Sitting 
Time: A Review of Experimental Studies. Med Sci Sports Exerc (2015) 
47(10):2053-61. Epub 2015/09/18. doi: 10.1249/MSS.0000000000000654. PubMed 
PMID: 26378942. 
237. Chrismas BCR, Taylor L, Cherif A, Sayegh S, Bailey DP. Breaking up 
prolonged sitting with moderate-intensity walking improves attention and 
executive function in Qatari females. PLoS One (2019) 14(7):e0219565. Epub 
2019/07/13. doi: 10.1371/journal.pone.0219565. PubMed PMID: 31299061. 
238. English C, Healy GN, Coates A, Lewis L, Olds T, Bernhardt J. Sitting and 
Activity Time in People With Stroke. Physical Therapy (2016) 96(2):193-201. doi: 
10.2522/ptj.20140522. PubMed PMID: WOS:000369775800008. 
239. English C, Janssen H, Crowfoot G, Bourne J, Callister R, Dunn A, et al. 
Frequent, short bouts of light-intensity exercises while standing decreases 
systolic blood pressure: Breaking Up Sitting Time after Stroke (BUST-Stroke) 
trial. International Journal of Stroke (2018) 13(9):932-40. doi: 
10.1177/1747493018798535. PubMed PMID: WOS:000454363000009. 
240. Falck RS, Davis JC, Liu-Ambrose T. What is the association between 
sedentary behaviour and cognitive function? A systematic review. British Journal 
of Sports Medicine (2017) 51(10):800-11. doi: 10.1136/bjsports-2015-095551. 
PubMed PMID: WOS:000400583100010. 
241. Valtorta NK, Kanaan M, Gilbody S, Ronzi S, Hanratty B. Loneliness and 
social isolation as risk factors for coronary heart disease and stroke: systematic 
review and meta-analysis of longitudinal observational studies. Heart (2016) 
102(13):1009-16. doi: 10.1136/heartjnl-2015-308790. PubMed PMID: 
WOS:000378716400008. 
242. Hommel M, Trabucco-Miguel S, Joray S, Naegele B, Gonnet N, Jaillard A, 
et al. Social dysfunctioning after mild to moderate first-ever stroke at vocational 
age. J Neurol Neurosur Ps (2009) 80(4):371-5. doi: 10.1136/jnnp.2008.157875. 
PubMed PMID: WOS:000264238800006. 
243. Brady MC, Clark AM, Dickson S, Paton G, Barbour RS. The impact of 
stroke-related dysarthria on social participation and implications for 
rehabilitation. Disabil Rehabil (2011) 33(3):178-86. doi: 
10.3109/09638288.2010.517897. PubMed PMID: WOS:000285553600002. 
  
353 
244. Mukherjee D, Levin RL, Heller W. The cognitive, emotional, and social 
sequelae of stroke: psychological and ethical concerns in post-stroke adaptation. 
Top Stroke Rehabil (2006) 13(4):26-35. Epub 2006/11/04. doi: 10.1310/tsr1304-
26. PubMed PMID: 17082166. 
245. Glymour MM, Weuve J, Fay ME, Glass T, Berkman LF. Social ties and 
cognitive recovery after stroke: Does social integration promote cognitive 
resilience? Neuroepidemiology (2008) 31(1):10-20. doi: 10.1159/000136646. 
PubMed PMID: WOS:000257115100002. 
246. Glass TA, Matchar DB, Belyea M, Feussner JR. Impact of social support on 
outcome in first stroke. Stroke (1993) 24(1):64-70. Epub 1993/01/01. doi: 
10.1161/01.str.24.1.64. PubMed PMID: 8418553. 
247. Tsouna-Hadjis E, Vemmos KN, Zakopoulos N, Stamatelopoulos S. First-
stroke recovery process: the role of family social support. Arch Phys Med Rehabil 
(2000) 81(7):881-7. Epub 2000/07/15. doi: 10.1053/apmr.2000.4435. PubMed 
PMID: 10895999. 
248. Glass TA, Maddox GL. The quality and quantity of social support: stroke 
recovery as psycho-social transition. Soc Sci Med (1992) 34(11):1249-61. Epub 
1992/06/01. doi: 10.1016/0277-9536(92)90317-j. PubMed PMID: 1641684. 
249. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke 
JP. The strengthening the reporting of observational studies in epidemiology 
(STROBE) statement: Guidelines for reporting observational studies. Plos 
Medicine (2007) 4(10):1623-7. doi: ARTN e296; 10.1371/journal.pmed.0040296. 
PubMed PMID: WOS:000251113600014. 
250. Drozdowska BA, Celis-Morales CA, Lyall DM, Quinn TJ. Social engagement 
after stroke–is it relevant to cognitive function? A cross-sectional analysis of UK 
Biobank data. AMRC Open Research (2019) 1(3):3. 
251. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK 
biobank: an open access resource for identifying the causes of a wide range of 
complex diseases of middle and old age. PLoS Med (2015) 12(3):e1001779. doi: 
10.1371/journal.pmed.1001779. PubMed PMID: 25826379. 
252. Guyomard V, Metcalf AK, Naguib MF, Fulcher RA, Potter JF, Myint PK. 
Transient ischaemic attack, vascular risk factors and cognitive impairment: a 
case-controlled study. Age Ageing (2011) 40(5):641-4. Epub 2011/07/14. doi: 
10.1093/ageing/afr079. PubMed PMID: 21749995. 
253. Not just a funny turn. The real impact of TIA. Stroke Association, (2014). 
254. Lyall DM, Celis-Morales CA, Anderson J, Gill JMR, Mackay DF, McIntosh AM, 
et al. Associations between single and multiple cardiometabolic diseases and 
cognitive abilities in 474 129 UK Biobank participants. European Heart Journal 
(2017) 38(8):577-83. doi: 10.1093/eurheartj/ehw528. 
255. Cullen B, Nicholl BI, Mackay DF, Martin D, Ul-Haq Z, McIntosh A, et al. 
Cognitive function and lifetime features of depression and bipolar disorder in a 
large population sample: Cross-sectional study of 143,828 UK Biobank 
participants. Eur Psychiat (2015) 30(8):950-8. doi: 
10.1016/j.eurpsy.2015.08.006. PubMed PMID: WOS:000365160100015. 
  
354 
256. Hagenaars SP, Harris SE, Davies G, Hill WD, Liewald DCM, Ritchie SJ, et al. 
Shared genetic aetiology between cognitive functions and physical and mental 
health in UK Biobank (N=112151) and 24 GWAS consortia. Mol Psychiatr (2016) 
21(11):1624-32. doi: 10.1038/mp.2015.225. PubMed PMID: 
WOS:000388719600017. 
257. Lyall DM, Cullen B, Allerhand M, Smith DJ, Mackay D, Evans J, et al. 
Cognitive Test Scores in UK Biobank: Data Reduction in 480,416 Participants and 
Longitudinal Stability in 20,346 Participants. Plos One (2016) 11(4). doi: ARTN 
e0154222; 10.1371/journal.pone.0154222. PubMed PMID: WOS:000374970600051. 
258. Fawns-Ritchie C, Deary IJ. Reliability and validity of the UK Biobank 
cognitive tests. Plos One (2020) 15(4). doi: ARTN e0231627; 
10.1371/journal.pone.0231627. PubMed PMID: WOS:000536019800023. 
259. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality 
and the North: Routledge (1988). 
260. Pendlebury ST. Stroke-related dementia: Rates, risk factors and 
implications for future research. Maturitas (2009) 64(3):165-71. doi: 
http://dx.doi.org/10.1016/j.maturitas.2009.09.010. 
261. Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and 
other vascular risk factors for dementia: Which factor matters most? A 
systematic review. Eur J Pharmacol (2008) 585(1):97-108. doi: 
10.1016/j.ejphar.2008.02.049. PubMed PMID: WOS:000256149300012. 
262. Skoog I. Risk-Factors for Vascular Dementia - a Review. Dementia (1994) 
5(3-4):137-44. doi: Doi 10.1159/000106711. PubMed PMID: 
WOS:A1994NP58000004. 
263. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in 
depression: a systematic review and meta-analysis. Psychol Med (2014) 
44(10):2029-40. Epub 2013/10/31. doi: 10.1017/S0033291713002535. PubMed 
PMID: 24168753. 
264. Schuch F, Vancampfort D, Firth J, Rosenbaum S, Ward P, Reichert T, et 
al. Physical activity and sedentary behavior in people with major depressive 
disorder: A systematic review and meta-analysis. J Affect Disord (2017) 210:139-
50. Epub 2016/12/30. doi: 10.1016/j.jad.2016.10.050. PubMed PMID: 28033521. 
265. Girard JM, Cohn JF, Mahoor MH, Mavadati SM, Hammal Z, Rosenwald DP. 
Nonverbal Social Withdrawal in Depression: Evidence from manual and automatic 
analysis. Image Vis Comput (2014) 32(10):641-7. Epub 2014/11/08. doi: 
10.1016/j.imavis.2013.12.007. PubMed PMID: 25378765. 
266. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. 
Prevalence and characteristics of probable major depression and bipolar disorder 
within UK biobank: cross-sectional study of 172,751 participants. PLoS One 
(2013) 8(11):e75362. doi: 10.1371/journal.pone.0075362. PubMed PMID: 
24282498. 
267. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should 
multiple imputation be used for handling missing data in randomised clinical 
trials - a practical guide with flowcharts. Bmc Medical Research Methodology 
(2017) 17. doi: ARTN 162; 10.1186/s12874-017-0442-1. PubMed PMID: 
WOS:000417509300002. 
355 
268. Lantz B. The large sample size fallacy. Scandinavian Journal of Caring 
Sciences (2013) 27(2):487-92. doi: 10.1111/j.1471-6712.2012.01052.x. PubMed 
PMID: WOS:000318815700034. 
269. Ford C. Interpreting log transformations in a linear model: University of 
Virginia Library (2018) [cited 2020 12 Oct]. Available from: 
https://data.library.virginia.edu/interpreting-log-transformations-in-a-linear-
model/. 
270. Bakrania K, Edwardson CL, Khunti K, Bandelow S, Davies MJ, Yates T. 
Associations Between Sedentary Behaviors and Cognitive Function: Cross-
Sectional and Prospective Findings From the UK Biobank. Am J Epidemiol (2018) 
187(3):441-54. doi: 10.1093/aje/kwx273. PubMed PMID: WOS:000426812300008. 
271. Leghsmith J, Wade DT, Hewer RL. Driving after a Stroke. Journal of the 
Royal Society of Medicine (1986) 79(4):200-3. doi: Doi 
10.1177/014107688607900404. PubMed PMID: WOS:A1986A981200004. 
272. Lings S, Jensen PB. Driving after stroke: a controlled laboratory 
investigation. Int Disabil Stud (1991) 13(3):74-82. Epub 1991/07/01. doi: 
10.3109/03790799109166688. PubMed PMID: 1774218. 
273. Fisk GD, Owsley C, Mennemeier M. Vision, attention, and self-reported 
driving behaviors in community-dwelling stroke survivors. Arch Phys Med Rehabil 
(2002) 83(4):469-77. Epub 2002/04/05. doi: 10.1053/apmr.2002.31179. PubMed 
PMID: 11932847. 
274. Shiue I. Duration of daily TV/screen watching with cardiovascular, 
respiratory, mental and psychiatric health: Scottish Health Survey, 2012-2013. 
Int J Cardiol (2015) 186:241-6. Epub 2015/04/02. doi: 
10.1016/j.ijcard.2015.03.259. PubMed PMID: 25828126. 
275. Keadle SK, Moore SC, Sampson JN, Xiao Q, Albanes D, Matthews CE. 
Causes of Death Associated With Prolonged TV Viewing: NIH-AARP Diet and 
Health Study. Am J Prev Med (2015) 49(6):811-21. Epub 2015/07/29. doi: 
10.1016/j.amepre.2015.05.023. PubMed PMID: 26215832. 
276. Dempsey PC, Howard BJ, Lynch BM, Owen N, Dunstan DW. Associations of 
television viewing time with adults' well-being and vitality. Preventive Medicine 
(2014) 69:69-74. doi: 10.1016/j.ypmed.2014.09.007. PubMed PMID: 
WOS:000346221600013. 
277. Fancourt D, Steptoe A. Television viewing and cognitive decline in older 
age: findings from the English Longitudinal Study of Ageing. Sci Rep (2019) 
9(1):2851. Epub 2019/03/02. doi: 10.1038/s41598-019-39354-4. PubMed PMID: 
30820029. 
278. Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans 
DA, et al. Participation in cognitively stimulating activities and risk of incident 
Alzheimer disease. JAMA (2002) 287(6):742-8. Epub 2002/02/20. doi: 
10.1001/jama.287.6.742. PubMed PMID: 11851541. 
279. Krell-Roesch J, Vemuri P, Pink A, Roberts RO, Stokin GB, Mielke MM, et al. 
Association Between Mentally Stimulating Activities in Late Life and the 
Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE 
epsilon 4 Genotype. Jama Neurology (2017) 74(3):330-6. doi: 
10.1001/jamaneurol.2016.3822. PubMed PMID: WOS:000397601900015. 
356 
280. Krell-Roesch J, Syrjanen JA, Vassilaki M, Machulda MM, Mielke MM, 
Knopman DS, et al. Quantity and quality of mental activities and the risk of 
incident mild cognitive impairment. Neurology (2019) 93(6):e548-e58. Epub 
2019/07/12. doi: 10.1212/WNL.0000000000007897. PubMed PMID: 31292224. 
281. Lampit A, Hallock H, Valenzuela M. Computerized Cognitive Training in 
Cognitively Healthy Older Adults: A Systematic Review and Meta-Analysis of 
Effect Modifiers. Plos Medicine (2014) 11(11). doi: ARTN e1001756; 
10.1371/journal.pmed.1001756. PubMed PMID: WOS:000347001600005. 
282. Lin JH, Lin RT, Tai CT, Hsieh CL, Hsiao SF, Liu CK. Prediction of poststroke 
dementia. Neurology (2003) 61(3):343-8. doi: Doi 
10.1212/01.Wnl.0000078891.27052.10. PubMed PMID: WOS:000184712600013. 
283. Potter GG, Helms MJ, Plassman BL. Associations of job demands and 
intelligence with cognitive performance among men in late life. Neurology 
(2008) 70(19):1803-8. doi: DOI 10.1212/01.wnl.0000295506.58497.7e. PubMed 
PMID: WOS:000256707200012. 
284. Then FS, Luck T, Luppa M, Arelin K, Schroeter ML, Engel C, et al. 
Association between mental demands at work and cognitive functioning in the 
general population - results of the health study of the Leipzig research center 
for civilization diseases (LIFE). J Occup Med Toxicol (2014) 9. doi: Artn 23; 
10.1186/1745-6673-9-23. PubMed PMID: WOS:000337528900001. 
285. Smart EL, Gow AJ, Deary IJ. Occupational complexity and lifetime 
cognitive abilities. Neurology (2014) 83(24):2285-91. doi: 
10.1212/Wnl.0000000000001075. PubMed PMID: WOS:000346070000019. 
286. Prince SA, Adamo KB, Hamel ME, Hardt J, Gorber SC, Tremblay M. A 
comparison of direct versus self-report measures for assessing physical activity in 
adults: a systematic review. International Journal of Behavioral Nutrition and 
Physical Activity (2008) 5. doi: Artn 56; 10.1186/1479-5868-5-56. PubMed PMID: 
WOS:000261316900001. 
287. Cheng ST, Chow PK, Song YQ, Yu ECS, Chan ACM, Lee TMC, et al. Mental 
and Physical Activities Delay Cognitive Decline in Older Persons with Dementia. 
American Journal of Geriatric Psychiatry (2014) 22(1):63-74. doi: 
10.1016/j.jagp.2013.01.060. PubMed PMID: WOS:000336050800008. 
288. Biddle SJH, Bennie JA, De Cocker K, Dunstan D, Gardiner PA, Healy GN, et 
al. Controversies in the Science of Sedentary Behaviour and Health: Insights, 
Perspectives and Future Directions from the 2018 Queensland Sedentary 
Behaviour Think Tank. International Journal of Environmental Research and 
Public Health (2019) 16(23). doi: ARTN 4762; 10.3390/ijerph16234762. PubMed 
PMID: WOS:000507275700069. 
289. Hallgren M, Nguyen TTD, Owen N, Vancampfort D, Smith L, Dunstan DW, 
et al. Associations of interruptions to leisure-time sedentary behaviour with 
symptoms of depression and anxiety. Translational Psychiatry (2020) 10(1). doi: 
ARTN 128; 10.1038/s41398-020-0810-1. PubMed PMID: WOS:000533424100003. 
290. Development and evaluation of strategies to reduce sedentary behaviour 
in patients after stroke and improve outcomes (RECREATE): Bradford Institute 




291. Forster A, Birch KM, Carter G, Clarke DJ, English C, Farrin A, et al. The 
REduCing sedentaRy bEhaviour After sTrokE Study (RECREATE): Development and 
evaluation of an intervention to improve outcomes.  11th World Stroke 
Congress; Montréal, Canada: Morressier (2018). 
292. Doherty A, Jackson D, Hammerla N, Plotz T, Olivier P, Granat MH, et al. 
Large Scale Population Assessment of Physical Activity Using Wrist Worn 
Accelerometers: The UK Biobank Study. Plos One (2017) 12(2). doi: ARTN 
e0169649; 10.1371/journal.pone.0169649. PubMed PMID: WOS:000396131700009. 
293. Woodfield R, Sudlow CLM, Grp UBSO, Outcomes UBF-u. Accuracy of 
Patient Self-Report of Stroke: A Systematic Review from the UK Biobank Stroke 
Outcomes Group. Plos One (2015) 10(9). doi: ARTN e0137538; 
10.1371/journal.pone.0137538. PubMed PMID: WOS:000360965800060. 
294. King's College London. SSNAP Anual CCG and LHB Portfolio for April 2017 - 
March 2018 admissions and discharges. (2018). 
295. Rundek T, Sacco RL. Prognosis after Stroke. In: Mohr JP, Wolf PA, Grotta 
JC, Moskowitz MA, Mayberg MR, von Kummer R, editors. Stroke (Fifth Edition). 
Saint Louis: W.B. Saunders (2011). p. 219-41. 
296. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. 
Multiple imputation for missing data in epidemiological and clinical research: 
potential and pitfalls. BMJ (2009) 338:b2393. Epub 2009/07/01. doi: 
10.1136/bmj.b2393. PubMed PMID: 19564179. 
297. Hawkley LC, Cacioppo JT. Loneliness matters: a theoretical and empirical 
review of consequences and mechanisms. Ann Behav Med (2010) 40(2):218-27. 
Epub 2010/07/24. doi: 10.1007/s12160-010-9210-8. PubMed PMID: 20652462. 
298. Luo Y, Hawkley LC, Waite LJ, Cacioppo JT. Loneliness, health, and 
mortality in old age: a national longitudinal study. Soc Sci Med (2012) 74(6):907-
14. Epub 2012/02/14. doi: 10.1016/j.socscimed.2011.11.028. PubMed PMID: 
22326307. 
299. Holt-Lunstad J, Smith TB, Baker M, Harris T, Stephenson D. Loneliness and 
Social Isolation as Risk Factors for Mortality: A Meta-Analytic Review. Perspect 
Psychol Sci (2015) 10(2):227-37. doi: 10.1177/1745691614568352. PubMed PMID: 
WOS:000351242300008. 
300. Ong AD, Uchino BN, Wethington E. Loneliness and Health in Older Adults: 
A Mini-Review and Synthesis. Gerontology (2016) 62(4):443-9. doi: 
10.1159/000441651. PubMed PMID: WOS:000378257900009. 
301. Cacioppo JT, Hawkey LC. Perceived social isolation and cognition. Trends 
Cogn Sci (2009) 13(10):447-54. doi: 10.1016/j.tics.2009.06.005. PubMed PMID: 
WOS:000270656300005. 
302. Tilvis RS, Kahonen-Vare MH, Jolkkonen J, Valvanne J, Pitkala KH, 
Strandberg TE. Predictors of cognitive decline and mortality of aged people over 
a 10-year period. J Gerontol a-Biol (2004) 59(3):268-74. PubMed PMID: 
WOS:000220368100010. 
303. Wilson RS, Krueger KR, Arnold SE, Schneider JA, Kelly JF, Barnes LL, et al. 
Loneliness and risk of Alzheimer disease. Arch Gen Psychiat (2007) 64(2):234-40. 
doi: DOI 10.1001/archpsyc.64.2.234. PubMed PMID: WOS:000243990900011. 
  
358 
304. Seeman TE, Miller-Martinez DM, Merkin SS, Lachman ME, Tun PA, 
Karlamangla AS. Histories of Social Engagement and Adult Cognition: Midlife in 
the U.S. Study. J Gerontol B-Psychol (2011) 66:141-52. doi: 
10.1093/geronb/gbq091. PubMed PMID: WOS:000293252000014. 
305. Parisi JM, Stine-Morrow EAL, Noh SR, Morrow DG. Predispositional 
Engagement, Activity Engagement, and Cognition among Older Adults. Aging, 
Neuropsychology, and Cognition (2009) 16(4):485-504. doi: 
10.1080/13825580902866653. 
306. Lovden M, Ghisletta P, Lindenberger U. Social participation attenuates 
decline in perceptual speed in old and very old age. Psychol Aging (2005) 
20(3):423-34. doi: 10.1037/0882-7974.20.3.423. PubMed PMID: 
WOS:000233022500006. 
307. Ghisletta P, Bickel J-F, Lövdén M. Does Activity Engagement Protect 
Against Cognitive Decline in Old Age? Methodological and Analytical 
Considerations. The Journals of Gerontology: Series B (2006) 61(5):P253-P61. 
doi: 10.1093/geronb/61.5.P253. 
308. Hosseini S, Chaurasia A, Oremus M. The Effect of Religion and Spirituality 
on Cognitive Function: A Systematic Review. The Gerontologist (2017) 59(2):e76-
e85. doi: 10.1093/geront/gnx024. 
309. Voas D, McAndrew S. Three Puzzles of Non-religion in Britain. Journal of 
Contemporary Religion (2012) 27(1):29-48. doi: 10.1080/13537903.2012.642725. 
310. Carmelli D, Swan GE, LaRue A, Eslinger PJ. Correlates of change in 
cognitive function in survivors from the Western Collaborative Group Study. 
Neuroepidemiology (1997) 16(6):285-95. doi: Doi 10.1159/000109699. PubMed 
PMID: WOS:000071101600003. 
311. Albert MS, Savage CR, Blazer D, Jones K, Berkman L, Seeman T, et al. 
Predictors of cognitive change in older persons: MacArthur studies of successful 
aging. Psychol Aging (1995) 10(4):578-89. doi: Doi 10.1037/0882-7974.10.4.578. 
PubMed PMID: WOS:A1995TL59300009. 
312. Richards M, Hardy R, Wadsworth ME. Does active leisure protect 
cognition? Evidence from a national birth cohort. Social science & medicine 
(2003) 56(4):785-92. 
313. Hatch SL, Feinstein L, Link BG, Wadsworth MEJ, RichardS M. The 
continuing benefits of education: Adult education and midlife cognitive ability in 
the British 1946 birth cohort. J Gerontol B-Psychol (2007) 62(6):S404-S14. doi: 
DOI 10.1093/geronb/62.6.S404. PubMed PMID: WOS:000253836400016. 
314. Orrell M, Sahakian B. Education and Dementia - Research Evidence 
Supports the Concept Use It or Lose It. Bmj-Brit Med J (1995) 310(6985):951-2. 
doi: DOI 10.1136/bmj.310.6985.951. PubMed PMID: WOS:A1995QT90400001. 
315. Ellwardt L, Aartsen M, Deeg D, Steverink N. Does loneliness mediate the 
relation between social support and cognitive functioning in later life? Social 
Science & Medicine (2013) 98:116-24. doi: 
https://doi.org/10.1016/j.socscimed.2013.09.002. 
316. Byrne C, Saville CWN, Coetzer R, Ramsey R. Stroke survivors experience 
elevated levels of loneliness: a multi-year analysis of the National Survey for 
Wales. medRxiv (2020):2020.07.02.20145417. doi: 
10.1101/2020.07.02.20145417. 
359 
317. Department for Digital Culture, Media & Sport, Prime Minister's Office. 
£20 million investment to help tackle loneliness. (2018). 
318. Masi CM, Chen HY, Hawkley LC, Cacioppo JT. A Meta-Analysis of 
Interventions to Reduce Loneliness. Pers Soc Psychol Rev (2011) 15(3):219-66. 
doi: 10.1177/1088868310377394. PubMed PMID: WOS:000292207700001. 
319. Dickens AP, Richards SH, Greaves CJ, Campbell JL. Interventions targeting 
social isolation in older people: a systematic review. Bmc Public Health (2011) 
11. doi: Artn 647; 10.1186/1471-2458-11-647. PubMed PMID: 
WOS:000294774000001. 
320. Theeke LA, Mallow JA. The Development of LISTEN: A Novel Intervention 
for Loneliness. Open J Nurs (2015) 5(2):136-43. Epub 2015/08/01. doi: 
10.4236/ojn.2015.52016. PubMed PMID: 26229740. 
321. Theeke LA, Mallow JA, Barnes ER, Theeke E. The Feasibility and 
Acceptability of LISTEN for Loneliness. Open J Nurs (2015) 5(5):416-25. Epub 
2015/09/25. doi: 10.4236/ojn.2015.55045. PubMed PMID: 26401420. 
322. Theeke L, Lucke-Wold AN, Mallow J, Horstman P. Life after stroke in 
Appalachia. Int J Nurs Sci (2017) 4(2):105-11. Epub 2017/03/10. doi: 
10.1016/j.ijnss.2017.02.005. PubMed PMID: 31406728. 
323. NHS Improvement - Stroke. Psychological care after stroke - Improving 




324. Lincoln KD. Social Support, Negative Social Interactions, and Psychological 
Well-Being. Soc Serv Rev (2000) 74(2):231-52. Epub 2000/06/01. doi: 
10.1086/514478. PubMed PMID: 26594064. 
325. Cohen S. Social relationships and health. Am Psychol (2004) 59(8):676-84. 
Epub 2004/11/24. doi: 10.1037/0003-066X.59.8.676. PubMed PMID: 15554821. 
326. Thompson SC, Sobolew-Shubin A. Overprotective Relationships - a 
Nonsupportive Side of Social Networks. Basic Appl Soc Psych (1993) 14(3):363-83. 
doi: DOI 10.1207/s15324834basp1403_8. PubMed PMID: WOS:A1993LW48100008. 
327. Croteau C, Le Dorze G. Overprotection, "speaking for", and conversational 
participation: A study of couples with aphasia. Aphasiology (2006) 20(2-4):327-
36. doi: 10.1080/02687030500475051. PubMed PMID: WOS:000237890000019. 
328. Bailey R. Examining daily physical activity in community-dwelling adults 
with stroke using social cognitive theory: an exploratory, qualitative study. 
Disabil Rehabil (2020) 42(18):2631-9. doi: 10.1080/09638288.2019.1568591. 
PubMed PMID: WOS:000464631800001. 
329. Haun J, Rittman M, Sberna M. The continuum of connectedness and social 
isolation during post stroke recovery. J Aging Stud (2008) 22(1):54-64. Epub 
2008/01/01. doi: 10.1016/j.jaging.2007.03.001. PubMed PMID: 26047096. 
330. Northcott S, Hilari K. Why do people lose their friends after a stroke? 
International Journal of Language & Communication Disorders (2011) 46(5):524-
34. doi: 10.1111/j.1460-6984.2011.00079.x. PubMed PMID: 
WOS:000295872600003. 
360 
331. Pels F, Kleinert J. Loneliness and physical activity: A systematic review. 
Int Rev Sport Exer P (2016) 9(1):231-60. doi: 10.1080/1750984x.2016.1177849. 
PubMed PMID: WOS:000382261400011. 
332. Drozdowska BA, Elliott E, Taylor-Rowan M, Shaw RC, Cuthbertson G, 
Langhorne P, et al. Cardiovascular risk factors indirectly affect acute post-stroke 
cognition through stroke severity and prior cognitive impairment: a moderated 
mediation analysis. Alzheimer's Research & Therapy (2020) 12(1):85. doi: 
10.1186/s13195-020-00653-y. 
333. Yang ZR, Wang HYY, Edwards D, Ding CY, Yan L, Brayne C, et al. 
Association of blood lipids, atherosclerosis and statin use with dementia and 
cognitive impairment after stroke: A systematic review and meta-analysis. 
Ageing Res Rev (2020) 57. doi: ARTN 100962; 10.1016/j.arr.2019.100962. 
PubMed PMID: WOS:000509630900012. 
334. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. 
Stroke (2004) 35(11 Suppl 1):2620-2. Epub 2004/09/18. doi: 
10.1161/01.STR.0000143318.70292.47. PubMed PMID: 15375299. 
335. Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular 
risk factors; a review. Int J Stroke (2012) 7(1):61-73. Epub 2011/12/23. doi: 
10.1111/j.1747-4949.2011.00731.x. PubMed PMID: 22188853. 
336. Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, et 
al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular 
disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc (2005) 
53(7):1101-7. 
337. Leritz EC, McGlinchey RE, Kellison I, Rudolph JL, Milberg WP. 
Cardiovascular Disease Risk Factors and Cognition in the Elderly. Curr Cardiovasc 
Risk Rep (2011) 5(5):407-12. doi: 10.1007/s12170-011-0189-x. PubMed PMID: 
22199992. 
338. Vakhnina NV, Nikitina LY, Parfenov VA, Yakhno NN. Post-stroke cognitive 
impairments. Neurosci Behav Physiol (2009) 39(8):719-24. Epub 2009/09/26. doi: 
10.1007/s11055-009-9198-3. PubMed PMID: 19779824. 
339. Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D. Poststroke 
dementia: incidence and relationship to prestroke cognitive decline. Neurology 
(2001) 57(7):1216-22. Epub 2001/10/10. doi: 10.1212/wnl.57.7.1216. PubMed 
PMID: 11591838. 
340. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, et al. Atrial 
fibrillation is independently associated with senile, vascular, and Alzheimer's 
dementia. Heart rhythm (2010) 7(4):433-7. 
341. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke 
with atrial fibrillation: the Copenhagen Stroke Study. Stroke (1996) 27(10):1765-
9. 
342. Kirino T. Ischemic tolerance. J Cereb Blood Flow Metab (2002) 
22(11):1283-96. Epub 2002/11/20. doi: 10.1097/01.WCB.0000040942.89393.88. 
PubMed PMID: 12439285. 
343. Weih M, Kallenberg K, Bergk A, Dirnagl U, Harms L, Wernecke K, et al. 
Attenuated stroke severity after prodromal TIA: a role for ischemic tolerance in 
the brain? stroke (1999) 30(9):1851-4. 
361 
344. Moncayo J, de Freitas GR, Bogousslavsky J, Altieri M, van Melle G. Do 
transient ischemic attacks have a neuroprotective effect? Neurology (2000) 
54(11):2089-94. doi: 10.1212/wnl.54.11.2089. 
345. Wegener S, Gottschalk B, Jovanovic V, Knab R, Fiebach JB, Schellinger 
PD, et al. Transient ischemic attacks before ischemic stroke: preconditioning the 
human brain? A multicenter magnetic resonance imaging study. Stroke (2004) 
35(3):616-21. 
346. Nishijima Y, Akamatsu Y, Weinstein PR, Liu J. Collaterals: Implications in 
cerebral ischemic diseases and therapeutic interventions. Brain Res (2015) 
1623:18-29. Epub 2015/03/17. doi: 10.1016/j.brainres.2015.03.006. PubMed 
PMID: 25770816. 
347. Liebeskind DS, Cotsonis GA, Saver JL, Lynn MJ, Cloft HJ, Chimowitz MI, et 
al. Collateral circulation in symptomatic intracranial atherosclerosis. J Cereb 
Blood Flow Metab (2011) 31(5):1293-301. Epub 2010/12/16. doi: 
10.1038/jcbfm.2010.224. PubMed PMID: 21157476. 
348. Romero JR, Pikula A, Nguyen TN, Nien YL, Norbash A, Babikian VL. 
Cerebral collateral circulation in carotid artery disease. Curr Cardiol Rev (2009) 
5(4):279-88. doi: 10.2174/157340309789317887. PubMed PMID: 21037845. 
349. Shuaib A, Butcher K, Mohammad AA, Saqqur M, Liebeskind DS. Collateral 
blood vessels in acute ischaemic stroke: a potential therapeutic target. Lancet 
Neurol (2011) 10(10):909-21. Epub 2011/09/24. doi: 10.1016/S1474-
4422(11)70195-8. PubMed PMID: 21939900. 
350. Wufuer A, Wubuli A, Mijiti P, Zhou J, Tuerxun S, Cai J, et al. Impact of 
collateral circulation status on favorable outcomes in thrombolysis treatment: A 
systematic review and meta-analysis. Exp Ther Med (2018) 15(1):707-18. Epub 
2018/02/06. doi: 10.3892/etm.2017.5486. PubMed PMID: 29399075. 
351. Liebeskind DS. Collateral circulation. Stroke (2003) 34(9):2279-84. 
352. Hedera P, Bujdakova J, Traubner P, Pancak J. Stroke risk factors and 
development of collateral flow in carotid occlusive disease. Acta Neurol Scand 
(1998) 98(3):182-6. Epub 1998/10/24. doi: 10.1111/j.1600-0404.1998.tb07291.x. 
PubMed PMID: 9786615. 
353. Ergul A, Abdelsaid M, Fouda AY, Fagan SC. Cerebral Neovascularization in 
Diabetes: Implications for Stroke Recovery and beyond. Journal of Cerebral 
Blood Flow & Metabolism (2014) 34(4):553-63. doi: 10.1038/jcbfm.2014.18. 
354. Rizk H, Allam M, Hegazy A, Khalil H, Helmy H, Hashem HS, et al. 
Predictors of poor cerebral collaterals and cerebrovascular reserve in patients 
with chronic total carotid occlusion. International Journal of Neuroscience 
(2019) 129(5):455-60. 
355. Pires PW, Dams Ramos CM, Matin N, Dorrance AM. The effects of 
hypertension on the cerebral circulation. Am J Physiol Heart Circ Physiol (2013) 
304(12):H1598-614. Epub 2013/04/16. doi: 10.1152/ajpheart.00490.2012. 
PubMed PMID: 23585139. 
356. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of 
risk factors, comorbidities, and comedications with ischemia/reperfusion injury 
and cardioprotection by preconditioning, postconditioning, and remote 
conditioning. Pharmacological reviews (2014) 66(4):1142-74. 
362 
357. Zheng Y, Wang M. Clinical study about effects of the acute fasting 
hyperglycemia and type 2 diabetes mellitus on ischemic preconditioning in 
patients with the first-ever acute anterior circulation infarction. Chinese Journal 
of Neurology (2008) 41(12):820-3. 
358. Fairchild AJ, McDaniel HL. Best (but oft-forgotten) practices: mediation 
analysis. Am J Clin Nutr (2017) 105(6):1259-71. Epub 2017/04/28. doi: 
10.3945/ajcn.117.152546. PubMed PMID: 28446497. 
359. Hayes AF. Introduction to mediation, moderation, and conditional process 
analysis: A regression-based approach: Guilford Publications (2017). 
360. Kasner SE, Chalela JA, Luciano JM, Cucchiara BL, Raps EC, McGarvey ML, 
et al. Reliability and validity of estimating the NIH stroke scale score from 
medical records. Stroke (1999) 30(8):1534-7. Epub 1999/08/06. doi: 
10.1161/01.str.30.8.1534. PubMed PMID: 10436096. 
361. Fussner J, Velasco C. Stroke coordinator boot camp: Assessing stroke - 
scores & scales. [PowerPoint Presentation]: American Stroke Association  [cited 




362. World Health Organization (WHO). International Classification of Diseases 
for Mortality and Morbidity Statistics (11th ed.) (2019). Available from: 
https://icd.who.int/. 
363. Hodkinson HM. Evaluation of a mental test score for assessment of mental 
impairment in the elderly. Age Ageing (1972) 1(4):233-8. Epub 1972/11/01. doi: 
10.1093/ageing/1.4.233. PubMed PMID: 4669880. 
364. Abbreviated Mental Test Score (AMTS). Occas Pap R Coll Gen Pract (1993) 
(59):28. PubMed PMID: 19790838. 
365. Lees RA, Hendry Ba K, Broomfield N, Stott D, Larner AJ, Quinn TJ. 
Cognitive assessment in stroke: feasibility and test properties using differing 
approaches to scoring of incomplete items. Int J Geriatr Psychiatry (2017) 
32(10):1072-8. Epub 2016/08/17. doi: 10.1002/gps.4568. PubMed PMID: 
27526678. 
366. Muthén LK, Muthén BO. Mplus User's Guide. Eighth Edition. Los Angeles, 
CA: Muthén & Muthén ((1998-2017)). 
367. Asparouhov T, Muthén B. Weighted least squares estimation with missing 
data. Mplus Technical Appendix (2010) 2010:1-10. 
368. Aiken LS, West SG, Reno RR. Multiple regression: Testing and interpreting 
interactions: Sage (1991). 
369. Wright S. Correlation and causation Part I. Method of path coefficients. J 
Agric Res (1920) 20:0557-85. PubMed PMID: WOS:000188347400034. 
370. Hayes AF. Partial, conditional, and moderated moderated mediation: 
Quantification, inference, and interpretation. Commun Monogr (2018) 85(1):4-
40. doi: 10.1080/03637751.2017.1352100. PubMed PMID: WOS:000428291600002. 
371. Shrout PE, Bolger N. Mediation in experimental and nonexperimental 
studies: new procedures and recommendations. Psychol Methods (2002) 
7(4):422-45. Epub 2003/01/18. PubMed PMID: 12530702. 
363 
372. Mallinckrodt B, Abraham WT, Wei MF, Russell DW. Advances in testing the 
statistical significance of mediation effects. J Couns Psychol (2006) 53(3):372-8. 
doi: 10.1037/0022-0167.53.3.372. PubMed PMID: WOS:000239045900009. 
373. Fritz MS, Mackinnon DP. Required sample size to detect the mediated 
effect. Psychol Sci (2007) 18(3):233-9. Epub 2007/04/21. doi: 10.1111/j.1467-
9280.2007.01882.x. PubMed PMID: 17444920. 
374. Preacher KJ, Rucker DD, Hayes AF. Addressing Moderated Mediation 
Hypotheses: Theory, Methods, and Prescriptions. Multivariate Behav Res (2007) 
42(1):185-227. Epub 2007/01/01. doi: 10.1080/00273170701341316. PubMed 
PMID: 26821081. 
375. Ditlevsen S, Christensen U, Lynch J, Damsgaard MT, Keiding N. The 
mediation proportion - A structural equation approach for estimating the 
proportion of exposure effect on outcome explained by an intermediate 
variable. Epidemiology (2005) 16(1):114-20. doi: 
10.1097/01.ede.0000147107.76079.07. PubMed PMID: WOS:000226079600017. 
376. Fairchild AJ, McQuillin SD. Evaluating mediation and moderation effects in 
school psychology: a presentation of methods and review of current practice. J 
Sch Psychol (2010) 48(1):53-84. Epub 2009/12/17. doi: 
10.1016/j.jsp.2009.09.001. PubMed PMID: 20006988. 
377. Hooper D, Coughlan J, Mullen M. Structural equation modelling: guidelines 
for determining model fit. The Electronic Journal of Business Research Methods 
(2008) 6(1):53-60. 
378. Manabe Y, Kono S, Tanaka T, Narai H, Omori N. High blood pressure in 
acute ischemic stroke and clinical outcome. Neurol Int (2009) 1(1):e1. Epub 
2009/01/01. doi: 10.4081/ni.2009.e1. PubMed PMID: 21577346. 
379. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke 
and subsequent outcome: a systematic review. Hypertension (2004) 43(1):18-24. 
Epub 2003/12/10. doi: 10.1161/01.HYP.0000105052.65787.35. PubMed PMID: 
14662649. 
380. Hong L, Cheng X, Lin L, Bivard A, Ling Y, Butcher K, et al. The blood 
pressure paradox in acute ischemic stroke. Ann Neurol (2019) 85(3):331-9. Epub 
2019/02/06. doi: 10.1002/ana.25428. PubMed PMID: 30720216. 
381. Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, et 
al. Social Determinants of Risk and Outcomes for Cardiovascular Disease: A 
Scientific Statement From the American Heart Association. Circulation (2015) 
132(9):873-98. Epub 2015/08/05. doi: 10.1161/CIR.0000000000000228. PubMed 
PMID: 26240271. 
382. Johnston SC. Ischemic preconditioning from transient ischemic attacks? 
Data from the Northern California TIA Study. Stroke (2004) 35(11 Suppl 1):2680-
2. Epub 2004/09/25. doi: 10.1161/01.STR.0000143322.20491.0f. PubMed PMID: 
15388902. 
383. Della Morte D, Abete P, Gallucci F, Scaglione A, D'Ambrosio D, Gargiulo G, 
et al. Transient ischemic attack before nonlacunar ischemic stroke in the 
elderly. J Stroke Cerebrovasc Dis (2008) 17(5):257-62. Epub 2008/08/30. doi: 
10.1016/j.jstrokecerebrovasdis.2008.03.004. PubMed PMID: 18755403. 
  
364 
384. Correia PN, Meyer IA, Eskandari A, Amiguet M, Hirt L, Michel P. 
Preconditioning by Preceding Ischemic Cerebrovascular Events. J Am Heart Assoc 
(2021) 10(16):e020129. Epub 2021/08/14. doi: 10.1161/JAHA.120.020129. 
PubMed PMID: 34387096. 
385. Hao Y, Xin M, Feng L, Wang X, Wang X, Ma D, et al. Review Cerebral 
Ischemic Tolerance and Preconditioning: Methods, Mechanisms, Clinical 
Applications, and Challenges. Front Neurol (2020) 11:812. Epub 2020/10/20. doi: 
10.3389/fneur.2020.00812. PubMed PMID: 33071923. 
386. Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z. Effects of 
aspirin on risk and severity of early recurrent stroke after transient ischaemic 
attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 
(2016) 388(10042):365-75. Epub 2016/05/23. doi: 10.1016/S0140-6736(16)30468-
8. PubMed PMID: 27209146. 
387. Sargento-Freitas J, Pagola J, Rubiera M, Flores A, Silva F, Rodriguez-Luna 
D, et al. Preferential Effect of Premorbid Statins on Atherothrombotic Strokes 
through Collateral Circulation Enhancement. Eur Neurol (2012) 68(3):171-6. doi: 
10.1159/000337862. PubMed PMID: WOS:000308607800009. 
388. Ovbiagele B, Saver JL, Starkman S, Kim D, Ali LK, Jahan R, et al. Statin 
enhancement of collateralization in acute stroke. Neurology (2007) 68(24):2129-
31. Epub 2007/06/15. doi: 10.1212/01.wnl.0000264931.34941.f0. PubMed PMID: 
17562834. 
389. Lang L, Clifford A, Wei L, Zhang D, Leung D, Augustine G, et al. 
Prevalence and determinants of undetected dementia in the community: a 
systematic literature review and a meta-analysis. BMJ Open (2017) 
7(2):e011146. Epub 2017/02/06. doi: 10.1136/bmjopen-2016-011146. PubMed 
PMID: 28159845. 
390. Oh H, Park J, Seo W. A 2-year prospective follow-up study of temporal 
changes associated with post-stroke cognitive impairment. Int J Nurs Pract 
(2018) 24(2):e12618. Epub 2018/01/02. doi: 10.1111/ijn.12618. PubMed PMID: 
29291599. 
391. del Ser T, Barba R, Morin MM, Domingo J, Cemillan C, Pondal M, et al. 
Evolution of cognitive impairment after stroke and risk factors for delayed 
progression. Stroke (2005) 36(12):2670-5. Epub 2005/10/29. doi: 
10.1161/01.STR.0000189626.71033.35. PubMed PMID: 16254227. 
392. Nys GM, van Zandvoort MJ, de Kort PL, Jansen BP, de Haan EH, Kappelle 
LJ. Cognitive disorders in acute stroke: prevalence and clinical determinants. 
Cerebrovasc Dis (2007) 23(5-6):408-16. Epub 2007/04/05. doi: 
10.1159/000101464. PubMed PMID: 17406110. 
393. Goodglass H, Kaplan E. The assessment of aphasia and related disorders. 
Philadelphia,: Lea & Febiger (1972).  
394. Benton A, Hamsher K. Multilingual aphasia examination manual. Iowa 
City: University of Iowa (1978). 
395. Jolles J, Houx PJ, van Boxtel MPJ, Ponds RWHM. The Maastricht Aging 
Study: Determinants of cognitive aging. Maastricht, The Netherlands: 
Neuropsych Publishers Maastricht (1995). 
  
365 
396. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et 
al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part 
I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 
(1989) 39(9):1159-65. Epub 1989/09/01. doi: 10.1212/wnl.39.9.1159. PubMed 
PMID: 2771064. 
397. Army Individual Test Battery. Manual of directions and scoring. 
Washington, DC: War Department, Adjutant General's Office (1944). 
398. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test 
Battery: Therapy and clinical interpretation. Tucson, AZ: Neuropsychological 
Press (1985). 
399. Tombaugh TN. Trail Making Test A and B: normative data stratified by age 
and education. Arch Clin Neuropsychol (2004) 19(2):203-14. Epub 2004/03/11. 
doi: 10.1016/S0887-6177(03)00039-8. PubMed PMID: 15010086. 
400. Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test. Boston, 
MA: Veterans Administration Medical Center (1978). 
401. Rey A. L'examen psychologique dans les cas d'encephalopathie 
traumatique. Archives de Psychologie (1941) 28:286-340. 
402. Osterrieth PA. Le test de copie d'une figure complexe; contribution à 
l'étude de la perception et de la mémoire. Archives de Psychologie (1944) 
30:206-356. 
403. Shin MS, Park SY, Park SR, Seol SH, Kwon JS. Clinical and empirical 
applications of the Rey-Osterrieth Complex Figure Test. Nat Protoc (2006) 
1(2):892-9. doi: 10.1038/nprot.2006.115. PubMed PMID: WOS:000251002500052. 
404. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. 
Maryland State Medical Journal (1965) 14:61-5. Epub 1965/02/01. PubMed PMID: 
14258950. 
405. Cesari M, Demougeot L, Boccalon H, Guyonnet S, Abellan Van Kan G, 
Vellas B, et al. A self-reported screening tool for detecting community-dwelling 
older persons with frailty syndrome in the absence of mobility disability: the 
FiND questionnaire. PLoS One (2014) 9(7):e101745. Epub 2014/07/08. doi: 
10.1371/journal.pone.0101745. PubMed PMID: 24999805. 
406. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, 
et al. The rapid assessment of fatigue severity in cancer patients: use of the 
Brief Fatigue Inventory. Cancer (1999) 85(5):1186-96. Epub 1999/03/26. doi: 
10.1002/(sici)1097-0142(19990301)85:5<1186::aid-cncr24>3.0.co;2-n. PubMed 
PMID: 10091805. 
407. Marshall AL, Smith BJ, Bauman AE, Kaur S. Reliability and validity of a 
brief physical activity assessment for use by family doctors. British Journal of 
Sports Medicine (2005) 39(5):294-7. doi: 10.1136/bjsm.2004.013771. PubMed 
PMID: WOS:000228635600011. 
408. Jenkinson C, Fitzpatrick R, Crocker H, Peters M. The Stroke Impact Scale: 
validation in a UK setting and development of a SIS short form and SIS index. 
Stroke (2013) 44(9):2532-5. Epub 2013/07/23. doi: 
10.1161/STROKEAHA.113.001847. PubMed PMID: 23868278. 
  
366 
409. Turner-Stokes L, Kalmus M, Hirani D, Clegg F. The Depression Intensity 
Scale Circles (DISCs): a first evaluation of a simple assessment tool for 
depression in the context of brain injury. J Neurol Neurosurg Psychiatry (2005) 
76(9):1273-8. Epub 2005/08/19. doi: 10.1136/jnnp.2004.050096. PubMed PMID: 
16107367. 
410. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: 
validity of a two-item depression screener. Med Care (2003) 41(11):1284-92. 
Epub 2003/10/30. doi: 10.1097/01.MLR.0000093487.78664.3C. PubMed PMID: 
14583691. 
411. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety 
disorders in primary care: prevalence, impairment, comorbidity, and detection. 
Ann Intern Med (2007) 146(5):317-25. Epub 2007/03/07. doi: 10.7326/0003-
4819-146-5-200703060-00004. PubMed PMID: 17339617. 
412. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief 
depression severity measure. J Gen Intern Med (2001) 16(9):606-13. Epub 
2001/09/15. doi: 10.1046/j.1525-1497.2001.016009606.x. PubMed PMID: 
11556941. 
413. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing 
generalized anxiety disorder: the GAD-7. Arch Intern Med (2006) 166(10):1092-7. 
Epub 2006/05/24. doi: 10.1001/archinte.166.10.1092. PubMed PMID: 16717171. 
414. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new 
measure for evaluating the severity of somatic symptoms. Psychosom Med (2002) 
64(2):258-66. Epub 2002/03/27. doi: 10.1097/00006842-200203000-00008. 
PubMed PMID: 11914441. 
415. Kroenke K, Spitzer RL, Williams JB, Lowe B. The Patient Health 
Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic 
review. Gen Hosp Psychiatry (2010) 32(4):345-59. Epub 2010/07/17. doi: 
10.1016/j.genhosppsych.2010.03.006. PubMed PMID: 20633738. 
416. Eaton WW, Smith C, Ybarra M, Muntaner C, Tien A. Center for 
Epidemiologic Studies Depression Scale: Review and Revision (CESD and CESD-R).  
The use of psychological testing for treatment planning and outcomes 
assessment: Instruments for adults, Volume 3, 3rd ed. Mahwah, NJ, US: 
Lawrence Erlbaum Associates Publishers (2004). p. 363-77. 
417. EuroQol Group. EuroQol - a new facility for the measurement of health-
related quality of life. Health Policy (1990) 16(3):199-208. Epub 1990/11/05. 
doi: 10.1016/0168-8510(90)90421-9. PubMed PMID: 10109801. 
418. Gjesfjeld CD, Greeno CG, Kim KH. A confirmatory factor analysis of an 
abbreviated social support instrument: The MOS-SSS. Res Social Work Prac (2008) 
18(3):231-7. doi: 10.1177/1049731507309830. PubMed PMID: 
WOS:000254983900006. 
419. Patchick E, Vail A, Wood A, Bowen A. PRECiS (Patient Reported Evaluation 
of Cognitive State): psychometric evaluation of a new patient reported outcome 
measure of the impact of stroke. Clin Rehabil (2016) 30(12):1229-41. Epub 
2016/01/02. doi: 10.1177/0269215515624480. PubMed PMID: 26721872. 
420. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and 
natural history of clinically identifiable subtypes of cerebral infarction. Lancet 
(1991) 337(8756):1521-6. Epub 1991/06/22. doi: 10.1016/0140-6736(91)93206-o. 
PubMed PMID: 1675378. 
367 
421. Brandt J, Spencer M, Folstein M. The telephone interview for cognitive 
status. Neuropsychiatry Neuropsychol Behav Neurol (1988) 1(2):111-7. 
422. Brandt J, Welsh KA, Breitner JC, Folstein MF, Helms M, Christian JC. 
Hereditary influences on cognitive functioning in older men. A study of 4000 twin 
pairs. Arch Neurol (1993) 50(6):599-603. Epub 1993/06/01. doi: 
10.1001/archneur.1993.00540060039014. PubMed PMID: 8503796. 
423. Jorm AF. A short form of the Informant Questionnaire on Cognitive 
Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med 
(1994) 24(1):145-53. Epub 1994/02/01. doi: 10.1017/s003329170002691x. 
PubMed PMID: 8208879. 
424. Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, et al. The 
AD8: a brief informant interview to detect dementia. Neurology (2005) 
65(4):559-64. Epub 2005/08/24. doi: 10.1212/01.wnl.0000172958.95282.2a. 
PubMed PMID: 16116116. 
425. Bennett HE, Thomas SA, Austen R, Morris AM, Lincoln NB. Validation of 
screening measures for assessing mood in stroke patients. Br J Clin Psychol 
(2006) 45(Pt 3):367-76. Epub 2006/12/07. doi: 10.1348/014466505x58277. 
PubMed PMID: 17147102. 
426. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence 
and development of a shorter version. Clinical Gerontologist: The Journal of 
Aging and Mental Health (1986). 
427. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. 
Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J 
Neuropsychiatry Clin Neurosci (2000) 12(2):233-9. Epub 2000/09/23. doi: 
10.1176/jnp.12.2.233. PubMed PMID: 11001602. 
428. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: 
correlates of feelings of burden. Gerontologist (1980) 20(6):649-55. Epub 
1980/12/01. doi: 10.1093/geront/20.6.649. PubMed PMID: 7203086. 
429. Sentinel Stroke National Audit Programme: King's College London  [cited 
2021 August 22]. Available from: https://www.strokeaudit.org/About-
SSNAP.aspx. 
430. Muthen B, Muthen LK. Integrating person-centered and variable-centered 
analyses: growth mixture modeling with latent trajectory classes. Alcohol Clin 
Exp Res (2000) 24(6):882-91. Epub 2000/07/11. PubMed PMID: 10888079. 
431. Desmond DW, Moroney JT, Sano M, Stern Y. Recovery of cognitive 
function after stroke. Stroke (1996) 27(10):1798-803. Epub 1996/10/01. doi: 
10.1161/01.str.27.10.1798. PubMed PMID: 8841333. 
432. Hochstenbach JB, den Otter R, Mulder TW. Cognitive recovery after 
stroke: a 2-year follow-up. Arch Phys Med Rehabil (2003) 84(10):1499-504. Epub 
2003/10/31. doi: 10.1016/s0003-9993(03)00370-8. PubMed PMID: 14586918. 
433. de Haan EH, Nys GM, Van Zandvoort MJ. Cognitive function following 
stroke and vascular cognitive impairment. Curr Opin Neurol (2006) 19(6):559-64. 




434. Srikanth VK, Quinn SJ, Donnan GA, Saling MM, Thrift AG. Long-term 
cognitive transitions, rates of cognitive change, and predictors of incident 
dementia in a population-based first-ever stroke cohort. Stroke (2006) 
37(10):2479-83. Epub 2006/09/02. doi: 10.1161/01.STR.0000239666.46828.d7. 
PubMed PMID: 16946165. 
435. Patel M, Coshall C, Rudd AG, Wolfe CD. Natural history of cognitive 
impairment after stroke and factors associated with its recovery. Clin Rehabil 
(2003) 17(2):158-66. Epub 2003/03/11. doi: 10.1191/0269215503cr596oa. 
PubMed PMID: 12625656. 
436. Liman TG, Heuschmann PU, Endres M, Floel A, Schwab S, Kolominsky-
Rabas PL. Changes in cognitive function over 3 years after first-ever stroke and 
predictors of cognitive impairment and long-term cognitive stability: the 
Erlangen Stroke Project. Dement Geriatr Cogn Disord (2011) 31(4):291-9. Epub 
2011/04/20. doi: 10.1159/000327358. PubMed PMID: 21502760. 
437. Muthen B, Shedden K. Finite mixture modeling with mixture outcomes 
using the EM algorithm. Biometrics (1999) 55(2):463-9. doi: DOI 10.1111/j.0006-
341X.1999.00463.x. PubMed PMID: WOS:000081320800018. 
438. Muthen B, Asparouhov T. Growth mixture modeling: Analysis with non-
Gaussian random effects. Ch Crc Handb Mod Sta (2009):143-65. PubMed PMID: 
WOS:000267748700006. 
439. Nagin DS, Land KC. Age, Criminal Careers, and Population Heterogeneity - 
Specification and Estimation of a Nonparametric, Mixed Poisson Model. 
Criminology (1993) 31(3):327-62. doi: DOI 10.1111/j.1745-9125.1993.tb01133.x. 
PubMed PMID: WOS:A1993LQ01600002. 
440. Jung T, Wickrama KA. An introduction to latent class growth analysis and 
growth mixture modeling. Social and personality psychology compass (2008) 
2(1):302-17. 
441. van de Schoot R, Sijbrandij M, Winter SD, Depaoli S, Vermunt JK. The 
GRoLTS-Checklist: Guidelines for Reporting on Latent Trajectory Studies. Struct 
Equ Modeling (2017) 24(3):451-67. doi: 10.1080/10705511.2016.1247646. 
PubMed PMID: WOS:000398193800010. 
442. van Mierlo M, van Heugten C, Post MWM, Hoekstra T, Visser-Meily A. 
Trajectories of health-related quality of life after stroke: results from a one-year 
prospective cohort study. Disabil Rehabil (2018) 40(9):997-1006. doi: 
10.1080/09638288.2017.1292320. PubMed PMID: WOS:000425689200002. 
443. Coulombe P, Selig JP, Delaney HD. Ignoring individual differences in times 
of assessment in growth curve modeling. Int J Behav Dev (2016) 40(1):76-86. doi: 
10.1177/0165025415577684. PubMed PMID: WOS:000366603500009. 
444. Berlin KS, Parra GR, Williams NA. An Introduction to Latent Variable 
Mixture Modeling (Part 2): Longitudinal Latent Class Growth Analysis and Growth 
Mixture Models. J Pediatr Psychol (2014) 39(2):188-203. doi: 
10.1093/jpepsy/jst085. PubMed PMID: WOS:000332344000007. 
445. Curran PJ, Obeidat K, Losardo D. Twelve Frequently Asked Questions 
About Growth Curve Modeling. J Cogn Dev (2010) 11(2):121-36. doi: Pii 
921688997; 10.1080/15248371003699969. PubMed PMID: WOS:000277567500001. 
  
369 
446. Shi D, DiStefano C, Zheng X, Liu R, Jiang Z. Fitting Latent Growth Models 
with Small Sample Sizes and Non-normal Missing Data. Int J Behav Dev (2021) 
45(2):179-92. Epub 2021/03/06. doi: 10.1177/0165025420979365. PubMed PMID: 
33664535. 
447. McNeish D, Wolf MG. Thinking twice about sum scores. Behav Res Methods 
(2020) 52(6):2287-305. doi: 10.3758/s13428-020-01398-0. PubMed PMID: 
WOS:000528112600001. 
448. Freitas S, Prieto G, Simoes MR, Santana I. Psychometric properties of the 
Montreal Cognitive Assessment (MoCA): an analysis using the Rasch model. Clin 
Neuropsychol (2014) 28(1):65-83. Epub 2014/01/11. doi: 
10.1080/13854046.2013.870231. PubMed PMID: 24404822. 
449. Dimitrov DM. Testing for Factorial Invariance in the Context of Construct 
Validation. Meas Eval Couns Dev (2010) 43(2):121-49. doi: 
10.1177/0748175610373459. PubMed PMID: WOS:000278947000004. 
450. Millsap RE, Cham H. Investigating factorial invariance in longitudinal data.  
Handbook of developmental research methods. New York, NY, US: The Guilford 
Press (2012). p. 109-26. 
451. Enders CK. The performance of the full information maximum likelihood 
estimator in multiple regression models with missing data. Educ Psychol Meas 
(2001) 61(5):713-40. doi: Doi 10.1177/0013164401615001. PubMed PMID: 
WOS:000171048800001. 
452. Peeters M, Zondervan-Zwijnenburg M, Vink G, van de Schoot R. How to 
handle missing data: A comparison of different approaches. Eur J Dev Psychol 
(2015) 12(4):377-94. doi: 10.1080/17405629.2015.1049526. PubMed PMID: 
WOS:000359482500001. 
453. Jackson H, Engelman M, Bandeen-Roche K. Robust Respondents and Lost 
Limitations: The Implications of Nonrandom Missingness for the Estimation of 
Health Trajectories. J Aging Health (2019) 31(4):685-708. doi: 
10.1177/0898264317747079. PubMed PMID: WOS:000461623000008. 
454. Muthen B, Asparouhov T, Hunter AM, Leuchter AF. Growth Modeling With 
Nonignorable Dropout: Alternative Analyses of the STAR*D Antidepressant Trial. 
Psychological Methods (2011) 16(1):17-33. doi: 10.1037/a0022634. PubMed PMID: 
WOS:000288300800002. 
455. Enders CK. Missing not at random models for latent growth curve 
analyses. Psychological Methods (2011) 16(1):1-16. doi: 10.1037/a0022640. 
456. Moore CM, MaWhinney S, Forster JE, Carlson NE, Allshouse A, Wang XS, et 
al. Accounting for dropout reason in longitudinal studies with nonignorable 
dropout. Stat Methods Med Res (2017) 26(4):1854-66. doi: 
10.1177/0962280215590432. PubMed PMID: WOS:000407924800019. 
457. Mehta PD, West SG. Putting the individual back into individual growth 
curves. Psychological Methods (2000) 5(1):23-43. doi: 10.1037//1082-
989x.5.1.23. PubMed PMID: WOS:000088349900002. 
458. Akaike H, editor. Information theory and an extension of the maximum 
likelihood principle. Budapest, Hungary: Akadémiai Kiadó (1973). 
459. Schwarz G. Estimating the Dimension of a Model. The Annals of Statistics 
(1978) 6(2):461-4. 
370 
460. Sclove SL. Application of model-selection criteria to some problems in 
multivariate analysis. Psychometrika (1987) 52(3):333-43. doi: 
10.1007/BF02294360. 
461. Ramaswamy V, Desarbo WS, Reibstein DJ, Robinson WT. An Empirical 
Pooling Approach for Estimating Marketing Mix Elasticities with Pims Data. 
Market Sci (1993) 12(1):103-24. doi: DOI 10.1287/mksc.12.1.103. PubMed PMID: 
WOS:A1993KY95900006. 
462. Celeux G, Soromenho G. An entropy criterion for assessing the number of 
clusters in a mixture model. J Classif (1996) 13(2):195-212. doi: Doi 
10.1007/Bf01246098. PubMed PMID: WOS:A1996VP96000001. 
463. Muthén BO. What is a good value of entropy? (2007) [cited 2020 November 
10]. Available from: 
http://www.statmodel.com/discussion/messages/13/2562.html?1237580237. 
464. Hipp JR, Bauer DJ. Local solutions in the estimation of growth mixture 
models. Psychological Methods (2006) 11(1):36-53. doi: 10.1037/1082-
989x.11.1.36. PubMed PMID: WOS:000236745400003. 
465. Qizilbash N, Gregson J, Johnson ME, Pearce N, Douglas I, Wing K, et al. 
BMI and risk of dementia in two million people over two decades: a retrospective 
cohort study. Lancet Diabetes Endo (2015) 3(6):431-6. doi: 10.1016/S2213-
8587(15)00033-9. PubMed PMID: WOS:000354880300020. 
466. Nguyen JCD, Killcross AS, Jenkins TA. Obesity and cognitive decline: role 
of inflammation and vascular changes. Frontiers in Neuroscience (2014) 8. doi: 
ARTN 375; 10.3389/fnins.2014.00375. PubMed PMID: WOS:000346564500001. 
467. Prickett C, Brennan L, Stolwyk R. Examining the relationship between 
obesity and cognitive function: A systematic literature review. Obes Res Clin 
Pract (2015) 9(2):93-113. doi: 10.1016/j.orcp.2014.05.001. PubMed PMID: 
WOS:000353068500001. 
468. Rubin DB. Multiple imputation for nonresponse in surveys. New York ;: 
Wiley (1987).  
469. Schafer JL. Analysis of Incomplete Multivariate Data (1st ed.). New York: 
Chapman and Hall/CRC (1997). 
470. Wayman JC. Multiple imputation for missing data: What is it and how can I 
use it? Annual Meeting of the American Educational Research Association, 
Chicago, IL (2003):2-16. 
471. Nakai M, Ke W. Review of the Methods for Handling Missing Data in 
Longitudinal Data Analysis. International Journal of Mathematical Analysis 
(2011) 5(1):1-13. 
472. Kelly-Hayes M, Wolf PA, Kase CS, Gresham GE, Kannel WB, D'Agostino RB. 
Time Course of Functional Recovery After Stroke: The Framingham Study. 
Journal of Neurologic Rehabilitation (1989) 3(2):65-70. doi: 
10.1177/136140968900300202. 
473. Tilling K, Sterne JA, Rudd AG, Glass TA, Wityk RJ, Wolfe CD. A new 
method for predicting recovery after stroke. Stroke (2001) 32(12):2867-73. Epub 
2001/12/12. doi: 10.1161/hs1201.099413. PubMed PMID: 11739989. 
474. Demain S, Wiles R, Roberts L, McPherson K. Recovery plateau following 
stroke: fact or fiction? Disabil Rehabil (2006) 28(13-14):815-21. Epub 
2006/06/17. doi: 10.1080/09638280500534796. PubMed PMID: 16777768. 
371 
475. Hankey GJ, Spiesser J, Hakimi Z, Bego G, Carita P, Gabriel S. Rate, 
degree, and predictors of recovery from disability following ischemic stroke. 
Neurology (2007) 68(19):1583-7. Epub 2007/05/09. doi: 
10.1212/01.wnl.0000260967.77422.97. PubMed PMID: 17485645. 
476. Sprigg N, Gray LJ, Bath PMW, Lindenstrom E, Boysen G, De Deyn PP, et al. 
Stroke severity, early recovery and outcome are each related with clinical 
classification of stroke: Data from the 'Tinzaparin in Acute Ischaemic Stroke 
Trial' (TAIST). Journal of the Neurological Sciences (2007) 254(1-2):54-9. doi: 
10.1016/j.jns.2006.12.016. PubMed PMID: WOS:000245391200011. 
477. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Stroke. Neurologic 
and functional recovery the Copenhagen Stroke Study. Phys Med Rehabil Clin N 
Am (1999) 10(4):887-906. Epub 1999/11/26. PubMed PMID: 10573714. 
478. Neiman J, Haapaniemi HM, Hillbom M. Neurological complications of drug 
abuse: pathophysiological mechanisms. Eur J Neurol (2000) 7(6):595-606. Epub 
2001/01/03. doi: 10.1046/j.1468-1331.2000.00045.x. PubMed PMID: 11136345. 
479. Fernández-Serrano MJ, Pérez-García M, Verdejo-García A. What are the 
specific vs. generalized effects of drugs of abuse on neuropsychological 
performance? Neurosci Biobehav Rev (2011) 35(3):377-406. Epub 2010/05/11. 
doi: 10.1016/j.neubiorev.2010.04.008. PubMed PMID: 20451551. 
480. Schulte MHJ, Cousijn J, den Uyl TE, Goudriaan AE, van den Brink W, 
Veltman DJ, et al. Recovery of neurocognitive functions following sustained 
abstinence after substance dependence and implications for treatment. Clinical 
Psychology Review (2014) 34(7):531-50. doi: 10.1016/j.cpr.2014.08.002. PubMed 
PMID: WOS:000344445600002. 
481. Rehm J, Hasan OSM, Black SE, Shield KD, Schwarzinger M. Alcohol use and 
dementia: a systematic scoping review. Alzheimers Research & Therapy (2019) 
11. doi: ARTN 1; 10.1186/s13195-018-0453-0. PubMed PMID: 
WOS:000454955400003. 
482. Brust JCM. Strokes and Substance Abuse. In: Biller J, Caplan L, editors. 
Uncommon Causes of Stroke. 3 ed. Cambridge: Cambridge University Press 
(2018). p. 429-36. 
483. Moos RH, Brennan PL, Mertens JR. Mortality-Rates and Predictors of 
Mortality among Late Middle-Aged and Older Substance-Abuse Patients. 
Alcoholism-Clinical and Experimental Research (1994) 18(1):187-95. doi: DOI 
10.1111/j.1530-0277.1994.tb00902.x. PubMed PMID: WOS:A1994MZ33500031. 
484. Roerecke M, Rehm J. Cause-specific mortality risk in alcohol use disorder 
treatment patients: a systematic review and meta-analysis. International 
Journal of Epidemiology (2014) 43(3):906-19. doi: 10.1093/ije/dyu018. PubMed 
PMID: WOS:000338127000035. 
485. Bill O, Zufferey P, Faouzi M, Michel P. Severe stroke: patient profile and 
predictors of favorable outcome. J Thromb Haemost (2013) 11(1):92-9. Epub 
2012/11/13. doi: 10.1111/jth.12066. PubMed PMID: 23140236. 
486. Treadwell SD, Thanvi B. Malignant middle cerebral artery (MCA) 
infarction: pathophysiology, diagnosis and management. Postgraduate Medical 
Journal (2010) 86(1014):235-42. doi: 10.1136/pgmj.2009.094292. PubMed PMID: 
WOS:000276081500008. 
372 
487. Balami JS, Chen RL, Grunwald IQ, Buchan AM. Neurological complications 
of acute ischaemic stroke. Lancet Neurol (2011) 10(4):357-71. doi: 
10.1016/S1474-4422(10)70313-6. PubMed PMID: WOS:000289185000019. 
488. Stern Y. What is cognitive reserve? Theory and research application of the 
reserve concept. Journal of the International Neuropsychological Society (2002) 
8(3):448-60. doi: 10.1017/S1355617702813248. PubMed PMID: 
WOS:000174602600010. 
489. National Institute for Health and Care Excellence (NICE). Cardiovascular 
disease: risk assessment and reduction, including lipid modification. Cinical 
guideline [CG181]. (2014) [updated 27 Sep 2016; cited 2021 February 11]. 
Available from: https://www.nice.org.uk/guidance/cg181. 
490. Lanza ST, Rhoades BL. Latent class analysis: an alternative perspective on 
subgroup analysis in prevention and treatment. Prev Sci (2013) 14(2):157-68. 
Epub 2011/02/15. doi: 10.1007/s11121-011-0201-1. PubMed PMID: 21318625. 
491. Nys GM, Van Zandvoort MJ, De Kort PL, Jansen BP, Van der Worp HB, 
Kappelle LJ, et al. Domain-specific cognitive recovery after first-ever stroke: a 
follow-up study of 111 cases. J Int Neuropsychol Soc (2005) 11(7):795-806. Epub 
2006/03/08. doi: 10.1017/s1355617705050952. PubMed PMID: 16519259. 
492. Klimkowicz-Mrowiec A, Dziedzic T, Slowik A, Szczudlik A. Predictors of 
poststroke dementia: results of a hospital-based study in poland. Dement Geriatr 
Cogn Disord (2006) 21(5-6):328-34. Epub 2006/03/02. doi: 10.1159/000091788. 
PubMed PMID: 16508296. 
493. Bell ML, Fairclough DL. Practical and statistical issues in missing data for 
longitudinal patient-reported outcomes. Stat Methods Med Res (2014) 23(5):440-
59. Epub 2013/02/22. doi: 10.1177/0962280213476378. PubMed PMID: 23427225. 
494. Mueller RO, Hancock GR. Best Practices in Quantitative Methods. (2008 
2021/02/15). [Internet]. Thousand Oaks, California: SAGE Publications, Inc. 
Available from: https://methods.sagepub.com/book/best-practices-in-
quantitative-methods. 
495. Schumacker RE, Lomax RG. A beginner's guide to structural equation 
modeling. Fourth edition. ed. New York, NY: Routledge (2016).  
496. Appelros P, Nydevik I, Seiger A, Terent A. Predictors of severe stroke - 
Influence of preexisting dementia and cardiac disorders. Stroke (2002) 
33(10):2357-62. doi: 10.1161/01.Str.0000030318.99727.Fa. PubMed PMID: 
WOS:000178515800011. 
497. Saposnik G, Cote R, Rochon PA, Mamdani M, Liu Y, Raptis S, et al. Care 
and outcomes in patients with ischemic stroke with and without preexisting 
dementia. Neurology (2011) 77(18):1664-73. doi: 
10.1212/WNL.0b013e31823648f1. PubMed PMID: WOS:000296590800007. 
498. Holt-Lunstad J, Smith TB, Layton JB. Social Relationships and Mortality 
Risk: A Meta-analytic Review. Plos Medicine (2010) 7(7). doi: ARTN e1000316; 
10.1371/journal.pmed.1000316. PubMed PMID: WOS:000280557200015. 
499. Gallant MP. The influence of social support on chronic illness self-
management: a review and directions for research. Health Educ Behav (2003) 
30(2):170-95. Epub 2003/04/16. doi: 10.1177/1090198102251030. PubMed PMID: 
12693522. 
373 
500. DiMatteo MR. Social support and patient adherence to medical treatment: 
a meta-analysis. Health Psychol (2004) 23(2):207-18. Epub 2004/03/11. doi: 
10.1037/0278-6133.23.2.207. PubMed PMID: 15008666. 
501. Essery R, Geraghty AW, Kirby S, Yardley L. Predictors of adherence to 
home-based physical therapies: a systematic review. Disabil Rehabil (2017) 
39(6):519-34. Epub 2016/04/22. doi: 10.3109/09638288.2016.1153160. PubMed 
PMID: 27097761. 
502. Corley J, Cox SR, Deary IJ. Healthy cognitive ageing in the Lothian Birth 
Cohort studies: marginal gains not magic bullet. Psychol Med (2018) 48(2):187-
207. Epub 2017/06/10. doi: 10.1017/S0033291717001489. PubMed PMID: 
28595670. 
503. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet 
Neurol (2012) 11(11):1006-12. Epub 2012/10/20. doi: 10.1016/S1474-
4422(12)70191-6. PubMed PMID: 23079557. 
504. Chapko D, McCormack R, Black C, Staff R, Murray A. Life-course 
determinants of cognitive reserve (CR) in cognitive aging and dementia - a 
systematic literature review. Aging Ment Health (2018) 22(8):915-26. Epub 
2017/07/14. doi: 10.1080/13607863.2017.1348471. PubMed PMID: 28703027. 
505. Carin-Levy G, Nicol K, van Wijck F, Mead GE. Delirium in acute stroke: A 
survey of screening and diagnostic practice in Scotland. International Journal of 
Stroke (2013) 8:74-. PubMed PMID: WOS:000330526900186. 
506. Siddiqi N, Harrison JK, Clegg A, Teale EA, Young J, Taylor J, et al. 
Interventions for preventing delirium in hospitalised non-ICU patients. The 
Cochrane database of systematic reviews (2016) 3:CD005563. Epub 2016/03/12. 
doi: 10.1002/14651858.CD005563.pub3. PubMed PMID: 26967259. 
507. Song J, Lee M, Jung D. The Effects of Delirium Prevention Guidelines on 
Elderly Stroke Patients. Clin Nurs Res (2018) 27(8):967-83. Epub 2017/07/25. 
doi: 10.1177/1054773817721400. PubMed PMID: 28737064. 
508. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing 
and reporting heterogeneity in treatment effects in clinical trials: a proposal. 
Trials (2010) 11:85. Epub 2010/08/14. doi: 10.1186/1745-6215-11-85. PubMed 
PMID: 20704705. 
509. Kent DM, Hayward RA. Limitations of applying summary results of clinical 
trials to individual patients: the need for risk stratification. JAMA (2007) 
298(10):1209-12. Epub 2007/09/13. doi: 10.1001/jama.298.10.1209. PubMed 
PMID: 17848656. 
510. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can 
greatly enhance the statistical power of clinical trial subgroup analysis. BMC 
medical research methodology (2006) 6(1):1-11. 
511. Collins R, Silarova B, Clare L. Dementia Primary Prevention Policies and 
Strategies and Their Local Implementation: A Scoping Review Using England as a 
Case Study. J Alzheimers Dis (2019) 70:S303-S18. doi: 10.3233/Jad-180608. 
PubMed PMID: WOS:000481670800023. 
512. Shah H, Albanese E, Duggan C, Rudan I, Langa KM, Carrillo MC, et al. 
Research priorities to reduce the global burden of dementia by 2025. Lancet 
Neurol (2016) 15(12):1283-92. PubMed PMID: WOS:000386315700023. 
374 
513. Kivipelto M, Mangialasche F, Ngandu T. Can lifestyle changes prevent 
cognitive impairment? Lancet Neurol (2017) 16(5):338-9. doi: 10.1016/S1474-
4422(17)30080-7. PubMed PMID: WOS:000398782100005. 
514. Richard E, Van den Heuvel E, Moll van Charante EP, Achthoven L, 
Vermeulen M, Bindels PJ, et al. Prevention of dementia by intensive vascular 
care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc 
Disord (2009) 23(3):198-204. Epub 2009/10/09. doi: 
10.1097/WAD.0b013e31819783a4. PubMed PMID: 19812459. 
515. Kivipelto M, Solomon A, Ahtiluoto S, Ngandu T, Lehtisalo J, Antikainen R, 
et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment 
and Disability (FINGER): study design and progress. Alzheimer's & dementia : the 
journal of the Alzheimer's Association (2013) 9(6):657-65. Epub 2013/01/22. doi: 
10.1016/j.jalz.2012.09.012. PubMed PMID: 23332672. 
516. Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues 
JF, et al. Mapt Study: A Multidomain Approach for Preventing Alzheimer's 
Disease: Design and Baseline Data. J Prev Alzheimers Dis (2014) 1(1):13-22. Epub 
2014/06/01. PubMed PMID: 26594639. 
517. Brainin M, Matz K, Nemec M, Teuschl Y, Dachenhausen A, Asenbaum-Nan 
S, et al. Prevention of poststroke cognitive decline: ASPIS--a multicenter, 
randomized, observer-blind, parallel group clinical trial to evaluate multiple 
lifestyle interventions--study design and baseline characteristics. Int J Stroke 
(2015) 10(4):627-35. Epub 2013/11/12. doi: 10.1111/ijs.12188. PubMed PMID: 
24206541. 
518. Lennon S, McKenna S, Jones F. Self-management programmes for people 
post stroke: a systematic review. Clin Rehabil (2013) 27(10):867-78. Epub 
2013/04/02. doi: 10.1177/0269215513481045. PubMed PMID: 23543340. 
519. Sadler E, Wolfe CD, Jones F, McKevitt C. Exploring stroke survivors' and 
physiotherapists' views of self-management after stroke: a qualitative study in 
the UK. BMJ Open (2017) 7(3):e011631. Epub 2017/03/12. doi: 
10.1136/bmjopen-2016-011631. PubMed PMID: 28283483. 
520. Comas-Herrera A, Wittenberg R, Pickard L, Knapp M. Cognitive 
impairment in older people: future demand for long-term care services and the 
associated costs. Int J Geriatr Psychiatry (2007) 22(10):1037-45. Epub 
2007/07/03. doi: 10.1002/gps.1830. PubMed PMID: 17603823. 
521. Leslie DL, Inouye SK. The importance of delirium: economic and societal 
costs. J Am Geriatr Soc (2011) 59 Suppl 2:S241-3. Epub 2011/12/07. doi: 
10.1111/j.1532-5415.2011.03671.x. PubMed PMID: 22091567. 
522. Wu YT, Fratiglioni L, Matthews FE, Lobo A, Breteler MM, Skoog I, et al. 
Dementia in western Europe: epidemiological evidence and implications for 
policy making. Lancet Neurol (2016) 15(1):116-24. Epub 2015/08/25. doi: 
10.1016/S1474-4422(15)00092-7. PubMed PMID: 26300044. 
523. Public Health England. From evidence into action: Opportunities to 
protect and improve the nation's health. London, UK: PHE Publications (2014). 
524. Bath PM, Krishnan K. Interventions for deliberately altering blood pressure 
in acute stroke. The Cochrane database of systematic reviews (2014) 
(10):CD000039. Epub 2014/10/30. doi: 10.1002/14651858.CD000039.pub3. 
PubMed PMID: 25353321. 
375 
525. Wang H, Tang Y, Rong X, Li H, Pan R, Wang Y, et al. Effects of early blood 
pressure lowering on early and long-term outcomes after acute stroke: an 
updated meta-analysis. PLoS One (2014) 9(5):e97917. Epub 2014/05/24. doi: 
10.1371/journal.pone.0097917. PubMed PMID: 24853087. 
526. Smith AD, Mangialasche F, Kivipelto M. Dementia research priorities-2. 
Lancet Neurol (2017) 16(3):181-2. Epub 2017/02/24. doi: 10.1016/S1474-
4422(16)30401-X. PubMed PMID: 28229885. 
 
